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Abstract  
 
Introduction 
Urinary tract infections (UTI) are one of the most common bacterial infections in hospital 
and community settings requiring antimicrobial treatment. Escherichia coli (E. coli), a 
bacterium frequently implicated in UTI, is becoming increasingly resistant to antimicrobials. 
Antimicrobial resistance (AMR) reduces the effectiveness of antimicrobial agents, leading to 
difficulty in treatment of patients, with the potential to prolong the duration of illness and 
increase mortality in patients. To date in Australia, there is a paucity of data comparing 
resistance patterns over time for hospital- and community-acquired E. coli UTI with no 
published data on incidence and risk of urinary E. coli resistance in Australia. Ciprofloxacin, a 
high priority critically important antimicrobial, is not recommended for empirical therapy of 
UTI yet resistance to this antimicrobial agent is increasing. There are no systematic reviews 
of studies investigating ciprofloxacin resistance in hospital- and community-acquired E. coli 
UTI. Therefore, the research program sought to address these knowledge gaps in three 
separate but interrelated studies. The research described in this thesis is the first of its kind 
in Australia.  
  
Aims 
The overall research program aim was to contribute to the body of knowledge about AMR in 
E. coli UTI. The individual study aims were to: (1) systematically review the literature and 
conduct a meta-analysis of international observational studies published in the last ten 
years, investigating ciprofloxacin resistance in community-acquired and hospital-acquired   
E. coli UTI; (2) evaluate AMR temporal trends and compare the prevalence of AMR in 
hospital-acquired and community-acquired E. coli UTI at the Canberra Hospital over a five-
year period and also evaluate trends and seasonal variation in antimicrobial use at the 
Canberra Hospital over a five-year period; and (3) evaluate the incidence and risk of 
antimicrobial resistant E. coli UTI in a cohort of Australian Capital Territory (ACT) residents 
over a five-year period. Each aim was addressed as a separate study. 
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Methods 
First, observational studies published between 2004 and 2014 were identified and 
systematically reviewed in study one. DerSimonian-Laird random-effects meta-analysis of 
studies was undertaken and pooled estimates of ciprofloxacin resistance were evaluated. 
Second, a large regional microbiology laboratory dataset was retrospectively reviewed to 
address the second and third study aims. For study two, a laboratory-based cross sectional 
study of E. coli UTI from patients attending Canberra Hospital was undertaken and time 
series analysis was performed to illustrate resistance trends at the hospital. Time series 
analysis was also performed on supplementary antimicrobial use data to evaluate trends 
and seasonal variation in antimicrobial use at the hospital. Finally, study three used a 
laboratory-based retrospective cohort design to determine the incidence and patient risk 
factors for single drug-, multidrug-, extensively drug- and pandrug-resistant E. coli UTI in a 
cohort of ACT residents. Studies two and three also addressed methodological issues with 
appropriately calculating prevalence and incidence of resistance respectively, using 
microbiological laboratory data. 
 
Results 
For study one, the systematic review and meta-analysis identified that ciprofloxacin 
resistance was significantly higher (P<0.0001) in hospital-acquired UTI (pooled resistance  
38%; 95% confidence interval (CI) 36–41%) compared with community-acquired UTI (27%; 
95% CI 24–31%). A significant rise in resistance over time was observed for studies reporting 
on community-acquired E. coli UTI (n=47, rs = 0.4313, P = 0.003). Resistance significantly 
varied by region and country and was higher in developing countries compared to 
developed countries.  
 
The cross sectional study of laboratory-based data undertaken in study two identified 
overall five-year resistance was high for ampicillin and trimethoprim. Resistance to 
amoxycillin-clavulanate, cefazolin, gentamicin and piperacillin-tazobactam was statistically 
significantly higher in hospital- compared to community-acquired UTI. Statistically significant 
increases in resistance over the five years were noted for amoxycillin-clavulanate, 
trimethoprim, ciprofloxacin, nitrofurantoin, cefazolin, gentamicin, ceftriaxone and 
trimethoprim-sulphamethoxazole. The study also provided evidence of the impact of 
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denominators selected for calculating resistance prevalence on resistance. Analysis of 
supplementary antimicrobial use data showed a decrease in overall hospital antimicrobial 
use over the five-year period but increased use of newer broad spectrum antimicrobials. 
Seasonal use of ceftriaxone at the hospital was identified. 
 
For study three, the laboratory-based retrospective cohort study showed incidence of 
resistance was high for ampicillin, trimethoprim and cefazolin. Although no possible 
pandrug-resistant E. coli UTI was identified, there was a relatively low incidence of 
multidrug- and possible extensively drug-resistant E. coli UTI. Multivariate logistic regression 
analyses indicated that female sex and age over 38 years was statistically significantly 
associated with single drug- and multidrug-resistance. A previously unrecognised Australian 
patient group that may be at high risk of developing an antimicrobial resistant E. coli UTI, 
specifically those receiving care at after-hours general practice health services, was 
identified. The study also provided new knowledge on an appropriate method for clearly 
identifying incident cases of resistant E. coli UTI using microbiological laboratory data. 
 
Discussion 
These findings have implications both nationally and internationally and have strengthened 
the evidence base for AMR through research consistent with the World Health Assembly’s 
global action plan on AMR. Despite all that is being done internationally through the World 
Health Organization and United Nations, as well as nationally through the recently 
developed Antimicrobial Use and Resistance in Australia Surveillance System, it is surprising 
to see rising resistance specifically in E. coli, the pathogen evaluated in this research 
program. Rising resistance might indicate that antimicrobials are still being misused, 
overused and inappropriately prescribed. There is more to be done in curtailing rising 
resistance. In addition, presence of multidrug- and possible extensively drug-resistant E. coli, 
although low in the ACT, emphasises the need for continued surveillance of AMR in E. coli 
UTI to inform development and implementation of effective interventions to reduce 
resistant E. coli UTI. It is important to note that as this thesis focused on microbiological 
laboratory data, which is only one aspect of what informs therapeutic management of E. coli 
UTI, the thesis could only inform some aspects of decision-making about prescribing.  
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Conclusions 
Based on the research findings, policy recommendations include: linkage of microbiological 
laboratory and clinical databases; compulsory completion of minimum patient data on 
microbiological laboratory request forms; development and implementation of policy 
limiting use of ciprofloxacin as an empirical agent for UTI management. Recommendations 
for clinical practice include: ongoing education of general practitioners who consult at after-
hours clinics on judicious use of antimicrobials; and education of healthcare staff on the 
importance of adequately completing laboratory request forms. Potential areas for future 
research include: prospective studies of patient-based AMR data and linking these data to 
antimicrobial use data; and examining the association between policy regulation on 
antimicrobial use and AMR. Recommendations for research methodology include: uptake of 
the new methodological approach for clearly identifying incident cases of resistant E. coli 
UTI; and further evaluation of the impact of denominators selected for calculating 
resistance prevalence. Recommendations for reporting of research include: establishment 
of an expert panel to develop a standardised classification system for infections based on 
the setting of acquisition to allow consistency in reporting as well as comparison of data; 
and improved compliance with reporting guidelines during journal submission processes. 
The findings will be provided to local health authorities with the aim of implementing the 
recommendations and informing clinical practice.  
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Glossary 
 
Antimicrobial A drug or other substance that prevents the 
growth of microbes or pathogens such as 
bacteria, fungi, parasites or viruses (adapted 
from Sefton, 2002) 
 
Antimicrobial resistance The ability of a microbe to resist the effect of 
an antimicrobial agent (Australian 
Commission on Safety and Quality in Health 
Care, 2013a) 
 
Community-acquired urinary tract infection Positive E. coli urine culture obtained within 
the first 48 hours of admission (including 
cultures from non-admissions such as 
outpatient clinics) 
 
Extensively drug-resistance “Non-susceptibility to at least one agent in 
all but two or fewer antimicrobial 
categories” (Magiorakos et al., 2012, p. 277) 
 
Incidence The number of new (incident) cases of a 
condition (e.g., a disease) in people at risk of 
developing the condition during a specified 
time period (Buttner & Muller, 2011; Porta, 
2014) 
 
Hospital-acquired urinary tract infection Positive E. coli urine culture obtained more 
than 48 hours after admission and within 48 
hours of discharge 
 
Isolate “An organism identified in pure form in a 
microbial culture” (Venes, 2013, p. 1299) 
 
Microbe “A unicellular or small multicellular organism 
including bacteria, fungi, viruses and 
protozoa” (Venes, 2013, p. 1510) 
 
Multidrug-resistance “Non-susceptibility to at least one agent in 
three or more antimicrobial categories” 
(Magiorakos et al., 2012, p. 277) 
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Pandrug-resistance “Non-susceptibility to all agents in all 
antimicrobial categories” (Magiorakos et al., 
2012, p. 277) 
 
Pathogen “A microorganism capable of producing a 
disease” (Venes, 2013, p. 1752) 
 
Prevalence The proportion of people with a disease 
either at a specified point in time (point 
prevalence) or during a particular period of 
time (period prevalence) (Buttner & Muller, 
2011) 
 
Surveillance  “Systematic and continuous collection, 
analysis, and interpretation of data, closely 
integrated with the timely and coherent 
dissemination of the results and assessment 
to those who have the right to know so that 
action can be taken” (Porta, 2014, p. 239) 
 
Urinary tract infection Positive laboratory confirmation of a 
quantitative culture of urine sample 
containing E. coli of greater than or equal to 
107 colony forming unit per litre of urine 
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Chapter 1: Introduction  
 
1.1 Overview 
Antimicrobial resistance (AMR) is a major global public health concern. In response to the 
threat of AMR in Australia, the first national AMR strategy was released in June 2015 
(Australian Government, 2015). Escherichia coli (E. coli), a Gram-negative bacterium, is 
identified both in Australia and globally as a priority organism for targeted AMR surveillance 
in human health because of its impact in hospital and community settings. This bacterium is 
frequently implicated in urinary tract infections (UTI), which are one of the most common 
bacterial infections in hospital and community settings. To date, there is no published 
research exploring the issue of AMR in urinary E. coli infections in Australia and there is a 
need to address the current research gaps, hence this research program.  
 
The aim of chapter one is to introduce the thesis subject of AMR in UTI caused by E. coli, 
provide some context to the thesis topic, outline the overall research program and 
individual study aims and highlight the significance of the research program. This chapter 
will begin with a synopsis of the thesis subject. A brief description of Australia and its health 
structure will be outlined. An overview of the history and classification of antimicrobial 
agents will be provided, including a discussion on antimicrobial use and development of 
AMR as well as the mechanisms of AMR. The evidence base for the importance of AMR 
surveillance will also be discussed. A brief description of the current status of AMR 
surveillance in Australia is provided, highlighting the key areas for development. 
 
Chapter one also contains an outline of the research program, which briefly describes the 
three studies which make up the research program, the significance as well as the 
importance of the research program. The study aims, research questions and hypotheses 
are also detailed within this chapter. The chapter will conclude with an outline of the thesis 
structure, which provides brief information on subsequent chapters.  
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1.2 Background of the author 
Working as a medical doctor in a developing country, I was faced daily with challenges on 
how to provide adequate care to patients using the limited resources available. It quickly 
became clear to me as a clinician that even in the presence of adequate resources, such as 
revolutionary medical equipment and novel drugs, it was imperative to ensure effective 
infection prevention and control strategies were being applied in order to control and 
prevent further spread of infection. Effective infection prevention and control strategies 
were also important to improving outcomes for the patients. My interest in infection 
prevention and control led to my undertaking a Master’s degree in Public Health and 
Tropical Medicine, from which I developed a keen interest in the field of research, 
culminating in accepting a position as a research associate at the Australian Catholic 
University. In this position, I took a lead role in the strategic planning and management of a 
project focused on reducing healthcare associated UTI in Australian acute care hospitals and 
aged care facilities. Particularly, working in this position provided me with insight into the 
issues related to managing UTI and raised key questions on how best to address the rising 
levels of resistance in drugs commonly used to treat UTI, as well as ensuring reliable and 
valid analysis of microbiology laboratory data on urine samples. 
 
1.3 Introduction to the thesis subject 
Urinary tract infections are one of the most frequently occurring bacterial infections in both 
hospital and community settings (Foxman, 2003; Hooton, 2012; Mazzulli, 2012). They are 
also the most common bacterial infections acquired by women (Stamm & Norrby, 2001). 
Urinary tract infections occur in men, but less commonly than in women (Foxman, 2003). 
Women are more predisposed to UTI because bacteria easily enter the bladder via the 
shorter female urethra (Foxman, 2003; Hooton, 2000). Although UTI can be caused by a 
wide range of bacterial and some fungal pathogens, a Gram-negative bacterium known as E. 
coli is the predominant pathogen isolated in patients (Nicolle, 2013; Ronald, 2002). Health 
implications of UTI include approximately 2.4 days of restricted activity and 1.2 work days 
lost (Foxman, 2002; Nicolle, 2008). Complicated infections (e.g. paraurethral or renal 
abscesses) may occur more frequently in patients with underlying health conditions, such as 
diabetes, leading to increased morbidity and frequency of hospitalisation (Foxman, 2002; 
Nicolle, 2005). Furthermore, UTI have the potential to spread to the bloodstream, causing 
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bacteremic UTI associated with increased mortality (Al-Hasan, Eckel-Passow, & Baddour, 
2010).  
 
Urinary tract infections are treated with antimicrobial agents, most commonly antibiotics as 
the majority of UTI are caused by bacteria (Mazzulli, 2012). Approximately one in three 
women will have had at least one UTI episode requiring treatment with an antimicrobial 
agent by 24 years of age (Foxman, 2003). In most cases, antimicrobials are prescribed 
empirically while awaiting results of the urine sample sent for laboratory culture (Vellinga, 
Cormican, Hanahoe, Bennett, & Murphy, 2011). Empirical treatment refers to the use of 
antimicrobials when treatment must be commenced before the culture susceptibility results 
are available, the clinical situation is not serious enough to warrant taking cultures, or 
appropriate material for culture cannot be obtained (Antibiotic Expert Groups, 2014). The 
rationale for the empirical approach is based on the predictable causative agents for UTI, 
the predictable susceptibilities of these pathogens to commonly used antimicrobials, the 
identification of a UTI based on clinical presentation and the likely positive response to 
short-course antimicrobial treatment (Stamm & Norrby, 2001). Despite the advantages of 
this approach, which include reduced laboratory testing costs and patient visits, a 
disadvantage may be the inappropriate use of antimicrobials as well as treatment failures 
resulting in recurrence of infection (Stamm & Norrby, 2001). Furthermore, the choice of 
empirical therapy for UTI is based on the local susceptibility patterns of common causative 
pathogens, which can change over time (Teoh et al., 2013). When suboptimal treatment is 
provided, pathogens causing UTI may develop resistance to antimicrobials (Trautner, 2010). 
Antimicrobial resistance leads to decreased efficacy of antimicrobial agents, making the 
treatment of patients difficult, expensive or in some instances impossible when resistance 
to multiple agents develop. Antimicrobial resistance may also prolong the duration of illness 
and increase mortality in patients (World Health Organization, 2014). Empirical therapy is 
still regarded as the best approach for UTI treatment (Little et al., 2010; Olson & Haith, 
2012), so monitoring of resistance patterns is essential to ensure appropriate treatment for 
patients.  
 
During the past two decades, there have been significant increases in the resistance 
patterns of bacteria to commonly used antimicrobials (Blaettler et al., 2009; Kronvall, 2010; 
Levy & Marshall, 2004; Linhares, Raposo, Rodrigues, & Almeida, 2013; Maraki, Mantadakis, 
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Michailidis, & Samonis, 2013; Tadesse et al., 2012). This is especially important for UTI 
because it is usually treated empirically. The changes in resistance patterns need to be taken 
into consideration when deciding on the most appropriate antimicrobial (Ronald, 2002). In 
addition, most infections can be classified based on the setting in which they are acquired 
(World Health Organization, 2002); that is, healthcare setting such as a hospital, or 
community setting (e.g. non-healthcare facility or patient’s home). These settings are not 
isolated from each other with opportunity for transfer of resistant pathogens between 
settings (Cohen, 1992). For example, hospital-acquired infections may not produce any 
clinical symptoms until the patient has been discharged home. Likewise, patients with 
community-acquired infections may receive treatment in healthcare facilities (World Health 
Organization, 2002). The issue of antimicrobial resistant E. coli UTI involves both hospital 
and community settings, hence describing AMR in UTI should take into account the setting 
of infection acquisition. 
 
The problem of AMR was initially addressed with the development of new antimicrobials. In 
recent years, the rate at which pharmaceutical companies discover new antimicrobial 
agents against resistant pathogens has been declining (Moellering, 2006). Pharmaceutical 
companies tend to pursue more profitable treatments such as development of drugs for 
treatment of chronic disease conditions, such as hypertension and cancer (Australian 
Commission on Safety and Quality in Health Care, 2013a; Power, 2006). Further, as 
pharmaceutical companies strive to survive in a commercial environment, it is difficult to 
justify the costs for research and development required for new antimicrobials. This is 
because evidence shows that resistance to a new antimicrobial is likely to develop in the 
near future, thereby rendering the new drug less marketable (Australian Commission on 
Safety and Quality in Health Care, 2013a). In addition, new antimicrobials are likely to be 
restricted to reduce their use, thereby leading to decreased revenue and discouraging 
commercial companies from investing in new antimicrobial development (Power, 2006). 
Hence, reliance solely on the development of new antimicrobials to address the issue of 
AMR is impractical and other strategies must be investigated (Australian Commission on 
Safety and Quality in Health Care, 2013a). Therefore, in the era of increasing AMR (Schito et 
al., 2009), it is necessary to undertake continued research in this area to ensure patients are 
effectively treated, resulting in good clinical outcomes. Routinely collected microbiology 
laboratory data serves as an importance data source for research evaluating AMR levels in 
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pathogens such as E. coli (Cornaglia et al., 2004). However, as routinely collected data are 
not primarily collected for the purposes of research, they pose some methodological 
challenges to the analyses of AMR data.  
 
This research program evaluates AMR in E. coli UTI, with the aim of providing knowledge 
about the resistance patterns of E. coli, the pathogen most frequently implicated in UTI. This 
research program provides research-based insight into resistance in hospital- and 
community-acquired E. coli UTI worldwide using data from published studies and also 
provides knowledge of resistant E. coli UTI in the Australian Capital Territory (ACT) using 
data from a regional microbiology laboratory. The research program highlights the 
methodological challenges with evaluating microbiological laboratory AMR data. The overall 
results from this research program have the potential to inform policy and clinical practice 
relating to AMR in E. coli UTI. The results provide global AMR data, including regional data 
which will specifically contribute to a national dataset, thereby serving as a baseline for 
monitoring successive interventions. The study findings will guide clinicians in their 
treatment decisions for UTI both internationally and nationally and contribute 
methodologically to analysis of future AMR data. 
 
1.3.1 Australia and its healthcare system  
Australia is the sixth largest country in the world by land mass with a land area of 
approximately 7.7 million km2 (Australian Government, 2016a). Its land mass is estimated to 
be 32 times greater than the United Kingdom (UK) and almost as great as the United States 
(US) (Australian Government, 2016a). As of 31 December 2015, Australia’s estimated 
resident population was 23.9 million people (Australian Bureau of Statistics, 2016) so it is a 
large country with a low population density. Australia has six states and two mainland 
territories.  
 
The World Health Organization (WHO) describes a health system as inclusion of all activities, 
whose principal aim is the promotion, restoration and maintenance of health (World Health 
Organization, 2016). The Australian healthcare system is multifaceted, consisting of public 
and private healthcare providers, settings and patients (Australian Institute of Health and 
Welfare, 2014). The health system comprises public health, primary health, emergency, 
hospital-based, rehabilitation and palliative services (Australian Institute of Health and 
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Welfare, 2014). Local, state, territory and Australian governments provide public health 
services. Some private health service providers include medical practices and private 
hospitals (Australian Institute of Health and Welfare, 2014). About 70% of hospital care is 
provided by public hospitals (Australian Commission on Safety and Quality in Health Care, 
2016).  
 
The healthcare system in Australia is primarily funded by federal, state and territory 
governments, with 42.4% of the total health expenditure contributed by the Australian 
federal government during 2011 and 2012 (Australian Institute of Health and Welfare, 
2014). The state and territory governments contributed 27.3% with the remaining 
contributions made by patients, private health insurers and accident compensation schemes 
(Australian Institute of Health and Welfare, 2014). The funding contribution by the 
Australian government includes the Medicare scheme. Medicare provides free or subsidised 
healthcare to all Australians and also subsidises a number of prescription medicines 
including antibiotics through the Pharmaceutical Benefits Scheme (Australian Commission 
on Safety and Quality in Health Care, 2016; Australian Institute of Health and Welfare, 
2014).  
 
In Australia, the primary healthcare system is a person’s first point of contact with the 
healthcare system (Australian Institute of Health and Welfare, 2014). This healthcare system 
includes services provided by a range of clinical and allied health professionals such as 
general medical and dental practitioners and physiotherapists (Australian Institute of Health 
and Welfare, 2014). Patients with UTI typically present to general medical practitioners. 
General practitioner waiting times vary across Australia with the proportion of people 
waiting longer than they felt acceptable for a general practitioner appointment decreasing 
over the last two years from 23% in 2013-14 to 19% in 2015-16 (Australian Bureau of 
Statistics, 2016). Given the complex mix of public and private funding of the Australian 
healthcare system, payment for general practitioner consultation and diagnostic testing may 
be covered through the Medicare scheme for eligible Australian permanent residents or 
may incur out-of-pocket expenses depending on the clinical service provided and type of 
testing required (Australian Government, 2017). Urine sample examination, which includes 
examination for cell count, culture, colony count and antimicrobial susceptibility testing, is 
covered under Medicare item number 69333 (Medicare Australia, 2016). Payment for this 
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item is eligible for a Medicare benefit or rebate under the Medicare scheme (Australian 
Government, 2017). 
 
In the primary healthcare system, general practitioners initially evaluate patients presenting 
with UTI based on clinical history and physical examination. A urine dipstick is performed at 
the time of consultation to check for nitrites and/or leukocyte esterases which may indicate 
the presence of UTI (Jarvis, Chan, & Gottlieb, 2014). General practitioners are guided by the 
Australian Therapeutic Guidelines for management of patients with UTI. The guidelines 
recommend that antimicrobial treatment can be commenced empirically in symptomatic 
patients (Antibiotic Expert Groups, 2014). In non-pregnant women who are suspected to 
have uncomplicated UTI, urine cultures and susceptibility testing are not mandatory. 
However, urine samples for cultures and susceptibility testing should be obtained prior to 
commencement of empirical antimicrobials in pregnant women, men, aged care residents, 
patients who have recently taken antimicrobials or failed treatment, patients with recurrent 
UTI and those who have travelled internationally within the past six months (Antibiotic 
Expert Groups, 2014).  
 
1.3.2 Study setting 
Australia’s capital city, Canberra, is located in the Australian Capital Territory (ACT), one of 
the mainland territories (Australian Government, 2016b). The estimated population of the 
ACT as of December 2015 was 393,000 (Australian Bureau of Statistics, 2016). Two of the 
three studies contributing to this research program utilised data belonging to the 
residents of the ACT, which were processed at the public regional microbiology laboratory, 
ACT Pathology. Australian Capital Territory Pathology is located within the Canberra 
Hospital (ACT Government, 2015a). This 600 bed hospital is the largest publicly-funded 
tertiary hospital in the ACT providing acute and specialist care services to people in the 
region (ACT Government, 2015b). Australian Capital Territory Pathology provides specialist 
pathology services to all inpatients of public hospitals in the ACT as well as people 
attending public hospital emergency departments and some specialist outpatient clinics 
(ACT Government, 2015a). ACT Pathology also services an estimated 13% of patients 
(Medicare Australia, 2016) attending private hospitals, general practice clinics and nursing 
homes in the community. Urine samples from patients attending the Canberra Hospital 
are processed at the laboratory and these data were included as part of the research 
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program. The rationale for the selection of the ACT, including ACT Pathology as the data 
collection site, as opposed to another state or territory and laboratory is because of the 
geographic isolation of the ACT, with almost all healthcare for ACT residents provided 
within the jurisdiction (Kennedy, Roberts, & Collignon, 2008). Also, the wide reach of ACT 
Pathology, with a dataset that includes data on ACT residents in both public and private 
hospital settings and also in the community, made it a very suitable site to obtain data for 
use as part of the research program. 
 
Recent data show that the median age of 35.1 years for ACT residents was slightly lower 
than the overall Australian median age of 37.4 years and the second lowest in comparison 
to other Australian states and territories (Australian Bureau of Statistics, 2015). In 2015, 
the ACT male to female sex ratio of 98.5 to 100 was similar to that for the whole of 
Australia (Australian Bureau of Statistics, 2015). There are no available jurisdictional data 
on the incidence and prevalence of E. coli UTI in Australia; however published data show 
that E. coli is the most common cause of bloodstream infection in Canberra with UTI 
identified as the most frequent focus of infection (Kennedy et al., 2008). The seven-day 
case fatality rate due to E. coli bloodstream infection in Canberra has been estimated to 
be 5% (Kennedy et al., 2008).  
 
1.3.3 History and classification of antimicrobial agents  
The development of antibiotics has been a major advancement in patient care. Their 
discovery is considered one of the most remarkable health-related events in the history of 
medicine (Aminov, 2010; Davies & Davies, 2010). For over 60 years, antibiotics have been 
regarded as the solution to curing hospital- and community-acquired infections (World 
Health Organization, 2014). The word ‘antibiotic’ was first used as a noun in 1941 by Dr 
Selman Waksman to describe compounds produced by microorganisms which prevent the 
growth of other microorganisms (Waksman, 1973). However, as this description only 
applied to naturally occurring compounds and with the development of synthesized 
antibiotics over the years, the description of an antibiotic has expanded to include a broader 
category known as antimicrobials (Mishra & Agrawal, 2012). An antimicrobial is a drug or 
substance that prevents the growth of microbes or pathogens such as bacteria, fungi, 
parasites or viruses (Sefton, 2002). The words antibiotic and antimicrobial are often used 
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interchangeably in the literature (Leekha, Terrell, & Edson, 2011). For the purpose of this 
research program, the word antimicrobial is used. 
 
In 1910, the first antimicrobial agent, salvarsan, was synthesized by Ehrlich and Hata for the 
treatment of syphilis (Davies & Davies, 2010). This was followed with the discovery of 
sulfonamides by Domagk in 1935. In 1928, Alexander Fleming discovered penicillin, which 
was eventually introduced for use in the 1940s (Davies & Davies, 2010; Fleming, 1929). With 
the discovery of these three antimicrobials, over the next two decades came the 
development of other antimicrobials in a period commonly referred to as the golden era of 
antimicrobial discovery, which is when most of the antimicrobials used today were 
discovered (Aminov, 2010; Davies & Davies, 2010). Subsequent antimicrobials were 
developed either from evaluating naturally occurring compounds or by chemically modifying 
previously discovered antimicrobials (Powers, 2004). Given the number of antimicrobials in 
existence from the 1940s to early 1960s, clinicians were presented with a wide variety of 
treatment options for their patients (Powers, 2004).  
 
Antimicrobials can be broadly classified based on their chemical structure. The major 
antimicrobial classes are penicillins, cephalosporins, fluoroquinolones, aminoglycosides, 
polypeptides or glycopeptides, tetracyclines, macrolides, chloramphenicol, ansamycins, 
lincosamides, trimethoprim, fosfomycin, carbapenems and 5-nitroimidazoles (Bryskier, 
2005; Mishra & Agrawal, 2012). The penicillins, cephalosporins and carbapenems are all 
members of the beta-lactam family (Bryskier, 2005). Antimicrobials can also be classified, 
based on their spectrum of activity against pathogens, into broad or narrow spectrum (van 
Saene, Fairclough, & Petros, 1998). Broad spectrum antimicrobials are effective against a 
broad range of Gram-negative and Gram-positive bacteria (Bryskier, 2005; Mishra & 
Agrawal, 2012). Examples of broad spectrum antimicrobials include tetracyclines, 
chloramphenicol and some cephalosporins and fluoroquinolones (Aldred, Kerns, & Osheroff, 
2014; Bryskier, 2005; Mishra & Agrawal, 2012). Narrow spectrum antimicrobials are only 
active against a specific group of pathogens. For example, glycopeptides are only effective 
against Gram positive bacteria (Mishra & Agrawal, 2012).  
 
The discovery and subsequent use of antimicrobials led to a dramatic reduction in morbidity 
and mortality due to infectious diseases in comparison to the pre-antibiotic era (Powers, 
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2004). For example, the use of sulfonamides decreased the mortality due to acute 
meningococcal meningitis to 10%, compared to 70–99% in the pre-antibiotic era (Powers, 
2004). However, the use of these ‘miracle’ drugs has been accompanied by the emergence 
of pathogens resistant to antimicrobials (Davies & Davies, 2010). Previously effective 
antimicrobials against certain pathogens are now no longer effective, which poses 
significant threats to public health and the possibility of return to the pre-antibiotic era if 
urgent action is not taken (Cohen, 1992; Davies & Davies, 2010). The next section describes 
the effect of antimicrobial use on the development of resistance. 
 
1.3.4 Antimicrobial use and development of AMR 
Overuse or misuse of antimicrobials may pose an important clinical challenge known as 
antimicrobial resistance (AMR) (Fishman, 2006). Antimicrobial resistance is the ability of a 
microbe to resist the effect of an antimicrobial agent (Australian Commission on Safety and 
Quality in Health Care, 2013a). This occurs when an antimicrobial agent is unable to perform 
its function as a result of a change in the microbe rendering the antimicrobial agent clinically 
ineffective (Australian Commission on Safety and Quality in Health Care, 2013a). As 
described in the previous section with the use of the words antibiotic and antimicrobial, the 
terms antibiotic resistance and antimicrobial resistance are also used synonymously. 
Antibiotic resistance, strictly speaking, refers to the development of resistant bacteria 
strains or the ability of bacteria to develop resistance to antibiotics (Tenover, 2006) as 
opposed to the inclusion of viruses, parasites and fungi. This research program will focus 
specifically on antibiotic resistance to bacteria, namely E. coli, although using the term AMR. 
The term AMR was chosen as it is more widely used (Robinson et al., 2016).  
 
Development of AMR is a naturally occurring process for microbes but is accelerated by the 
selective pressure resulting from the misuse and overuse of antimicrobials both in humans 
and animals (World Health Organization, 2014). Alexander Fleming, who discovered the 
antibiotic known as penicillin, raised concerns while giving his Nobel Prize speech in 1945 
that bacterial pathogens could develop resistance to antimicrobial agents (World Health 
Organization, 2014). Not surprisingly, with the development of each new antimicrobial 
agent there has been detection of resistance to the agent following subsequent use (Davies 
& Davies, 2010; Levy & Marshall, 2004). Antimicrobial resistant bacteria were first identified 
in hospital settings in the 1930s but subsequently appeared in the community as well (Levy 
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& Marshall, 2004). The overuse and misuse of antimicrobial agents will continue to provide 
selective pressures with further development and spread of AMR (Cohen, 1992). 
 
Antimicrobials have now become widely used and also misused in both human populations 
and food-producing animals (World Health Organization, 2014). The increase in use is 
further driving resistance as the greater the number of antimicrobials used, the higher the 
chances that antimicrobial resistant pathogens will succeed in the fight for survival (Center 
for Disease Dynamics, Economics and Policy, 2015a). There is evidence globally (Center for 
Disease Dynamics, Economics and Policy, 2015b; World Health Organization, 2014) showing 
an increase in resistance of urinary E. coli isolates to commonly prescribed antimicrobials. 
There is also strong evidence to support the association between antimicrobial use and this 
development of resistance in E. coli UTI (Bergman et al., 2009; Goossens, Ferech, Vander 
Stichele, & Elseviers, 2005). A critique of the evidence is provided in the literature review 
chapter (chapter two). The evidence highlights the need for continued monitoring of AMR 
patterns in E. coli UTI, a common infection in both hospital and community settings. This 
research program aims to contribute to the body of knowledge about AMR patterns in E. 
coli UTI and use the findings to make recommendations for clinical practice, future research 
as well as development of policies targeted towards control of AMR and antimicrobial use.  
 
1.3.5 Antimicrobial resistance and One Health 
The One Health concept is described as “a worldwide strategy for expanding 
interdisciplinary collaborations and communications in all aspects of health care for people, 
animals and the environment” (Gibbs, 2014, p. 86). It is now acknowledged that the issue of 
AMR is a One Health issue recognising the connection between human, animal and 
environmental health (Australian Government, 2015; Robinson et al., 2016). Transmission of 
urinary E. coli isolates to humans has been identified to occur through environmental 
exposures including food, animal and travel (Nicolle, 2013; Robinson et al., 2016). There is 
evidence to show widespread dissemination of antimicrobial resistant urinary E. coli clones 
both within Australia and globally (Johnson et al., 2009). Also, a population-based 
surveillance study in Canada reported a significantly increased risk of isolation of urinary E. 
coli isolates with overseas travel, particularly to India, the Middle East and Africa (Laupland, 
Church, Vidakovich, Mucenski, & Pitout, 2008). Furthermore, the use of antimicrobials in 
animals as well as subsequent deposition of antimicrobial residues in the environment is 
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also driving the spread of AMR in general (Center for Disease Dynamics, Economics and 
Policy, 2015a). The increased demand for food-producing animals due to worldwide 
population growth is leading to higher use of antimicrobials in the agricultural sector, also 
favouring the development of resistance (Center for Disease Dynamics, Economics and 
Policy, 2015a). Some of the antimicrobials used in agriculture and aquaculture end up in the 
environment, adding to the burden of AMR in both animals and humans (Center for Disease 
Dynamics, Economics and Policy, 2015a; Daghrir & Drogui, 2013). A One Health approach to 
surveillance of antimicrobial resistant E. coli infections is therefore important, with 
collaboration from the medical, veterinary and agricultural sectors (Australian Government, 
2015). Although the effect of environmental exposures as well as antimicrobial use in food 
animals is important in addressing the issue of AMR, this topic is not central to the thesis 
and will not be covered further. 
 
1.3.6 Mechanisms of resistance to antimicrobial agents  
The mechanisms of AMR are multifaceted. Resistance can either be intrinsic or acquired. 
Intrinsic resistance refers to the naturally occurring resistance of bacteria to antimicrobials 
(Sefton, 2002). Some bacterial species have intrinsic resistance to one or more antimicrobial 
classes. When this occurs, the strains of that bacterial species are also resistant to all agents 
in those antimicrobial groups (Tenover, 2006). In acquired resistance, bacteria that were 
initially susceptible to an antimicrobial agent become resistant, multiply and spread under 
the selective pressure, following the use of the antimicrobial agent (Tenover, 2006). 
Acquired resistance can either be genetic or biochemical (Sefton, 2002). Genetic resistance 
can occur either from mutation or from acquiring resistant genes from other bacterial 
species. Acquisition of resistant genes may occur through genetic mechanisms such as 
conjugation, transduction or transformation (Tenover, 2006). Conjugation occurs either 
when resistance genes that contain plasmid, a type of genetic material, are transferred from 
Gram-negative bacteria to other bacteria or during the process of mating between Gram-
positive bacteria. In transduction, transfer of resistance genes between bacteria occurs via 
bacterial viruses, also known as bacteriophage. During transformation, resistant bacteria 
undergo cell lysis with release of their DNA, which is acquired and incorporated into the 
DNA fragments of susceptible bacteria (Tenover, 2006). These processes of exchange of 
genetic material that encode resistance between bacteria are the main mechanisms by 
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which many bacteria have developed resistance to multiple antimicrobial agents (Tenover, 
2006). 
 
Possible mechanisms for acquired biochemical resistance by bacteria include production of 
drug inactivating enzymes, decreased cell permeability, modification of an existing target 
and acquisition of a target by-pass system (Sefton, 2002). For example, bacteria may modify 
or change the existing target, which is described as the specific location or site the 
antimicrobial drug is designed to attach to on the bacterium (Tenover, 2006). They may also 
produce enzymes that destroy or inactivate the antimicrobial agent before it has an effect. 
Bacteria may also alter a protein channel on their cell wall or outer membrane, preventing 
the antimicrobial drug from entering the bacterial cell wall. Finally, they may use what are 
known as efflux pumps to expel the antimicrobial agent from the bacterial cell, thereby  
by-passing its target site without it having an effect on the bacteria (Tenover, 2006). 
 
Acquired AMR mechanisms in Enterobacteriaceae such as E. coli include production of 
enzymes known as β-lactamases (Paterson, 2006a). These include extended-spectrum β-
lactamases (ESBLs) such as: ‘active on CefoTaXime, first isolated in Munich’ (CTX-M) 
enzymes; AmpC β-lactamases; and carbapenemases. Other resistance mechanisms 
exhibited by Gram-negative bacteria are alterations to target enzymes and plasmid-
mediated resistance (Paterson, 2006a). Resistance to specific antimicrobials such as 
fluoroquinolones occurs by alterations to the chromosomal gene leading to changes in the 
target mechanism or by alterations to the cytoplasmic membrane efflux protein gene, 
resulting in modifications to the permeation mechanism (Dalhoff, 2012a). The development 
and spread of resistance in Enterobacteriaceae, including E. coli, threatens to create species 
that will become resistant to all currently available antimicrobials (Paterson, 2006a).  
 
1.3.7 The importance of surveillance of antimicrobial resistant E. coli UTI 
Surveillance can be defined as “systematic and continuous collection, analysis, and 
interpretation of data, closely integrated with the timely and coherent dissemination of the 
results and assessment to those who have the right to know so that action can be taken” 
(Porta, 2014, p. 239). Surveillance of AMR can therefore be described as the collection, 
analysis and interpretation of data on antimicrobial resistant bacteria, including 
antimicrobial use. Evidence shows that judicious use of antimicrobials may reduce AMR, 
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hence surveillance of AMR should be undertaken in conjunction with data collection on 
antimicrobial use (World Health Organization, 2002). Antimicrobial resistance surveillance is 
the foundation for evaluating the burden of resistance and for providing information for 
action in support of strategies developed at the local, national, regional and global levels 
(World Health Organization, 2015a). The main aim of undertaking AMR surveillance is to 
detect changes in resistance of organisms to antimicrobial agents and inform clinicians, 
policy makers and the general public about such changes as soon as possible (Bax et al., 
2001). Surveillance is vital to understanding AMR, as the collection of reliable data can help 
guide actions aimed at prevention and control of AMR spread and also evaluate the 
outcomes of interventions directed at tackling the problem (World Health Organization, 
2014). Surveillance is also essential in monitoring the public health impact of AMR and 
antimicrobial use. Furthermore, dissemination of information obtained from AMR 
surveillance studies can educate the public and consumers about rational antimicrobial use 
(Bax et al., 2001).  
 
Given the frequency of occurrence of UTI both in hospital and community settings, with an 
increasing trend in resistance to urinary E. coli globally (World Health Organization, 2014), it 
is essential to undertake resistance surveillance of this bacterium. The Infectious Diseases 
Society of America also recommends undertaking surveillance of E. coli and other UTI 
causing pathogens to monitor changes in AMR (Warren et al., 1999). Antimicrobial 
resistance has been identified as a predictor of treatment failure, especially in patients with 
hospital-acquired UTI (Koningstein et al., 2014), further emphasising the need for continued 
monitoring of resistance patterns in E. coli UTI. Surveillance of resistance in urinary E. coli 
isolates is important in understanding the extent and significance of the problem. Global 
surveillance is vital as evidence shows that resistance genes are able to cross international 
borders (Bax et al., 2001). National level surveillance is also essential as the data can inform 
policy decisions such as updates to antibiotic guidelines, as well as identify priority areas for 
public health action; for example, regulatory measures for antimicrobial use (Shaban, 
Cruickshank, & Christiansen, 2013). As most UTIs are treated empirically with treatment 
based on the local susceptibility patterns of the common causative bacteria, surveillance of 
resistant E. coli at the local level is important. Data obtained from local surveillance are 
most highly beneficial for clinicians who require these data to guide empirical therapy, 
because resistance problems vary based on the hospital type and patient case mix (Bax et 
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al., 2001). For example, published studies have shown that urinary E. coli resistance to 
trimethoprim-sulphamethoxazole can vary considerably by geographic region (Gupta, Sahm, 
Mayfield, & Stamm, 2001; Sahm, Thornsberry, Mayfield, Jones, & Karlowsky, 2001) 
emphasising the importance of local level surveillance.  
 
A major advancement in AMR surveillance is the increasing use of routine susceptibility data 
from the microbiology laboratory (Cornaglia et al., 2004). These data represent an 
inexpensive and easily accessible source for AMR information. Data can be electronically 
downloaded directly from the microbiology laboratory database and can be linked to 
population denominators (Cornaglia et al., 2004). Furthermore, WHO recognises the 
importance of laboratory-based surveillance in the control of AMR (World Health 
Organization, 2001). Urine cultures represent the most common type of culture processed 
by the microbiology laboratory, accounting for 24% to 40% of submitted cultures to the 
laboratory, with 80% of these cultures sent from outpatient settings (Wilson & Gaido, 2004). 
Therefore analysis of this large and widely accepted laboratory-based data source provides 
an opportunity for AMR surveillance in urinary E. coli isolates.  
 
To successfully address AMR, it is important to monitor resistance prevalence and incidence. 
Local surveillance of resistance will provide current information on resistance prevalence 
and incidence (Levy & Marshall, 2004). Specifically, treatment of patients with 
antimicrobials should be tailored to the local resistance levels. This research program 
provides an in-depth analysis of routine susceptibility data obtained from a territory-level 
microbiology laboratory and makes available information on changes in urinary E. coli 
resistance, thereby helping in the development of policies aimed at control of AMR and 
providing recommendations for antimicrobial use in regards to UTI.  
 
1.3.8 Current status of AMR surveillance in Australia 
In June 2015, Australia released its first national AMR strategy in response to the increasing 
problem of AMR, with the goal of minimising the emergence and spread of AMR and 
ensuring the continued availability of antimicrobials which are effective (Australian 
Government, 2015). Prior to the release of the strategy, AMR supervision in Australia was by 
the Antimicrobial Resistance Standing Committee which was formed in 2012 (Shaban et al., 
2013). This committee recommended: improvement in the current systems of data 
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gathering; reporting on antimicrobial use and AMR patterns; and the establishment of a 
national coordinating centre (Shaban et al., 2013), which are all included in the current 
strategy. The seven objectives as they appear in the new national AMR strategy (Australian 
Government, 2015, p.5) are:  
1) Increase awareness and understanding of antimicrobial resistance, its implications, and 
actions to combat it through effective communication, education and training. 
2) Implement effective antimicrobial stewardship practices across human health and 
animal care settings to ensure the appropriate and judicious prescribing, dispensing and 
administering of antimicrobials. 
3) Develop nationally coordinated One Health surveillance of antimicrobial resistance and 
antimicrobial usage. 
4) Improve infection prevention and control measures across human health and animal 
care settings to help prevent infections and the spread of antimicrobial resistance. 
5) Agree a national research agenda and promote investment in the discovery and 
development of new products and approaches to prevent, detect and contain 
antimicrobial resistance. 
6) Strengthen international partnerships and collaboration on regional and global efforts to 
respond to antimicrobial resistance. 
7) Establish and support clear governance arrangements at the local, jurisdictional, 
national and international levels to ensure leadership, engagement and accountability 
for actions to combat antimicrobial resistance (Australian Government, 2015, p.5). 
 
The Australian Commission on Safety and Quality in Health Care (ACSQHC) has the role of 
implementing Australia’s national surveillance of resistance and antimicrobial use in human 
health (Australian Government, 2015). In June 2016, the ACSQHC released the first national 
report on antimicrobial use and resistance in human health with data obtained using the 
new Antimicrobial Use and Resistance in Australia (AURA) Surveillance System (Australian 
Commission on Safety and Quality in Health Care, 2016). The surveillance system brings 
together existing initiatives to allow integrated analysis and national reporting of AMR and 
antimicrobial use data (Australian Commission on Safety and Quality in Health Care, 2016). 
The AURA report integrates data from public and private facilities, as well as the community, 
and the findings will be used to inform clinical and public health decision making as well as 
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monitor and evaluate the effectiveness of interventions (Australian Commission on Safety 
and Quality in Health Care, 2016).  
 
Although high-quality and coordinated surveillance of AMR and antimicrobial use in both 
hospital and community settings, identified in objective three of the national strategy, is a 
key priority to tackling the worldwide issue of AMR, surveillance alone cannot solve the 
issue. The other six objectives in the national strategy are also important to minimising 
further resistance development and spread. Although they are not the focus of this research 
program, these objectives are essential. 
 
 To ensure a targeted approach to surveillance of AMR, it is important to focus on priority 
organisms (Australian Government, 2015). Escherichia coli is one of the seven bacteria of 
international concern identified by the WHO (World Health Organization, 2014). This 
bacterium is also listed as a priority organism for targeted surveillance in human health in 
the Australian national resistance strategy because of its impact in both hospital and 
community settings (Australian Government, 2015), and is therefore the bacterium 
evaluated in this research program. 
 
A well conducted research study aimed to provide AMR data specifically in urinary E. coli at 
the territory level will help address some of the current gaps, including those outlined in the 
national strategy, hence this research program. The findings of this research program will 
contribute to future national surveillance reports, further strengthening the quality of AMR 
reporting. 
 
1.4 The doctoral research program 
This doctoral research program comprises three separate but interrelated studies focused 
on providing knowledge about AMR in urinary E. coli infections. In the first study, a 
systematic review and meta-analysis of observational studies published in the last ten years, 
investigating ciprofloxacin resistance in community- and hospital-acquired E. coli UTI was 
undertaken. This provided a broad context of the issues around AMR in E. coli UTI with the 
opportunity for me to address some of the issues using my own dataset in the subsequent 
two studies. The second study described the AMR temporal trends of E. coli UTI over five 
years, from January 2009 to December 2013, at the Canberra Hospital (an Australian tertiary 
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level hospital) and compared the prevalence of resistance between hospital- and 
community-acquired E. coli UTI. The second study also evaluated trends and seasonal 
variation in antimicrobial use at the Canberra Hospital. The third study evaluated the 
incidence and risk of antimicrobial resistant E. coli UTI in a cohort of ACT residents over the 
same five-year period.  
 
The three studies utilised three different datasets. Study one utilised data from published 
literature. Study two and study three utilised data from a territory microbiology laboratory, 
specifically ACT Pathology. Study two also utilised supplementary data on antimicrobial use 
for the Canberra Hospital. There is no similar published research in Australia. 
 
1.4.1 Significance of the research 
These three studies are both significant and timely given the recent release of Australia’s 
first AMR strategy (Australian Government, 2015), with this research program aligning with 
objective 3 of the national strategy, which is the development of nationally coordinated One 
Health surveillance of AMR and antimicrobial use. Further, the global action plan on AMR 
was recently endorsed at the May 2015 World Health Assembly calling all countries to 
implement national strategies within the next two years (World Health Organization, 
2015a). Five objectives were outlined at the Assembly, one of which is to strengthen the 
knowledge and evidence base of AMR through surveillance and research. This research 
program aligns with that objective. The academic community has been identified as having 
an important role to play in generating knowledge on AMR incidence and prevalence, which 
can be translated into practice (World Health Organization, 2015a). 
 
The rationale for undertaking this research program is, first, to contribute internationally to 
the evidence base of AMR by providing data on global estimates of resistance to commonly 
used antimicrobials in the treatment of E. coli UTI. Data from countries worldwide may 
justify reconsidering the empirical use of ciprofloxacin in countries where it is recommended 
as first choice for UTI treatment and making recommendations for strategies to counteract 
the development of further resistance. The second major significance of this research 
program is the potential for use of the study outcomes to inform decisions on the treatment 
of patients with UTI based on local resistance patterns. Antibiotics prescribed for UTI are 
based on national treatment guidelines but local resistance patterns should be used to 
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refine therapy due to the regional variability of AMR (Gupta, Sahm, et al., 2001; Schito et al., 
2009). One of the five essential strategies for antimicrobial stewardship in hospitals, 
according to the ACSQHC, includes modifying the local prescribing guidelines according to 
local organisms and susceptibility patterns (McKenzie, Rawlins, & Del Mar, 2013). Third, the 
findings also have the potential to guide therapeutic recommendations for UTI based on site 
of acquisition. Although the effects of AMR, such as increased risks of complications and 
longer hospital stay, are mainly felt in healthcare facilities, the greatest use of antimicrobials 
occurs in the community (Coxeter, Looke, Hoffmann, Lowe, & Del Mar, 2013). Comparing 
resistance in hospital- and community-acquired UTI may provide satisfactory data to make 
both AMR control policy and therapeutic recommendations for UTI based on site of 
acquisition. The fourth major significance of this research program is the potential to 
provide information on patient risk factors associated with resistant E. coli UTI and use this 
information to target specific patient groups that are at risk of developing resistant E. coli 
UTI, thereby preventing further development of resistance. Fifth, the research program will 
contribute to improving the quality of analysis of microbiological laboratory data which are 
not collected primarily for research purposes, and proffer approaches to addressing some of 
the methodological challenges in the synthesis of these data. 
 
Resistance to frequently prescribed antimicrobials used for treating UTI has adverse health 
consequences, with a higher risk of patient morbidity and mortality, further highlighting the 
need for research in this area. Antimicrobial resistance data is useful in understanding 
resistance trends, determining best treatment options for patients, informing health policy, 
identifying important areas for interventions, and monitoring the effect of interventions to 
contain further spread of resistance (World Health Organization, 2012). In summary, the 
outcomes of these studies will provide information on global and local resistance trends 
which will serve as data for action towards development and implementation of AMR 
control policies; identify areas for interventions; contribute methodologically to synthesis of 
resistance data from the microbiological laboratory, and also inform the treatment 
guidelines for UTI both internationally and nationally. As the focus of the thesis is on 
microbiological laboratory data, which is only one aspect of what informs therapeutic 
management of E. coli UTI, the thesis will only inform some aspects of decision-making 
about prescribing.  
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1.4.2 Study aims 
The overall research program aim is to contribute to the body of knowledge about AMR in E. 
coli UTI. The individual study aims are to:  
1) Systematically review the literature and conduct a meta-analysis of observational 
studies published in the last ten years, investigating ciprofloxacin resistance in 
community-acquired and hospital-acquired E. coli UTI. 
2) (a) Evaluate AMR temporal trends and compare the prevalence of AMR in hospital-
acquired and community-acquired E. coli UTI at the Canberra Hospital over a five-year 
period. 
(b) Evaluate trends and seasonal variation in antimicrobial use at the Canberra Hospital 
over a five-year period. 
3) Evaluate the incidence and risk of antimicrobial resistant E. coli UTI in a cohort of ACT 
residents over a five-year period. 
Each aim will be addressed in a separate study. 
 
1.4.3 Study one – Systematic review of ciprofloxacin resistance in E. coli UTI 
Background:  
Ciprofloxacin is the most commonly prescribed fluoroquinolone for UTI and during the last 
ten years urinary E. coli resistance to ciprofloxacin has increased (Mcquiston, Rosborg, 
Sternhagen, Llor, & Bjerrum, 2013). The fluoroquinolone class of antimicrobials is also listed 
as one of the highest priority critically important class of antimicrobial agents because they 
are used in the treatment of more serious infections, for example, septicaemia. Therefore, 
resistance to fluoroquinolones can have significant clinical implications. Systematic and 
accurate global data about the prevalence of ciprofloxacin resistance in hospital- and 
community-acquired E. coli UTI are absent. These data may guide effective empirical 
therapy of UTI internationally and also make available information to assist with control of 
resistant bacteria. In addition, the pooled data can provide a baseline for future 
interventions to be measured. A systematic review of the literature also has the potential to 
identify gaps in published AMR studies which can be addressed in the other two research 
studies. 
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Research question:  
1) For studies published from 1st January 2004 to 31st December 2014, what is the 
prevalence of ciprofloxacin resistance in community-acquired E. coli UTI compared to 
hospital-acquired infections? 
 
Research hypotheses:  
1) It was hypothesised that at an international level there would be a higher prevalence of 
ciprofloxacin resistance in hospital-acquired E. coli UTI than community-acquired 
infections.  
2) It was hypothesised that ciprofloxacin resistance would be higher in developing 
countries compared to developed countries.  
 
1.4.4 Study two – Prevalence of antimicrobial resistance in E. coli UTI 
Background:  
Urinary E. coli isolates are becoming increasingly resistant to current antimicrobials, hence 
research examining resistance patterns is paramount to inform effective treatment 
regimens and improve clinical outcomes of patients. No Australian data that directly 
compare resistance patterns over time for hospital-acquired and community-acquired UTI 
were located after an extensive literature search. Comparing resistance prevalence in 
hospital- and community-acquired UTI may provide data to make therapeutic 
recommendations for UTI based on site of acquisition. Despite the evidence to support the 
association between antimicrobial use and development of resistance, to my knowledge 
there are no published studies demonstrating the association between antimicrobial use 
and AMR in E. coli UTI in Australia, hence additional data on antimicrobial use for Canberra 
Hospital were obtained. The antimicrobial use data were found to be for all infections, not 
only UTI, and could not be linked to the AMR data. Hence the analysis of supplementary 
antimicrobial use data is included separately and provides results of the trends and seasonal 
variation in antimicrobial use at the Canberra Hospital. 
 
Research questions:  
1) For the period January 2009 to December 2013, does the prevalence of AMR differ for 
hospital-acquired E. coli UTI when compared with community-acquired UTI at the 
Canberra Hospital? 
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2) For the period January 2009 to December 2013, what is the AMR trend of E. coli UTI at 
the Canberra Hospital? 
3) For the period January 2009 to December 2013, what is the trend and seasonal variation 
in antimicrobial use at the Canberra Hospital? 
 
Research hypotheses:  
1) It was hypothesised that at the Canberra Hospital there would be a higher prevalence of 
AMR in hospital-acquired E. coli UTI than community-acquired E. coli UTI.  
2) It was hypothesised that at the Canberra Hospital there would be an increasing trend in 
resistance prevalence over the five-year period. 
3) It was hypothesised that at the Canberra Hospital there would be an increasing trend in 
antimicrobial use over the five-year period. 
 
1.4.5 Study three – Incidence of antimicrobial resistance in E. coli UTI 
Background:  
In Australia, the Australian Group on Antimicrobial Resistance (AGAR) reports only on 
prevalence without providing any estimates of incidence. There are no available Australian 
data to provide information on the incidence of antimicrobial resistant UTI over time. 
Prevalence data provide information on disease burden, that is, how common antimicrobial 
resistant UTI is. Conversely, incidence data provide information on the risk of disease 
occurrence, which can help identify specific patient groups that are at risk of developing 
antimicrobial resistant E. coli UTI. Obtaining both incidence and prevalence data are 
important because they provide information about the health status of a population and 
contribute to disease management decisions.  
 
Research questions:  
1) For the period January 2009 to December 2013, what is the incidence and risk of 
antimicrobial resistant E. coli UTI in a cohort of ACT residents?  
 
Research hypotheses:  
1) It was hypothesised that there would be an increasing incidence of resistance in a cohort 
of ACT residents with E. coli UTI over the five-year period.  
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1.5 Thesis structure 
This thesis is divided into seven chapters. It is a thesis by publication and contains three 
manuscripts (two peer reviewed publications in Q1 ranking (Scimago, 2016) journals – 2015 
Impact Factors for publications one and two are 2.690 and 3.234 respectively). A third 
manuscript is being revised for resubmission to the Medical Journal of Australia (Q1 ranking 
journal, 2015 Impact Factor of 3.369) based on feedback received from the Journal. 
Appendix A1 provides a list of publications included in the thesis. For ease of reading, 
manuscripts are inserted in a form consistent with non-published sections and there is a 
single reference list at the end of the thesis. The tables and figures are numbered 
consecutively in each chapter to also allow for ease of reading. The thesis is solely my work. 
Given that this is a thesis by publication, for the published papers the contribution of each 
author is clearly articulated (Appendix A2). Excluding the published papers, reference to 
myself is in the first person singular everywhere else in the thesis. Published manuscripts 
are provided as appendices in the format they appear online (Appendices B and C).  
 
Chapter two comprises an extensive literature review, which begins with a summary of the 
epidemiology, aetiology, types and treatment of UTI. International and national literature is 
used to describe in detail the issue of AMR with its consequent health and financial 
implications, especially in regards to E. coli UTI. This chapter also explores the complex 
nature of AMR given the multiple factors that may propagate resistance development in E. 
coli UTI, with a particular emphasis on antimicrobial use. Evidence to support this is 
obtained from a broad range of peer reviewed and grey literature. The final section of this 
chapter highlights the gaps in knowledge and the key areas to be addressed in the research 
program. 
 
Chapter three presents the methodology of the three studies. While this chapter provides a 
comprehensive discussion of the methods used in undertaking the research, a brief 
presentation of the methods is also provided in each of the manuscripts given that it is a 
thesis by publication. Hence, there may be some repetition of the methods in the thesis. 
Chapter three includes a discussion of the methodological considerations taken into account 
during the conduct of the studies and provides details of the data collection processes, data 
analysis and ethical conduct.  
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The fourth chapter comprises the results of study one as a published systematic review and 
meta-analysis of observational studies investigating ciprofloxacin resistance in community- 
and hospital-acquired E. coli UTI. The review has been published (Fasugba, Gardner, 
Mitchell, & Mnatzaganian, 2015) and is incorporated into this thesis in its published version 
(section 4.2 and Appendix B).  
 
Chapter five provides the findings of the second study, which compares the prevalence of 
resistance in community- and hospital-acquired E. coli UTI over five years at the Canberra 
Hospital. Study two also describes the AMR temporal trends and seasonal variation of E. coli 
UTI over the same period. Study two has been published (Fasugba et al., 2016) and is 
incorporated into the thesis in its published version (section 5.2 and Appendix C). This 
chapter also reports on the analysis of supplementary antimicrobial use data over the study 
period at the Canberra Hospital.  
 
The sixth chapter details the results of study three, which investigates the incidence and risk 
of resistance to E. coli UTI in a cohort of ACT residents. The study also provides information 
of the incidences of multidrug-resistant, extensively drug-resistant and pandrug-resistant E. 
coli UTI. The manuscript reporting the findings of study three was finalised, submitted to 
and reviewed by the Medical Journal of Australia while the thesis was under examination. 
The journal review suggested that the manuscript be revised as a short report focusing on 
the incidence findings. Given the brevity of a short report, the detailed, previously 
submitted version of the manuscript has been included in the thesis. A short report focusing 
on the incidence findings is being prepared for resubmission to the Medical Journal of 
Australia.  
 
Chapter seven presents the discussion, which synthesises the overall results, links together 
the three studies and highlights their contribution to knowledge in regards to controlling 
antimicrobial resistant urinary E. coli infections. The strengths and limitations of the 
research are provided. The clinical and policy implications of the research are stated. This 
chapter concludes by providing a summary of recommendations for future research.  
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1.6 Summary 
This chapter introduced the thesis topic of AMR in E. coli UTI. To adequately control AMR 
levels, it is necessary to monitor AMR prevalence and incidence and provide timely data to 
influence action. Surveillance of AMR is essential to understanding resistance trends, 
developing therapeutic guidelines and assessing the success of interventions. Collection, 
analysis and evaluation of AMR data in urinary E. coli isolates will help to better understand 
the problem of AMR in E. coli, support ongoing activities at the international and local level 
and inform activities aimed at controlling resistance in this pathogen. This will be the focus 
of the three studies in this research program. The findings will provide information that can 
be applied at an international level on ciprofloxacin resistance in E. coli UTI in various world 
regions and provide baseline data for future interventions to be measured. These studies 
also have the potential to inform decisions on the treatment of patients with UTI based on 
local resistance patterns and may influence therapy for UTI based on site of acquisition.  
 
The next chapter presents a detailed review of the literature on AMR in E. coli UTI with 
evidence of the gaps in knowledge as they relate to Australia. 
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Chapter 2: Literature review  
 
2.1 Overview 
In this chapter a review of the international and national published and grey literature about 
the thesis subject, AMR in E. coli UTI, is provided with a critique of the quality of analysis 
and reporting in the existing literature. The evidence from the literature is used to situate 
the thesis topic within the broader context of AMR. In order to contain the thesis subject, 
the topic of ‘One Health and AMR’, which was briefly discussed in the introduction chapter, 
is not considered in the literature review. The specific objectives of the literature review are 
to: (1) describe the epidemiology, health and economic implications, aetiology, types and 
treatment of UTI; (2) quantify antimicrobial use in humans both globally and in Australia; (3) 
discuss the health and economic implications of AMR in general and specifically in 
antimicrobial resistant E. coli UTI as well as describe global and Australian AMR patterns and 
trends in E. coli infections; (4) demonstrate the potential link between antimicrobial use and 
resistance in humans; (5) highlight the importance of the microbiology laboratory in AMR 
surveillance; and (6) identify the gaps in evidence as related to global and Australian 
surveillance of antimicrobial resistant E. coli UTI.  
 
2.2 Search strategy 
Three broad searches of the literature were performed. First, the electronic bibliographic 
databases – EMBASE, MEDLINE, PubMed and CINAHL – were searched using the following 
combination of terms: ‘antimicrobial resistance’; ‘antibiotic resistance’; ‘Escherichia coli’; 
‘urinary tract infections’; ‘antimicrobials’; ‘antimicrobial use’, and ‘surveillance’. Searches 
were undertaken for words in the title, keywords or abstract. Medical Subject Heading 
(MeSH) terms were also used: ‘Escherichia coli’ [MeSH]; ‘Drug Resistance’ [MeSH]; ‘Urinary 
Tract Infections’ [MeSH]. Second, another search of the electronic bibliographic databases 
was conducted to obtain information specific to Australia, hence the addition of the search 
term ‘Australia’ was used in conjunction with the other aforementioned search terms. Third, 
where there was a lack of information on a specific topic in the peer reviewed literature, 
information was sourced from grey literature by searching websites of government 
organisations and health agencies; in particular, a paucity of published literature on AMR in 
Australia was identified. Websites of the ACSQHC, AGAR, territory and state governments 
were searched for relevant information. In addition, where seminal international reports 
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from notable organisations like the WHO were cited in the peer reviewed literature, these 
grey literature were also sourced to obtain important information relevant to the literature 
review.  
 
As a result of variation in the use of the terms ‘antimicrobial’ and ‘antibiotic’, search 
strategies utilised both terms. The reference lists of papers retrieved were screened to 
locate additional papers. There were no time limits applied to the search strategy, as 
preliminary searches identified that limiting the search period to the last ten to fifteen years 
excluded relevant studies which have contributed significantly to describing the 
epidemiology of UTI, and also studies that have contributed to gaining a better 
understanding of the changes in AMR patterns over time, their impact and association with 
antimicrobial use. Search results were limited to studies published in the English language 
and studies involving humans. To focus the discussion in this chapter and address the 
specific objectives of the literature review, I therefore included only papers: describing the 
epidemiology, health and economic implications, aetiology, types and treatment of UTI; 
quantifying antimicrobial use in humans both globally and in Australia; discussing the health 
and economic implications of AMR in E. coli UTI; describing global and Australian AMR 
patterns and trends in E. coli infections; demonstrating the potential link between 
antimicrobial use and resistance in humans; and discussing the importance of the 
microbiology laboratory in AMR surveillance. 
 
In total, 28,991 peer reviewed papers were retrieved from the combined electronic 
database searches. After the exclusion of duplicates, 7,102 papers were remaining. Initial 
review of the titles and abstracts of these papers was undertaken. All papers deemed 
irrelevant to the objectives of the literature review were excluded. For example, studies 
describing diagnostic testing of UTI and modelling of resistance mechanisms and virulence 
genes in E. coli isolates were not included. In total, 6,484 papers were excluded with 618 
papers remaining. Further review of the remaining 618 papers was undertaken and studies 
that described AMR in non-E. coli isolates (such as Klebsiella pneumoniae) and non-urinary 
E. coli isolates (such as intestinal or bloodstream isolates) were excluded. These types of 
studies were excluded to ensure the review was focused on describing resistance in E. coli 
UTI. The final number of peer reviewed papers included in the literature review was 85. 
Searches of government organisation and international health agency websites for grey 
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literature retrieved 19 relevant papers for inclusion in the literature review. Hence, the final 
number of papers included in the literature review was 104. 
 
2.3 Urinary tract infections 
This section first describes the epidemiology of UTI, providing incidence and prevalence data 
on international and national estimates of UTI. The risk factors as well as population groups 
most affected by UTI are highlighted. Second, the health and economic implications of UTI 
are discussed, highlighting the impact of UTI on quality of life as well as the adverse health 
outcomes resulting from this infection. The economic burden associated with UTI is also 
stated. Third, the section also provides an overview of the aetiology and types of UTI. The 
final part of this section discusses the treatment of UTI and the current international and 
national therapeutic recommendations are outlined. 
 
2.3.1 Epidemiology  
Urinary tract infections are one of the most common bacterial infections affecting people in 
hospitals as well as in the community (Laupland, Ross, Pitout, Church, & Gregson, 2007). 
Data from the combined National Ambulatory Health Care Surveys in the US for 2009–2010 
showed that UTI accounted for approximately 9.8 million visits to ambulatory care settings 
such as primary care, outpatient and emergency departments (Centers for Disease Control 
and Prevention & National Center for Health Statistics, 2015). This may be an 
underestimation in the US as the data are not based on all ambulatory care visits. In the UK, 
prevalence of UTI was estimated as 6.0% from 2008 to 2010, although this is based on data 
from children aged five years and below attending general practice clinics (O’Brien, 
Edwards, Hood, & Butler, 2013). Urinary tract infection was said to be the third most 
common healthcare-associated infection (HAI) (19% of all HAIs) in the 2011–2012 point 
prevalence survey of HAIs in Europe (European Centre for Disease Prevention and Control, 
2013). In Beijing, China, UTI was noted to be the second most frequently identified HAI in 
2014, accounting for 15% of all HAIs (Liu, Wu, Cai, & Zhou, 2016). A limitation of most of 
these studies is that the majority of national data have either estimated UTI prevalence or 
incidence in specific subpopulations such as females or in particular settings; that is, 
healthcare-associated UTI, further highlighting the difficulty with global estimation of UTI. 
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In Australia, there are no available national overall incidence and prevalence data on UTI. As 
it is not a notifiable disease, estimates are difficult to determine. Despite this limitation, 
estimates of UTI incidence in Australia were obtained from studies identified from the 
literature search. Results from Western Australia showed the average monthly incidence of 
Staphylococcus saprophyticus UTI was 152 per 1000 UTI in 1993 (Schneider & Riley, 1996). 
Another study conducted in New South Wales in children below 15 years showed an 
increase from 0.5 to 0.9 per 1000 children in the age standardised annual incidence of UTI 
between 1981 and 1994 (Craig, Irwig, Knight, & Roy, 1997). These studies were conducted 
over two decades ago. Data were obtained from a single private pathology laboratory in the 
first study and a specific age group from one state in the second study, thereby limiting 
generalisability of these findings to the Australian population more widely. A recent study 
from 82 hospitals and 17 aged care facilities in Australia reported a point prevalence of 1.4% 
and 1.5% respectively for healthcare-associated UTI (Mitchell, Fasugba, Beckingham, 
Bennett, & Gardner, 2016). An incidence of 1.73% was reported from eight hospitals during 
a four-year period also for healthcare-associated UTI (Mitchell, Ferguson, Anderson, Sear, & 
Barnett, 2016). The prevalence or incidence of community-acquired UTI was not 
investigated in these studies.  
 
Females are more predisposed to UTI as bacteria easily enter the bladder via the short 
urethra with reported incidence rates being higher than males. For example, in men below 
50 years of age, the incidence of UTI has been approximated to be 0.0005–0.0008 per 
person-year (Seminerio, Aggarwal, & Sweetser, 2011) compared with an incidence of  
0.5–0.7 per person-year in young women (Hooton et al., 1996). Although the latter study 
was prospective, with over 96% of participants followed up, these results are not 
generalisable to all young women given the strict inclusion criteria. The inclusion criteria 
included women who were about to begin using a new contraceptive method or women 
who started contraception within six weeks of being enrolled into the study and had not 
used this contraceptive method in the last three months. Urinary tract infections not only 
affect young women and men but also the very young and old, demonstrating the presence 
of this infection across all age groups. In fact, UTI is considered high on the list of differential 
diagnosis for an infant presenting with fever in the first few months of life. A prevalence of 
9% was reported in infants less than 60 days old in the US. The authors acknowledge that 
their findings may not be generalisable to other clinical settings because study participants 
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were patients evaluated only in the emergency department (Zorc et al., 2005). Recent 
findings from a prospective study of 598 elderly women aged 65–80 years reported a 
prevalence of about 17% (n=99) (Marques et al., 2012). In this study, no information was 
provided on the follow-up rate with the potential for underestimation of UTI prevalence if a 
large proportion of participants were lost to follow-up.  
 
The major risk factors for UTI include the use of spermicidal agents, frequent sexual 
intercourse, a prior UTI episode and having a first-degree female family member with a 
history of UTI (Hooton, 2012). Particular groups of people who have a higher risk of 
developing a UTI include diabetics, pregnant women, the elderly, people with multiple 
sclerosis, those with underlying urologic anomalies, as well as immune compromised 
patients such as those with human immunodeficiency virus (HIV) and cancer (Foxman & 
Brown, 2003).  
 
Although an accurate estimate of the worldwide incidence or prevalence of UTI is difficult to 
determine, evidence shows that UTI is an infection which commonly affect females and 
males, including children and the elderly.  
 
2.3.2 Health and economic implications of UTI  
Urinary tract infections pose significant health and economic implications to society. They 
are a cause of morbidity in the community and also in the hospital (Rogers & Peterson, 
2011). Urinary tract infections impact considerably on the quality of life of those affected. 
An investigation of the impact of UTI on the health-related quality of life of female nurses in 
Taiwan showed that symptoms of UTI, such as urinary frequency and urgency, negatively 
impacted on the quality of life of the participants, especially in relation to their physical 
health (Liao et al., 2009). Recurrent episodes of infection also occur. Recurrent infection 
may be either re-infection, caused by a new infecting organism, or relapsing infection, 
caused by the same organism present before therapy. Relapse may occur either because the 
infecting organism was not completely eradicated from the genitourinary tract by 
antimicrobial therapy or because of re-infection by a persistent colonizing strain in the gut 
reservoir (Nicolle, 2002). In a cohort study of 113 women enrolled at the University of 
Michigan in the US, 27% (n=30) experienced a recurrent infection within six months of the 
first infection (Foxman, 1990). Determination of recurrence was based on review of medical 
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records which may not have sufficiently documented information on UTI, thereby 
underestimating the recurrence rates.  
 
Significant adverse health outcomes may occur, especially in people who have a higher risk 
of developing a UTI, such as pregnant women and immunocompromised patients. For 
example, there is a greater risk of development of pyelonephritis and pre-eclampsia in 
pregnant women (Matuszkiewicz-Rowińska, Małyszko, & Wieliczko, 2015). 
Immunocompromised patients, for example patients undergoing organ transplant and those 
with HIV, have a higher rate of bacteremia which occurs when UTI spread to the 
bloodstream (Tolkoff-Rubin & Rubin, 1997). A retrospective study of UTI patients presenting 
to an emergency department in Israel in 2004 reported the presence of bacteremia in 15% 
of patients with a UTI (Bahagon, Raveh, Schlesinger, Rudensky, & Yinnon, 2007). In patients 
presenting with bacteremic UTI, the 30-day all-cause mortality rate can be as high as 25% 
(Hounsom, Grayson, & Melzer, 2011). This may be an underestimation as patients with 
septicaemia who did not have a blood culture taken were excluded from the study 
(Hounsom et al., 2011). Factors such as age of patient and presence of underlying medical 
conditions influence the progression to mortality in patients with bacteremic UTI. If 
antimicrobial treatment is delayed, this may negatively affect the patient’s outcome 
(Foxman, 2002; Hounsom et al., 2011; Van Nieuwkoop et al., 2010). When UTI is not 
associated with mortality, patients may require additional stay in hospital of up to four days, 
which places a significant economic burden on the health system (Mitchell, Ferguson, et al., 
2016).  
 
The economic burden of UTI is substantial, primarily due to the frequency of occurrence of 
UTI (Foxman, 2002). A case control study of UTI in female college students found that each 
episode of UTI resulted, on average, in 6.1 days of symptoms, 2.4 restricted activity days, 1.2 
work or class days lost including 0.4 bed days (Foxman & Frerichs, 1985). Although this study 
was conducted over thirty years ago, it was identified from the literature search as the study 
primarily cited, representing seminal work undertaken in this area with no other studies 
providing such data to date. Given the study population, the findings may not be 
generalisable to all people. Estimation of costs is based on physician visits, antimicrobial 
therapy, laboratory diagnosis, hospitalisation as well as non-medical costs attributed to 
work days lost and morbidity (Foxman, 2002). In the US, it is estimated that over $1 billion is 
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expended for community-acquired UTI and $451 million for healthcare-associated UTI 
respectively (Hsueh et al., 2011; Jacobsen, Stickler, Mobley, & Shirtliff, 2008). In Italy, the 
mean yearly cost per patient for the diagnosis and treatment of UTI was estimated to be 
€229, with antimicrobial therapy identified as contributing the most to the total cost (Ciani, 
Grassi, & Tarricone, 2013). This cost estimate was deemed to be conservative given the 
model assumption that consumption of healthcare resources was constant over the study 
period as well as the exclusion of indirect costs including loss of productivity (Ciani et al., 
2013). Annual estimates from Ireland are approximately €19.2 million at the national level 
and this is said to cover general practice consultations, antimicrobial therapy and laboratory 
costs (Callan et al., 2014). The cost estimates for UTI reported in this section should be 
interpreted in relation to the varying population sizes for the countries mentioned. In 
Australia, it is estimated that approximately 380,600 extra bed-days are used in public 
hospitals each year by patients acquiring a UTI in hospital (Mitchell, Ferguson, et al., 2016).  
 
The health and economic implications of a potentially preventable disease such as UTI are 
considerable, which demands further investigation. Especially of importance is the use of 
antimicrobials for the treatment of this common infection, with an increase in the risk of 
patients developing antimicrobial resistance. This research program, which evaluates AMR 
in UTI, has the potential to inform policy making that may improve health and economic 
outcomes for patients and the health system as a whole. 
 
2.3.3 Aetiology and types of urinary tract infections 
Over 80% of UTIs are caused by E. coli (Nicolle, 2008; Rogers & Peterson, 2011). This Gram-
negative bacterium belongs to the Enterobacteriaceae family, which comprises Gram-
negative bacteria responsible for important hospital- and community-acquired infections 
(Australian Group on Antimicrobial Resistance, 2011). The remaining 20% are caused by 
other bacteria in the Enterobacteriaceae family such as Klebsiella, Proteus and Enterobacter 
species as well as other pathogens, which include Staphylococcus saprophyticus, 
Enterococcus species, Group B streptococcus and Pseudomonas aeruginosa (Mazzulli, 2012; 
Ronald, 2002).  
 
Urinary tract infections can be classified based on location of UTI acquisition and provision 
of healthcare services, into either community-acquired UTI or the broad category of 
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healthcare-associated UTI, which includes hospital-acquired infections. Classification based 
on location of infection acquisition is discussed in detail in the methods chapter as this is an 
important methodological consideration. Subsequent paragraphs in this section will focus 
specifically on the types of UTI based on anatomical and clinical classification.  
 
Urinary tract infections can be classified anatomically depending on the part of the urinary 
tract affected. Infection of the lower urinary tract affecting the bladder is referred to as 
cystitis. Upper urinary tract infection involving the renal tissue is referred to as 
pyelonephritis (Flores-Mireles, Walker, Caparon, & Hultgren, 2015; Kumar, Dave, Wolf, & 
Lerma, 2015; Lichtenberger & Hooton, 2008). Cystitis and pyelonephritis can be further 
classified clinically into uncomplicated or complicated UTI (Kumar et al., 2015), as discussed 
in the next paragraph.  
 
The clinical grouping of uncomplicated and complicated UTI depends on the host condition 
(Nielubowicz & Mobley, 2010). Uncomplicated UTI affects otherwise healthy individuals 
presenting, for example, as uncomplicated cystitis and uncomplicated pyelonephritis 
(Nicolle, 2008). Patients with uncomplicated UTI have no evidence of structural 
abnormalities of the urinary tract (Flores-Mireles et al., 2015; Hooton, 2012). Complicated 
UTI affects people with a structurally and functionally abnormal urinary tract or those with 
an underlying medical or surgical health issue (Lichtenberger & Hooton, 2008; Neal & 
Durwood, 2008). Complicated UTI is associated with factors that have an effect on the 
urinary tract or host defense such as urinary obstruction, pregnancy, diabetes mellitus and 
immunosuppression (Flores-Mireles et al., 2015). Complicated UTI could present as acute 
pyelonephritis with intrarenal, perirenal or pararenal abscess and septicaemia (Neal & 
Durwood, 2008; Nielubowicz & Mobley, 2010).  
 
2.3.4 Treatment of urinary tract infections 
Antibiotics are considered the standard treatment for bacterial UTI. They aim to eliminate 
the causative organisms and provide symptom relief to patients (Jancel & Dudas, 2002; 
Stuck et al., 2012). Urinary tract infections account for about 15% of outpatient antibiotic 
prescriptions in the US (Stuck et al., 2012). In Australia, there is no information on the 
proportion of antibiotic prescriptions for UTI, as the available data on antimicrobial use from 
the National Antimicrobial Utilisation Surveillance Program (NAUSP) do not include the 
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indication for which antimicrobials are utilised (Government of South Australia, 2013). 
These data are collected by NAUSP for compilation and processing from contributing health 
facilities who submit their total monthly antimicrobial usage and bed occupancy data 
(Government of South Australia, 2013). The treatment protocol for UTI in Australia is based 
on the Therapeutic Guidelines: Antibiotic (Antibiotic Expert Groups, 2014). In many cases, 
treatment is wholly empirical, meaning that the prescribed antibiotic is not reviewed against 
microbiology results but the antibiotic choice is based on prior knowledge of the most likely 
causative agent along with its local resistance patterns (Leekha et al., 2011). Therefore it is 
important to monitor the resistance patterns of these pathogens to make sure that patients 
are provided with the most appropriate antimicrobial treatment (Jancel & Dudas, 2002; 
Linhares et al., 2013). ‘Appropriate’ treatment is described as treatment to which the 
pathogen is susceptible (Paul et al., 2010). The reverse, that is, inappropriate treatment, 
leads to the development of resistant pathogens and recurrence of infection (Trautner, 
2010). 
 
In Australia, first choice treatment for acute uncomplicated UTI is trimethoprim, cephalexin, 
amoxycillin-clavulanate or nitrofurantoin (Antibiotic Expert Groups, 2014). Fluoroquinolones 
such as ciprofloxacin are not recommended as first-line UTI drugs (Antibiotic Expert Groups, 
2014). Their use has been restricted in Australia since the early 1990s as they are classified 
as a reserve antimicrobial drug (Cheng et al., 2012). Likewise in the US, the Infectious 
Diseases Society of America (IDSA) guidelines recommend their use for treatment of more 
severe infections other than acute cystitis as they are associated with the development of 
resistance (Gupta et al., 2011). Fluoroquinolones have been listed by the WHO as one of the 
highest priority critically important antimicrobials alongside third and fourth generation 
cephalosporins, macrolides and glycopeptides (WHO Advisory Group on Integrated 
Surveillance of Antimicrobial Resistance, 2012). An important use of this list is to address 
prevalence data gaps on these critically important antimicrobials (WHO Advisory Group on 
Integrated Surveillance of Antimicrobial Resistance, 2012). Fluoroquinolones have an 
important role in the treatment of more severe infections, such as septicaemia; therefore 
resistance to fluoroquinolones can have serious clinical consequences. Fluoroquinolones are 
also one of few existing treatment options available for serious Salmonella species and E. 
coli infections. Resistance to fluoroquinolones emerges fast, and it should therefore be used 
with caution and reserved for severe infections, and be preceded by antimicrobial 
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susceptibility testing of the bacteria involved (Mcquiston et al., 2013). Ciprofloxacin is the 
most commonly prescribed fluoroquinolone for UTI (Schaeffer, 2002). This antimicrobial 
agent has broad Gram-negative organism coverage, and is well absorbed from the 
gastrointestinal tract after oral administration with high urinary excretion rate (Schaeffer, 
2002).  
 
To date, fluoroquinolones, particularly ciprofloxacin, are used as the drugs of choice for UTI 
in countries where the level of resistance to other antimicrobials such as ampicillin or 
trimethoprim-sulfamethoxazole is high (Liu et al., 2011; Maraki et al., 2013). A growing 
resistance to trimethoprim-sulfamethoxazole may have favoured the use of ciprofloxacin, 
leading to a rise in ciprofloxacin-resistant E. coli UTI. The increasing resistance to 
ciprofloxacin has important implications for the treatment of bacterial infections like UTI. 
The lack of quantitative syntheses of overall ciprofloxacin-resistant E. coli UTI prevalence is a 
major gap identified in the literature and the first study of this research program will 
address this gap.  
 
Non-antimicrobial treatment of uncomplicated UTI has been investigated as a potential 
means to reduce unnecessary antimicrobial prescribing and subsequent resistance. 
Published evidence from randomised controlled trials comparing antimicrobial treatment 
with placebo or alternative treatment options such as delayed (48 hours) antimicrobials or 
ibuprofen showed that patients in the placebo and delayed antimicrobial groups had 
significant delays in improvement of symptoms and bacteriological cure (Little et al., 2010; 
Gágyor et al., 2012). Although patients in the ibuprofen group had significantly fewer 
antimicrobial courses, they had a significantly higher total symptom burden with more 
patients having pyelonephritis (Gágyor et al., 2015). Further research with larger sample 
sizes are recommended to further investigate the effectiveness of non-antimicrobial 
approaches in treatment of UTI.   
 
As antimicrobials are considered the mainstay of treatment for UTI, the next section 
discusses antimicrobial use in humans and provides evidence to show increase in 
antimicrobial use, including those used for the treatment of UTI.  
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2.4 Quantifying antimicrobial use in humans 
This section provides an overview of the current state of global and national antimicrobial 
consumption in humans. First, global antimicrobial use is discussed and suggested methods 
for quantifying antimicrobial use to allow for comparison of rates between countries are 
described. Evidence to support the increase in global antimicrobial use for human health is 
provided, including antimicrobials used in the treatment of UTI. The second part of this 
section discusses antimicrobial use in Australia. The organisations responsible for 
monitoring antimicrobial use in Australia are stated. Current estimates of antimicrobial use 
in Australian hospitals as well as the community setting are also provided. The effect of 
antimicrobial use in livestock production is not central to the thesis and will not be covered.   
 
2.4.1 Global antimicrobial use 
Appropriate measurement of antimicrobial use is essential to determine consumption 
trends over time as well as compare consumption levels between countries (Filius et al., 
2005). A number of methods have been suggested for quantifying this antimicrobial use. 
Initial estimates of antimicrobial use were reported as the proportion of patients who were 
prescribed antimicrobials while hospitalised (Polk, Fox, Mahoney, Letcavage, & MacDougall, 
2007). The current and most widely used measurement is the WHO recommended number 
of defined daily doses per 100 patient days (Filius et al., 2005). The Defined Daily Dose 
(DDD) is defined as “the assumed average maintenance dose per day for a drug used for its 
main indication in adults” (WHO Collaborating Centre for Drug Statistics Methodology, 
2015, p. 22). Although this unit allows for drug use comparisons between countries, it is 
simply a measurement unit and is not a reflection of the recommended or prescribed dose 
in patients (Monnet, 2007). Some authors have proposed using the number of days of 
therapy (DOT) as an alternative measure given the limitations of the DDD, which include a 
lack of DDDs for some antimicrobials, inability to apply DDDs to paediatric patients as well 
as the potential to underestimate antimicrobial exposure when there are reductions in the 
administered daily dose for patients with impaired kidney function (Monnet, 2007; Polk et 
al., 2007). Further still, antimicrobial drug use has been measured by other authors using 
standard units which refer to a single dose of the drug, which may be in form of a pill, 
capsule or ampoule (Van Boeckel et al., 2014). Despite the different measurements 
described above, the DDD is still recognised as the standard measurement worldwide 
because it is endorsed by the WHO and can be reliably used globally for measuring 
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antimicrobial use in both inpatients and outpatients (Monnet, 2007). Furthermore, its 
widespread use allows for worldwide comparison to facilitate benchmarking (Monnet, 
2007). 
 
Antimicrobial use for human health is said to be increasing considerably (World Health 
Organization, 2015a). Between 2000 and 2010, antimicrobial use was estimated to have 
increased by 36% in 71 countries, from approximately 50 billion to 70 billion standard units 
(number of doses) (Van Boeckel et al., 2014). Reporting of antimicrobial use with DDDs was 
not possible given the lack of global data using DDDs, hence the use of standard units which 
was the measurement unit used in the most comprehensive global dataset for this study 
(Van Boeckel et al., 2014). The largest absolute increases in antimicrobial use were for 
cephalosporins, broad-spectrum penicillins and fluoroquinolones, antimicrobial classes used 
in the treatment of UTI. Countries rated as the top global consumers in 2010 were India, 
China and the US (Van Boeckel et al., 2014). Among the high-income countries, 
antimicrobial use increased substantially between 2000 and 2010 in Australia and New 
Zealand, from 25 to 87 units per person and 26 to 70 units per person respectively (Van 
Boeckel et al., 2014). 
 
It is estimated that about 20% of antimicrobials are used in hospitals with about 80% used in 
community settings, which include general practitioner clinics and non-prescription use 
(Kotwani & Holloway, 2011). Over-the-counter or non-prescription antimicrobial use varies 
by country depending on whether prescription-only laws are enforced. A systematic review 
investigating global non-prescription antimicrobial use reported that for countries outside 
Europe and the US, estimates of over-the-counter antimicrobial use ranged from 19% to 
over 90% (Morgan, Okeke, Laxminarayan, Perencevich, & Weisenberg, 2011). Additional 
evidence from the systematic review showed that levels of antimicrobial-resistant bacteria 
were higher in populations with frequent use of non-prescription antimicrobials (Morgan et 
al., 2011). A number of limitations were noted, including combining studies with diverse 
population groups as well as the use of a search period spanning over 40 years, which may 
have resulted in the inclusion of studies which no longer mirror current prescription 
practices in some countries.  
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2.4.2 Antimicrobial use in Australia  
In Australia, systematic surveillance of antimicrobial use in humans is provided by voluntary 
participation NAUSP (Gottlieb & Nimmo, 2011). The National Antimicrobial Prescribing 
Survey (NAPS) is a voluntary annual point prevalence survey undertaken by health facilities 
(Australian Commission on Safety and Quality in Health Care, 2016). The NAPS also reports 
data on the appropriateness of antimicrobial prescribing. The recent development of the 
Aged Care National Antimicrobial Prescribing Survey (acNAPS) also allows for collection of 
antimicrobial use data in Australian residential aged care facilities (Australian Commission 
on Safety and Quality in Health Care, 2016). Surveillance of antimicrobial use enables 
hospital administrators and clinicians to examine their antimicrobial use over time, and 
compare with similar hospitals.  
 
There are approximately 22 million antibiotic prescriptions written annually in Australian 
primary care settings, ranking Australia as one of the major users of antibiotics in the 
industrialised world (McKenzie et al., 2013). Over 1100 prescriptions per 1000 population 
are dispensed in Australia (Australian Commission on Safety and Quality in Health Care, 
2016). This is higher than the US, England, Scotland, Canada and Sweden which have 
prescriptions of less than 850/1000 population (Australian Commission on Safety and 
Quality in Health Care, 2016). In regards to community antimicrobial use, compared to 
Denmark, the Netherlands and Sweden, with a DDD of less than 15/1000 population/day, 
Australia’s DDD is almost double this value at nearly 23/1000 population/day (McKenzie et 
al., 2013). Australia’s hospital antimicrobial use is higher than Netherlands, Norway, 
Sweden, Canada and Denmark, at an estimated 3 DDD/1000 population per day in Australia 
but lower than England and Scotland, which both have DDDs over 4/1000 population per 
day (Australian Commission on Safety and Quality in Health Care, 2016). It should be noted 
that given the variability in the data collection processes in different countries, these 
comparisons are not absolute. 
 
It is estimated that about 38% of all Australian hospital patients are prescribed an 
antimicrobial agent on any given day (Australian Commission on Safety and Quality in Health 
Care, 2015). In 2014, based on data from the 129 participating hospitals that submitted data 
to NAUSP, total antimicrobial use in hospitals was 936 DDD/1000 occupied bed days 
(Australian Commission on Safety and Quality in Health Care, 2015). Hospital antimicrobial 
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use was found to vary by states and territories with the highest rate reported in Tasmania 
and the lowest in Queensland. Urinary tract infections were the fourth most common 
indication (6.7%) requiring an antimicrobial prescription. In the community, 46% of 
Australian residents were prescribed at least one antimicrobial agent in 2014 (Australian 
Commission on Safety and Quality in Health Care, 2015). This equates to almost half of the 
total population surveyed. Antimicrobial use was estimated to be 24 DDD/1000 population 
per day and was noted to be highest in children below 9 years of age and adults above 65 
years. The highest source of antimicrobial prescriptions (88%) was from general 
practitioners. Data from the first pilot of the acNAPS undertaken in 186 residential aged care 
facilities in 2015 showed that about 11% of residents received an antimicrobial, with UTI 
identified as the second most common reason (17%) requiring an antimicrobial (Australian 
Commission on Safety and Quality in Health Care, 2016). The acNAPS data are not 
representative of all Australian aged care facilities, given that this was a pilot study in 
preparation for national surveillance (Australian Commission on Safety and Quality in Health 
Care, 2016). 
 
Overuse of antimicrobials in humans has significant health implications, particularly AMR 
which is discussed in the next section.   
 
2.5 Antimicrobial resistance 
The WHO has described AMR as an international threat to public health, threatening the 
successful prevention and treatment of bacterial, viral, parasitic and fungal infections 
(World Health Organization, 2012, 2014). As such, research into its prevention and 
reduction is very important. Antimicrobial resistance is on the rise globally and available 
data suggest that this problem is neither country nor region specific, affecting both 
industrialised and non-industrialised countries. In all six WHO regions (Africa, Americas, 
Eastern Mediterranean, European, South-East Asia and Western Pacific), high resistance 
have been noted in bacteria that cause common hospital- and community-acquired 
infections such as UTI and pneumonia (World Health Organization, 2014). This section 
discusses the health and economic burden of AMR in general and specifically in resistant  
E. coli UTI. International and national evidence in support of the rising AMR in E. coli UTI are 
also discussed. 
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2.5.1 Health and economic implications of AMR in general 
In general, AMR has significant health implications to society. It results in increased patient 
morbidity and mortality. Antimicrobial resistance may lead to treatment failure, resulting in 
death, especially in already critically unwell patients who are more at risk because of their 
relative immune deficiency and high exposure to antimicrobial agents (Tenover, 2006). In 
the European Union, Iceland and Norway, approximately 25,000 patients died in 2007 from 
antimicrobial resistant infections. About two-thirds of these deaths were due to Gram-
negative bacterial infections from third-generation cephalosporin-resistant E. coli, Klebsiella 
pneumoniae and carbapenem-resistant Pseudomonas aeruginosa (European Centre for 
Disease Prevention and Control, 2009). However, AMR is also a problem for Gram-positive 
bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant 
Enterococcus faecium (European Centre for Disease Prevention and Control, 2009). Infection 
control problems may arise from spread of resistant bacteria in both healthcare facilities 
and in the community. Spread within the community creates significant concerns for 
infection control in long-term care facilities and day care centres, due to increased 
population mobility (Tenover, 2006). Antimicrobial resistance prolongs the duration of 
illness, increases the risks of complications and leads to longer hospital stay, thereby leading 
to greater healthcare costs for patients.  
 
The authors of the report of the Review on Antimicrobial Resistance in the UK estimate 
that by 2050 the global financial cost of AMR will be approximately US$100 trillion, with ten 
million lives at risk of developing a resistant infection each year if the issue of AMR is not 
addressed (O'Neill, 2016). The economic burden of AMR also includes loss of productivity 
and increased cost of diagnostics and treatment (World Health Organization, 2012). Direct 
healthcare costs in the US have been estimated to be as high as $20 billion with loss of 
productivity costing $35 billion per year (Centers for Disease Control and Prevention, 2013). 
In the European Union the estimated total cost to society of AMR is €1.5 billion each year 
(European Centre for Disease Prevention and Control, 2009). The estimated cost of AMR to 
the health budget in Australia is over $250 million annually and double this amount to the 
community (Shaban et al., 2013). Most determinations of costs attributable to AMR are 
approximate values because they have been derived from small, often non-representative 
databases. Furthermore, these estimates were derived from reports or websites of notable 
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organisations, demonstrating the lack of published research on the overall health and 
economic burden associated with AMR at the population level.  
 
2.5.2 Health and economic implications of AMR in UTI caused by E. coli 
According to the most recent WHO report on AMR surveillance, E. coli is reported as one of 
the nine bacterial pathogens of global concern that are responsible for some of the common 
infections that occur in community and hospital settings (World Health Organization, 2014). 
Antimicrobial resistance in E. coli poses significant health and economic implications for 
society. Results from a recent systematic review showed significant increases in mortality 
for patients with third-generation cephalosporin and fluoroquinolone-resistant E. coli 
infections, compared to those with non-resistant infections (World Health Organization, 
2014). Furthermore, the review results also showed that patients with a resistant bacterial 
infection had higher care needs compared to those without a resistant infection. The 
proportion of patients needing admission to the intensive care unit was significantly higher 
(P=0.03) for patients with a fluoroquinolone resistant E. coli compared to those with non-
resistant infections (World Health Organization, 2014). The presence of confounding in the 
majority of the included studies was identified as a concern by the reviewers as well as the 
inclusion of studies with small sample sizes (World Health Organization, 2014). For example, 
a case control study aimed at determining the outcomes of patients with ciprofloxacin-
gentamicin-resistant E. coli UTI found that E. coli bacteremia, septic shock and death within 
30 days were more common among cases than controls (P=0.01, P=0.02 and P=0.04 
respectively). Cases were also more likely than controls to relapse within two months 
(P=0.002). These associations were statistically significant (Pépin, Plamondon, Lacroix, & 
Alarie, 2009). Although controls were selected from the same population as cases, matching 
was not done, introducing the potential for confounding. While this study was also limited 
to a single hospital and the findings may not be generalisable to all populations, especially 
given that resistance has been shown to vary geographically, it illustrates some of the 
common study design problems.  
 
Regarding the economic burden of antimicrobial resistant UTI, a study from the UK reported 
that between 2002 and 2004, patients with an antibiotic (specifically ampicillin)-resistant E. 
coli UTI received general practice costs that were £3.64 higher on average (P=0.008) than 
those of patients with an antibiotic sensitive UTI (Alam et al., 2009). Another study from 
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Thailand reported that between 2003 and 2004, hospitalisation costs were higher in 
patients with community-onset ESBL-producing E. coli infections (median, US $528 vs $108, 
respectively; P<0.001) compared to patients without infections (Apisarnthanarak et al., 
2007). The authors acknowledge that their sample size of 46 patients with community-onset 
ESBL-producing E. coli was small and therefore limited the ability to detect other possible 
outcomes in these patients. Although the study evaluated community-onset infections, data 
were obtained from inpatients and may not be applicable to outpatients and those with 
hospital-onset infections. Again, design flaws are evident in regards to the conduct of AMR 
studies.   
 
Knowledge of the health and economic implications of AMR, including the impact of AMR 
on patient outcomes, is important for both hospitals and clinicians as it provides motivation 
to hospitals to implement programs tailored towards control of AMR and antimicrobial use 
(Eliopoulos, Cosgrove, & Carmeli, 2003). The review of literature identified a dearth of 
research quantifying the health and economic implications of antimicrobial resistant E. coli 
UTI in Australia, highlighting the need for more research on AMR in E. coli UTI in Australia.   
 
2.5.3 Antimicrobial resistance patterns and trends in E. coli infections 
There is evidence to show that resistance to antimicrobials used to treat E. coli infections is 
increasing globally (World Health Organization, 2015a). Available data on global resistance 
published in 2014 by WHO showed at least 50% resistance to fluoroquinolones and third 
generation cephalosporins in E. coli in five WHO regions (World Health Organization, 2014). 
Data from ResistanceMap, developed by Centre for Disease Dynamics, Economics and Policy 
(CDDEP), also provides information on global AMR in E. coli isolates (Figure 1) (Center for 
Disease Dynamics, Economics and Policy, 2015b). Resistance for the four antimicrobial 
classes assessed were noted to be highest in India, which is a developing country, compared 
to South Africa, UK, US and Australia, which are developed countries. In comparison to 
international data from South Africa, UK and US, Australian E. coli resistance were lower. 
The aggregated data from ResistanceMap represent invasive E. coli isolates sourced from 
blood and cerebrospinal fluid, highlighting the lack of global data on AMR specific to E. coli 
isolates sourced from urinary samples. There was a lack of published studies comparing 
antimicrobial resistant E. coli UTI in developing versus developed countries. This evidence 
gap will be addressed in the first study of the research program. 
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Figure 1 Antibiotic resistance for Escherichia coli isolates  
Source: CDDEP 2015 sources include: AGAR (Australia); SRL Diagnostics (India); SASCM (South Africa); EARS-
Net (Europe) and TSN (USA). 
The chart displays the data for each country from ResistanceMap (CDDEP 2015). Data collection year varies by 
country (Australia-2013; India-2014; South Africa-2014; United Kingdom-2013; United States-2012). 
 
Various international studies demonstrate an increase in the incidence and prevalence of 
resistance of E. coli UTI to commonly prescribed antimicrobials (Blaettler et al., 2009; 
Kronvall, 2010; Linhares et al., 2013; Maraki et al., 2013; Swami, Liesinger, Shah, Baddour, & 
Banerjee, 2012; Tadesse et al., 2012). Some of these studies also evaluated resistance 
patterns, taking into consideration individual patient risk factors such as sex and age 
(Blaettler et al., 2009; Linhares et al., 2013; Swami et al., 2012). The recently released first 
Australian report on antimicrobial use and AMR also reported increases in AMR in E. coli. 
Urinary E. coli resistance in 2014 were highest for ampicillin (amoxicillin) (42.3%) (Australian 
Commission on Safety and Quality in Health Care, 2016). Resistance also varied by states 
and territories although this finding was based on blood culture E. coli isolates (Australian 
Commission on Safety and Quality in Health Care, 2016). Results from a population-based 
retrospective study conducted in Tasmania, Australia, showed that E. coli resistance was 
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highest for amoxicillin (35%) and trimethoprim (14%) (Meumann, Mitchell, McGregor, 
McBryde, & Cooley, 2015). In addition, a significant increase in resistance was noted for 
amoxycillin clavulanate, from 3.4% in 2010 to 4.1% in 2012 (P=0.03) (Meumann et al., 2015). 
These Australian data do not include information about the age, sex, comorbidities, prior 
antibiotic exposure of patients and other clinical data. In addition, these data report on AMR 
prevalence with no available Australian data to provide information on the risk of disease 
occurrence, that is, incidence of antimicrobial resistant UTI over time. Hence collection of 
AMR data, which includes additional information on potential risk factors for AMR as well as 
more detailed statistical analyses, are required to better describe the issue of AMR in E. coli 
UTI in Australia. The second and third studies of the research program will address these 
gaps.  
 
Previously published international studies have shown that AMR prevalence differs for 
hospital- and community-acquired UTI (Cullen et al., 2012; Ma & Wang, 2013; Perrin, 
Donnio, Heurtin-Lecorre, Travert, & Avril, 1999). In Australia, the Australian Group on 
Antimicrobial Resistance (AGAR) collects data on AMR prevalence in Gram-negative 
bacteria, including E. coli and Klebsiella species (Australian Group on Antimicrobial 
Resistance, 2011). The data collected by AGAR are not specifically UTI data, but include data 
on bacteria that may cause UTI. The surveys conducted by AGAR occur annually but 
alternate between community-onset and hospital-onset infections (Australian Group on 
Antimicrobial Resistance, 2013). Since the first community-onset Australian AMR prevalence 
survey conducted by AGAR in 2008, a gradual rise has been observed in the overall 
percentage of E. coli strains resistant to beta-lactam antibiotics (Australian Group on 
Antimicrobial Resistance, 2013). From 2008 to 2012, gentamicin resistance increased from 
3.5% to 4.3%. Ciprofloxacin resistance appears to be increasing (from 4.2% in 2008, 5.4% in 
2010, to 7.0% in 2012) despite government restrictions on its use in both the community 
and in hospitals (Australian Group on Antimicrobial Resistance, 2011, 2013; Cheng et al., 
2012). Also, multi-resistance (acquired resistance to more than three agents) in E. coli 
increased from 4.5% in 2008 to 7.6% in 2012 (Australian Group on Antimicrobial Resistance, 
2013). Similarly, since the first hospital-onset AMR prevalence surveys conducted by AGAR 
in 2009, resistance to beta-lactam agents has also been on the increase (Australian Group 
on Antimicrobial Resistance, 2011). E. coli resistance to ampicillin rose from 47.8% in 2009 
to 50.5% in 2011 (Australian Group on Antimicrobial Resistance, 2011). Likewise, urinary E. 
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coli resistance to ciprofloxacin increased from 8% in 2009 to 11% in 2011 (Australian Group 
on Antimicrobial Resistance, 2011).  
 
Although the AGAR undertakes hospital- and community- onset AMR prevalence surveys 
within Australia, the data are limited. Isolates categorised as community-onset are those 
obtained from non-hospitalised UTI patients, outpatient and patients from emergency 
departments or general practitioners, while hospital-onset isolates were obtained from 
various clinical specimens in patients hospitalised for over 48 hours. Although similar 
bacterial isolates (that is, E. coli) are included in both surveys, the use of varied clinical 
samples prevents direct comparison of these data between both groups and also among 
other studies. The second study of the research program will address this limitation by 
providing results of directly comparable data on hospital- and community-acquired E. coli 
UTI.  
 
In recent years, a growing concern has been the emergence of extended spectrum beta-
lactamase (ESBL) producing E. coli (Nicolle, 2008). Extended spectrum beta-lactamase 
producing organisms are resistant to beta-lactams, cephalosporins and other classes of 
antimicrobials, with carbapenems recognised as the most suitable treatment option for 
infections caused by ESBL-producing E. coli (Mazzulli, 2012). Results from the Study for 
Monitoring Antimicrobial Resistance Trends (SMART) found the prevalence of ESBL was 
17.9% in urinary E. coli isolates obtained from hospital inpatients in countries worldwide 
(Hoban, Nicolle, Hawser, Bouchillon, & Badal, 2011). In Australia, about 7% to 12% of E. coli 
was found to be ESBL-producing E. coli (Australian Commission on Safety and Quality in 
Health Care, 2016). The presence of ESBL-producing E. coli isolates in both hospital and 
community settings has the potential to impact considerably on UTI treatment, as these 
pathogens are susceptible to a limited number of antimicrobials.  
 
The Australian data reported in this section were obtained from reports and only one peer 
reviewed published paper on AMR in E. coli UTI in Australia was identified during the 
literature search (Meumann et al., 2015). In addition, data from reports were mainly based 
on E. coli isolates from a number of sources and not specifically urine isolates. This 
highlights the lack of rigorously conducted studies evaluating AMR in urinary E. coli isolates 
in Australia.  
63 
 
 
The next section brings together sections 2.4 and 2.5 by providing evidence to demonstrate 
the potential link between antimicrobial use and AMR.  
 
2.6 The potential link between antimicrobial use and resistance in humans 
Antimicrobial overuse or misuse is a known risk factor for the development of AMR in 
humans (Costelloe, Metcalfe, Lovering, Mant, & Hay, 2010). Demonstrating an association 
between antimicrobial use and urinary E. coli resistance is therefore important in developing 
strategies to combat AMR and improve understanding of the epidemiology of AMR (Hillier, 
Magee, Howard, & Palmer, 2002; Schechner, Temkin, Harbarth, Carmeli, & Schwaber, 2013). 
Several international studies have demonstrated this association. For example, in a study 
involving 26 European countries, the results showed statistically significant correlations for 
ciprofloxacin (Spearman correlation=0.74; 95% confidence interval=0.35-0.91; P=0.002) and 
cotrimoxazole (Spearman correlation=0.71; 95% confidence interval=0.29-0.90; P=0.005) 
use and their resistance in E. coli in 14 of the 26 countries (Goossens et al., 2005). Bergman 
et al. (2009) also found a number of associations between E. coli resistance and 
antimicrobial use. Significant associations were seen for: nitrofurantoin use and 
nitrofurantoin resistance (P<0.0001); cephalosporin use and nitrofurantoin resistance 
(P=0.029); fluoroquinolone use and ampicillin resistance (P=0.005); as well as amoxicillin use 
and fluoroquinolone resistance (P=0.003). In these studies, antimicrobial consumption was 
not stratified by length of therapy or number of antimicrobial drugs. It has been suggested 
that the varying associations for antimicrobial use and resistance may be attributable to a 
number of factors, including geographical differences in the resistance selection pressure, 
different statistical models used for assessing associations, differences in age and gender 
distribution and the use of patient or population level resistance and antimicrobial use data 
(Bergman et al., 2009; Goossens et al., 2005). 
 
The association between ciprofloxacin use and the development of its resistance in UTI 
pathogens is also clearly documented in international studies. A recent Irish study involving 
72 general practices found higher ciprofloxacin resistance levels (5.5%) in practices with 10 
prescriptions per month, compared with resistance levels of 3% in practices with one 
prescription per month (Vellinga, Murphy, Hanahoe, Bennett, & Cormican, 2010). Although 
widespread use of this agent may have thus resulted in a rise in ciprofloxacin resistance, the 
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authors clearly state that their results should be interpreted with caution as data on 
antimicrobial prescribing was not representative of the entire population. In the 
Netherlands and US, an association has also been shown between high fluoroquinolone 
prescriptions and a rise in bacterial resistance (Goettsch et al., 2000; Zervos et al., 2003). 
These associations were statistically significant. 
 
A detailed search of the literature revealed a lack of published Australian data aimed at 
determining the association between antimicrobial use and resistance in urinary E. coli 
isolates, with only one study identified. Findings from this study showed a statistically 
significant association between amoxicillin and amoxicillin-clavulanic acid use and resistance 
to these antimicrobials (Meumann et al., 2015). 
 
2.7 Importance of the microbiology laboratory in AMR surveillance 
The role of the microbiology laboratory is essential both in the detection and surveillance of 
AMR in the hospital and community (World Health Organization, 2001). Processing and 
examination of urine samples makes up a large part of the workload undertaken in 
microbiology laboratories. These laboratories are tasked with the job of performing urine 
cultures and antimicrobial susceptibility testing to obtain information on the causative 
pathogen and preferred antimicrobial(s) for treatment (Burd & Kehl, 2011; Wilson & Gaido, 
2004). Microbiology laboratories are also responsible for collating susceptibility data to 
facilitate analysis for monitoring resistance prevalence and incidence and the possible 
detection of resistance trends. They are the initial sources for identification of emerging 
AMR patterns (Cantón, 2005; Reller et al., 2001). Therefore, accurate implementation of 
procedures by the microbiology laboratory as well as interpretation of susceptibility testing 
results is crucial to the quality of data produced for AMR reporting. 
 
Collation and analysis of data from both public and private microbiology laboratories is 
highly valuable in providing an understanding of microbes and their susceptibility patterns 
(Coxeter et al., 2013). Useful data exist within various laboratory services across Australia 
(Shaban et al., 2013) but are not widely used and certainly not coordinated nationally. By 
retrospectively reviewing large amounts of these data for specific bacterial species over a 
period of time, the information obtained can help evaluate resistance patterns over time 
and assist in developing treatment guidelines (Shaban et al., 2013).  
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2.8 Gaps in global AMR surveillance 
The global issue of AMR has been highlighted with evidence from the literature review 
showing the presence of antimicrobial resistant E. coli isolates in various countries and 
world regions (World Health Organization, 2014). In response to this crisis, the global action 
plan on AMR was approved at the World Health Assembly in May 2015 (World Health 
Organization, 2015a). A number of priority areas have been identified, representing 
knowledge gaps that need to be addressed through surveillance of AMR and research. 
These include: collection and analysis of data to identify the incidence and prevalence of 
resistant pathogens and geographical AMR patterns; understanding the development and 
spread of resistance; characterisation of emerging resistance in pathogens with an 
understanding of the mechanisms; understanding the social and behavioural factors that 
propagate resistance; clinical studies on the prevention and treatment of frequently 
occurring bacterial infections; and research on the economics and costs of AMR (World 
Health Organization, 2015a).  
 
Furthermore, the WHO’s global report on AMR surveillance also highlighted information 
gaps on AMR patterns in bacteria of significant public health importance, one of which is E. 
coli (World Health Organization, 2014). The report also documented the lack of an 
international standard for the collection and reporting of AMR data in human health as well 
as the absence of a global forum for rapid dissemination of AMR information (World Health 
Organization, 2014). 
 
The knowledge gaps in AMR surveillance described above have been noted on a global level 
but are also applicable to the current AMR surveillance situation in Australia. This is 
discussed in the next section.   
 
2.9 Gaps in Australian AMR surveillance 
There are major gaps in our knowledge of the magnitude of AMR in Australia; and also 
hospital and community resistance levels, specifically for UTI pathogens. The lack of 
information about the magnitude of AMR in Australia has mainly been due to the absence 
of well-developed systems to evaluate antibiotic use and levels of AMR in various settings 
(Shaban et al., 2013). With the recent establishment of the Antimicrobial Use and Resistance 
in Australia (AURA) Surveillance System, better coordination of AMR and antimicrobial use 
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data is expected. Improvements in coordination have already been demonstrated with the 
release of Australia’s first report on antimicrobial use and resistance in human health, in 
June 2016 (Australian Commission on Safety and Quality in Health Care, 2016), integrating 
data from a range of sources. Despite the establishment of the AURA Surveillance System, 
there is still work to be done in regards to ensuring adequate surveillance of AMR. Some of 
these gaps are: improvement in the analysis and interpretation of AMR data; wide coverage 
of AMR data from various geographical locations and patient settings; improvement in data 
collection methods to facilitate proper benchmarking, and continued monitoring of 
resistance patterns (Australian Commission on Safety and Quality in Health Care, 2016). 
Strengthening of the surveillance process is needed to ensure collection of relevant data 
which can inform action aimed at control of AMR.  
 
Another important gap in surveillance of AMR in Australia is linkage of AMR data to other 
important data such as antimicrobial usage (Australian Government, 2015; Nimmo, Bell, & 
Collignon, 2003). There is potential to use the longitudinal antimicrobial use data from 
NAUSP and AMR data from microbiological laboratories to explore associations between 
antimicrobial consumption and resistance at hospital level (McNeil, Cruickshank, & Duguid, 
2010), but to date in Australia these data have not been fully utilised specifically for UTI 
pathogens such as E. coli.  
 
The AMR summit held in Australia in 2011 listed surveillance of AMR as one of the main 
action plans. Knowledge of hospital and community resistance levels, bacteria type and 
location were key recommendations for surveillance. The summit also recommended that 
the UTI causing bacteria, specifically E. coli and other Gram-negative bacteria, be given 
priority as the emerging resistance in these organisms poses a major new threat (Gottlieb & 
Nimmo, 2011). According to Gottlieb and Nimmo (2011), the incidence of AMR in Australia 
is still poorly described and measuring its extent in community-acquired and healthcare-
associated infections is essential to describing the issue.  
 
As highlighted in previous sections of this chapter (sections 2.3.4 and 2.5.3), some of these 
gaps will be addressed in the research program. Specifically, the first study will address the 
knowledge gaps on the global incidence and prevalence of resistant E. coli UTI and 
geographical AMR patterns, by systematically reviewing the literature to comprehensively 
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evaluate AMR resistance in E. coli UTI, specifically in ciprofloxacin, a high priority critically 
important antimicrobial agent. The systematic review also provided an opportunity for me 
to gain an in-depth understanding of the methodological issues in regards to undertaking 
AMR studies using laboratory-based data. Hence the research program also retrospectively 
reviews AMR data on E. coli UTI from a microbiology laboratory to address some of the gaps 
described above. The second study of the research program evaluates AMR temporal trends 
and compares the prevalence of AMR in hospital- and community-acquired E. coli UTI at the 
Canberra Hospital over a five-year period. The third study evaluates the incidence and risk 
of antimicrobial resistant E. coli UTI in a cohort of ACT residents over a five-year period. 
Obtaining both incidence and prevalence data are necessary to provide information about 
the health status of people and contribute to disease management decisions (Buttner & 
Muller, 2011). In light of the impact of antimicrobial usage patterns on AMR highlighted in 
the literature review, as well as potential to use antimicrobial use data from NAUSP, 
determining antimicrobial use trends at the hospital level is undertaken as part of the 
second study of the research program. 
 
The research program aims to address some of the gaps identified from the literature 
review and use the research findings to contribute towards strengthening AMR surveillance 
in Australia and also globally. Rich data sources exist in Australia and the potential for use of 
these data in the control of AMR and overuse or misuse of antimicrobials are currently not 
maximised. This research program exploits these data and makes available information on 
AMR patterns in E. coli UTI at the hospital and community levels, including trends in 
antimicrobial use at the hospital level.  
 
2.10 Summary 
Urinary tract infections are common infections that occur worldwide and have a significant 
health, economic and financial burden on society. Bacteria which cause UTI, most commonly 
E. coli, are becoming more resistant to currently prescribed antimicrobials. Therefore, 
monitoring AMR patterns is an essential part of guiding therapy in patients with UTI and can 
also provide data which can be used for the development of policies aimed at controlling 
further development and spread of AMR in E. coli.  
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This comprehensive review of the literature has identified that there are knowledge gaps on 
global prevalence and incidence of resistant E. coli UTI and geographical AMR patterns. The 
review of the literature also identified: the lack of published studies on AMR in E. coli UTI in 
Australia as well as considerable gaps in knowledge regarding hospital and community 
resistance levels; incidence of antimicrobial resistant E. coli UTI over time; and risk factors 
for the presence of resistant E. coli UTI in Australia. It is apparent that rich data, which can 
be analysed thoroughly using detailed statistical techniques to produce more 
comprehensive findings, exist in Australia. These rich data that exist within microbiology 
laboratories in Australia, which have been identified as key to controlling the spread of 
resistance, are currently being underutilised and they have the potential to inform 
strategies to prevent further development and spread of resistance.  
 
This literature review has provided insight into the evidence gaps for AMR surveillance in E. 
coli UTI on a global level as well as in Australia. This research program is timely, especially 
given the recent release of the national AMR strategy in Australia. The outcomes of the 
three studies that make up this research program have the potential to: inform AMR control 
policies; influence therapy for UTI as it relates to the locality; contribute methodologically to 
analysis of microbiological laboratory data; and also contribute to enhancing AMR 
surveillance at the territory and national level. The following chapter discusses the design 
and methodology for undertaking each of the studies in the research program.
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Chapter 3: Research methodology 
 
3.1 Overview 
This chapter outlines the individual methods used to undertake each study and address 
each study’s aims. The first section of this chapter describes the methodological issues 
taken into consideration during the conduct of these studies. To avoid repetition of the 
methods used for undertaking the individual studies, this chapter provides an overview of 
the study methods with justification for the choice of methodological approaches 
undertaken. Specific information on the data collection processes used in each study, as 
well as details of the statistical analysis procedures, is presented in the study chapters. This 
chapter concludes with a discussion of the ethical concerns of informed consent, 
confidentiality and data security. 
 
The methodological approach to conducting the three studies, which this research program 
comprises, is underpinned by the positivist paradigm. The French philosopher, August 
Comte, who first referred to the term ‘positivism’ in the 19th century, argued that the truth 
about reality can only be revealed through scientific knowledge (Kaboub, 2008; Mack, 
2010). He believed that knowledge generation could only be achieved through the use of 
observation or human reasoning using a scientific methodology (Kaboub, 2008). This is 
likened to constructing an experiment, in a controlled environment or laboratory, in an 
objective manner without any interactions with the external world (Aliyu, Bello, Kasim, & 
Martin, 2014). The positivist research paradigm follows a scientific and systematic approach 
to the conduct of research and has been shown to support the use of quantitative 
methodology in data collection and analysis (Mackenzie & Knipe, 2006; Mukherji & Albon, 
2009). This scientific paradigm aims to provide predictions and generalisation of research 
findings to the wider population. The methods employed often generate quantitative data 
with the use of descriptive and inferential statistical analysis tests (Scotland, 2012). The 
positivist paradigm has been criticised for its lack of subjectiveness, as reality is constructed 
on multiple factors and it is impossible to exclude subjective human involvement in 
constructing reality (Tuli, 2010). In response to this, those in favour of the positivist 
paradigm have argued that rather than claim absolute objectivity, the positivist approach 
seeks a certain degree of objectivity (Mack, 2010). Nevertheless, the choice of research 
paradigm depends on the research question that is being answered. This research program 
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therefore follows the positivist philosophical approach, as the aims of the three studies 
were most effectively addressed using research designs, data collection methods and data 
analyses techniques consistent with the quantitative methodological approach, to 
determine the prevalence and incidence of antimicrobial resistant urinary E. coli. 
 
3.2 Methodological considerations  
The use of microbiological laboratory data poses methodological challenges. These 
challenges relate to the appropriate and universally acceptable threshold for microbiological 
laboratory confirmation of a UTI, definitions for categorisation of infections based on setting 
of acquisition (e.g., hospital versus community) and the use of antimicrobial susceptibility 
testing (AST) categories in determining resistance. This section discusses these topics and 
also outlines the decisions made regarding the analytic methods used in this research 
program.  
 
3.2.1 Threshold for laboratory confirmation of UTI 
Processing urine cultures forms a large part of the workload undertaken in microbiology 
laboratories and clinicians mainly rely on the generation of accurate results from the 
laboratory to make therapeutic recommendations for management of patients with UTI 
(Burd & Kehl, 2011). Traditionally, laboratory UTI diagnosis has been based on a quantitative 
culture of a urine sample containing a pathogen of greater than or equal to 105 colony 
forming unit (cfu) per millilitre of urine (Kass, 1957; Kass & Finland, 2002; Stamm et al., 
1982). However, this criterion was established in studies using women with acute 
pyelonephritis and asymptomatic bacteriuria (Kass, 1957; Kass & Finland, 2002). While the 
majority of patients with UTI are females, most of them present with acute uncomplicated 
cystitis and studies have shown that more than one-third of these patients have bacterial 
colony counts less than 105 cfu/ml (Stamm et al., 1982). The 105 cfu/ml cut-off, although 
chosen for its high specificity, has also been shown to have a sensitivity of about 50% (Burd 
& Kehl, 2011; Orenstein & Wong, 1999). Hence many microbiology laboratories use lower 
counts as a cut-off for interpreting results of urine cultures (Burd & Kehl, 2011; Wilson & 
Gaido, 2004). To increase the sensitivity of the urine culture test without making it 
impractical for use by clinicians and microbiology laboratories, a count of 104 cfu per 
millilitre (107cfu/L) of urine is commonly used (Wilson & Gaido, 2004).   
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Australian Capital Territory Pathology reports colony counts per litre of urine as opposed to 
per millilitre of urine. Hence using a conversion factor of 1000 (as 1L = 1000mL and 1 µL = 
1000mL), a colony count of 105cfu/mL equates to 108cfu/L. Urine culture is done with a 1µL 
loop; for example, 100 colonies on the plate (100cfu in 1 µL of urine) will be equivalent to a 
colony count of either 100x103 cfu/mL or 100x106 cfu/L. When there are between 10–100 
colonies on the plate, more often nearer 100, the result is recorded as 107–108cfu/L. These 
urine samples may come from patients who have commenced empirical antibiotic 
treatment or those with a significant cell count with a leucocyte response, hence making the 
cut-off of 107–108cfu/L clinically significant. Therefore, for the two studies of this research 
program that utilised data from ACT Pathology microbiology laboratory, a colony count of 
107 cfu/L (104 cfu/ml) was used to confirm the diagnosis of UTI. This 107 cfu/L cut-off is 
commonly used as it increases the sensitivity of the urine culture test, making it a practical 
threshold (Wilson & Gaido, 2004) – a criterion used by various studies reporting on AMR of 
urinary E. coli (Laupland et al., 2007; Linhares et al., 2013; McGregor, Elman, Bearden, & 
Smith, 2013). Furthermore, this urine culture cut-off point has been used in reports by the 
National Association of Testing Authorities accredited clinical microbiology laboratory.  
 
3.2.2 Categorisation of healthcare-associated, hospital- and community-acquired 
infections 
To ensure appropriate interpretation of the study findings, especially in relation to empirical 
antimicrobial therapy, the allocation of the place of acquisition of infection is important 
because this relates to the range of potential organisms causing infection, providing an 
opportunity to identify areas to target interventions that aim to reduce AMR development.   
Infections have traditionally been categorised as hospital- or community-acquired based on 
the setting of acquisition (Cardoso et al., 2014; Kollef et al., 2008), which also applies to UTI. 
However, the last ten years witnessed changes in healthcare delivery in many countries with 
procedures that were primarily performed during hospital admission now conducted 
routinely as outpatient procedures (Horcajada et al., 2013). These changes have led to the 
emergence of a group of infections, which could not be solely categorised as hospital- or 
community-acquired infections, belonging to a wider category known as healthcare-
associated infections (HAI) (Cardoso et al., 2014). Evidence shows that patients with HAI 
have similar pathogens and outcomes when compared to patients with hospital-acquired 
infections (Bishara et al., 2012). 
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Furthermore, the changes in healthcare delivery make it difficult to clearly define what 
constitutes a healthcare setting (Sydnor & Perl, 2011). Patients freely transition within 
sometimes loosely defined levels of the healthcare system, for example between long-term 
care or rehabilitation services to acute-care centres (Sydnor & Perl, 2011), and this further 
complicates the definition of a healthcare setting, making it harder to define HAI. The 
Centers for Disease Control and Prevention (CDC) defines HAI as “a localized or systemic 
condition resulting from an adverse reaction to the presence of an infectious agent(s) or its 
toxin(s). There must be no evidence that the infection was present or incubating at the time 
of admission to the acute care setting” (Horan, Andrus, & Dudeck, 2008, p. 309). Infections 
present on admission are considered to be ‘community-acquired’ and these are not 
reported as healthcare associated (Horan et al., 2008). Although the CDC definition is 
commonly used, a recent systematic review assessing HAI definitions used in clinical studies 
found that there was still no consensus on the most appropriate definition (Cardoso et al., 
2014). For example, Friedman et al. (2002) have broadly described HAI as infections present 
at the time of, or within 48 hours of, hospital admission with the fulfilment of specific 
criteria, some of which include receiving intravenous therapy within 30 days before 
infection, being hospitalised for two days or more within the previous 90 days or residing in 
a long-term care facility. Table 1 displays other widely used definitions for healthcare 
associated, hospital-acquired and community-acquired infections. While the exact reason 
for having so many definitions is unknown, possible explanations could be the creation of 
definitions to suit specific patient populations or being based on hospital protocols. Of note, 
some of these definitions overlap, for example those used by Cullen et al. (2012) and AGAR 
(Australian Group on Antimicrobial Resistance, 2011, 2013) are similar. Furthermore, some 
are very general (National Audit Office, 2009) and others are more specific (Friedman et al., 
2002). 
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Table 1 Definitions for healthcare associated, hospital-acquired and community-
acquired infections 
Reference Healthcare-associated  Hospital-acquired Community-acquired 
Centers for 
Disease Control 
and Prevention, 
2016, p. 2–4 
“The date of event of the 
National Healthcare Safety 
Network site-specific infection 
criterion occurs on or after the 
3rd calendar day of admission 
to an inpatient location where 
day of admission is calendar 
day 1” 
 “The date of event of the 
National Healthcare Safety 
Network site-specific 
infection criterion occurs 
during the present on 
admission time period, 
which is defined as the day 
of admission to an inpatient 
location (calendar day 1), 
the 2 days before admission, 
and the calendar day after 
admission” 
National Audit 
Office, 2009, p. 
62 
“An infection acquired via the 
provision of healthcare in 
either a hospital or 
community setting” 
“An infection that 
was neither 
present nor 
incubating at the 
time of a patient’s 
admission which 
normally manifests 
itself more than 
three nights after 
the patient’s 
admission to 
hospital” 
 
Friedman et al., 
2002, p. 792 
“Infection present at the time 
of hospital admission or within 
48 hours of admission if the 
patient fulfilled any of the 
following criteria:               
(a) Received intravenous 
therapy at home; received 
wound care or specialized 
nursing care through a health 
care agency, family, or friends; 
or had self-administered 
intravenous medical therapy 
in the 30 days before the 
bloodstream infection. 
Patients whose only home 
therapy was oxygen use were 
excluded.  
(b) Attended a hospital or 
hemodialysis clinic or received 
intravenous chemotherapy in 
the 30 days before the 
bloodstream infection.  
(c) Was hospitalized in an 
acute care hospital for 2 or 
more days in the 90 days 
“Infection present 
in patients who 
had been 
hospitalized for 48 
hours or longer” 
“Infection present at the 
time of hospital admission 
or within the 48 hours after 
hospital admission”  
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before the bloodstream 
infection. 
(d) Resided in a nursing home 
or long-term care facility” 
Perrin et al., 
1999, p. 274 
 “Infections 
occurring more 
than 72 hours after 
admission” 
“Infections were considered 
community-acquired when 
they occurred within the 
first 72 hours of entering the 
care centre” 
Meier, Weber, 
Zbinden, Ruef, 
& Hasse, 2011, 
p. 334 
  “Infections were rated as 
community-acquired if they 
did not fulfill any of the 
following criteria: (1) patient 
received intravenous 
therapy or specialized 
wound care at home; (2) 
patient received 
hemodialysis treatment or 
antineoplastic 
chemotherapy in the 30 
days before the infection; 
(3) patient was hospitalized 
in an acute care center 2 
days in the 90 days before 
infection; (4) patient resided 
in a nursing home or long-
term care facility” 
Cullen et al., 
2012, p. 1200 
 “Hospital in-
patients with urine 
samples limited to 
those sent more 
than 48 h after 
admission” 
“Samples originated from 
the offices of referring GPs 
were grouped with samples 
arriving at the laboratory 
from the emergency room. 
These samples were 
grouped as ‘community 
samples’ and comprise the 
pathogens seen outside of 
the hospital setting” 
Australian 
Group on 
Antimicrobial 
Resistance, 
2012, p. 6 
 “Isolates were from 
different patients 
hospitalised for 
more than 48 
hours” 
 
Australian 
Group on 
Antimicrobial 
Resistance, 
2013, p. 9 
  “All isolates were collected 
from non-hospitalised 
patients with urinary tract 
infections, including those 
presenting to emergency 
departments, outpatient 
departments or to 
community practitioners” 
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A limitation of most studies reporting on UTI as acquired in the hospital or community is 
their inconsistent description of these settings (Kouchak & Askarian, 2012). For example, 
some papers have included all hospitalised patients when referring to hospital-acquired UTI 
(Piéboji et al., 2004) as opposed to applying a timeframe to define infection cut-off. Other 
studies have included patients after 48 hours of admission (Ma & Wang, 2013) and, further 
still, after 72 hours of admission (Perrin et al., 1999), demonstrating the variability in 
defining infection cut-off. These inconsistencies in definitions also relate to community-
acquired UTI (Gupta, Sahm, et al., 2001; Horcajada et al., 2013; Linhares et al., 2013; Perrin 
et al., 1999). Nonetheless, the most widely used cut-off period to define a community-
acquired UTI is 48 hours, based on criteria from the CDC (Horan et al., 2008). Infections 
present on or after the third calendar day of hospital admission (that is, day three and 
onwards) are considered HAI (Centers for Disease Control and Prevention, 2016). Infections 
present within two calendar days of admission, the day of admission and the day after 
admission, are considered to be community-acquired (Centers for Disease Control and 
Prevention, 2016).  
 
The use of the terminologies ‘acquired’ versus ‘onset’ is also debatable. It has been 
suggested by experts in the field of microbiology (P. Collignon, personal communication, 
May 5, 2016) that ‘onset’ might be a more appropriate term as it is often not certain where 
exactly these infections are specifically ‘acquired’ but it is assumed the symptoms and/or 
signs begin to manifest in either the hospital or community setting. In a paper reporting on 
blood stream infections, ‘community-acquired’ infections were categorised as a subset of 
‘community-onset’ infections (Hoenigl et al., 2014), which further demonstrates the 
variability in the use of these terms. There is still much ongoing debate about these terms 
with no specific ‘correct term’ agreed upon, and with these terms often used 
interchangeably.  
 
For the purpose of this research program, I used the terms ‘community-acquired UTI’ versus 
‘hospital-acquired UTI’ as opposed to a wider definition of healthcare-associated UTI. Given 
the lack of consensus on an appropriate definition for HAI as well as the wide scope of this 
definition, which may not be accurately reflected when using retrospective laboratory data, 
the main data source for this research program, it was reasonable to use the terms hospital- 
and community-acquired. Published research has demonstrated the challenges of using the 
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wider healthcare-associated definition, which may require additional work by staff 
collecting the data to identify HAI cases, validation of these data and potential bias in the 
absence of an internationally accepted definition (Mitchell, Collignon, McCann, Wilkinson, & 
Wells, 2014). The use of the 48 hour rule to define hospital-acquired UTI based on the CDC 
definition makes the studies undertaken in this research program comparable to 
internationally published research. Antimicrobial resistance patterns will also be 
investigated in community-acquired UTI using this rule, with community-acquired infections 
defined as infections occurring in the community or within 48 hours of admission. 
 
3.2.3 The use of antimicrobial susceptibility testing categories in determining resistance 
Antimicrobial susceptibility testing (AST) has been described as the most important task 
carried out by the microbiology laboratory with relevance to the management of patients 
with infections (Doern, 2011). The aim of undertaking AST is to identify the presence of AMR 
in individual bacterial isolates and to confirm susceptibility to antimicrobial agents used for 
treating a specific infection (Reller, Weinstein, Jorgensen, & Ferraro, 2009). Furthermore, 
the capacity of the microbiology laboratory to adequately perform AST has the potential to 
influence surveillance of AMR (World Health Organization, 2014). When antimicrobial 
susceptibility tests are performed for isolates, the results are categorised by the 
microbiology laboratory as susceptible (also known as sensitive), intermediate or resistant 
to an antimicrobial, using interpretative criteria known as cut-offs or breakpoints (Hindler & 
Stelling, 2007; Turnidge & Paterson, 2007).  
 
The susceptible category means that isolates are inhibited by the normally attainable levels 
of the antimicrobial agent when the recommended dosage for that site of infection is used 
(Reller et al., 2009; Turnidge & Paterson, 2007). The intermediate category refers to isolates 
for which the clinical response is likely to be less than those of susceptible isolates. This 
category also serves as a buffer zone to prevent an isolate from being categorised as 
susceptible at a certain time, and then resistant at another time, because of uncontrollable 
factors during testing (Reller et al., 2009; Rodloff, Bauer, Ewig, Kujath, & Müller, 2008; 
Turnidge & Paterson, 2007). The resistant category means that isolates are not inhibited by 
the usually attainable concentrations of the antimicrobial agent when the normal 
recommended dosage is used, and are likely to be associated with therapeutic failure (Reller 
et al., 2009; Rodloff et al., 2008; Turnidge & Paterson, 2007). These terms assist clinicians in 
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making therapeutic decisions to inform effective management of patients. Specifically, they 
provide information on whether an infecting pathogen is likely to respond to a certain 
antimicrobial when prescribed at the recommended dosage for the infection site (Jenkins & 
Jerris, 2011). It is important that the laboratory accurately categorises isolates using the 
most current recommended criteria, to prevent inaccurate reporting of patients’ test 
results, as clinicians depend on this information to decide on the choice of antimicrobial in 
the management of patients (Reller et al., 2009).  
 
While determination of the cut-offs (also referred to as breakpoints) has been the 
responsibility of the American Clinical and Laboratory Standards Institute (CLSI) – also 
formerly known as the National Committee for Clinical Laboratory Standards (NCCLS) – and 
the European Union Committee for Antimicrobial Susceptibility Testing (EUCAST), these two 
organisations are separate and often provide differing breakpoints for the same 
antimicrobial (Doern, 2011; Schreckenberger & Binnicker, 2011). This lack of one uniform 
international standard for AST prevents meaningful comparison of published resistance 
prevalence and incidence between countries and regions. Issues may also arise in within-
country comparison, as even in Australia different susceptibility testing standards are 
currently being used across the country (Australian Government, 2015). The inconsistencies 
in interpretation can be such that pathogens categorised as resistant in one laboratory 
could be categorised as susceptible when tested in another laboratory (World Health 
Organization, 2014). For this research program, the CLSI criteria were applied by ACT 
Pathology to the data used in studies two and three. The reasons for this choice, as opposed 
to EUCAST, were that the CLSI criteria were the most commonly used criteria and the CLSI 
guidelines were freely available and acceptable internationally, with the EUCAST criteria 
only becoming freely available in the last couple of years. Also, the CLSI criteria are still 
being predominantly used in most Australian laboratories, allowing for comparisons (A. Das, 
personal communication, 19 June, 2015). 
 
In analysing AST data, a decision has to be made on which of the three categories 
(susceptible, intermediate or resistant isolates) will be the focus of the analysis. For 
microbiologists and epidemiologists, the emphasis is on monitoring changes in antimicrobial 
resistance trends, therefore the proportion of resistant isolates is of greater interest in 
comparison to the proportion of susceptible isolates (Hindler & Stelling, 2007). Also, analysis 
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of resistance data has the potential to identify possible emerging resistances (Hindler & 
Stelling, 2007), which in turn could inform strategies to promptly curtail further 
development and spread of resistance. In regards to the use of intermediate isolates when 
analysing AST data, the CLSI recommends excluding intermediate isolates altogether from 
analysis of susceptibility data because clinicians generally do not prescribe antimicrobials to 
patients based on this category (Hindler & Stelling, 2007). Despite this, some studies 
reporting on urinary E. coli resistance have included intermediate isolates with resistant 
isolates in the calculation of resistance (Maraki et al., 2013; Sorlozano et al., 2014; Swami et 
al., 2012). Others have included intermediate isolates with susceptible isolates (Kahlmeter & 
Poulsen, 2012), while some studies have designated a ‘non-susceptible category’ which 
includes both resistant and intermediate isolates (Ironmonger et al., 2015). Given the 
definition of intermediate isolates, there may be some basis to their inclusion but there is 
still much debate on whether they should be included or not. For this research program, 
only isolates considered to be resistant based on AST data were included in the final analysis 
dataset. 
 
The five-year cumulative antimicrobial susceptibility data obtained from ACT Pathology for 
the second and third studies of this research program included all three categories, that is, 
susceptible, intermediate and resistant isolates. As the focus of this research program is 
monitoring resistance trends with the aim of using the results to guide local empirical 
therapy, make policy recommendations for prevention of further development of resistance 
and methodological contributions to the analysis of microbiological laboratory data, the 
main emphasis for studies two and three was the reporting and interpretation of resistance 
data, based on the CLSI recommendations. 
 
3.2.4 Approach to managing duplicate isolates 
For many patients, repeated infections requiring multiple specimen or sample collection is 
common. Repeated infections with the same or different pathogens may occur, giving rise 
to duplicate isolates from the same individual. These duplicate isolates are usually included 
in a single antibiogram (Lee et al., 2004). An antibiogram is a report of cumulative AST 
results for a specified period of time (Hindler & Stelling, 2007; Lee et al., 2004). The 
presence of duplicate isolates per patient has the potential to overestimate resistance 
(Huovinen, 1985; Lee et al., 2004; Shannon & French, 2002a).  
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To prevent overestimation or inflation of the reported resistance, efforts should be made to 
exclude duplicate isolates per patient from the antibiogram prior to data analysis, and a 
number of approaches or methods have been proposed. These include identification using 
patient-based approaches (first isolate per patient) and identification based on antibiogram 
or phenotypic pattern of the isolates (Cornaglia et al., 2004). The patient-based approach, 
also known as the time criterion, eliminates duplicate isolates by using only the first isolate 
per patient during a specific timeframe (Cornaglia et al., 2004; Hindler & Stelling, 2007). 
Each patient has an equal contribution to the total number of isolates (Hindler & Stelling, 
2007). Different time periods have been suggested to be used as a cut-off for considering an 
isolate as a duplicate. This cut-off has ranged from five days (Sahm, Marsilio, & Piazza, 1999) 
to 365 days (Shannon & French, 2002a), with longer time limits giving rise to lower 
resistance. A study investigating three time limits (5, 30 and 365 days) for exclusion of 
duplicate isolates for antimicrobial resistance surveillance found that 365 days was the most 
appropriate and excluded them after this period. This time limit was considered to be the 
best option given that patients may be admitted in hospital for long periods or may need 
therapy that requires frequent re-admission to the hospital (Shannon & French, 2002a).  
 
The method of identifying the first isolate per patient has been by far the most commonly 
used in published studies (Shannon & French, 2002a, 2002b). The CLSI guidelines also 
recommend using this approach when calculating resistance and reporting antimicrobial 
susceptibility data (Hindler & Stelling, 2007). A study comparing resistance trends over three 
years, when using the first isolate per patient and all isolates, found that the rates of 
methicillin-resistant Staphylococcus aureus did not significantly differ over time when all 
isolates were used (P=0.86), but the rates significantly decreased over the study period 
when the first isolate per patient was used (P=0.006) (Lee et al., 2004). This difference was 
attributed to the varying proportions of duplicate isolates each year (Lee et al., 2004). It is 
advised that analysis of AMR data should include each individual isolate, in order to ensure 
sensitivity, but this isolate should only be included once to guarantee specificity (Cornaglia 
et al., 2004). This is especially true for UTI where multiple samples are often sent from the 
same patient. This approach is also consistent with published studies on resistance in UTI 
pathogens including E. coli (McGregor et al., 2013; Swami et al., 2012). In addition, 
according to Bax et al. (2001) who evaluated the strengths and weaknesses of AMR 
surveillance systems, using only the first isolate per patient is reported as usual practice 
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when calculating resistance. Despite the widespread use and acceptability of this approach, 
there are a number of limitations. Using the first isolate per patient approach may lead to 
an underestimation of the resistance, by selecting only the first isolate from a single patient 
within the observation period. Also, detection of resistance selection is not possible using 
this approach (Cornaglia et al., 2004). However, this method is straightforward and can be 
easily undertaken as long as there is a unique patient identifier provided in the antibiogram 
(Cornaglia et al., 2004). 
 
A second approach involves identifying duplicate isolates from the same patient based on 
the antibiogram pattern or specific phenotypic characteristics. This involves including only 
the first isolate with a similar antimicrobial susceptibility pattern to the other identified 
isolates during the surveillance period (Cornaglia et al., 2004). For this approach, time limits 
are not required for eliminating duplicate isolates. The presence of at least one major 
difference in the antimicrobial susceptibility pattern of two isolates from a single patient 
signifies that these are different isolates and not duplicates (Cornaglia et al., 2004). To 
ideally identify duplicate isolates using the antibiogram or phenotypic pattern approach, 
antimicrobial susceptibility tests should include marker antibiotics and when these are not 
available, the differences used to identify the duplicate isolates must be clearly stated 
(Cornaglia et al., 2004). The advantage of this approach in identifying duplicate or multiple 
isolates, compared to the first isolate per patient approach, is its ability to detect selection 
of resistance (Rodríguez, Sirvent, López-Lozano, & Royo, 2003). However, using the 
antibiogram pattern criterion requires expertise from microbiological staff, making it 
subjective and difficult to verify (Rodríguez et al., 2003). Also, deciding on what 
characteristics to use to distinguish isolates may be challenging (Hindler & Stelling, 2007).  
 
Other approaches that have been suggested for identifying duplicate isolates include 
selecting the last isolate, selecting only the most resistant isolate or the most susceptible 
isolate and also calculating a weighted average of an individual patient’s susceptibility. 
These approaches are not considered more accurate than the first isolate per patient 
approach and are not generally recommended (Cornaglia et al., 2004; Hindler & Stelling, 
2007). 
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Despite the arguments for eliminating duplicate isolates from the antibiogram to prevent 
overestimation of prevalence, there are certain situations where the inclusion of all isolates 
is required. For example, in determining incidence of AMR, it is necessary to include all 
isolates in the antibiogram to accurately identify the first resistant isolate, as incidence by 
definition refers to following up an individual until development of the outcome (Buttner & 
Muller, 2011); in this case, an antimicrobial resistant E. coli UTI. Subsequent duplicate 
resistant isolates are of no importance for the incidence and need not be included after 
identifying the first resistant isolate. Without the presence of all isolates from an individual 
in the antibiogram, calculating the incidence will not be feasible because all isolates are 
needed to identify the incident case for that individual. In addition, in cases where it is 
necessary to estimate the length of time a patient has had a resistant infection, the 
presence of duplicate isolates are required (Cornaglia et al., 2004). Also, inclusion of all 
isolates in the antibiogram is necessary when calculating laboratory workload and costs (Bax 
et al., 2001). It is recommended that when duplicate isolates are identified for a single 
patient, these isolates are labelled and excluded, depending on the indication of the 
analysis. 
 
For the two studies in this research program, which utilised microbiology data from the ACT 
Pathology laboratory, both methods were used. In calculating the prevalence of resistance, 
the first isolate per patient per year was used for analysis in accordance with the CLSI 
criteria. This approach was essential to prevent overestimation of the AMR prevalence. For 
determining the incidence of resistant E. coli UTI, all isolates per patient were included in 
the dataset. Each patient was followed up until the occurrence of the outcome to identify 
incident cases, after which successive occurrences of the outcome, if any, were censored. 
Further details of the analyses are provided in the study chapters.   
 
3.3 Systematic review and meta-analysis of observational studies 
The first study in this research program aimed to systematically review the literature and 
conduct a meta-analysis of observational studies published in the last ten years, 
investigating ciprofloxacin resistance in community-acquired and hospital-acquired E. coli 
UTI. As described by the Cochrane Collaboration, “a systematic review attempts to collate 
all empirical evidence that fits pre-specified eligibility criteria in order to answer a specific 
research question” (Higgins and Green 2011, p. 1.2.2). The systematic review approach 
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makes use of an unbiased, objective and transparent process to identify, appraise and 
synthesize all literature specific to the research question (Egger & Smith, 2008). Given the 
methodological rigour of systematic reviews, they have been identified as a reference 
standard for synthesizing evidence in healthcare (Moher et al., 2015). Systematic reviews 
may include the use of statistical methods to combine and summarise the results of two or 
more primary studies in a technique referred to as meta-analysis (Greenhalgh, 1997b; 
Moher et al., 2015). Meta-analyses have the potential to provide more accurate estimates 
of the effect of the outcome on the study population compared to the estimates from single 
studies (Moher et al., 2015). They also enable investigations of the uniformity of evidence 
across studies, and provide an opportunity for investigation of differences between studies 
when they exist (Higgins & Green, 2011).  
 
Traditionally, systematic reviews and meta-analyses have been applied to randomised 
controlled trials (Stroup et al., 2000). However, certain research questions are not suited to 
the randomised controlled trial design and can only be answered using an observational 
study design, which may include cross-sectional, cohort or case-control designs (Stroup et 
al., 2000). For example, in studies of risk factors where it is deemed unethical to expose 
patients to harmful risk factors or in the case of this research program where I aimed to 
answer a research question which can only be undertaken using data from observational 
studies. In such situations, systematic reviews and meta-analyses of observational data are 
the only feasible choice. Systematic reviews and meta-analyses of observational studies 
have gained popularity in research and are now as common as those of randomised trials 
(Egger, Smith, & Schneider, 2008), despite a number of arguments about the inclusion of 
observational studies in systematic reviews. These mainly relate to the absence of 
randomisation in observational studies and differences in study designs which may lead to 
confounding and various biases (Egger et al., 2008; Shrier et al., 2007; Stroup et al., 2000). 
Notwithstanding, systematic reviews and meta-analyses of observational studies, when 
conducted with standard systematic review principles, have the potential to provide 
important evidence to inform clinical and policy decision making, including the ability to 
make recommendations for future research (Egger et al., 2008; Shrier et al., 2007; Stroup et 
al., 2000).  
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3.3.1 Conduct of the systematic review and meta-analysis 
The systematic review undertaken as part of this research program used a fixed step-by-
step process as recommended by the Cochrane Collaboration (Higgins & Green, 2011).  
 
Preparation and registration of the systematic review protocol 
First, in order to reduce the potential for bias in the systematic review process, the 
proposed methods to be used for undertaking the systematic review were carefully planned 
and documented prior to commencement of the review (Higgins & Green, 2011). These 
included the review question, search strategies, inclusion and exclusion criteria, data 
extraction process, assessment of quality of the included studies and data synthesis (Garg, 
Hackam, & Tonelli, 2008). A research protocol was prepared and registered, which is an 
essential part of the review process as it reduces the effect of reviewer bias, promotes 
consistency and transparency of the review process and reduces the likelihood for 
duplication of reviews (Higgins & Green, 2011; Moher et al., 2015). Furthermore, a protocol 
is especially important for a review of observational studies given the higher propensity for 
potential confounding factors in the individual studies (Higgins & Green, 2011). The protocol 
for undertaking this systematic review and meta-analysis providing details of the a priori 
methods was registered on the International Prospective Register of Ongoing Systematic 
Reviews (PROSPERO). This international register was established by the Centre for Reviews 
and Dissemination, University of York (Moher et al., 2015). Details of the protocol are 
provided in Appendix D. 
 
Formulation of the systematic review question 
The research or review question was defined precisely, based on the study Population, 
Intervention or exposure of interest, Comparator (if relevant) and study Outcomes, which 
are generally referred to using the acronym PICO (Higgins & Green, 2011). For this review, 
the population included studies of patients with E. coli UTI. The exposure of interest was 
studies of patients in a hospital or community setting. A comparator or control was not 
applicable and the outcome was the prevalence or incidence of ciprofloxacin resistant E. coli 
UTI in both settings. The focused approach to defining the review question was important 
because this determined whether each potentially relevant paper identified was included or 
excluded (Greenhalgh, 1997b).  
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Inclusion and exclusion criteria 
The inclusion and exclusion criteria for this systematic review were based on the 
components of the review question as well as the types of observational studies that were 
specific to answering the question. All observational study types were considered. Other 
factors considered included the distinction of the study settings into hospital or community 
and the diagnosis of UTI. As studies included in this systematic review were from different 
parts of the world, with varying laboratory protocols and patient populations in regards to 
defining UTI and setting of infection acquisition respectively, it was essential to choose a 
standard reference to make comparison in regards to the differences in study locations and 
populations. For these reasons, a colony count of 107 cfu/L (104 cfu/ml) which was used to 
confirm the diagnosis of UTI for the two studies of this research program that utilised data 
from ACT Pathology microbiology laboratory (discussed in section 3.2.1) could not be used 
for the systematic review. The CDC definition of microbiologically confirmed UTI (≥105 
cfu/ml) was selected and studies that did not use the CDC definitions were excluded. The 
widely accepted CDC definition was also used, as discussed in section 3.2.2, to classify UTI 
into hospital- or community-acquired using the 48 hour rule. For the purpose of this review, 
all studies published in non-English were retrieved but, given the time and cost constraints 
to obtain different language interpreters, these studies were later excluded. Further details 
of the study inclusion and exclusion criteria are provided in Chapter Four. 
 
Search strategy 
For this review, I undertook searches using MEDLINE, EMBASE and Cochrane electronic 
bibliographic databases. These databases are regarded as important bibliographic databases 
to use for undertaking searches of relevant literature (Higgins & Green, 2011). They index a 
large number of journal articles with some degree of reference overlapping depending on 
the topic (Higgins & Green, 2011). Although MEDLINE indexes more journals in more 
languages than EMBASE (Garg et al., 2008), EMBASE is considered to have more recent 
articles than MEDLINE, with better coverage of European literature (Greenhalgh, 1997a). In 
addition to these three electronic databases, other electronic databases searched were 
CINAHL and Scopus. These are subject specific databases which are also useful to obtain 
relevant information (Higgins & Green, 2011). Hand-searching the reference lists of articles 
identified from the databases for additional papers was also done. Authors of included 
studies were contacted when deemed necessary to obtain additional information and only 
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published studies were included. Although biomedical journals and bibliographic databases 
are commonly used sources of information for a systematic review, hand-searching the 
reference lists of retrieved articles is also an important source of identifying articles relevant 
to the systematic review and meta-analysis. Grey literature, which includes unpublished 
studies, was not included. It is suggested that they should also be included when relevant to 
the review question to prevent distortion of the results (Egger & Smith, 2008). However, the 
inclusion of unpublished studies has the potential to include data of lesser quality, given the 
high possibility that unpublished data are not peer reviewed and also may have been 
obtained through less rigorous methodological techniques, therefore making these data 
prone to bias (Crowther & Cook, 2007).  
 
A comprehensive search strategy was developed to undertake this systematic review and 
meta-analysis. For example, although the review question focused on ciprofloxacin 
resistance, the search parameters also included broad terms such as ‘antimicrobial 
resistance’ and ‘antibiotic resistance’. The use of broad search terms tailored to the PICO 
parameters ensured the systematic review process was focused enough to prevent inclusion 
of unnecessary studies but wide enough to ensure relevant studies were included. 
 
Study selection and data extraction 
After the identified studies were screened against the study inclusion and exclusion criteria, 
I proceeded with extracting the relevant information from the studies that met the criteria. 
A copy of the data extraction form is included as an appendix (Appendix E). The literature 
strongly recommends that the process of screening papers against the study inclusion and 
exclusion criteria, including extraction of data from eligible papers, should be undertaken 
independently by at least two reviewers to reduce subjectivity (Egger & Smith, 2008; Higgins 
& Green, 2011; Lyman & Kuderer, 2005). As this systematic review and meta-analysis was 
undertaken by me as partial fulfilment towards a doctoral degree, I was primarily 
responsible for undertaking the systematic review. To ensure objectivity and rigour during 
the review process, 10% of retrieved papers were screened by my supervisors and data 
from 10% of eligible papers were extracted by my supervisors. Kappa coefficient was used 
to assess agreement between me and each supervisor. 
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Quality and risk of bias assessment 
Assessment of methodological quality and risk of bias of eligible papers was also 
undertaken. As the risk of bias tool developed by the Cochrane Collaboration is better suited 
to randomised controlled trials and not observational studies, it was not applicable for use 
in this systematic review. Therefore the Newcastle-Ottawa Scale (NOS), recommended by 
the Cochrane Collaboration and shown to be valid and reliable, was used (Wells et al., 
2014). The NOS is a bias tool which judges a study against eight items categorised into three 
domains, namely, selection of the study groups, group comparability and ascertainment of 
exposure or outcome (Wells et al., 2014). It uses a star system to assess the quality of 
studies and assigns a maximum of nine stars for studies with the lowest risk of bias when 
rated against all three domains (Wells et al., 2014). I first pilot tested the Scale and the 
original items of the Scale were subsequently modified to be in line with the systematic 
review question. A copy of the modified version of the NOS used for this review is included 
as an appendix (Appendix E). 
 
The Cochrane Collaboration recommends against using scales that produce a summary 
quality score (Higgins & Green, 2011). This is because scales have been found to be 
unreliable tools for assessment of validity and are also less transparent (Higgins & Green, 
2011). Furthermore, the summary quality score involves assigning ‘weights’ to different 
items in the scale, and it is difficult to justify the weights assigned. Therefore a criterion-
based evaluation, in which critical assessments are made separately for different criteria 
with a focus on the major components of the design of the studies, is preferred (Higgins & 
Green, 2011; Stroup et al., 2000).  
 
Data synthesis 
Based on the data obtained from eligible studies, an initial descriptive analysis of the studies 
was performed. For example, the demographic characteristics of the included studies were 
described, such as the sex of the study populations, geographic location of the studies and 
study designs. Synthesis of the data also involved undertaking a meta-analysis. Meta-
analysis is a statistical approach that involves combining data from two or more individual 
studies (Higgins & Green, 2011). This quantitative analytical technique has the potential to 
increase the power and provide a more precise effect estimate than from a single study. It 
also provides an opportunity to resolve conflicting findings that may be seen in individual 
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studies (Haidich, 2011; Higgins & Green, 2011). Meta-analysis can be undertaken under the 
assumption of a fixed-effects model or a random-effects model (Egger & Smith, 2008). In a 
fixed-effects model, the assumption is that the true effect in each study is the same or is 
‘fixed’, while the random-effects model incorporates variation, allowing for heterogeneity 
between the studies (Blettner, Sauerbrei, Schlehofer, Scheuchenpflug, & Friedenreich, 1999; 
Higgins & Green, 2011). While there is no perfect method, if the choice is to use the 
random-effects model then the approach should be to identify and explain sources of 
heterogeneity rather than overlook it (Egger & Smith, 2008). A random-effects model is 
considered to be more conservative than the fixed effects model (Crowther & Cook, 2007) 
and was used in this systematic review and meta-analysis, specifically the DerSimonian and 
Laird method (DerSimonian & Laird, 1986; Higgins & Green, 2011). This method 
incorporates an estimate of the between-study variation into both the study weights and 
the standard error of the estimate of the common effect. The precision of an estimate from 
each included study was represented by the inverse of the variance of the outcome pooled 
across all studies. If the value of the pooled prevalence was within the 95% confidence 
interval, then the effect size was statistically significant at the 5% level (P<0.05). A single 
meta-analysis of all included studies was not undertaken for this review due to the presence 
of clinical heterogeneity in regards to the study setting, that is, hospital and community 
settings. Also, as the aim of the study was to compare ciprofloxacin resistance in both 
settings, comparison of the pooled rates from each setting was required. Therefore a 
separate meta-analysis was performed for studies undertaken in each setting. The outcome 
was the prevalence or incidence of ciprofloxacin resistant E. coli UTI. Meta-analysis involved 
a combination of both prevalence and incidence values with no differentiation between 
these two different statistics. Although it was very difficult to differentiate between these 
two statistics, due to underreporting of published studies, the majority of the studies were 
prevalence and only a few were considered to be incidence studies. The poor 
methodological reporting of most studies, which posed a difficulty in differentiating 
between the two statistics, was stated as a limitation in this study, presented in Chapter 
Four.  
 
Investigation of heterogeneity 
Every review process is likely to identify studies with diverse study designs, patient 
populations, interventions and methodological quality (Garg et al., 2008). Therefore, the 
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decision on whether or not it is appropriate to interpret the results of a meta-analysis 
should be made after investigating heterogeneity. Heterogeneity can either be clinical (for 
example, diverse patient populations and interventions) or statistical (inconsistent results or 
effect estimates across studies) (Crowther & Cook, 2007). An important statistic for 
quantifying statistical heterogeneity across studies is the I2 statistic (Higgins & Green, 2011). 
The I2 statistic describes the percentage variability across studies due to heterogeneity and 
not by chance (Higgins, Thompson, Deeks, & Altman, 2003). Values below 25% indicate low 
heterogeneity, 25–75% moderate heterogeneity and over 75% high heterogeneity (Higgins 
et al., 2003). For this review, heterogeneity was quantified using the I2 statistic. In addition 
to quantifying heterogeneity, an important part of undertaking a meta-analysis is 
investigating potential sources of heterogeneity (Garg et al., 2008). Heterogeneity was 
investgated in this review by undertaking subgroup analyses and by running meta-
regressions.  
 
Analysis of subgroups 
Subgroup analysis was planned for as documented in the systematic review protocol. 
Subgroup analysis may help to provide a clearer picture on the sources of heterogeneity 
(Deeks, Altman, & Bradburn, 2008; Higgins & Green, 2011). It involves sorting out studies 
into categories based on certain study characteristics and undertaking a separate meta-
analysis for each category (Gagnier, Moher, Boon, Beyene, & Bombardier, 2012). Subgroup 
analyses are usually used when the study characteristic can be grouped as categorical 
variables (Deeks et al., 2008). The choice of study characteristics or covariates to include in 
the subgroup analysis was based on knowledge of the published literature in regards to 
potential risk factors for AMR. For instance, published evidence shows that AMR varies by 
age (Adam et al., 2013) and geographical location (Gupta, Sahm, et al., 2001; Schito et al., 
2009), hence separate meta-analyses for subsets of participants based on age group and 
geographical region were undertaken for this systematic review and meta-analysis. In 
addition, the choice of covariates to include in the analysis was guided by my clinical 
expertise and supervisors.  
 
Meta-regression 
Meta-regression explores the sources of heterogeneity by comparing the effect size to the 
characteristics of the included studies (Thompson & Higgins, 2002). This approach is used 
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for study characteristics that are continuous variables and also those that are categorical 
variables (Deeks et al., 2008; Thompson & Higgins, 2002). Meta-regression uses an approach 
similar to linear or logistic regression where the outcome variable is predicted by the values 
of one or more covariates (Higgins & Green, 2011; Thompson, 2008). The outcome variable 
refers to the effect estimate (Higgins & Green, 2011), which in this research program is the 
ciprofloxacin resistance, while the covariates are the characteristics of the included studies 
that have the potential to modify the size of the effect estimate (Higgins & Green, 2011). An 
advantage of meta-regression is the ability to allow multiple covariates to be evaluated 
simultaneously (Baker, White, Cappelleri, Kluger, & Coleman, 2009; Higgins & Green, 2011). 
Despite this advantage, the lack of complete data from individual studies, as well as the 
inclusion of a limited number of studies in most systematic reviews, has been identified as 
limitations to undertaking a meta-regression as there may be a potential bias to interpreting 
the results (Thompson & Higgins, 2002). It is therefore recommended that this statistical 
procedure is not used when there are less than ten studies included in the meta-analysis 
(Higgins & Green, 2011). As there were more than ten studies included in the meta-analysis 
for this systematic review, a meta-regression was feasible.   
 
Similar to meta-analysis, the fixed-effects and random-effects models also apply to meta-
regression (Baker et al., 2009). In a fixed-effects model, the effect estimate among studies is 
assumed to be the same or fixed and any difference noted between studies is as a result of 
chance, while the random-effects model assumes that the effect estimate is different across 
the studies and allows for incorporation of the heterogeneity that cannot be explained by 
the covariates (Baker et al., 2009; Thompson & Higgins, 2002). For this systematic review 
and meta-analysis, I chose to use a random-effects meta-regression to take into account any 
residual variability between the studies not due to the covariates. The meta-regression 
analysis produces a regression coefficient which describes changes to the outcome variable 
based on a unit increase in a covariate (Baker et al., 2009; Higgins & Green, 2011). A positive 
coefficient indicates an increase in the outcome variable while a negative coefficient is 
consistent with a decrease (Baker et al., 2009). The test of statistical significance indicates 
whether or not a linear relationship exists between the outcome variable and covariate 
(Higgins & Green, 2011). 
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Assessment of publication bias 
Publication bias is described as the favoured publication of studies with statistically 
significant results (also encompasses studies published in English (language bias), studies 
that are freely available or cheap to purchase (cost bias) (Rothstein, Sutton, & Borenstein, 
2006)). Including such studies alone in a systematic review and meta-analysis has the 
potential to distort the review findings (Egger, Dickersin, & Smith, 2008). Assessment of 
publication bias was undertaken by visual inspection of the funnel plot analysis. The funnel 
plot is a graph of the effect estimates from the individual studies included in the systematic 
review against the sample size (Egger, Smith, Schneider, & Minder, 1997). It is similar to a 
simple scatter plot but differs in that the effect estimate is plotted on the horizontal axis 
and the sample size on the vertical axis (Sterne, Egger, & Smith, 2008). It appears as an 
inverted funnel when there is no bias with the effect estimates from small studies scattering 
more widely at the lower end of the graph and narrowing upwards with large studies. An 
asymmetrical funnel plot may signify presence of publication bias (Sterne et al., 2008). 
 
Reporting of the systematic review and meta-analysis 
Reporting of the systematic review and meta-analysis, which was undertaken as part of this 
research program, was guided by and complied with the guidelines on preferred reporting 
items for systematic reviews and meta-analyses (PRISMA) (Liberati et al., 2009). Guidelines, 
for example PRISMA and Meta-analysis Of Observational Studies in Epidemiology, have 
been developed to assist authors with the process of reporting systematic reviews and 
meta-analyses, to decrease the likelihood of misleading conclusions and reduce the 
inadequacy of reporting (Moher, Liberati, Tetzlaff, & Altman, 2009; Stroup et al., 2000). 
Chapter Four provides the results of the systematic review and meta-analysis. 
 
3.4 Statistical analysis of microbiological laboratory surveillance data 
The second and third studies of this research program utilised retrospective data from a 
regional microbiological laboratory, ACT Pathology. Study two aimed to evaluate AMR 
temporal trends and compare the prevalence of AMR in hospital-acquired and community-
acquired E. coli UTI at the Canberra Hospital over a five-year period. Study three aimed to 
evaluate the incidence and risk of antimicrobial resistant E. coli UTI in a cohort of ACT 
residents over a five-year period. The microbiological laboratory, as previously stated in the 
literature review chapter (Chapter Two), has been identified as a rich source of untapped 
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data in regards to surveillance of AMR (Cornaglia et al., 2004). Retrospective studies 
evaluate events that have already occurred before the study onset, for example, evaluating 
previously collected patient records in a database (Buttner & Muller, 2011; Sedgwick, 
2013b). In comparison, prospective studies evaluate events that occur after the study 
begins. Retrospective designs allow timely access to data and overcome the long follow-up 
period to development of the outcome associated with prospective designs (Euser, Zoccali, 
Jager, & Dekker, 2009). The main disadvantage of retrospective studies is the likelihood for 
incomplete data with respect to potential risk factors associated with the outcome under 
study, as the researcher has no control over data that have been collected in the past (Euser 
et al., 2009; Sedgwick, 2014; Song & Chung, 2010). However, retrospective studies analysing 
large amounts of AST data over a period of time are able to provide important data on AMR 
trends as well as changes in resistance and also generate information to guide clinical 
decision making (Shaban et al., 2013). The results from analyses of these data will assist with 
the development of policies towards control and further development of AMR in hospital 
and community settings and also at a population level. These results can be achieved by 
applying different statistical analyses, which may have some methodological challenges. The 
following sections discuss the statistical techniques used in undertaking studies two and 
three of this research program. When a statistical technique was applied to only one of 
these two studies, this will be stated. 
 
3.4.1 Approach to calculating the prevalence of resistance  
Study two evaluated AMR temporal trends and compared the prevalence of AMR in 
hospital-acquired and community-acquired E. coli UTI at the Canberra Hospital from January 
2009 to December 2013. This study followed a cross sectional design, making it a ‘period 
prevalence study’ because of the five-year period. Prevalence quantifies the proportion of 
people with the disease either at a specified point in time (point prevalence) or during a 
particular period of time (period prevalence) (Buttner & Muller, 2011). In period prevalence, 
both prevalent (pre-existing) and incident (new) cases of the disease are included in the 
numerator and the denominator is usually the total population during the observation 
period (Buttner & Muller, 2011). Prevalence is generally used to evaluate the occurrence or 
burden of a specific disease in the hospital, community and population as a whole.  
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In calculating the prevalence of antimicrobial resistant E. coli UTI, the data were analysed in 
a stepwise fashion. The first step was a descriptive analysis of the whole dataset containing 
information on the distribution of all urine samples processed by the microbiology 
laboratory for Canberra Hospital during the five-year period. The descriptive analysis 
entailed calculating the yearly and overall five-year proportions of positive bacterial urine 
samples and specifically positive E. coli urine samples, including the number of samples 
requested per patient each year. This analysis was important to determine whether there 
had been any change in the urine sample requesting pattern over the study period. The next 
step involved calculating the overall prevalence of resistance as well as the prevalence of 
resistance based on setting of acquisition, that is, hospital or community. The dataset was 
limited to the first isolate per patient based on the principles discussed previously (section 
3.2.4), in regards to handling duplicate isolates. Hence, only the first positive E. coli UTI per 
patient per year was included in the analysis. It is important to note that this first positive 
culture was not necessarily resistant. The numerator was the number of antimicrobial 
resistant E. coli UTI. Urinary E. coli resistance was checked for against 12 antimicrobials, 
namely: ampicillin/amoxicillin; amoxycillin-clavulanate; cefazolin/cephalexin; trimethoprim; 
nalidixic acid; ciprofloxacin; nitrofurantoin; gentamicin; ceftriaxone; trimethoprim-
sulphamethoxazole; meropenem, and piperacillin-tazobactam. The choice of an appropriate 
denominator for calculating the prevalence required careful consideration because of the 
complexities associated with analysing microbiological laboratory data. This is discussed in 
the next paragraph. 
 
A major challenge of using microbiological laboratory data is the occurrence of selection 
bias due to selection of patients who have urine samples sent for culture. Cultures are often 
biased towards patients with recurrent and complicated UTI as well as those with resistant 
infections (Gupta et al 2011). For example, the Australian Therapeutic Guidelines described 
in section 1.3.1 of the Introduction chapter (Chapter One) recommends that urine samples 
for cultures and susceptibility testing should be obtained from pregnant women, men, aged 
care residents, patients who have recently taken antimicrobials or failed treatment, patients 
with recurrent UTI and those who have travelled internationally within the past six months. 
Therefore, evaluating resistance based on selection of samples from these patients has the 
potential to skew the data to more resistant cases and falsely elevate the resistance levels.  
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Another challenge worth highlighting is the potential for testing bias resulting from the 
analytic methods used in laboratories (Cornaglia et al., 2004; Hindler & Stelling, 2007). Some 
laboratories, including ACT Pathology, undertake routine first-line AST followed by more 
extensive testing with second-line antimicrobials only for isolates resistant to at least three 
of the routine antimicrobials. The routine first-line antimicrobials tested for the research 
study were ampicillin/amoxicillin, amoxycillin-clavulanate, cephalexin/cefazolin, 
trimethoprim, nalidixic acid, ciprofloxacin, nitrofurantoin and gentamicin. The isolates which 
were found to be resistant to at least three of the routinely tested antimicrobials were 
tested against second-line antimicrobials, namely ceftriaxone, trimethoprim-
sulphamethoxazole, meropenem and piperacillin-tazobactam. Calculation of resistance 
prevalence for urinary E. coli isolates tested against second-line antimicrobials, using the 
total number of isolates tested against each agent as the denominator, may bias the results 
towards a higher prevalence of resistance (Cornaglia et al., 2004; Hindler & Stelling, 2007). 
Preliminary analysis using the total number of isolates tested against each antimicrobial as 
the denominator demonstrated that this potentially could overestimate the resistance for 
the second-line antibiotics. To overcome this potential limitation, isolates which had only 
first-line antimicrobials tested were separated from the ones which had additional testing 
with second-line antimicrobials. The total number of isolates tested was used as the 
denominator for those isolates that were tested against second-line antimicrobials. This was 
the most appropriate denominator choice to use based on the assumption that isolates 
were initially not tested for second-line antimicrobials, because they were considered highly 
unlikely to be resistant to these antimicrobials. The denominator therefore also included 
those isolates tested for first-line antimicrobials. Using this approach reduced the risk of 
overestimating resistance prevalence but, on the other hand, it could have underestimated 
the true resistance prevalence. 
 
3.4.2 Comparison of resistance prevalence in hospital- and community-acquired UTI 
Comparison of data based on different patient characteristics, including setting of infection 
acquisition, is essential for evaluating resistance trends (Cornaglia et al., 2004). Often, data 
needed for these comparisons are lacking in terms of quality. This may be attributed to poor 
recording of patient clinical information on laboratory forms, including an absence of 
computing systems that are able to link patient medical records to laboratory records 
(Cornaglia et al., 2004). The wide reach of ACT Pathology, the microbiology laboratory from 
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which data were obtained for studies two and three, further contributed to the uniqueness 
of the dataset in regards to undertaking comparisons based on the setting of infection 
acquisition, that is, hospital or community. The ACT Pathology laboratory provides specialist 
pathology services to: patients of public and private hospitals; specialist and general 
practitioner clinics; nursing homes, and the general community. Given the wide reach of 
ACT Pathology with the potential for incompleteness of data, comparison based on the site 
of infection acquisition was only undertaken in study two, which evaluated the prevalence 
of AMR at a single hospital.   
 
As described earlier in this chapter (section 3.2.2), positive urine cultures were classified 
into hospital- and community-acquired UTI using criteria from the CDC definition (Horan et 
al., 2008). Samples collected 48 hours or more after admission and within 48 hours after 
discharge were termed hospital-acquired, and samples collected within 48 hours of 
admission or from outpatients were classified as community-acquired. To ensure valid 
comparisons based on setting of acquisition, the data had to be thoroughly managed and 
evaluated to detect any errors. The admission dataset was obtained separately from the 
medical record service of the hospital and contained information on admission and 
discharge dates. This required merging with the laboratory dataset. Factors which posed 
methodological challenges included incorrectly entered and missing unique patient 
identification numbers as well as patient administrative discharges that did not necessarily 
indicate separate hospital admissions. An administrative discharge refers to patients who 
have been technically discharged and no longer in full care of the hospital, for example, 
geriatric patients waiting to be transferred to aged care facilities (Department of Health 
Western Australia, 2012). For such patients, the first admission date and last discharge date 
were considered. All observations without a unique patient identification number were 
excluded from the final analysis as it was impossible to classify samples from these patients 
as hospital- or community-acquired. Also, these could have included duplicates of existing 
resistance isolates. Although these observations were not included in the main analysis, 
they were included as part of the descriptive analysis for all urine samples described above, 
in section 3.4.1. After the cleaning and merging of the two datasets (laboratory and 
admission datasets), date of admission to the hospital was used to calculate the interval 
between admission and urine sample collection. The discharge date was used to correlate 
for hospital-acquired infections to ensure the sample was taken when the patient was an 
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inpatient or within 48 hours after discharge. Observations with a unique patient 
identification number but no admission date were grouped as community samples, as these 
were outpatients who did not require hospital admission although they were managed in 
the hospital (A. Das, personal communication, February 11, 2015). 
 
The calculated resistance prevalence was compared between hospital- and community-
acquired E. coli UTI. Sample size was estimated to ensure the study was adequately 
powered to detect a clinically significant difference in resistance between the two groups. 
Some of the considerations when calculating a sample size include the type I error (also 
referred to as alpha), power, the clinically relevant difference and variability (Noordzij et al., 
2010). Type I error occurs when we incorrectly reject the null hypothesis when it is actually 
true that there is no difference between the groups (Jones, Carley, & Harrison, 2003). 
Conventionally, the alpha or type I error is set at 0.05 meaning that the probability of 
reaching a false positive conclusion and rejecting the null hypothesis is less than 5% 
(Noordzij et al., 2010). The power of a study refers to the probability of correctly detecting a 
difference between two groups if it truly exists (Whitley & Ball, 2002). Power prevents the 
occurrence of a type II error (also referred to as beta), which means falsely accepting the 
null hypothesis (false negative conclusion) when there is in fact a difference between the 
two groups (Jones et al., 2003; Noordzij et al., 2010). The beta is conventionally set at 0.20, 
meaning that the probability of reaching a false negative conclusion and accepting the null 
hypothesis is less than 20% (Noordzij et al., 2010). The clinically relevant difference is the 
smallest effect of interest between the two groups that is hoped to be detected by 
undertaking the study and the variability refers to the standard deviation of the variable of 
interest in the study population (Jones et al., 2003; Noordzij et al., 2010). The clinically 
relevant difference and variability are usually estimated using data from similar published 
studies or pilot studies and may be combined to give an effect size (Noordzij et al., 2010). In 
calculating the sample size for hospital- and community-acquired UTI in this research 
program, an alpha of 0.05%, power of 80% and effect size estimated from published 
research (Cullen et al., 2012) were used. Further details of the methods for study two are 
provided in Chapter Five. 
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3.4.3 Approach to calculating the incidence of resistance 
Study three evaluated the incidence and AMR trend in a cohort of ACT residents over a five-
year period using a laboratory-based retrospective cohort study design (Buttner & Muller, 
2011). Incidence quantifies the number of new (incident) cases of a condition (e.g., a 
disease) in people at risk of developing the condition during a specified time period (Buttner 
& Muller, 2011; Porta, 2014). Incidence may be expressed as a proportion (sometimes called 
cumulative incidence) or as a rate (referred to as incidence rate or person-time rate). The 
cumulative incidence refers to the proportion of people who are initially disease-free and 
develop the disease during a specified time period (Buttner & Muller, 2011; Centers for 
Disease Control and Prevention, 2012). The denominator for the cumulative incidence is the 
initial people who are at risk. It can also be described as the probability of developing a 
disease over a specific period of time and as such is a measure of risk. In contrast to 
cumulative incidence, the incidence rate incorporates ‘time’ into the denominator and is 
calculated as the number of new cases of disease during a specified period of time divided 
by the total disease-free time each person was observed (Buttner & Muller, 2011; Centers 
for Disease Control and Prevention, 2012).  
 
For estimating incidence, it is necessary to define the initial disease-free people who are at 
risk of developing the disease, as incidence involves following up people who are healthy to 
detect those who develop the disease or otherwise stay disease-free. Such cohort studies 
may involve observing a large group of people for a sufficient number of years to generate 
reliable incidence data, using persons or person-time of observation as the denominator. 
The denominator for calculating incidence should exclude all pre-existing disease cases 
(prevalent cases) to clearly identify the initial disease-free population at risk for developing 
the outcome (Buttner & Muller, 2011). In reality it may be difficult to obtain an accurate 
estimate of the disease-free people at risk and this limitation should be acknowledged when 
reporting results of cumulative incidence (Buttner & Muller, 2011). Furthermore, as people 
are enrolled or enter studies at different times, and also leave at different times for various 
reasons (development of the outcome or change location), the dynamic nature of 
populations constantly changes the people at risk (Buttner & Muller, 2011; Vandenbroucke 
& Pearce, 2012). 
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For this research project, the incidence of antimicrobial resistant E. coli UTI was measured 
using the cumulative incidence or incidence proportion. The five-year AST microbiological 
laboratory data was such that people submitted urine samples to ACT Pathology at different 
calendar time periods, highlighting the dynamic nature of populations with people entering 
and leaving the study at various time points. Multiple samples were also submitted to the 
laboratory from the same individuals. All urine samples submitted by people in the cohort 
over the five-year period were included in the analysis dataset. Hence the inclusion of all 
urine samples in the dataset, with the presence of multiple rows per person, allowed the 
creation of a ‘follow-up’ of each person as opposed to restricting the dataset to the first 
isolate per person. This demonstrates how AST data can be used not only for identifying 
prevalence of resistance but also incidence. The date of submission of first urine sample to 
the laboratory during the study period was taken as the follow-up start date for each person 
in the cohort. All urine samples submitted were followed up until the development of the 
outcome, which is antimicrobial resistant E. coli UTI. The first development of the outcome 
in each person was identified as an incident case comprising the numerator. Determination 
of the denominator involved defining all the people at risk of developing the outcome. 
These were people who submitted a urine sample to ACT Pathology, were ACT residents and 
were free of an antimicrobial resistant E. coli UTI at the start of follow-up. To identify the 
people at risk, it was important to define a period free of infection. As this was a 
retrospective study with data obtained from the 1st of January 2009, ideally all those with 
the outcome on this date needed to be excluded. Given that data from December 2008 
were not available to distinguish people who had an infection carried from the previous 
year from those who truly had an incident infection on the 1st of January 2009, excluding 
people with the outcome on the 1st of January had the potential to underestimate the 
incidence of resistance. As stated in the previous paragraph, determination of the people at 
risk is generally one of the difficulties when estimating cumulative incidence, more so with 
laboratory data which are not collected for research purposes. Hence for this research 
program, the denominator used for calculating the five-year cumulative incidence was the 
cohort of ACT residents who submitted urine samples to ACT Pathology for processing over 
the five-year period. The denominator for calculating the annual cumulative incidence was 
the cohort of ACT residents who submitted urine samples each year. 
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Calculating an incidence rate as opposed to a cumulative incidence was not practical 
although it overcomes the problems associated with dynamic populations (Buttner & 
Muller, 2011). The incidence rate relies on the total time each person was observed until 
the development of the outcome, loss to follow-up, death or end of study (Centers for 
Disease Control and Prevention, 2012). As retrospective microbiological laboratory data 
were used for determining the incidence and individuals were not actually ‘followed up’, 
precise calculation of the person-time of observation was not feasible. Individuals who did 
not develop the outcome were censored at the end of follow-up. It is possible that some 
may have redeveloped symptoms of UTI but not have had a urine sample taken or, further 
still, the urine sample may have been processed elsewhere.  
 
Therefore to maximize use of the available laboratory data, while acknowledging the 
strengths and limitations of both cumulative incidence and incidence rate, the cumulative 
incidence was used to determine incidence of AMR for this research program. Further 
methodological details and results of the incidence of AMR are reported in Chapter Six. 
 
An important issue I considered when evaluating the incidence of resistance in the cohort of 
ACT residents was determining how representative of the whole ACT population was the 
cohort of residents who submitted urine samples for processing to ACT Pathology. As 
mentioned in Chapter One, the ACT Pathology laboratory provides specialist pathology 
services to patients in the region and this includes patients in public and private hospitals, 
specialist clinics, general practice clinics, nursing homes and the community (ACT 
Government, 2015a). Almost 100% of urine samples from all inpatients of public hospitals 
in the ACT, as well as people attending emergency departments and specialist outpatient 
clinics of the public hospitals, are processed by ACT Pathology. The non-public hospital 
samples are processed by either ACT Pathology or private laboratories in the ACT (P. 
Collignon, personal communication, 8 November, 2016). This mix of laboratories makes it 
difficult to estimate incidence. In addition, the AST method used by private laboratories 
differs slightly from the CLSI method used by ACT Pathology, which was described above in 
section 3.2.3 (A. Das, personal communication, 8 November, 2016), further limiting the 
estimation of resistance incidence. To obtain as close an estimate as possible for the 
number of non-public hospital urine samples (private hospital and community samples) 
processed by ACT Pathology, data were obtained from the Medicare statistics website 
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(Medicare Australia, 2016). As previously mentioned in the introduction chapter (Chapter 
One), the funding contribution by the Australian Government towards healthcare includes 
the Medicare scheme (Australian Institute of Health and Welfare, 2014). Medicare provides 
free or subsidised healthcare to all Australians and this includes the cost of most laboratory 
investigations (Australian Institute of Health and Welfare, 2014). Urine sample examination, 
which includes examination for cell count, culture, colony count and AST, is covered under 
Medicare item number 69333 (Medicare Australia, 2016). There were a total of 283,543 
requests for this item billed to Medicare for the five-year study period from January 2009 to 
December 2013 in the ACT (Medicare Australia, 2016). This number excludes urine sample 
requests ordered for public patients in public hospitals, which are funded under a different 
arrangement (Medicare Australia, 2016; A. Das, personal communication, 11 November, 
2016). A total of 146,915 urine samples belonging to patients whose residential status was 
ACT were processed over the five years by ACT Pathology. Of these samples, 110,791 
belonged to inpatients of public hospitals in the ACT as well as people attending 
emergency departments and specialist outpatient clinics of the public hospitals. It is 
important to note that for billing purposes, emergency department patients are 
categorised as public hospital patients (A. Das, personal communication, 11 November, 
2016). The remaining 36,124 samples of the 146,915 samples processed by ACT Pathology 
belonged to non-public hospital patients (that is, private hospital and community 
samples), which are billed to Medicare by ACT Pathology (A. Das, personal communication, 
11 November, 2016) and therefore inclusive of the 283,543 samples billed to Medicare 
over the five years. Private laboratories therefore process the majority of private hospital 
and community samples in the ACT which are billed to Medicare (283,543-
36,124=247,419).  
 
Based on the available information described above, I therefore estimated that ACT 
Pathology processes approximately 100% of urine samples from inpatients, emergency 
department and specialist outpatient clinic patients of public hospitals, and at least 13% of 
urine samples from patients in the community and private hospitals whose residential 
status is ACT. The cohort comprised 57,873 ACT residents whose urine samples were 
processed at ACT Pathology during the period of 1st January 2009 to 31st December 2013, 
of whom an estimated 71% were inpatients, emergency department and specialist 
outpatient clinic patients of public hospitals and the remaining 29% were patients in the 
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community and from private hospitals. Although the incidence of resistance evaluated in 
this research program is not representative of the ACT population, the results reported in 
the thesis are the best available incidence to date on E. coli UTI resistance in the ACT.  
 
3.4.4 Estimating the effect of factors that may predict AMR 
During statistical analysis, it is important to adjust for the presence of covariates or patient-
related factors because this may provide information on the risk of development of AMR in 
individuals. Patient-related factors include continuous variables such as age or categorical 
variables like sex (Bradburn, Clark, Love, & Altman, 2003; Clark, Bradburn, Love, & Altman, 
2003). For studies two and three of the research program, certain variables potentially 
available in the microbiological laboratory dataset were considered to account for potential 
risk factors for resistance. These variables were: age; sex; hospital length of stay; hospital 
ward; presence of catheter; diagnosis related group (DRG) codes; origin of urine sample, 
and socioeconomic status. The DRG is a classification system that categorises the episodes 
of care of patients admitted to hospital into groups with similar medical conditions and 
usage of hospital resources (Australian Institue of Health and Welfare, 2016). The sample 
origin refers to the health service requesting or ordering the urine sample test. 
Socioeconomic status was determined using the Australian Socio-Economic Indexes for 
Areas, based on the residential postcode. This index score ranks areas in Australia based on 
their relative socioeconomic indicators of advantage and disadvantage, with lower scored 
areas being more disadvantaged than higher scored areas.  
 
To allow for proper comparison, variables that were only available for one comparison 
group were not used. These included the hospital length of stay, hospital ward and DRG, 
which were only available for patients with hospital-acquired UTI. In addition, there were 
limitations to stratifying the data based on the hospital ward variable because patients may 
not necessarily be admitted on a ward based on their diagnosis. Data on the presence or 
absence of catheter could not be included in the analysis due to the poor quality of 
reporting on this variable, with a lot of missing data. Administrative coding data procedural 
codes (International Statistical Classification of Diseases and Related Health Problems, Tenth 
Revision (ICD-10)) were considered for use as an alternative to assess for presence of 
catheter specimens, but as evidence shows that coding data underestimates catheter use in 
hospitals (Gardner, Mitchell, Beckingham, & Fasugba, 2014), evaluating this potential risk 
101 
 
factor was not feasible. Although the variables described above were recognised as 
potential risk factors for resistance development, examination of the data fields revealed 
the methodological problems associated with analysing retrospective microbiological 
laboratory data. These data are not collected primarily for the purpose of the research being 
undertaken, with the likelihood for missing data on potential risk factors. Based on the 
available data, the potential confounders to account for resistance in the analysis were age, 
sex, origin of urine sample and socioeconomic status.  
 
Multiple covariates can be adjusted for using multivariate modelling techniques. The first 
technique I considered for studies two and three was the Cox Proportional Hazards 
Regression, which is a semi-parametric survival analysis or “time-to-event” analysis 
technique that describes the relationship between the incidence of an event and a set of 
covariates (Bradburn et al., 2003; Cox, 1972). Microbiological laboratory data is such that 
patients submit samples at different times, meaning that participants enter and leave the 
study as occurs in a dynamic population. Therefore, not all patients are observed for the 
same length of time and some have not developed the event of interest at the end of the 
follow-up period and are therefore right censored (Bradburn et al., 2003; Buttner & Muller, 
2011). Right censoring occurs when a patient does not experience the outcome by the end 
of the study, or is lost to follow-up during the study, or experiences an event outside the 
outcome that prevents further follow-up (Clark et al., 2003). These features make 
microbiological laboratory data suitable for the application of survival analysis approaches, 
including Cox analysis and Kaplan-Meier plots. Kaplan-Meier plots describe and compare 
graphically the time to event by variables of interest (Balakrishnan, 2014). As study two 
evaluated prevalence and Cox analysis is better suited to incidence studies, Cox analysis was 
no longer considered a suitable technique for study two. Time series models were used for 
study two, which is discussed below in the subsequent section (section 3.4.5).  
 
For this research program, the time to event is the time to occurrence of an antimicrobial 
resistant E. coli UTI. The period of observation starts from the day a urine sample is 
submitted to ACT Pathology for processing and finishes either when the event occurs, last 
healthcare encounter or the study end date. In preparing the dataset for study three for Cox 
analysis, preliminary analysis showed that restricting the data to the first positive E. coli UTI 
per person, an approach used by other studies which assessed incidence of resistant urinary 
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E. coli isolates (Swami et al., 2012), did not allow Cox regression analysis to be undertaken. 
This was because it excluded the time to event component of the data and did not allow the 
follow-up period to be clearly defined. Kaplan-Meier curves generated were also not 
indicative of incidence. Hence to appropriately define the follow-up period for each 
individual to undertake Cox analysis, inclusion of all urine samples belonging to the cohort 
of ACT residents over the five-year period was necessary. This has been previously described 
in section 3.4.3 above, discussing the approach to calculating the incidence of resistance. 
After undertaking the Cox regression analysis, it is important to verify that the proportional 
hazard assumption holds to ensure meaningful interpretation of the results. This 
assumption means that the hazard of the event in a group is a constant multiple of the 
hazard in the other group. That is, both hazard curves are proportional over time and do not 
overlap (Bradburn et al., 2003; Clark et al., 2003). Violation of the proportional hazard 
assumption was verified in the data, using the scaled Schoenfeld residuals statistical test 
(Grambsch & Therneau, 1994), preventing the use of Cox regression analysis for study three. 
 
The logistic regression model was considered as a statistical method to adjust for the effect 
of multiple covariates on resistance risk because it is appropriate for binary outcomes (in 
this instance, resistance – ‘yes’ or ‘no’). Logistic regression is a statistical analysis technique 
that is able to investigate the relationship between an outcome variable (for example, 
antimicrobial resistance) and one or more covariates or predictor variables (age, sex etc.) 
simultaneously (Balakrishnan, 2014; Sedgwick, 2013a). It is well suited to binary outcome 
variables because it is a flexible and easily used mathematical function and also provides a 
meaningful interpretation of the analysis (Balakrishnan, 2014). It estimates the probability 
of occurrence of the outcome, based on the values of the covariates or predictor variables 
(Sedgwick, 2013a). In the presence of two or more covariates, the logistic regression model 
is extended to the multiple or multivariate logistic regression model (Tai & Machin, 2013). 
The logistic regression results are typically presented as odds ratios, which refer to the ratio 
of the probability of occurrence of the outcome in the presence of a covariate to the 
probability of the occurrence of the outcome in the absence of the covariate (Bland & 
Altman, 2000). This method was therefore used for study three. 
 
The Hosmer-Lemeshow test was used to assess the goodness of fit of the model (Archer & 
Lemeshow, 2006). In this research program, multivariate logistic regression models were 
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constructed for each antimicrobial agent and assessment of the models showed good fit to 
the data. Additional detail is provided in Chapter Six, which discusses study three. 
 
3.4.5 Approach to calculating change in resistance patterns over time 
To examine the changes in AMR patterns over time in study two, time series analysis was 
considered an appropriate statistical analysis technique because the dataset contained 
observations with a time-ordered sequence. That is, observations in the dataset are 
arranged according to the time of AMR development. This time-ordered sequence is 
referred to as time series and the statistical method applied to time series data is called 
time series analysis (Wei, 2013). The three main concepts in time series analysis include 
trend, serial dependence and stationarity (Crawley, 2012). Trend refers to a consistent 
upward or downward direction of the data. Serial dependence means that observations in a 
time series may be correlated with one another, and stationarity means that the time series 
data does not change over time, that is, no trend (Crawley, 2012). In certain situations, such 
as for antimicrobial susceptibility test data, the data demonstrate non-stationary 
phenomenon with time-varying resistance patterns. In addition, time series data may 
demonstrate seasonal cycles (Wei, 2013). Seasonality is a pattern that shows periodic 
repetitive fluctuations over time (Wei, 2013).  
 
Time series data can be fitted to one of three models. These include the autoregressive 
model, moving average model and autoregressive moving average model (Box & Jenkins, 
1976). As the name implies, the autoregressive model regresses the variable under 
observation against past values of itself (Crawley, 2012). The moving average model 
averages the random variations in observations over a certain time period. It is the easiest 
way of identifying patterns in time series data (Crawley, 2012). The autoregressive moving 
average model includes the properties of both the autoregressive and moving average 
models. These models are incorporated in commonly used statistical analysis software. For 
the purpose of this research program, time series analysis was used to identify trends and 
seasonal variation in resistance patterns. A non-stationary autoregressive model was 
constructed and multiple time series models were fitted to also account for patient risk 
factors. The Dickey-Fuller and augmented Dickey-Fuller tests were used to assess a unit root 
in the time series data. These unit root tests investigate whether a time series variable (in 
this instance, resistance) is non-stationary using the autoregressive model (Dickey & Fuller, 
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1979). Both the Dickey-Fuller and augmented Dickey-Fuller statistics are negative numbers; 
the more negative, the stronger the rejection of the null hypothesis (that there is unit root 
at some level of confidence). 
 
The choice of time unit used in the time series analysis was based on exploratory analysis I 
undertook, using various time intervals. Yearly rates were not a suitable choice due to loss 
of power with too few data points. Also, the time series plots did not show the true picture 
of the fluctuating rates. Of all available analytic options, quarterly data provided a better 
picture of the trend in antimicrobial resistance patterns and this was further investigated on 
a seasonal basis. Further information is provided in Chapter Five, which reports on study 
two. 
 
3.5 Ethical considerations 
The National Statement on Ethical Conduct in Human Research (National Health and 
Medical Research Council, Australian Research Council, & Australian Vice-Chancellors’ 
Committee, 2014) informed the design, ethics and conduct of this research program. For 
study one of the research program ethics approval was not obtained because the systematic 
review and meta-analysis undertaken in this study utilised aggregate data from published 
studies, for which ethics approval had already been granted. Furthermore, there are 
currently no processes in place for ethical approval of systematic reviews (Vergnes, 
Marchal-Sixou, Nabet, Maret, & Hamel, 2010). Despite this, the research program complied 
with the guidelines for merit and integrity. For studies two and three, ethics approval was 
obtained from ACT Health Human Research Ethics Committee (ETHLR.14.223) and 
Australian Catholic University Human Research Ethics Committee (2014 276N) (See 
Appendices F.1 and F.2 respectively for approval letters). Additional approval for the 
supplementary data on antimicrobial use included in study two was obtained from ACT 
Health Human Research Ethics Committee and the Executive Director Performance 
Information Branch, ACT Health (See Appendices F.3 and F.4). The specific principles 
relevant to these studies are informed consent, and privacy and confidentiality (National 
Health and Medical Research Council et al., 2014), which are discussed below. 
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3.5.1 Informed consent 
Consent from individual patients to participate in studies two and three was not obtained 
and approval was granted to waive consent. Section 2.3.9 of the National Statement on 
Ethical Conduct in Human Research outlines the principles for waiving consent. It was 
impracticable to obtain consent for a number of reasons, consistent with the rationale in 
the National Statement. These reasons are discussed. 
 
The research is low risk with no interventions and no harm or discomfort as a result. Also, 
the results of the research are not individualised or, indeed, patient identifiable. Conduct of 
the research did not require direct involvement of patients, but only collected existing 
information obtained as a result of their contact with the laboratory. The second and third 
studies undertaken in this research program aggregated existing data in a manner which 
enabled the proposed research question to be answered. Furthermore, no other 
alternatives for fuller disclosure were possible. A patient will have a urine sample taken 
based on the clinical assessment and decisions of the treating medical practitioner. A urine 
sample can be taken for any number of reasons and any number of organisms may be 
found. If consent from the patient was required in this instance, it would mean that every 
person who had a urine sample collected would need to consent to the study. This is not 
only impractical but impossible to ensure it was implemented. Verbal consent for taking a 
urine sample would be expected for clinical purposes, consistent with current practices. 
Obtaining consent from each person would also necessitate me having access to a greater 
level of personal information (such as address and telephone numbers). Once data were 
collected and matched across databases, no re-identifiable patient information was kept. If 
consent was required and results of the study communicated to patients, re-identifiable 
information would need to be kept by me, potentially for an extended period of time.  
 
In addition, the potential benefits of the research to the public and wider community 
outweigh the risks or harm associated with not obtaining consent. When UTI is treated 
inappropriately, pathogens causing UTI such as E. coli may develop resistance to 
antimicrobials (Trautner, 2010). Resistance to commonly prescribed antimicrobials used in 
the treatment of UTI has adverse health consequences, with an increased risk of morbidity 
and mortality in patients (World Health Organization, 2014). This research program seeks to 
provide a better understanding of antimicrobial resistant E. coli UTI in Australia. In doing so, 
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it is envisaged this will guide therapeutic recommendations for UTI and provide information 
on patient risk factors associated with resistant UTI pathogens, thereby assisting in the 
designing and evaluation of interventions to reduce antimicrobial resistant E. coli UTI, 
including public health measures. 
 
3.5.2 Confidentiality and data security  
Data for studies two and three were collected from the microbiology laboratory records but, 
in doing this, privacy of data was maintained. The privacy and confidentiality of patients and 
patient data was maintained by ensuring that no re-identifiable information was stored 
after the conclusion of data analysis. I required re-identifiable data, specifically the patients’ 
unit record number, to ensure accurate linkage of data obtained from the pathology 
department and the Clinical Record Service. Following the data analysis process, information 
that allowed the data to be re-identifiable was permanently deleted. The research results 
were produced and published in such a way that a patient’s information cannot be 
identified or cause harm of any description to patients. No individual data were reported. 
 
There were additional measures to ensure patient privacy. The review of patients’ 
microbiology laboratory records was undertaken by ACT Pathology staff and I was only 
provided with information specific to the research program, under supervision of the ACT 
Health staff member who is also a co-investigator of studies two and three. In doing so, an 
additional safeguard was in place to ensure that only information relevant to studies two 
and three were reviewed. I did not directly review the medical records of patients or have 
access to the systems that retrieve this information. The data collected were stored in a 
password protected Microsoft Excel document and only stored through my own password 
protected computer access on a secure computer network at the Australian Catholic 
University. 
 
The non-identifiable data for studies two and three will be kept for a period of five years 
from the point of any publication relating to the research. This timeframe is chosen to 
comply with point 2.1.1 of the Australian Code for the Responsible Conduct of Research 
(National Health and Medical Research Council, Australian Research Council, & Australian 
Vice-Chancellors’ Committee, 2007). After this period, the computer file (Microsoft Excel 
spreadsheet) will be permanently deleted and as such includes deleting the file from the 
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recycle bin on the relevant computers. The study undertaken is deemed low risk as there 
are no interventions and no harm or discomfort likely to be caused by the study. It can also 
be argued that it is in the community's interest to ensure access to information about UTI 
and AMR as these conditions pose a significant problem for patient safety (Tenover, 2006; 
World Health Organization, 2014). 
 
3.6 Summary 
This chapter has provided a detailed discussion of the methodological approaches to 
undertaking the three studies in this research program. For study one, important 
methodological considerations for the systematic review and meta-analysis include: the 
development of a protocol; explicitly stated inclusion and exclusion criteria; development of 
the search strategy; an appropriate quality and risk of bias assessment tool; adequate data 
synthesis, and reporting the review based on recommended reporting guidelines. For 
studies two and three, analysis of microbiological laboratory data had to take into account 
certain methodological issues prior to undertaking the analysis. These issues include: 
classification of samples based on the setting of infection acquisition; the use of AST 
categories in calculating resistance; identification and exclusion of duplicate isolates when 
required, and laboratory threshold for defining UTI. An understanding of these factors is 
essential in the analysis of published AMR data and data obtained from a microbiological 
laboratory database, as they ultimately affect the interpretation and reporting of AMR 
prevalence and incidence. Using evidence from the literature, a rationale for how these 
issues will be handled in undertaking the studies in this research program has been 
provided. 
 
An explanation of the methods used for undertaking each study, along with the rationale for 
the approaches undertaken, has also been provided. Application of standard systematic 
review principles to published data for study one provided the opportunity to identify 
potential areas where further research is required; in particular the methodological quality 
of published studies, some of which were addressed in studies two and three. Despite the 
complexities associated with analysing microbiological laboratory data for studies two and 
three, this research program has been able to demonstrate the wide applicability of AST 
data using a number of statistical analysis techniques, and thereby provide methodological 
contributions to the research community in regards to analysing this type of data. In many 
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AMR studies, the terms ‘prevalence’ and ‘incidence’ are commonly used interchangeably, 
with prevalence more often evaluated (Bax et al., 2001). The methods outlined in this 
chapter show that both prevalence and incidence, two statistical calculations serving 
different purposes, are possible using data from a regional microbiological laboratory. In 
addition, the methodological issues with analysing these data have been highlighted. 
 
This chapter has also outlined the ethical principles that informed the design, ethics and 
conduct of this research program, focusing on informed consent as well as confidentiality 
and data security in relation to studies two and three. The next chapter reports the findings 
of study one, the systematic review and meta-analysis of observational studies investigating 
ciprofloxacin resistance in hospital-acquired and community-acquired E. coli UTI. 
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Chapter 4: Study one – Systematic review of ciprofloxacin resistance in E. coli 
UTI 
 
4.1 Overview 
Fluoroquinolones are ranked as one of the highest priority critically important antimicrobials 
because they are a key treatment measure for severe infections, such as septicaemia. 
Fluoroquinolones, predominantly ciprofloxacin, are now frequently prescribed for the 
treatment of UTI because of the increasing resistance of E. coli to other commonly used 
antimicrobials, such as trimethoprim-sulphamethoxazole (Mehnert-Kay, 2005). It is believed 
that excessive use of this group of antimicrobials may have led to the increase in resistance 
of urinary E. coli isolates to these agents observed in many countries (Nickel, 2007). 
Increasing resistance to fluoroquinolones may therefore have serious clinical consequences 
for patients with severe infections. 
 
There is evidence to support the association between AMR and ciprofloxacin use (Goettsch 
et al., 2000; Vellinga et al., 2010). Although restrictions have been placed on the use of 
ciprofloxacin in countries such as Australia (Cheng et al., 2012), there is evidence both 
nationally and internationally to show that resistance to this agent is still increasing. Reports 
from AGAR show that E. coli resistance to ciprofloxacin increased in the community from 
4.2% in 2008 to 7.0% in 2012 and in hospitals from 8% in 2009 to 11% in 2011 (Australian 
Group on Antimicrobial Resistance, 2011, 2013). In addition, a retrospective ecological study 
in Denmark, which assessed the effects of patent loss and generic introduction of 
ciprofloxacin on ciprofloxacin resistance rates, found that within a year following patent loss 
the number of ciprofloxacin brands increased from three to ten (Jensen et al., 2010). 
Ciprofloxacin use increased from 0.13 to 0.33 DDD/1000 inhabitant-days in the four years 
following patent loss and resistance to urinary E. coli isolates increased by 200% during the 
same period (Jensen et al., 2010). 
 
To preserve the use of this critically essential antimicrobial in the treatment of patients, it is 
necessary to provide comprehensive evidence in support of the increasing resistance, which 
will be used to inform policy decisions both nationally and internationally in relation to 
antimicrobial stewardship and, in this instance, regulatory control for ciprofloxacin use. This 
chapter presents the published manuscript of the first study undertaken as part of this 
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research program (Fasugba et al., 2015). In study one, I systematically reviewed the 
literature and undertook a meta-analysis of eligible studies examining ciprofloxacin 
resistance in community- and hospital-acquired urinary E. coli infections. The findings of 
study one have been published and are presented in section 4.2 along with 
recommendations for limiting ciprofloxacin use to prevent further increases in resistance to 
this agent. Supplementary tables (or Additional files) in the published paper are provided in 
Appendix G of the thesis.  
 
4.2 Publication one: Ciprofloxacin resistance in community- and hospital-acquired 
Escherichia coli urinary tract infections: a systematic review and meta-analysis of 
observational studies  
      
Author details  
1 Faculty of Health Sciences, Australian Catholic University, 223 Antill Street, Watson, Australian 
Capital Territory 2602, Australia. 2 Faculty of Arts, Nursing and Theology, Avondale College of Higher 
Education, 185 Fox Valley Road, Wahroonga, New South Wales 2076, Australia. 3 School of Allied 
Health, Faculty of Health Sciences, Australian Catholic University, 17 Young Street, Fitzroy, Victoria 
3065, Australia 
 
4.2.1 Abstract 
Background: During the last decade the resistance rate of urinary Escherichia coli (E. coli) to 
fluoroquinolones such as ciprofloxacin has increased. Systematic reviews of studies 
investigating ciprofloxacin resistance in community- and hospital-acquired E. coli urinary 
tract infections (UTI) are absent. This study systematically reviewed the literature and where 
appropriate, meta-analysed studies investigating ciprofloxacin resistance in community- and 
hospital-acquired E. coli UTI.  
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Methods: Observational studies published between 2004 and 2014 were identified through 
Medline, PubMed, Embase, Cochrane, Scopus and Cinahl searches. Overall and sub-group 
pooled estimates of ciprofloxacin resistance were evaluated using DerSimonian-Laird 
random-effects models. The I2 statistic was calculated to demonstrate the degree of 
heterogeneity. Risk of bias among included studies was also investigated.  
Results: Of the identified 1134 papers, 53 were eligible for inclusion, providing 54 studies for 
analysis with one paper presenting both community and hospital studies. Compared to the 
community setting, resistance to ciprofloxacin was significantly higher in the hospital setting 
(pooled resistance 0.38, 95% CI 0.36-0.41 versus 0.27, 95% CI 0.24-0.31 in community-
acquired UTI, P<0.001). Resistance significantly varied by region and country with the 
highest resistance observed in developing countries. Similarly, a significant rise in resistance 
over time was seen in studies reporting on community-acquired E. coli UTI. 
Conclusions: Ciprofloxacin resistance in E. coli UTI is increasing and the use of this 
antimicrobial agent as empirical therapy for UTI should be reconsidered. Policy restrictions 
on ciprofloxacin use should be enhanced especially in developing countries without current 
regulations.  
 
4.2.2 Background 
Urinary tract infections (UTI) are one of the most frequent bacterial infections affecting 
people both in the community and in hospitals (Laupland et al., 2007). It is estimated that 
about 150 million people per annum are diagnosed with UTI worldwide (Gupta, Hooton, & 
Stamm, 2001). A recent World Health Organization (WHO) report on antimicrobial 
resistance (AMR) surveillance specified nine bacteria of international concern which are 
responsible for some of the most common infections in community and hospital settings 
(World Health Organization, 2014). Escherichia coli (E. coli), the pathogen most often 
implicated in UTI, is listed as one of the nine. In all six WHO regions (Africa, Americas, 
Eastern Mediterranean, European, South-East Asia and Western Pacific) high rates of 
antimicrobial resistance have been observed in this pathogen (World Health Organization, 
2014). 
 
Ciprofloxacin is the most commonly prescribed fluoroquinolone for UTI because it is 
available in oral and intravenous preparations (Schaeffer, 2002). It is well absorbed from the 
gastrointestinal tract after oral administration. It also has a documented safety profile, 
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broad Gram-negative organism coverage and high urinary excretion rate (Schaeffer, 2002). 
During the last decade the resistance rate of E. coli to fluoroquinolones such as ciprofloxacin 
has increased (Mcquiston et al., 2013). A ten year analysis of urinary E. coli specimens in 
Switzerland, found an increasing trend in resistance to ciprofloxacin, from 1.8% to 15.9% 
(Blaettler et al., 2009). Fluoroquinolones are ranked as one of four of the highest priority 
critically important antimicrobials (WHO Advisory Group on Integrated Surveillance of 
Antimicrobial Resistance, 2012) as they have an important role in the treatment of more 
severe infections, such as septicaemia. Therefore resistance to fluoroquinolones can have 
serious clinical consequences. They are one of few available therapies for serious Salmonella 
spp. and E. coli infections (Mcquiston et al., 2013). Resistance to fluoroquinolones emerges 
quickly, and this is likely to be related to the biology of resistance as well as a direct 
response to drug pressure (Redgrave, Sutton, Webber, & Piddock, 2014). They should 
therefore be used with caution and reserved for severe infections, and preceded by 
antimicrobial susceptibility testing of the bacteria involved (Mcquiston et al., 2013). The 
most recent Infectious Diseases Society of America (IDSA) guidelines recommend that 
fluoroquinolones should be reserved for important uses due to their propensity for 
ecological unfavorable effects of antimicrobial therapy such as the selection of drug-
resistant pathogens and colonisation or infection with multidrug-resistant organisms (Gupta 
et al., 2011). 
 
Recent prescribing guidelines recommend reserving ciprofloxacin use for more severe 
infections and resistance to this agent is increasing prompting further research in this area 
(Blaettler et al., 2009; Linhares et al., 2013; Ma & Wang, 2013). Published quantitative 
syntheses of overall ciprofloxacin-resistant E. coli UTI prevalence and incidence in hospital 
and community settings are absent. This systematic review of observational studies 
therefore aims to compare ciprofloxacin resistance in both settings. Knowledge about 
ciprofloxacin resistance in hospital- and community-acquired E. coli UTI will provide 
information for control of resistant pathogens. This review also has the potential to provide 
a basis for which future interventions can be evaluated. The findings will, in addition, make 
available information on ciprofloxacin resistance in various regions of the world providing 
some evidence for further regulatory control of ciprofloxacin use globally. 
 
 
113 
 
4.2.3 Methods 
Protocol and registration: The protocol for conducting this review has been registered and 
can be accessed on the International prospective register of systematic reviews (PROSPERO) 
(available at www.york.ac.uk/inst/crd with registration number: CRD42014014473). Prior to 
registration, the protocol was reviewed by a reviewer external to the study team. Ethics 
approval was not sought as this review synthesized data from published studies for which 
approval had already been obtained. 
Search strategy: We conducted a systematic review of observational (cross sectional, cohort 
and case control) studies published in the last eleven years (2004-2014) reporting on 
ciprofloxacin resistance in community- and hospital-acquired E. coli UTI. This time limit is 
based on changes in the microbiology and epidemiology of antimicrobial resistant 
pathogens which occurred in the past decade with subsequent changes in treatment 
regimens and patient outcomes (United States Interagency Task Force on Antimicrobial 
Resistance, 2011). Reporting of this review complied with the preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) (Liberati et al., 2009). 
The electronic bibliographic databases MEDLINE/PubMed, EMBASE, Cochrane, CINAHL and 
Scopus were searched. Searches were conducted for words in the title or abstract or within 
the full text of the papers. These included both keywords only and keywords with medical 
subject headings (MeSH) using the search terms ‘resistance’, ‘urinary tract infection’ and 
‘Escherichia coli’ from 1st January 2004 to 31st December 2014 (see Additional file 1). The 
reference lists of papers identified from the electronic databases were hand-searched for 
additional papers. 
Inclusion and exclusion criteria: Papers were included if they reported prevalence or 
incidence rates of ciprofloxacin resistance in community- or hospital-acquired E. coli UTI. 
Papers reporting on urinary E. coli ciprofloxacin susceptibility in which resistance rate could 
be calculated were also included. We included papers involving adults and/or children. Only 
peer reviewed manuscripts were considered. Grey material which includes unpublished 
literature, conference abstracts, letters to editors, newsletters and reports were excluded. 
Non-peer reviewed literature were also excluded. Papers written in languages other than 
English were also excluded. In addition, papers not clearly specifying the setting (hospital-
acquired or community-acquired); drug (ciprofloxacin) or sample (urine) were excluded. 
Papers that focused on specific sub-populations (e.g. diabetics and patients with recurrent 
UTI) were also excluded as these did not represent the general population. This review 
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included only papers that used the Centers for Disease Control and Prevention (CDC) 
definition of microbiologically confirmed UTI (≥105 colony forming unit/ml) (Centers for 
Disease Control and Prevention, 2015). 
Definitions: For the purpose of this review, a study was defined as all data from a published 
paper with the only distinction being ‘hospital’ or ‘community’ setting. Therefore, if a single 
paper meeting the eligibility criteria reported data on both settings, they were included as 
two separate studies. 
Community-acquired UTI was defined as positive samples obtained from (i) outpatient 
clinics; (ii) general practice (GP) clinics; (iii) emergency departments; (iv) within 48 hours of 
hospital admission or (v) from nursing homes or residential aged care facilities (Bouchillon, 
Badal, Hoban, & Hawser, 2013; Cullen et al., 2012; Sanchez, Master, Karlowsky, & Bordon, 
2012). 
Hospital-acquired UTI was defined as positive samples obtained (i) after 48 hours of hospital 
admission or (ii) within 48 hours of hospital discharge (Bouchillon et al., 2013). 
Important changes in healthcare delivery over the last few years have seen some usually 
inpatient procedures now more often than not performed on an outpatient basis (Horcajada 
et al., 2013). Patients transition freely within sometimes loosely defined levels of the health 
care system, for example between long-term care or rehabilitation services, to acute-care 
centres (Henderson et al., 2013; Sydnor & Perl, 2011). This study only considered hospital-
acquired UTI as opposed to a wider definition of healthcare-associated UTI, to avoid this 
confusion.  
Study selection: The titles and abstracts of all papers identified in the electronic databases 
were examined and assessed for relevance and appropriateness to the principal objective of 
the systematic review. Irrelevant studies were excluded. Full texts of the potentially relevant 
papers were printed and carefully assessed against the systematic review inclusion and 
exclusion criteria. Those not meeting the criteria were excluded. The remaining papers 
deemed to have data relevant to the systematic review and meta-analysis were assessed for 
quality and risk of bias.   
The study selection process and other stages of the review were performed by the lead 
author (OF). At each stage, 10% of papers identified were also screened against the study 
criteria independently by other authors (AG, GM and BM). Discrepancies in either the 
application of inclusion or exclusion of papers, quality assessment or on data extraction 
were discussed among all authors to make the final decision. 
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Data extraction process: Data were extracted by one author (OF) and 10% of papers eligible 
for data extraction were independently extracted by another author (AG). Data extraction 
was compared between AG and OF demonstrating 100% agreement for all items except the 
study design. This variable was therefore assessed by all authors. Where there was missing 
information on the study design of papers to be included in the meta-analysis, attempts 
were made to contact the authors. When there was no response, consensus on the study 
design was reached by all authors. Agreement between authors was assessed using Kappa 
coefficient. The agreement between all authors in deciding on the study design was 71% 
(Kappa (95% CI) = 0.429 (0.154-0.703), P Value=0.003). Papers for which no agreement 
could be reached on the design, based on insufficient information, were assigned as non-
classifiable. Any other missing information in the included papers was recorded as ‘not 
stated’.  
The first author, year of study, country of study, study setting, age and sex distribution, co-
morbidities, sample size, study design, study aim, antimicrobial susceptibility testing 
method, ciprofloxacin resistance rate, risk factors for ciprofloxacin resistance (i.e. previous 
antibiotic use) and mortality data (if reported) were extracted. Where the ciprofloxacin 
resistance rate was not available, the susceptibility rate was used to determine resistance. 
Risk of bias in individual studies: Quality and risk of bias of the final papers included in the 
review was conducted using a modified version of the Newcastle-Ottawa Scale (NOS) which 
is a risk of bias assessment tool for observational studies recommended by the Cochrane 
Collaboration (Higgins & Green, 2011; Wells et al., 2014). Content validity and inter-rater 
reliability of this tool have been established (Wells et al., 2014). Studies were rated by 
assigning a judgment of ‘Low risk’ of bias, ‘High risk’ of bias, or ‘Unclear risk’ of bias 
according to published criteria (Higgins & Green, 2011). 
 
4.2.4 Data analysis 
Pooled ciprofloxacin resistance proportions (with 95% confidence intervals) in patients with 
E. coli UTI were separately calculated and compared between hospital and community 
settings using a random-effects meta-analysis model based on DerSimonian and Laird 
method (Cooper, Hedges, & Valentine, 2009; DerSimonian & Laird, 1986). This method 
incorporates an estimate of the between-study variation into both the study weights and 
the standard error of the estimate of the common effect. The precision of an estimate from 
each included study was represented by the inverse of the variance of the outcome pooled 
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across all studies. If the value of the pooled prevalence was within the 95% CI, then the 
effect size was statistically significant at the 5% level (P<0.05). The heterogeneity among 
studies was assessed by using the I2 statistic with a P value of <0.05 considered statistically 
significant, and I2 values below 25% indicating low heterogeneity, 25-75% moderate 
heterogeneity and over 75% high heterogeneity (Higgins et al., 2003). Subgroup analyses 
were done by risk of bias, study duration, age group, UTI symptoms, world region and 
economy of country (categorised as developed and developing using the World Bank 
classification (World Bank Group, 2015)). A meta-regression analysis was used to determine 
the effect of measured covariates on the observed heterogeneity in resistance estimates 
across studies (Cooper et al., 2009). Assessment of publication bias was estimated using 
funnel plots. Further analysis was undertaken to examine pooled ciprofloxacin resistance 
over time using the median study year. For studies occurring over 2 years, the first year was 
used; for studies occurring over 4 years, the 2nd year was used; for those over 6 years, the 
3rd year was used. The non-parametric Spearman’s rho correlation coefficient was 
calculated to determine significance in resistance trend over time. Statistical analyses were 
undertaken using -Stata statistical software (version 13) (StataCorp, 2013). 
 
4.2.5 Results 
Study selection: Electronic database searches identified 15,062 potential studies and 31 
additional studies were identified through hand searching. After 11,397 duplicates were 
removed, 3696 articles remained for title and abstract screening. We assessed 1134 as 
potentially eligible and retrieved the full text of these articles. After applying inclusion and 
exclusion criteria, 53 papers (5%) were deemed to have data relevant to the systematic 
review and meta-analysis. These 53 papers consisted of 54 studies comprising three 
hospital-acquired E. coli UTI studies and 51 community-acquired E. coli UTI studies. There 
was one paper that compared resistance in both hospital and community settings hence 
reported as two studies (Bouchillon et al., 2013). The PRISMA flow chart describing the 
papers identified from the search strategy and reasons for exclusion is shown in Figure 1. 
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                                          Figure 1 PRISMA flow diagram of study selection 
                                                          *54 studies from 53 papers 
Papers identified through database 
searching=15,062 
 
Papers identified through hand 
searching=31 
 
Papers after duplicates 
removed=3696 
 
Full-text papers assessed for 
eligibility=1134 
 
Papers excluded= 2562 
 
Papers screened=3696 
 
Papers reporting urinary E. coli 
resistance/susceptibility to 
ciprofloxacin=225 
Papers included in systematic 
review=53 
 
Full-text papers excluded, with 
reasons=909 
• Not in English=256 
• Letters to Editor=30 
• E. coli isolates from non-urinary 
sources=4 
• Reviews=9 
• Editorial comment=10 
• Book=1 
• Ciprofloxacin resistance not 
reported=174 
• Papers reporting resistance to 
ciprofloxacin combined with 
other drugs=41 
• Papers reporting resistance of    
E. coli isolates from urine 
combined with other sources=40 
• Gram-negative organism 
resistance to ciprofloxacin (not   
E. coli only)=45 
• Urinary E. coli resistance to 
ciprofloxacin reported but setting 
not clear or defined by study 
criteria=232 
• Duplicate study population=4 
• Full text not held in any 
Australian library=49 
• Interlibrary loan not retrieved by 
study due date=14 
 
 
 
 
 
 
 
Studies included in quantitative 
synthesis* (meta-analysis) =54 
 
Papers with laboratory defined 
urinary E. coli cfu count of ≥105 
CFU/mL=81 
 
Papers with UTI 
Laboratory 
diagnosis/cfu count 
not defined by 
study criteria=144 
 
Papers with specific 
sub-populations=28 
• Diabetics=4 
• Patients with 
recurrent UTI=3 
• Pregnant 
women=5 
• Children with 
HIV=1 
• Children with 
sickle cell 
anaemia=1 
• Patients with 
acute 
pyelonephritis=2 
• Patients with 
asymptomatic 
bacteriuria=1 
• Patients with 
only ESBL-
positive E. coli   
UTI=2 
• Patients with 
urinary E. coli 
isolates included 
and not 
infection=9 
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Study characteristics: Geographically, 53 of the 54 studies were carried out in Asia (28%; 
n=15), Europe (24%; n=13), Middle East (15%; n=8), Africa (13%; n=7), North America (11%; 
n=6) and South America (7%; n=4). The remaining study was conducted in multiple countries 
[28]. There were 17 (31%) studies conducted in developed countries and 36 (67%) in 
developing countries. The majority of the studies (80%) followed a cross sectional design. 
The duration of studies ranged from 2 months to 84 months (median=15.5; IQR=12.0-30.0). 
The mean age and sex proportion of patients with an E. coli UTI were stated in 13% (n=7) 
and 44% (n=24) of studies respectively. Most study populations included patients of both 
sexes although 19% (n=10) included only women. Antimicrobial susceptibility testing and 
interpretation was performed using the disk diffusion method (74%) and Clinical and 
Laboratory Standards Institute (CLSI) criteria (83%) respectively in most studies. Table 1 
provides further details on the description of the included studies. 
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Table 1 Description of studies included in meta-analysis 
Study author Country Design* Setting Risk of 
bias 
Study 
duration¥ 
(months) 
Number 
of positive       
E. coli UTI 
samples+ 
Number of 
ciprofloxacin 
resistant      
E. coli 
Proportion 
resistant      
(95% CI) 
Standard 
error 
Weight# 
(%) 
Ahmad, 2012  
 
India Cross sectional  
 
Community 
 
Unclear 
 
24 318 48   
 
0.15 (0.11, 0.19)         0.02 
 
2.09 
Akoachere et al, 2012 
 
Cameroon Cross sectional  
 
Community 
 
Low 
 
12 43 11  
 
0.26 (0.13, 0.39) 0.07 
 
1.61 
Akram et al, 2007 
 
India Cross sectional  
 
Community 
 
High 
 
12 61 42 
 
0.69 (0.57, 0.80) 0.06 
 
1.70 
AlSweih et al, 2005 
 
Kuwait Cross sectional  
 
Community 
 
High 
 
12 1535  81  
 
0.05 (0.04, 0.06) 0.01 2.15 
 Al-Tawfiq et al, 2009  
 
Saudi Arabia Cohort  
 
Community 
 
High 
 
12 
 
2281  592  
 
0.26 (0.24, 0.28) 0.01 
 
2.14 
Ansbach et al, 2013 
 
USA Cross sectional  
 
Community 
 
High 
 
7 98 2   
 
0.02 (-0.01, 0.05) 0.01 
 
2.12 
Arabi et al, 2013 Iran Cross sectional  Community Low 33 103 23   0.22 (0.14, 0.30) 0.04 1.91 
Araujo et al, 2011  Brazil Cross sectional  Community Unclear 24 391 36   0.09 (0.06, 0.12) 0.01 2.12 
Arslan et al, 2005  Turkey Cross sectional Community Low 5 514 135   0.26 (0.22, 0.30) 0.02 2.09 
Astal, 2005  Palestine Cross sectional Community High 6 252 30   0.12 (0.08, 0.16) 0.02 2.09 
Azap et al, 2010 Turkey Cohort Community Unclear 12 464 139   0.30 (0.26, 0.34) 0.02 2.08 
Bahadin et al, 2011 
 
Singapore Cross sectional  
 
Community 
 
Unclear 
 
12 90       22 
 
0.24 (0.16, 0.33) 0.05 
 
1.86 
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Study author Country Design* Setting Risk of 
bias 
Study 
duration¥ 
(months) 
Number 
of positive       
E. coli UTI 
samples+ 
Number of 
ciprofloxacin 
resistant      
E. coli 
Proportion 
resistant      
(95% CI) 
Standard 
error 
Weight# 
(%) 
Biswas et al, 2006 
 
India Cross sectional 
 
Community 
 
High 
 
36 354 124  
 
0.35 (0.30, 0.40) 0.03 
 
2.05 
Bouchillon et al, 2013  USA Cross sectional Community High 24 723 234 0.32 (0.29, 0.36) 0.02 2.10 
Bouchillon et al, 2013  USA Cross sectional Hospital High 24 253 103  0.41 (0.35, 0.47) 0.03 11.83 
Dash et al, 2013  India Cross sectional  Community Low 30 397 212 0.53 (0.48, 0.58) 0.03 2.05 
Dimitrov et al, 2004  Kuwait Cross sectional  Community High 84 780 92  0.12 (0.10, 0.14) 0.01 2.13 
Farshad et al, 2011  
 
Iran Cross sectional  
 
Community 
 
Low 
 
12 90 8   
 
0.09 (0.03, 0.15) 0.03 
 
2.01 
Ghadiri et al, 2012  
 
Iran Cross sectional  
 
Hospital 
 
High 
 
24 200 80  
 
0.40 (0.33, 0.47) 
 
0.03 
 
9.41 
Gobernado et al, 2007  
 
Spain Cross sectional  
 
Community 
 
Low 
 
12 2292 418  
 
0.18 (0.17, 0.20) 0.01 
 
2.14 
Ho et al, 2010  Hong Kong Cross sectional  Community Low 24 271 35  0.13 (0.09, 0.17) 0.02 2.09 
Hoban et al, 2011  
Multiple 
countries Cross sectional  
 
Hospital 
 
High 
 
24 1643 624  
 
0.38 (0.36, 0.40) 
 
0.01 
 
78.76 
Ismaili et al, 2011  Belgium Cohort  Community High 24 189 5  0.03 (0.00, 0.05) 0.01 2.13 
Kashef et al, 2010  Iran Cross sectional  Community High 30 578 180 0.31 (0.27, 0.35) 0.02 2.09 
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Study author Country Design* Setting Risk of 
bias 
Study 
duration¥ 
(months) 
Number 
of positive       
E. coli UTI 
samples+ 
Number of 
ciprofloxacin 
resistant      
E. coli 
Proportion 
resistant      
(95% CI) 
Standard 
error 
Weight# 
(%) 
Kiffer et al, 2007 Brazil Cross sectional  Community Unclear 48 22679 2699 0.12 (0.11, 0.12) 0.002 2.15 
Killgore et al, 2004  
 
USA Case-control 
 
Community 
 
Low 
 
12 120 40  
 
0.33 (0.25, 0.42) 0.04 
 
1.89 
Kimando et al, 2010  Kenya Cross sectional  Community Unclear 6 92 6 0.07 (0.01, 0.12) 0.03 2.05 
Kothari et al, 2008  India Cross sectional Community High 6 361 260  0.72 (0.67, 0.77) 0.02 2.06 
Kurutepe et al, 2005 Turkey NC Community High 72 880 174  0.20 (0.17, 0.22) 0.01 2.12 
Lau et al, 2004  Taiwan Cross sectional  Community Unclear 13 80 14  0.17 (0.09, 0.26) 0.04 1.89 
Ljuca et al, 2010  
Bosnia & 
Herzegovina Cross sectional  
 
Community 
 
High 
 
36 43 4  
 
0.09 (0.01, 0.18) 0.04 
 
1.87 
Longhi et al, 2012  Italy NC  Community Low 6 154 36  0.23 (0.17, 0.30) 0.03 1.98 
Martinez et al, 2012  
 
Colombia Cross sectional  
 
Community 
 
High 
 
2 102 39   
 
0.38 (0.29, 0.48) 0.05 
 
1.83 
Miragliotta et al, 2008  Italy Cohort  Community Low 60 2589 422  0.16 (0.15, 0.18) 0.01 2.14 
Molina-Lopez et al, 2011  
 
México Cross sectional  
 
Community 
 
High 
 
48 119 65  
 
0.55 (0.46, 0.64) 0.05 
 
1.86 
Moreira et al, 2006 Brazil Cross sectional  Community Unclear 15 544 65  0.12 (0.09, 0.15) 0.01 2.12 
Murugan et al, 2012 India Cohort  Community High 12 204 144 0.71 (0.64, 0.77) 0.03 2.00 
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Study author Country Design* Setting Risk of 
bias 
Study 
duration¥ 
(months) 
Number 
of positive       
E. coli UTI 
samples+ 
Number of 
ciprofloxacin 
resistant      
E. coli 
Proportion 
resistant      
(95% CI) 
Standard 
error 
Weight# 
(%) 
Muvunyi et al, 2011 Rwanda Cross sectional  Community Low 6 72 23 0.32 (0.21, 0.43) 0.05 1.75 
Mwaka et al, 2011  Uganda Cross sectional  Community High NS 27 9 0.33 (0.16, 0.51) 0.09 1.32 
Ni Chulain et al, 2005  
 
Ireland Cross sectional  Community High 
 
5 723 18  0.02 (0.01, 0.04) 0.01 2.15 
Olson et al, 2012  USA Cross sectional  Community Unclear 16 95 4   0.04 (0.00, 0.08) 0.02 2.08 
Otajevwo, 2013  Nigeria Cross sectional Community High 6 5 4  0.80 (0.45, 1.15) 0.18 0.63 
Prakash et al, 2013  India Cross sectional  Community Low NS 23 16  0.70 (0.51, 0.88) 0.10 1.26 
Randrianirina et al, 2007 
 
Madagascar Cross sectional 
 
Community 
 
Low 
 
28 607 100  
 
0.16 (0.14, 0.19) 0.02 
 
2.12 
Rani et al, 2011  India Cross sectional  Community Unclear 6 208 151  0.73 (0.67, 0.79) 0.03 2.01 
Shaifali et al, 2012  India Cross sectional  Community Unclear 12 46 28 0.61 (0.47, 0.75) 0.07 1.54 
Shariff et al, 2013  India Cross sectional  Community High 18 491 160  0.33 (0.28, 0.37) 0.02 2.08 
Sire et al, 2007  Senegal Cross sectional  Community Low 33 1010 157  0.16 (0.13, 0.18) 0.01 2.13 
Sood et al, 2012  India NC  Community High 30 214 160  0.75 (0.69, 0.81) 0.03 2.02 
Stratchounski et al, 2006  
 
Russia NC  
 
Community 
 
Low 
 
48 
 
423 18 
 
0.04 (0.02, 0.06) 0.01 
 
2.14 
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Study author Country Design* Setting Risk of 
bias 
Study 
duration¥ 
(months) 
Number 
of positive       
E. coli UTI 
samples+ 
Number of 
ciprofloxacin 
resistant      
E. coli 
Proportion 
resistant      
(95% CI) 
Standard 
error 
Weight# 
(%) 
Vellinga et al, 2012  Ireland Case-control Community Low 9 633 78  0.12 (0.10, 0.15) 0.01 2.12 
Wang et al, 2014  China Cross sectional Community High 8 129 91   0.71 (0.63, 0.78) 0.04 1.92 
Yildirim et al, 2010  Turkey Cross sectional Community Unclear 24 450 85  0.19 (0.15, 0.23) 0.02 2.10 
Yolbas et al, 2013  Turkey Cross sectional Community High 12 113 24  0.21 (0.14, 0.29) 0.04 1.93 
*Non-classifiable design 
¥Not stated 
+Study denominator 
#Weights are from random-effects analysis using DerSimonian-Laird model 
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Pooled ciprofloxacin resistance: Figures 2 and 3 show the forest plots of studies reporting on 
ciprofloxacin resistance in community-acquired E. coli UTI by economy and region, 
respectively. Figure 4 shows the forest plot of studies reporting on ciprofloxacin resistance 
in hospital-acquired E. coli UTI. Compared with the community setting, resistance to 
ciprofloxacin in E. coli UTI was significantly higher in the hospital setting (P<0.001). Overall, 
the pooled rate for ciprofloxacin resistance in patients with community-acquired E. coli UTI 
was 0.27 (95% CI: 0.240-0.310), compared with 0.38 (95% CI: 0.360-0.410) in the hospital 
setting. There was substantial heterogeneity among the community setting studies 
(I2=98.8%, P<0.0001), but very little in the hospital ones (I2=<0.010%, P=0.641). Further 
analysis of studies reporting on community-acquired E. coli UTI by region (figure 3) showed 
that Asia had the highest pooled resistance. Analysis by economy based on the World Bank 
classification (figure 2) showed a higher pooled resistance in developing countries. 
 
Resistance over time in community-acquired UTI studies: Figure 5 shows the scatter plot of 
ciprofloxacin resistance in 47 studies reporting on community-acquired UTI using the 
median study year for each study. Four studies did not provide data on the year(s) the study 
was conducted and were excluded from this analysis (Kimando, Okemo, & Njagi, 2010; 
Mwaka, Mayanja-Kizza, Kigonya, & Kaddu-Mulindwa, 2011; Prakash & Saxena, 2013; 
Shaifali, Gupta, Mahmood, & Ahmed, 2012). The results of the Spearman’s rho correlation 
test showed a statistically significant rise in resistance over time (n=47, rs=0.431, P=0.003). 
Similar findings were observed for developing countries. There was no significant rise in 
resistance over time in developed countries. 
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Figure 2 Forest plot of ciprofloxacin resistance in community-acquired E. coli UTI by 
economy 
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Figure 3 Forest plot of ciprofloxacin resistance in community-acquired E. coli UTI by 
region 
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NOTE: Weights are from random effects analysis
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Figure 4 Forest plot of ciprofloxacin resistance in hospital-acquired E. coli UTI 
Spearman's correlation coefficient = 0.431, P value = 0.003
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Figure 5 Scatter plot of ciprofloxacin resistance in community-acquired UTI by year 
of study (1998-2012) 
   N=47 (4 studies excluded due to missing information on year study was conducted) 
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Subgroup analyses: Sub-group analysis was conducted within each major setting. For 
community-acquired UTI studies (Table 2), there was a significant difference in the pooled 
resistance within each subgroup examined (risk of bias, study duration, economy, region, 
age group and UTI symptoms). The subgroup analyses results for studies reporting on 
hospital-acquired E. coli UTI (see Additional file 2) showed no difference in the pooled 
resistance within the subgroups examined (region, economy and UTI symptoms). When 
both settings were compared (see Additional file 3), there were significant differences noted 
for risk of bias (high), study duration (>12 months), economy (developed), region 
(Americas), age group (adults and children) and UTI symptoms (P<0.001). There were no 
data available on mortality for comparison between settings. 
 
Table 2 Subgroup analyses of pooled ciprofloxacin resistance in community setting 
Subgroup Community Setting                    
N=51 
P value* 
Pooled resistance 
Risk of bias 
 
Low and unclear             
n=28 studies 
0.221 <0.0001 
High                                 
n=23 studies 
0.337 
Study 
duration* 
 
≤12 months 
n=25 studies 
0.323 <0.0001 
>12months 
n=24 studies 
0.219 
Economy 
 
Developed 
n=16 studies 
0.141 <0.0001 
Developing 
n=35 studies 
0.345 
Region 
 
Africa, Asia and Middle 
East 
n=29 studies 
0.361 <0.0001 
Europe, North and South 
America 
n=22 studies 
0.174 
Age group* 
 
Adults and children ǂ 
n=24 studies 
0.265 <0.0001 
Adults only 
n=19 studies 
0.302 
UTI symptoms Symptomatic and 
asymptomatic patients               
n=11 studies  
0.185 
 
<0.0001 
Symptomatic patients 
only                                                     
n=40 studies 
0.295 
n=number of studies reporting on community-acquired UTI 
*Comparing pooled resistance for difference in subgroup in community setting 
*Studies with missing information on this sub-analysis were not included 
ǂ Studies reporting resistance in adults and children or children only 
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Meta-regression analyses: Random-effects meta-regression analyses of studies reporting on 
community-acquired E. coli UTI showed that country’s economy (P=0.008), Asia as a region 
(P=0.002), high risk of bias (P=0.003), year of study (P=0.020) and studies using only children 
as the study population (P=0.030) were the study factors significantly accounting for the 
observed heterogeneity, responsible for 61% of the between study variance (Adjusted R2) in 
ciprofloxacin resistance.  
 
Risk of bias: When studies were assessed for risk of bias using the Newcastle-Ottawa scale, 
30% (n=16) were assessed as having a low risk of bias; 22% (n=12) unclear risk of bias and 
48% (n=26) were deemed to have a high risk of bias. Further analysis of the 16 low risk 
studies only was consistent with findings reported from the analysis of all studies. An 
increasing resistance trend over time was also observed, however this increase did not 
reach statistical significance because of reduced statistical power. 
 
4.2.6 Discussion 
The findings of this systematic review and meta-analysis highlight the higher ciprofloxacin 
resistance in hospital-acquired E. coli UTI when compared to community-acquired UTI. 
There is also substantial evidence that ciprofloxacin resistance in community-acquired E. coli 
UTI has been increasing in recent years. Resistance was also found to be significantly higher 
in developing countries reporting on E. coli UTI in community settings.  
 
Antimicrobial resistance has been described as an international hazard to public health 
threatening the successful prevention and treatment of bacterial, viral, parasitic and fungal 
infections (World Health Organization, 2012, 2014). As such, research into its prevention 
and reduction is very important. Our estimated pooled ciprofloxacin resistance of 27% and 
38% in community and hospital-acquired E. coli UTI respectively could not be compared to 
any other systematic review findings because, to our knowledge, this is the first systematic 
review and meta-analysis comparing ciprofloxacin resistance in community and hospital-
acquired E. coli UTI. However, national data from five WHO regions show at least 50% 
resistance to fluoroquinolones (ciprofloxacin, norfloxacin or ofloxacin) in E. coli (World 
Health Organization, 2014). Data on E. coli in the WHO report are from various settings and 
sources (including blood and urine) hence cannot be directly compared with the results 
from our systematic review. Another recent review on global fluoroquinolone resistance 
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epidemiology reported a range of 2% to 69% for fluoroquinolone resistance in 
uncomplicated community-acquired UTI and up to 98% in complicated cases, with 
fluoroquinolone resistance in healthcare-associated UTI ranging from 6% to 62% (Dalhoff, 
2012a). The findings from our systematic review are within the above reported ranges. 
However, the latter ranges were wide and the data were from a number of different Gram-
negative uropathogens and not specifically E. coli accounting for the higher rates. Available 
published data show relatively high rates of urinary E. coli resistance to ciprofloxacin (Azap 
et al., 2010; Hassanzadeh & Motamedifar, 2007; Killgore, March, & Guglielmo, 2004; 
Molina-López et al., 2011; Otajevwo, 2013; Sood & Gupta, 2012; Wang et al., 2014) 
prompting the need for a renewed effort in the further prevention of spread of resistance to 
this antimicrobial agent.  
 
We found that urinary E. coli resistance to ciprofloxacin was higher in the hospital compared 
to the community setting. Our finding is comparable to individual studies which have 
assessed urinary E. coli resistance to ciprofloxacin in both, hospital and community settings 
(Chulain, Murray, Corbett-Feeney, & Cormican, 2005; Ljuca, Zvizdic, Hamzic, Kalajdzija, & 
Ljuca, 2010; Longhi et al., 2012; Prakash & Saxena, 2013; Shariff, Shenoy, Yadav, & 
Radhakrishna, 2013; Wang et al., 2014). However, often studies do not apply the criterion of 
48 hours post admission used in our systematic review for identifying hospital-acquired UTI 
(Al Sweih, Jamal, & Rotimi, 2005; Shariff et al., 2013). The Canadian national surveillance 
study (CANWARD), a large population-based study undertaken from 2007 to 2009, further 
confirms our finding of higher resistance in the hospital setting (Karlowsky et al., 2011). 
Inpatients had a significantly higher urinary E. coli resistance to ciprofloxacin. Similar 
findings were reported by Cullen et al. in Dublin (Cullen et al., 2012). This is not an unusual 
finding and may be attributed to the selective pressure resulting from antimicrobial use in 
hospital settings (Karlowsky et al., 2011). Patients in hospital, already acutely ill, become 
more at risk of developing a resistant infection because of potential immune deficiency and 
relative high exposure to antimicrobial agents (Tenover, 2006). Furthermore, hospitalized 
patients are more likely to be exposed to practices that result in cross infection or 
transmission of organisms. These and other risk factors enable the spread of resistance. This 
has significant implications for patient care as antimicrobial resistance may lead to 
treatment failure resulting in death.  
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The results of our systematic review showed a significant rise in resistance over time in the 
community setting. This finding is supported by a number of US-based studies investigating 
antimicrobial resistance trend in outpatients. A fivefold increase (from 3% to 17.1%) in 
ciprofloxacin resistance was observed from 2000 to 2010 by Sanchez et al. (2012) in 
comparison with other antibiotics investigated (Maraki et al., 2013). Our findings are also 
consistent with Blaettler et al. (2009) who found that over a ten year period (1997-2007), 
similar to the timeframe for our review, resistance increased significantly for ciprofloxacin 
from 1.8% to 15.9% in Switzerland. This increase coincided with a rise in ciprofloxacin use in 
Switzerland (Blaettler et al., 2009). These findings suggest that with increase in the use of 
fluoroquinolones generally over time, resistance ciprofloxacin is likely to further increase. It 
is now known that antimicrobial overuse or misuse is a risk factor for the development of 
AMR (Costelloe et al., 2010). The specific effect of ciprofloxacin use on the development of 
its resistance in UTI pathogens is also clearly documented. A recent Irish study involving 72 
general practices found higher ciprofloxacin resistance levels (5.5%) in practices with 10 
prescriptions per month compared with resistance levels of 3% in practices with one 
prescription per month (Vellinga et al., 2010). Wide spread use of this agent may have thus 
resulted in a rise in ciprofloxacin resistance. In the Netherlands and United States, an 
association has also been shown between high fluoroquinolone prescriptions and a rise in 
bacterial resistance (Goettsch et al., 2000; Zervos et al., 2003). Furthermore, changes in 
antimicrobial prescribing practices have been shown to precede changes in resistance rates. 
A study by Gottesman et al. (2009) in Israel found a significant decrease in E. coli resistance 
to ciprofloxacin following a nationwide restriction on ciprofloxacin use. Resistance 
decreased from 12% in the pre-intervention period to 9% in the intervention period. Our 
results pose a strong argument for the development of more stringent criteria limiting 
ciprofloxacin use. In addition, other strategies such as adequate surveillance and 
monitoring, reinforcement of existing infection prevention and control measures as well as 
new technological advancement will help reduce the widespread problem of antimicrobial 
resistance (Australian Commission on Safety and Quality in Health Care, 2013b; Australian 
Government, 2015; Dancer, 2013) but these aspects are not within the scope of this paper. 
 
Our finding of a significant rise in resistance over time also has implications for the 
development of treatment guidelines. The national recommendations for first-choice 
empiric antibiotic treatment of UTI vary considerably (Mcquiston et al., 2013). In countries 
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like Spain, Taiwan and Turkey, the treatment choice for uncomplicated UTI are 
fluoroquinolones (Infectious Diseases Society of the Republic of China, 2000; Karaca et al., 
2005; Mcquiston et al., 2013). In 2000, fluoroquinolones were prescribed for treatment of 
uncomplicated UTI in Switzerland in 64% of cases (Naber, 2000).  There is concern that 
resistance to ciprofloxacin resulting from its first-line use may be associated with an 
increase in multidrug resistance (Olson & Haith, 2012). The most recent IDSA guidelines 
(Gupta et al., 2011) advise using nitrofurantoin, trimethoprim-sulphamethoxazole, 
fosfomycin or pivmecillinam for first-line treatment of acute uncomplicated cystitis.  
Fluoroquinolones should be reserved for important uses other than acute cystitis or used as 
an alternative only when these recommended agents cannot be used (Gupta et al., 2011). 
We recommend that ciprofloxacin should not be used as a first-line treatment option for UTI 
as continuous increases in resistance to ciprofloxacin further weaken the effectiveness of 
this drug. 
 
Additional findings from the meta-analysis showed that resistance was significantly higher in 
developing countries compared to developed countries. A major factor accounting for this 
difference is the use of over-the-counter or non-prescription antibiotics which occur 
commonly in developing countries (Okeke et al., 2005; Okeke, Lamikanra, & Edelman, 1999). 
Although this review did not directly consider antimicrobial resistance in relation to 
prescribing for the included studies, evidence shows that over-the-counter or non-
prescription use results in unnecessary and excessive use of antibiotics. Some of the 
included studies in our review clearly state that there are no restrictions for over-the-
counter prescribing of antimicrobials within their countries (Ahmad, 2013; Akoachere, 
Yvonne, Akum, & Seraphine, 2012; Akram, Shahid, & Khan, 2007; Arabi & Banazadehi, 2013; 
Astal, 2005; Dash, Padhi, Mohanty, Panda, & Parida, 2013; Kashef, Djavid, & Shahbazi, 2010; 
Kimando et al., 2010; Kothari & Sagar, 2008; Murugan, Savitha, & Vasanthi, 2012; Sire et al., 
2007). A recent systematic review investigating global non-prescription antimicrobial use 
found that resistance was common in communities with frequent non-prescription 
antimicrobial use (Morgan et al., 2011). Non-prescription use was highest in Africa, Asia and 
Middle East at 100%, 58% and 39% respectively (Morgan et al., 2011). In our review, further 
analyses by region showed that Asia had the highest pooled resistance to ciprofloxacin with 
a significantly higher resistance in Africa, Asia and Middle East combined compared with 
Europe and the Americas. Our finding is supported by a recent paper by Dalhoff (2012b) 
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reporting that fluoroquinolone resistance was highest in the Asia-Pacific region and 
moderate to low in Europe and North America. Furthermore, there is evidence to show that 
countries that have developed control policies to regulate non-prescription use have seen a 
decrease in antimicrobial use and resistance rates (Morgan et al., 2011). Based on our 
findings, we therefore emphasise the need for the development of policies restricting over-
the-counter antimicrobial use in countries that do not have such policies thereby 
contributing to the prevention of patient morbidity and mortality associated with resistant 
infections. It is noteworthy to mention that another important factor contributing to 
antimicrobial resistance is the use of antibiotics in livestock for growth promotion (Maron, 
Smith, & Nachman, 2013). Extensive antimicrobial use in food animal production has been 
associated with antimicrobial resistance globally (Maron et al., 2013). This has considerable 
implications for human health with the need to protect the efficacy of these antimicrobials 
to ensure their effectiveness for the treatment of humans.   
 
A large variation in ciprofloxacin resistance was found in studies reporting on community-
acquired UTI. This variation highlights the significance of local resistance monitoring to 
guide the development of local antibiotic guidelines. The random-effects meta-regression 
model confirmed that a number of factors significantly accounted for the variations in 
ciprofloxacin resistance. These include economy (developed and developing), Asia as a 
region, year of study, studies including only children and studies with a high risk of bias. The 
first three factors have been discussed in detail in the preceding paragraphs. We found that 
resistance was lower in studies involving only children. This finding is in line with a number 
of studies which have compared resistance in adults and children showing significantly 
higher ciprofloxacin resistance in adults compared to children (Owumi, Banaei, & Shortliffe, 
2014; Storby, Österlund, & Kahlmeter, 2004). Increased age has also been shown to be 
significantly associated with ciprofloxacin resistance (Blaettler et al., 2009; Karlowsky et al., 
2011). Given that children are less exposed to antimicrobials with limited ciprofloxacin use 
in the paediatric age group, this finding is expected (Adefurin, Sammons, Jacqz-Aigrain, & 
Choonara, 2011; Owumi et al., 2014; Storby et al., 2004). Although the importance of 
intrafamilial cross-infection of resistant pathogens is yet to be confirmed, it has been 
suggested that fluoroquinolone resistance may to some extent be dependent on cross-
infection with transfer from adults to children (Storby et al., 2004). Given this assumption, it 
is necessary to also monitor resistance levels in children to prevent further resistance 
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development in this vulnerable age group. Other likely causes of higher resistance in adults 
may be the greater likelihood of comorbidities with more frequent contact with healthcare 
settings (Karlowsky et al., 2011). The last factor found to account for heterogeneity between 
studies was high risk of bias. Most of the studies included in the review were found to have 
a high risk of bias as assessed using the NOS scale. These studies lacked methodological 
rigour including absence of the inclusion of possible confounding factors (such as age, sex 
and previous use of an antimicrobial) in the design and analysis of the studies. The poor 
reporting of observational studies poses limitations for conducting meta-analysis of these 
studies. Better presentation of definitions would enable inclusion in systematic reviews of 
some categories that had to be excluded in this review. Observational studies are more 
prone to confounding bias (von Elrn, 2004) further emphasising the need for adherence to 
reporting guidelines such as such as that based on the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) Statement (Vandenbroucke et al., 2007) to 
ensure clear and comprehensive reporting prior to publication acceptance. The poor quality 
of many studies initially retrieved for this review resulted in a large number being excluded. 
Therefore the information provided in this systematic review and meta-analysis of 54 
observational studies may not sufficiently address ciprofloxacin resistance globally but may 
provide satisfactory evidence to inform future interventions. 
 
In addition, this systematic review highlights the weaknesses in the quality of antimicrobial 
resistance data that are being collected in various regions. These weaknesses have 
implications for development of effective surveillance systems to monitor resistance 
globally and strategies to prevent further resistance development. The need for the 
implementation of national and global surveillance systems to detect and continuously 
monitor AMR cannot be overemphasised. These systems would enable prospective studies 
to be conducted and would play a major role in curtailing the widespread effect of 
antimicrobial resistance and help healthcare providers in deciding on the most appropriate 
empirical therapy for UTI to ensure proper management of patients. Governments need to 
put in place policies to restrict over-the-counter use and inappropriate prescribing of 
ciprofloxacin and other antimicrobials to prevent further development of resistance.  
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Strengths and limitations 
There are a number of notable strengths to our review. To our knowledge, this is the first 
systematic review to compare the overall prevalence of ciprofloxacin resistance in 
community- and hospital-acquired E. coli UTI. We undertook a comprehensive literature 
search process to identify and screen articles against eligibility criteria. Given that generic 
versions of ciprofloxacin were first marketed at different times in various countries, our 
choice of 2004 as the start date was therefore made on the basis of changes in the 
epidemiology of antimicrobial resistant pathogens which had resulted in changes to 
treatment regimens. A further strength of this systematic review is the development of a 
peer reviewed, registered protocol prior to undertaking the review. For studies to be 
included in the review, they were restricted to those that used a standard laboratory UTI 
criterion of ≥105 cfu/mL as recommended by the CDC. Although applying the internationally 
recognised CDC criteria may definitely be considered a strength as it ensures the quality and 
uniformity of included studies, this criterion limited the number of hospital-acquired UTI 
studies included in our systematic review. Despite this, resistance was still found to be 
higher in the hospital setting compared to the community setting similar to published 
studies. While lower counts of uropathogens are relevant for acute episodes of 
uncomplicated cystitis, the use of different colony counts makes comparison of data 
between studies difficult. Including all urinary E. coli isolates was considered but not done 
because this existing surveillance criterion (≥105 cfu/mL and 48 hours cut off) is usually 
applied to defining infections not isolates. Also, including all isolates carries the risk of 
including duplicates. This approach poses some degree of ascertainment bias as our 
systematic review focuses on laboratory identified UTI which may not only underestimate 
the total number of UTI but also lead to selection of samples from complicated cases 
thereby overestimating resistance. Another limitation is the wide variation of resistance 
estimates between studies and the inclusion of studies having substantial clinical and 
methodological heterogeneity. Visual inspection of the funnel plot (figure 6) showed 
asymmetry suggesting evidence of publication bias, with studies reporting high resistance 
rates being more likely to be published posing a limitation to this review. Also, the quality 
and risk of bias of some of the studies included in the review were assessed as high. These 
limitations were addressed by undertaking a random-effects meta-analysis with subsequent 
subgroup analyses and random-effects meta-regression to explain the sources of 
heterogeneity. For studies in which the design was not stated, the review authors faced 
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difficulties in categorising such studies hence some of these studies were grouped as non-
classifiable. These studies did not provide clear and explicit information on the methods 
used for conducting the studies. This emphasises the need for implementation and 
adherence to clear reporting standards prior to publication of papers. Furthermore, in some 
included studies, adjustments were not made for important confounding factors relevant to 
antimicrobial resistance such as antibiotic use and patient demographics including age and 
sex. For this systematic review, studies on samples obtained from emergency department 
(ED) patients were classified as community-acquired samples. Included papers did not 
provide any information on whether some of these patients may have returned from a 
recent hospitalisation and represented to the ED. Ideally, these should be considered as 
hospital-acquired infections as some of these patients may have been discharged in the 
previous 48 hours. For the purpose of this review and to overcome inherent variations in 
how individual studies have defined these patients, we classified all papers reporting on ED 
patients as community-acquired UTI studies. It was not possible to determine the potential 
effect of samples obtained from nursing home or residential aged care studies on the 
pooled resistance because this participant group did not meet the inclusion criteria for 
analysis. Furthermore, classification of this setting as hospital or community remains 
controversial. Finally, validity issues may have arisen from the use of different antimicrobial 
susceptibility test and interpretation methods with differing breakpoints which tend to 
change over the years. To date, there is still no worldwide consensus on the most suitable 
antimicrobial susceptibility testing method with the fact that various countries and even 
laboratories within the same country use different tests and interpretative criteria. 
Subgroup analysis for AST method was considered but not done because almost all studies 
used the disk diffusion method and CLSI criteria.  
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Figure 6 Funnel plot of studies included in meta-analysis 
 
4.2.7 Conclusion 
Ciprofloxacin resistance in E. coli UTI is increasing. The use of this antimicrobial agent as 
empirical therapy for UTI should be reconsidered and efforts should be made to limit its use 
to clinical conditions for which there are clear therapeutic indications. Policy restrictions on 
ciprofloxacin use need to be developed and enforced especially in developing countries that 
are yet to have such policies put in place. Further research is needed to describe 
ciprofloxacin resistance in hospital-acquired E. coli UTI using widely accepted definitions.  
 
4.3 Summary 
This is the most comprehensive published systematic review to date that has compared 
ciprofloxacin resistance rates in hospital- and community-acquired UTI. This systematic 
review and meta-analysis of observational studies published over a period of eleven years 
has identified that ciprofloxacin resistance is present in both the hospital and community. 
Worldwide evidence obtained from this study shows that resistance to this agent is on the 
increase regardless of country. Given the rising resistance rates to ciprofloxacin, despite 
recommendations against its use for first-line empiric treatment of UTI, undertaking this 
systematic review and meta-analysis was timely. The results of this systematic review and 
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meta-analysis provide justification for limiting the use of this agent, not only in hospital 
settings where higher resistance was noted, but also in the community where an increasing 
trend was noted for both developed and developing countries. This published manuscript 
further emphasises that the issue of AMR is neither country nor region specific. The study 
findings provide an opportunity to inform policy and practice, especially in relation to 
antimicrobial prescribing. Continuous surveillance and monitoring of ciprofloxacin 
resistance rates in all regions of the world is recommended to ensure that this antimicrobial 
agent, as well as other agents within the fluoroquinolone group, is preserved for important 
use. This systematic review also highlights the poor quality of AMR data and lack of 
methodological rigour when conducting AMR studies in various countries. This has 
implications for development of interventions to control further development and spread of 
resistance.   
 
The next chapter presents the findings of the second study. The focus of subsequent studies 
will now be on antimicrobial susceptibility test data obtained from ACT Pathology 
microbiology laboratory. Study two reports on a time series analyses of five-year 
antimicrobial resistant urinary E. coli prevalence data at the Canberra Hospital. 
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Chapter 5: Study two – Prevalence of antimicrobial resistance in E. coli UTI 
 
5.1 Overview 
Escherichia coli has been identified by the WHO as one of the key bacteria demonstrating 
significant increases in resistance levels to antimicrobials, which is a major concern (World 
Health Organization, 2015a). Increasing resistance of urinary E. coli to antimicrobials has 
also been demonstrated in a number of studies published worldwide (Bouchillon et al., 
2013; Linhares et al., 2013; Maraki et al., 2013), highlighting the importance of continued 
monitoring of resistance patterns in this bacterium to ensure implementation of strategies 
to prevent further resistance development and spread. Previously, antimicrobial resistant 
infections were primarily associated with healthcare settings, but during the last ten years 
increasing levels of antimicrobial resistant infections have been noted in the community as 
well (O'Neill, 2016). This emphasises the need to ensure resistance monitoring occurs both 
in hospital and community settings.  
 
There is published evidence to demonstrate the association between AMR and antimicrobial 
use (Goossens et al., 2005; Gottesman et al., 2009; López-Lozano et al., 2000). Resistance 
rates have been correlated with antimicrobial prescribing at the hospital level (Gallini et al., 
2010; Vernaz et al., 2011) as well as in community settings (Goossens et al., 2005; 
Gottesman et al., 2009). To fully comprehend the epidemiology and impact of AMR, 
evaluating both AMR and antimicrobial use data is important (O'Neill, 2016). The 
information obtained can inform clinical practice and contribute to development of policies 
to control further development and spread of AMR, thereby improving patient outcomes 
(O'Neill, 2016). Evaluating AMR and antimicrobial use can also provide baseline data to 
monitor the effectiveness of future interventions.  
 
Chapter Five (section 5.2) presents the published manuscript of the second study (Fasugba 
et al., 2016) undertaken as part of the research program. The supplementary (S1) table cited 
in the published manuscript is provided in Appendix G of the thesis. In study two, I used 
data from a microbiological laboratory to describe temporal trends of resistance prevalence 
and seasonality of antimicrobial resistant urinary E. coli isolates over five years, from 
January 2009 to December 2013, at the Canberra Hospital. Evaluation of the data also 
involved comparison of the prevalence of resistance in hospital- and community-acquired 
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urinary E. coli infections. Study two was also informed by findings from study one (reported 
in Chapter Four), which identified methodological issues with the conduct and reporting of 
AMR studies, one of which was calculation of the prevalence of resistance.  
 
Given the strong evidence in support of the association between antimicrobial use and 
development of resistance, additional data on antimicrobial use for Canberra Hospital were 
obtained. However, the analysis of antimicrobial use data was not included in the 
manuscript along with the resistance data for a number of reasons. First, the antimicrobial 
use data are ecological and are for all infections, not only UTI. Second, the antimicrobial use 
data are for all Canberra Hospital inpatients, which are a small subset of the resistance data 
(80% of which are community-acquired), making the antimicrobial use and AMR datasets 
non-comparable. Hence, the analysis of supplementary antimicrobial use data is included 
separately (section 5.3). Section 5.3 extends the study further by undertaking a time series 
analysis to evaluate trends and seasonal variation in antimicrobial use at the Canberra 
Hospital over a five-year period.  
 
5.2 Publication two: Five-year antimicrobial resistance patterns of urinary Escherichia 
coli at an Australian tertiary hospital: time series analyses of prevalence data  
      
 
 
5.2.1 Abstract  
This study describes the antimicrobial resistance temporal trends and seasonal variation of 
Escherichia coli (E. coli) urinary tract infections (UTI) over five years, from 2009 to 2013, and 
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compares prevalence of resistance in hospital- and community-acquired E. coli UTI. A cross 
sectional study of E. coli UTI from patients attending a tertiary referral hospital in Canberra, 
Australia was undertaken. Time series analysis was performed to illustrate resistance trends. 
Only the first positive E. coli UTI per patient per year was included in the analysis. A total of 
15,022 positive cultures from 8724 patients were identified. Results are based on 5333 first 
E. coli UTI, from 4732 patients, of which 84.2% were community-acquired. Five-year hospital 
and community resistance rates were highest for ampicillin (41.9%) and trimethoprim 
(20.7%). Resistance was lowest for meropenem (0.0%), nitrofurantoin (2.7%), piperacillin-
tazobactam (2.9%) and ciprofloxacin (6.5%). Resistance to amoxycillin-clavulanate, cefazolin, 
gentamicin and piperacillin-tazobactam were significantly higher in hospital- compared to 
community-acquired UTI (9.3% versus 6.2%; 15.4% versus 9.7%; 5.2% versus 3.7% and 5.2% 
versus 2.5%, respectively). Trend analysis showed significant increases in resistance over five 
years for amoxycillin-clavulanate, trimethoprim, ciprofloxacin, nitrofurantoin, trimethoprim-
sulphamethoxazole, cefazolin, ceftriaxone and gentamicin (P<0.05, for all) with seasonal 
pattern observed for trimethoprim resistance (augmented Dickey-Fuller statistic=4.136; 
P=0.006). An association between ciprofloxacin resistance, cefazolin resistance and 
ceftriaxone resistance with older age was noted. Given the relatively high resistance rates 
for ampicillin and trimethoprim, these antimicrobials should be reconsidered for empirical 
treatment of UTI in this patient population. Our findings have important implications for UTI 
treatment based on setting of acquisition. 
 
5.2.2 Introduction  
Urinary tract infections (UTI) are predominantly bacterial infections affecting people both in 
the community and in hospitals (Laupland et al., 2007). Over 80% are caused by Escherichia 
coli (E. coli), a Gram-negative bacillus (Nicolle, 2008). Data from the combined National 
Ambulatory Health Care Surveys in the United States (US) for 2009-2010 showed that UTI 
accounted for approximately 9.8 million visits to ambulatory care settings such as primary 
care, outpatient and emergency departments (Centers for Disease Control and Prevention & 
National Center for Health Statistics, 2015). Visits due to UTI were estimated to be 0.8% of 
all ambulatory care visits (Centers for Disease Control and Prevention & National Center for 
Health Statistics, 2015). In Australia, national data on UTI are unavailable but recent 
estimates from 82 hospitals and 17 aged care facilities reported a point prevalence of 1.4% 
and 1.5% respectively for healthcare-associated UTI (Mitchell, Fasugba, et al., 2016). 
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While UTI are a major infection burden globally, the growing problem of antimicrobial 
resistance (AMR) can result in treatment failures and increased cost of healthcare (Howard, 
Scott, Packard, & Jones, 2003). There is evidence to show that the AMR pattern of urinary E. 
coli is increasing (Blaettler et al., 2009). In Switzerland, an analysis of urinary E. coli 
specimens obtained from a university hospital from 1997 to 2007 found an increasing trend 
in resistance to trimethoprim/sulfamethoxazole, ciprofloxacin and amoxycillin/clavulanic 
acid (from 17.4% to 21.3%, 1.8% to 15.9%, and 9.5% to 14.5%, respectively) (Blaettler et al., 
2009). The Australian Group on Antimicrobial Resistance (AGAR) which undertakes AMR 
prevalence surveys within Australia also noted a gradual rise in overall percentage of E. coli 
strains resistant to beta-lactam antibiotics and ciprofloxacin (Australian Group on 
Antimicrobial Resistance, 2012). From 2009 to 2011, resistance of hospital-onset E. coli 
isolates to ampicillin and ciprofloxacin increased from 48% to 51% and 8% to 11% 
respectively (Australian Group on Antimicrobial Resistance, 2012). Furthermore, the 
resistance rates of urinary E. coli to various antimicrobials show large inter-country 
variability (Karlowsky, Kelly, Thornsberry, Jones, & Sahm, 2002). Only a few studies have 
shown that E. coli resistance rates differ for hospital-acquired and community-acquired UTI 
(Cullen et al., 2012; Ma & Wang, 2013; Perrin et al., 1999). Measuring and comparing the 
levels of AMR in both hospital- and community-acquired UTI is essential because although 
effects of AMR are mainly felt in healthcare facilities, the greatest use of antimicrobials 
occurs in the community (Coxeter et al., 2013). Comparing resistance rates in hospital- and 
community-acquired UTI may influence therapeutic recommendations for UTI based on 
setting of acquisition. 
 
The prevalence of AMR including hospital and community urinary E. coli resistance levels is 
not completely known in Australia. Obtaining this information is important because it not 
only provides knowledge about the health status of a population, but also contributes to 
disease management decisions (Buttner & Muller, 2011). This study describes the AMR 
temporal trends and seasonal variation of E. coli UTI over five years at an Australian tertiary 
hospital. The study also compares the prevalence of resistance between hospital- and 
community-acquired E. coli UTI. 
 
 
 
143 
 
5.2.3 Materials and Methods 
Study design and setting 
A retrospective cross sectional design was used. The study was conducted with data from 
ACT Pathology which is based at a tertiary referral hospital, the Canberra Hospital and 
Health Services. This is Australian Capital Territory’s (ACT) main hospital which provides 
acute and specialist care services to over 600,000 people in the surrounding region. The 600 
bed publicly-funded hospital which includes an emergency department and intensive care 
unit, offers a comprehensive range of health services such as acute inpatient and day 
services, outpatient services, women's and children's services and pathology services. Solid 
organ transplant services are not offered in Canberra.  
Human research ethics approval was granted by ACT Health Human Research Ethics 
Committee’s Low Risk Sub-Committee and Australian Catholic University Human Research 
Ethics Committee. Consent from patients was not obtained as a waiver of consent was 
granted by the ethics committees.  
 
Urine sample and data collection 
The microbiology records of inpatients and those attending Canberra Hospital who had 
urine samples processed at ACT Pathology from January 2009 to December 2013 were 
retrospectively reviewed. Demographic data and clinical information such as date of birth, 
gender, admission date, specimen collection date and antimicrobial susceptibility test result 
were obtained from the microbiology laboratory database and administrative record 
system. 
 
Bacterial isolation and identification  
Urine samples were analysed and processed based on the microbiology laboratory 
standards (Australian Capital Territory Pathology, 2013). For this study, a culture with 
presence of ≥107 colony forming unit (cfu) per litre of urine was considered positive for UTI 
based on the laboratory recommendations. This 107 cfu/L cut-off is commonly used as it 
increases the sensitivity of the urine culture test making it a practical threshold (Wilson & 
Gaido, 2004). The criterion has also been used by several studies reporting on antimicrobial 
resistance of urinary E. coli (Laupland et al., 2007; Linhares et al., 2013; McGregor et al., 
2013). Cultures with three or more bacterial species isolated were considered contaminated 
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and excluded. Only the first positive E. coli UTI per patient per year was included in the final 
analysis.  
 
Definitions 
Urine cultures were classified based on the setting of acquisition of infection (hospital-
acquired and community-acquired, also known as hospital-onset and community-onset) 
using criteria from the Centers for Disease Control and Prevention definitions (Horan et al., 
2008). Positive E. coli urine cultures obtained within the first 48 hours of admission 
(including cultures from non-admissions such as outpatient clinics) were defined as 
community-acquired UTI. Positive cultures obtained more than 48 hours after admission 
and within 48 hours of discharge were defined as hospital-acquired UTI.  
 
Antimicrobial susceptibility testing 
Antimicrobial susceptibility was performed by a disc diffusion method and the automated 
minimum inhibitory concentration (MIC) method using Vitek2 (Biomerieux Diagnostics). 
Interpretation was based on Clinical Laboratory Standard Institute (CLSI, formerly NCCLS) 
criteria (Clinical and Laboratory Standards Institute, 2014). Based on a stepwise laboratory 
testing protocol used during the study period, all significant E. coli (>107cfu/L) isolated after 
overnight incubation on culture had disc susceptibility testing done. The antibiotic discs 
used for these tests were ampicillin (10µg), amoxycillin-clavulanate (augmentin) (30µg), 
cephalexin/cefazolin (30 µg), trimethoprim (5µg), nalidixic acid (30 µg), ciprofloxacin (5 µg), 
nitrofurantoin (300 µg) and gentamicin (10µg). The isolates which were found to be 
resistant to at least three of the routinely tested antibiotics were then sent for Vitek2 
testing to determine the MICs for ceftriaxone, trimethoprim-sulphamethoxazole, 
meropenem and piperacillin-tazobactam in addition to the routinely tested antibiotics. 
Direct susceptibility testing method on urine specimens for E. coli has been validated at ACT 
Pathology and is comparable to the CLSI recommended methods.  
The quality control strains used for disc diffusion tests were E. coli ATCC 25922, E. faecalis 
ATCC 29212 and for Vitek E. coli ATCC 25922, P. aeruginosa ATCC 27853, E. faecalis ATCC 
29212, S. aureus ATCC 29213. 
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Extended spectrum beta lactamase (ESBL) confirmation  
Detection of ESBL-producing isolates was performed with combination discs of cefotaxime 
(30µg), cefotaxime/clavulanic acid (30/10µg), ceftazidime (30µg) and ceftazidime/clavulanic 
acid (30/10µg) whenever required according to CLSI guidelines (Wilson & Gaido, 2004). 
Extended spectrum beta lactamase production was inferred when the zone diameter of the 
disc with clavulanate was ≥5mm larger than the disc without clavulanate for the same 
antibiotic. K. pneumoniae ATCC 700603 was used as the quality control strain. 
 
5.2.4 Data analysis 
The overall 5-year and yearly resistance rates of E. coli to the routinely tested first-line 
antimicrobials on over 4,000 isolates (ampicillin, amoxycillin-clavulanate, 
cephalexin/cefazolin, ciprofloxacin, gentamicin, nalidixic acid, and trimethoprim) were 
calculated by dividing the number of urinary E. coli isolates resistant to each antimicrobial 
by the number of isolates tested against an individual antimicrobial agent. For the isolates 
which were sent for further susceptibility testing on Vitek2 against second-line 
antimicrobials (ceftriaxone, trimethoprim-sulphamethoxazole, meropenem, piperacillin-
tazobactam and nitrofurantoin), the denominator used in calculating the resistance rates 
was the total number of isolates included in the study. This denominator was used based on 
the assumption that isolates were initially not tested for the Vitek2 antibiotics because they 
were considered highly unlikely to be resistant to these antibiotics. Hence in order not to 
overestimate the resistance rates of these isolates the denominator included all isolates 
tested on both antibiotic discs and Vitek2. The binomial exact 95% confidence intervals (CI) 
of the resistance percentages were calculated. The 5-year resistance rates were compared 
for community- and hospital-acquired isolates. The chi-square test was used to check for 
statistically significant differences in AMR between both groups. Mean differences in age 
between the two groups were tested using Student’s t-tests. A time series analysis was 
performed separately for all antimicrobials tested to identify patterns in resistance (trends 
and seasonal variation) over the five-year period. Seasonality is a pattern that shows 
periodic repetitive fluctuations over time. An autoregressive (AR) model was constructed to 
assess time-varying resistance patterns (i.e., resistance is non-stationary, or changing, over 
time) and multiple time series models were fitted to also account for age and sex. The 
analysis on age and sex followed an ecological study design because these variables were 
aggregated for each season. The Dickey-Fuller (DF) and the augmented Dickey-Fuller (ADF) 
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tests were used to assess a unit root in the time series data. Both DF and ADF statistics are 
negative numbers; the more negative, the stronger the rejection of the null hypothesis (that 
there is unit root at some level of confidence). These unit root tests investigate whether a 
time series variable (e.g., resistance) is non-stationary using the AR model (Dickey & Fuller, 
1979). Urinary E. coli isolates for which the antimicrobial showed an intermediate 
susceptibility category (amoxycillin-clavulanate, trimethoprim, and ciprofloxacin) were 
excluded from the final analysis. A significance level of P < 0.05 was used. Data were 
analysed using STATA statistical software (version 13, StataCorp). 
 
5.2.5 Results 
A total of 106,512 urine samples from 47,727 patients attending Canberra Hospital from 
2009 to 2013 were processed by ACT Pathology. Of these, 14.1% (n=15,022) had positive 
cultures with E. coli being the most common organism isolated in 7670 (51.1%) samples. The 
distribution of samples by study year is shown in S1 Table.  
 
Of the 7670 E. coli cultures, most (7103 isolates) could be further classified as community- 
or hospital-acquired UTI based on available data. The data were then restricted to the first 
positive E. coli UTI per patient per year of which there were 5346 positive E. coli UTI but only 
5333 had susceptibility test results. Hence 5333 E. coli UTI belonging to 4732 patients in the 
5-year period were included in the final analysis. The majority (84.2%, n=4492) of UTI were 
classified as community-acquired and 15.8% (n=841) as hospital-acquired. The mean age of 
all patients was 57.0 years (SD=27.5) and patients were mostly female (80.2%, n=3795). 
There was a significant difference in age between patients with hospital- and community-
acquired E. coli UTI (mean age 67.2 years versus 55.1 years, P<0.001) but no significant 
differences in gender.  
 
Antimicrobial resistance 
All 5333 isolates had routine susceptibility testing performed against first-line antimicrobials 
and the overall 5-year and stratified (hospital- and community-acquired) AMR rates are 
summarised in Table 1. Of the 5333 isolates, 1599 (29.9%) were sent for further 
antimicrobial susceptibility testing for second-line antimicrobials on Vitek2. The overall 5-
year resistance rates to these second-line antimicrobials are reported in Table 2. 
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Table 1 Resistance profile of urinary E. coli isolates sent for routine susceptibility testing from 2009 to 2013 by setting 
 COMMUNITY HOSPITAL TOTAL 
Antibiotic Year Number of 
community 
isolates 
tested 
R 
n (%) 
95% CI of 
resistance 
percentage 
Number of 
hospital 
isolates 
tested 
 
R 
n (%) 
95% CI of 
resistance 
percentage 
Total 
number 
of isolates 
tested* 
R 
n (%) 
95% CI of 
resistance 
percentage 
Ampicillin 2009 835  331 (39.6) 36.3-43.1 143  71 (49.7) 41.2-58.1 978  402 (41.1) 38.0-44.3 
 2010 897  358 (39.9) 36.7-43.2 182  70 (38.5) 31.4-45.9 1079  428 (39.7) 36.7-42.7 
 2011 1037  443 (42.7) 39.7-45.8 189  91 (48.2) 40.8-55.5 1226  534 (43.6) 40.8-46.4 
 2012 939  412 (43.9) 40.7-47.1 173  74 (42.8) 35.3-50.5 1112  486 (43.7) 40.8-46.7 
 2013 784  315 (40.2) 36.7-43.7 154  71 (46.1) 38.1-54.3 938  386 (41.2) 38.0-44.4 
 Total 4492  1859(41.4) 39.9-42.8  841  377 (44.8) 41.4-48.3 5333  2236(41.9) 40.6-43.3 
AMC 2009 785  24 (3.1) 2.0-4.5 133  6 (4.5) 1.7-9.6 918  30 (3.3) 2.2-4.6 
 2010 832  49 (5.9) 4.4-7.7 172  11 (6.4) 3.2-11.2 1004  60 (6.0) 4.6-7.6 
 2011 981  61 (6.2) 4.8-7.9 170  17 (10.0) 5.9-15.5 1151  78 (6.8) 5.4-8.4 
 2012 895  71 (7.9) 6.2-9.8 161  19 (11.8) 7.3-17.8 1055  89 (8.4) 6.8-10.3 
 2013 754  58 (7.7) 5.9-9.8 145  23 (15.9) 10.3-22.8 899  81 (9.0) 7.2-11.1 
 Total 4247 263 (6.2) 5.5-6.9 781  76 (9.3) 7.7-12.0 5027  338 (6.7) 6.0-7.5 
Cefazolin 2009 821  60 (7.3) 5.6-9.3 129  14 (10.9) 6.1-17.5 950  74 (7.8) 6.2-9.7 
 2010 885  96 (10.9) 8.9-13.1 179  24 (13.4) 8.8-19.3 1064  120 (11.3) 9.4-13.3 
 2011 1019  103 (10.1) 8.3-12.1 178  30 (16.9) 11.7-23.2 1197  133 (11.1) 9.4-13.0 
 2012 917  82 (8.9) 7.2-11.0 168  26 (15.5) 10.4-21.8 1085  108 (10.0) 8.2-11.9 
 2013 776  89 (11.5) 9.3-13.9 151  30 (19.9) 13.8-27.1 927  119 (12.8) 10.8-15.2 
 
 
 
 
 
Total 4418 430 (9.7) 8.9-10.6 805 124 (15.4) 13.0-18.1 5223 554 (10.6) 9.8-11.5 
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 COMMUNITY HOSPITAL TOTAL 
Antibiotic Year Number of 
community 
isolates 
tested 
R 
n (%) 
95% CI of 
resistance 
percentage 
Number of 
hospital 
isolates 
tested 
 
R 
n (%) 
95% CI of 
resistance 
percentage 
Total 
number 
of isolates 
tested* 
R 
n (%) 
95% CI of 
resistance 
percentage 
Trimethoprim 2009 830  153 (18.4) 15.9-21.2 143  28 (19.6) 13.4-27.0 973  181 (18.6) 16.2-21.2 
 2010 897  172 (19.2) 16.6-21.9 181  33 (18.2) 12.9-24.6 1078  205 (19.0) 16.7-21.5 
 2011 1036  217 (20.9) 18.5-23.6 189  42 (22.2) 16.5-28.8 1225  259 (21.1) 18.9-23.5 
 2012 939  200 (21.3) 18.7-24.1 173  40 (23.1) 17.1-30.1 1112  240 (21.6) 19.2-24.1 
 2013 784  181 (23.1) 20.2-26.2 154  36 (23.4) 16.9-30.9 938  217 (23.1) 20.5-26.0 
 Total 4486  923 (20.6) 19.4-21.8 840  179 (21.3) 18.6-24.2 5326    1102(20.7) 19.6-21.8 
Nalidixic acid 2009 826  63 (7.6) 5.9-9.7 143  12 (8.4) 4.4-14.2 969  75 (7.7) 6.1-9.6 
 2010 892  73 (8.2) 6.5-10.2 182  12 (6.6) 3.5-11.2 1074  85 (7.9) 6.4-9.7 
 2011 1034  109 (10.5) 8.7-12.6 188  22 (11.7) 7.5-17.2 1222  131 (10.7) 9.0-12.6 
 2012 755  56 (7.4) 5.7-9.5 140  17 (12.1) 7.2-18.7 895  73 (8.2) 6.4-10.1 
 2013 585  33 (5.6) 3.9-7.8 103  11 (10.7) 5.5-18.3 688  44 (6.4) 4.7-8.5 
 Total 4092  334 (8.2) 7.3-9.0 756  74 (9.8) 7.8-12.1 4848  408 (8.4) 7.6-9.2 
Ciprofloxacin  2009 808  33 (4.1) 2.8-5.7 139  7 (5.0) 2.0-10.1 947  40 (4.2) 3.0-5.7 
 2010 701  35 (5.0) 3.5-6.9 150  4 (2.7) 0.7-6.7 851  39 (4.6) 3.3-6.2 
 2011 795  52 (6.5) 4.9-8.5 156  10 (6.4) 3.1-11.5 951  62 (6.5) 5.0-8.3 
 2012 749  56 (7.5) 5.7-9.6 143  11 (7.7) 3.9-13.3 892  67 (7.5) 5.9-9.4 
 2013 631  60 (9.5) 7.3-12.1 135  17 (12.6) 7.5-19.4 766  77 (10.1) 8.0-12.4 
 
 
 
 
 
 
Total 3684 236 (6.4) 5.6-7.2 723 49 (6.8) 5.1-8.9 4407 285 (6.5) 5.8-7.2 
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 COMMUNITY HOSPITAL TOTAL 
Antibiotic Year Number of 
community 
isolates 
tested 
R 
n (%) 
95% CI of 
resistance 
percentage 
Number of 
hospital 
isolates 
tested 
 
R 
n (%) 
95% CI of 
resistance 
percentage 
Total 
number 
of isolates 
tested* 
R 
n (%) 
95% CI of 
resistance 
percentage 
Gentamicin 2009 514  17 (3.3) 1.9-5.2 85  5 (5.9) 1.9-13.2 599  22 (3.7) 2.3-5.5 
 2010 893  23 (2.6) 1.6-3.8 182  2 (1.1) 0.1-3.9 1075  25 (2.3) 1.5-3.4 
 2011 1036  38 (3.7) 2.6-5.0 189  12 (6.4) 3.3-10.8 1225  50 (4.1) 3.0-5.3 
 2012 931  40 (4.3) 3.1-5.8 172  12 (7.0) 3.7-11.9 1102  52 (4.7) 3.5-6.1 
 2013 783  36 (4.6) 3.2-6.3 154  10 (6.5) 3.2-11.6 937  46 (4.9) 3.6-6.5 
 Total 4157  154 (3.7) 3.2-4.3 782  41 (5.2) 3.8-7.0 4938  195 (3.9) 3.4-4.5 
*Note that not all 5333 isolates were tested against each antimicrobial. Isolates not tested: AMC=3; Cefazolin=110; Trimethoprim=3; Nalidixic acid=485; 
Ciprofloxacin=893; Gentamicin=395  
Number of isolates with intermediate susceptibility to an antimicrobial: AMC=303; Trimethoprim=4; Ciprofloxacin=33 
R=Resistant 
n= Number of isolates  
AMC=Amoxycillin-clavulanate; TMP-SMX=Trimethoprim-sulphamethoxazole 
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Table 2 Resistance profile of urinary E. coli isolates sent for further testing on Vitek2 from 2009 to 2013 by setting 
Year Setting N Antibiotic 
Ceftriaxone TMP-SMX MER PIT NIT 
R 
n (%) 
95% CI of 
resistance 
percentage 
R 
n (%) 
95% CI of 
resistance 
percentage 
R 
n (%) 
95% CI of 
resistance 
percentage 
R 
n (%) 
95% CI of 
resistance 
percentage 
R 
n (%) 
95% CI of 
resistance 
percentage 
2009 CA 835 12 (1.4) 0.7-2.5 58 (6.9) 5.3-8.9 0 (0.0) - 2 (0.2) 0.0-0.9 14 (1.7) 0.9-2.8 
 HA 143 2 (1.4) 0.2-5.0 12 (8.4) 4.4-14.2 0 (0.0) - 0 (0.0) - 4 (2.8) 0.8-7.0 
 Total 978 14 (1.4) 0.8-2.4 70 (7.2) 5.6-9.0 0 (0.0) - 2 (0.2) 0.0-0.7 18 (1.8) 1.1-2.9 
2010 CA 897 22 (2.5) 1.5-3.7 76 (8.5) 6.7-10.5 0 (0.0) - 27 (3.0) 2.0-4.3 15 (1.7) 0.9-2.7 
 HA 182 4 (2.2) 0.6-5.5 11 (6.0) 3.1-10.6 0 (0.0) - 4 (2.2) 0.6-5.5 5 (2.7) 0.9-6.3 
 Total 1079 26 (2.4) 1.6-3.5 87 (8.1) 6.5-9.9 0 (0.0) - 31 (2.9) 2.0-4.1 20 (1.9) 1.1-2.8 
2011 CA 1037 46 (4.4) 3.3-5.9 99 (9.5) 7.8-11.5 0 (0.0) - 19 (1.8) 1.1-2.8 17 (1.6) 1.0-2.6 
 HA 189 13 (6.9) 3.7-11.5 30 (15.9) 11.0-21.9 0 (0.0) - 9 (4.8) 2.2-8.8 3 (1.6) 0.3-4.6 
 Total 1226 59 (4.8) 3.7-6.2 129 (10.5) 8.9-12.4 0 (0.0) - 28 (2.3) 1.5-3.3 20 (1.6) 1.0-2.5 
2012 CA 939 43 (4.6) 3.3-6.1 102 (10.9) 8.9-13.0 1 (0.1) 0.0-0.6 33 (3.5) 2.4-4.9 35 (3.7) 2.6-5.1 
 HA 173 13 (7.5) 4.1-12.5 22 (12.7) 8.1-18.6 0 (0.0) - 15 (8.7) 4.9-13.9 5 (2.9) 0.9-6.6 
 Total 1112 56 (5.0) 3.8-6.5 124 (11.1) 9.4-13.1 1 (0.1) 0.0-0.5 48 (4.3) 3.2-5.7 40 (3.6) 2.6-4.9 
2013 CA 784 45 (5.7) 4.2-7.6 87 (11.1) 9.0-13.5 0 (0.0) - 30 (3.8) 2.6-5.4 42 (5.4) 3.9-7.2 
 HA 154 15 (9.7) 5.6-15.6 25 (16.2) 10.8-23.0 0 (0.0) - 16 (10.4) 6.1-16.3 4 (2.6) 0.7-6.5 
 Total 938 60 (6.4) 4.9-8.2 112 (11.9) 9.9-14.2 0 (0.0) - 46 (4.9) 3.6-6.5 46 (4.9) 3.6-6.5 
Total CA 4492 168 (3.7) 3.2-4.3 422 (9.4) 8.6-10.3 1 (0.0) 0.0-0.1 111 (2.5) 2.0-3.0 123 (2.7) 2.3-3.3 
 HA 841 47 (5.6) 4.1-7.4 100 (11.9) 9.8-14.3 0 (0.0) - 44 (5.2) 3.8-7.0 21 (2.5) 1.6-3.8 
 Total 5333 215 (4.0) 3.5-4.6 522 (9.8) 9.0-10.6 1 (0.0) 0.0-0.1 155 (2.9) 2.5-3.4 144 (2.7) 2.3-3.2 
R=Resistant 
N= Number of isolates tested 
CA=Community isolates; HA=Hospital isolates  
TMP-SMX=Trimethoprim-sulphamethoxazole; MER=Meropenem; PIT=Piperacillin-tazobactam; NIT=Nitrofurantoin 
151 
 
The highest overall 5-year resistance rates to urinary E. coli for both hospital and community 
isolates combined were seen for ampicillin (41.9%; 95% CI=40.6-43.3) and trimethoprim 
(20.7%; 95% CI=19.6-21.8). The lowest resistance rates were for meropenem (0.0%), 
nitrofurantoin (2.7%; 95% CI=2.3-3.2) and piperacillin-tazobactam (2.9%; 95% CI=2.5-3.4). 
Resistance to amoxycillin-clavulanate, cephalexin/cefazolin, gentamicin and piperacillin-
tazobactam was significantly higher in hospital- compared to community-acquired UTI 
(P<0.001, P<0.001, P=0.043 and P=0.002, respectively). For ampicillin, trimethoprim, 
nalidixic acid, ciprofloxacin, ceftriaxone and trimethoprim-sulphamethoxazole, resistance 
rates were also higher for hospital- compared with community-acquired UTI but this did not 
reach statistical significance (Fig 1).  
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Figure 1 Five-year resistance rates of hospital- and community-acquired E. coli UTIs 
by selected antibiotics 
amp=ampicillin; tri=trimethoprim; cef=cefazolin; amc=amoxycillin-clavulanate; 
cip=ciprofloxacin; pit=piperacillin-tazobactam; gen=gentamicin; nit=nitrofurantoin 
** 0.001 < P value < 0.05 
** P < 0.001 
 
Trend analysis showed a significant increase in resistance to amoxycillin-clavulanate, 
trimethoprim, ciprofloxacin, nitrofurantoin, trimethoprim-sulphamethoxazole, cefazolin, 
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ceftriaxone and gentamicin over the five-year period (Fig 2). There was no significant 
increase in resistance for ampicillin, nalidixic acid, meropenem and piperacillin-tazobactam. 
A seasonal pattern was only observed for trimethoprim (ADF statistic=-4.136; P=0.006) with 
higher resistance rates for this antimicrobial seen in the summer months. Regression 
analysis indicated an association between increasing age and resistance to ciprofloxacin 
(regression coefficient=0.01; P=0.004), cefazolin (regression coefficient=0.004; P=0.038) and 
ceftriaxone (regression coefficient=0.01; P=0.002). 
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Figure 2 Seasonal antimicrobial resistance rates for E. coli UTIs  
1=Summer; 2=Autumn; 3=Winter; 4=Spring 
P=significance level for an increasing trend 
AMC=Amoxycillin-clavulanate; TMP-SMX=Trimethoprim-sulphamethoxazole 
 
ESBL production 
Overall 5-year prevalence of ESBL-producing E. coli isolates was 1.9% (95% CI=1.5-2.3; 
n=100). Extended spectrum beta-lactamase production was low by international standards 
but was significantly higher in hospital-acquired (3.0%; 95% CI=1.9-4.4; n=25) compared 
with community-acquired UTI (1.7%; 95% CI=1.3-2.1; n=75, P=0.01). The levels of ESBL-
producing E. coli increased from 0.7% (95% CI=0.0-3.8) in hospital-acquired UTI in 2009 to 
6.5% (95% CI=3.2-11.6) in 2013. An increase was also noted for community-acquired UTI 
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(0.6%; 95% CI=0.2-1.4 in 2009 to 3.7%; 95% CI=2.5-5.3 in 2013). The increasing trend in ESBL 
production over the five years was statistically significant for both hospital (P=0.035) and 
community-acquired UTI (P<0.001). 
 
5.2.6 Discussion  
This study provides information about the AMR pattern of E. coli UTI in an Australian tertiary 
hospital. To our knowledge this is the first Australian study to compare AMR in hospital- and 
community-acquired E. coli UTI and assess AMR temporal trends and seasonal variation of E. 
coli UTI over time. Our results showed that overall resistance was highest for ampicillin and 
trimethoprim. We also found significantly higher resistance rates in hospital- compared to 
community-acquired UTI for amoxycillin-clavulanate, cephalexin/cefazolin, gentamicin and 
piperacillin-tazobactam with an increasing resistance trend for eight of the twelve 
antimicrobials tested which include the four commonly used antimicrobials for first-line 
treatment of UTI in Australia. 
 
In Australia, trimethoprim, cephalexin, amoxycillin-clavulanate or nitrofurantoin are 
recommended for first-line treatment of UTI (Antibiotic Expert Groups, 2014). The Infectious 
Diseases Society of America (IDSA) and European Society for Microbiology and Infectious 
Diseases recommend trimethoprim-sulphamethoxazole as an appropriate treatment choice 
if local resistance rates do not exceed 20%. The IDSA guidelines also recommend that 
amoxycillin or ampicillin should not be used alone for empirical treatment because of the 
relatively poor efficacy and the relatively high prevalence of AMR to these agents worldwide 
(Gupta et al., 2011). Given the high levels of resistance to ampicillin and trimethoprim 
identified in this study, the appropriateness of these antimicrobials in the management of 
UTI in this patient population should be assessed. The IDSA suggests that beta-lactam 
agents, including amoxycillin-clavulanate are appropriate choices for therapy when other 
recommended agents cannot be used (Gupta et al., 2011). Based on our findings, the 
majority of UTIs have very low resistance to amoxycillin-clavulanate and nitrofurantoin 
which are commonly used for UTI treatment in Canberra. Ciprofloxacin, which is 
recommended in Australia for complicated UTI, was also found to have a low resistance 
rate. Through the national pharmaceutical subsidy scheme, the use of quinolones in humans 
has been restricted in Australia. Quinolone use in food-producing animals is also not 
permitted. Therefore, fluoroquinolone resistance in the community has been slow to 
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emerge and has remained at low levels in important pathogens such as E. coli compared to 
most countries (Cheng et al., 2012). Our overall resistance rates are also generally lower 
than reported for other single site studies (Cullen et al., 2012; Wang et al., 2014), 
demonstrating that resistance may vary geographically, as shown in a recent meta-analysis 
(Fasugba et al., 2015). The explanation for the varying resistance rates is not clearly 
understood but possible reasons have been postulated. A study conducted in the US 
demonstrated a geographic gradient in resistance with the highest resistance rates noted in 
the Pacific region and lowest rates in the South Atlantic region (Sannes, Kuskowski, & 
Johnson, 2004). It was suggested that geographic clustering of resistance phenotypes may 
have accounted for the geographic differences in resistance. It is therefore possible that the 
lower rates we found in comparison to those reported for other single site studies may be 
due to lower levels of bacteria with resistance phenotypes in our locality. Another possible 
suggestion for geographic variation in resistance is the differences in antimicrobial use 
(Gupta et al., 2001; Sannes et al., 2004). Several studies have demonstrated an association 
between antimicrobial use and resistance (Bergman et al., 2009; Goossens et al., 2005; 
Vellinga et al., 2010). Hence it is probable that the lower resistance noted may be as a result 
of lower antimicrobial use resulting in lower antimicrobial selection pressure. This 
emphasises the need for continued local monitoring of resistance patterns to ensure 
appropriate treatment for people in the locality. 
 
The sample size of the data was able to detect some significant differences between 
community- and hospital-acquired UTI resistance rates but for some antimicrobials the 
differences observed could not be confirmed statistically, possibly due to an insufficient 
sample size. Overall, we found lower rates of antibiotic resistance for community- compared 
with hospital-acquired E. coli UTI, consistent with other studies (Bouchillon et al., 2013; 
Cullen et al., 2012). The difference in resistance rates is however only small and supports the 
view that E. coli, a bacterium carried in the bowel and acquired in the community, is brought 
into hospital usually by patients themselves rather than being hospital-acquired. This finding 
may also have been partially dictated by our methodology from using the first positive UTI 
per person per year. The different resistance rates for hospital- and community-acquired 
urinary E. coli isolates seen in this study are comparable with findings reported previously 
(Ma & Wang, 2013; Perrin et al., 1999). Similar results have been seen in blood culture 
isolates of E. coli in Canberra (Kennedy et al., 2008). While the difference in resistance rates 
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was not large and most antimicrobial use occurs in the community, the proportion of 
patients receiving antimicrobials is much higher in the hospital and hence explains the 
difference seen (Zarb et al., 2012). We agree with recommendations that to accurately 
represent E. coli resistance rates, antibiograms should be stratified by setting of infection 
onset (Swami et al., 2012).  
 
The increasing resistance trend noted in our study for the eight antimicrobials is consistent 
with previously reported Australian data and published studies from other developed 
countries (Australian Group on Antimicrobial Resistance, 2011; Blaettler et al., 2009; Cullen 
et al., 2012; Hsu et al., 2010; Wong et al., 2014). The increasing trend may be attributable to 
antimicrobial overuse or misuse which is a known risk factor for the development of AMR 
(Costelloe et al., 2010). However, clinical data on hospital antimicrobial use at the study 
location showed stable rates for most antimicrobials tested (data not shown). We also found 
seasonal increases in trimethoprim resistance especially in summer months. The literature 
suggests a possible seasonality with UTI incidence (Freeman, Anderson, & Sexton, 2009; 
Perencevich et al., 2008) but this was not demonstrated in our study. It is possible that 
seasonality in UTI may lead to seasonal variation in antimicrobial use with subsequent 
seasonal resistance patterns although to our knowledge, this is yet to be demonstrated in 
published studies. Evidence currently exists to show higher use of antimicrobials in winter 
months which is likely related to the increased incidence of respiratory tract infections 
during that period with consequent increases in resistance during winter (Dagan et al., 2008; 
Sun, Klein, & Laxminarayan, 2012). Therefore the seasonal trimethoprim resistance is a 
potentially important finding which should be explored in future studies especially in 
relation to antimicrobial use. The ecological analysis conducted in this study showed an 
association between older age and resistance to ciprofloxacin, cefazolin and ceftriaxone 
consistent with published studies (Adam et al., 2013; Blaettler et al., 2009; Swami et al., 
2012). The association between increasing age and increased resistance is not surprising 
given that the physiological changes caused by aging and increased comorbidities 
predispose to a higher risk of infection leading to more contact with healthcare settings and 
hence more frequent exposure to antibiotics (Adam et al., 2013). 
 
It is worth emphasising that our overall ESBL rate of 1.9% was low compared to most other 
published studies (Bouchillon et al., 2013). Results from the 2009-2011 SMART study in the 
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US reported an ESBL rate of 6.8% for E. coli UTI (Bouchillon et al., 2013). Although our 
reported ESBL rate is relatively low, the presence and increasing trend of ESBL-producing E. 
coli in both hospital- and community-acquired UTI pose considerable public health concern. 
This is because this organism renders many of the conventional empirical treatment options 
for UTI ineffective especially in community-acquired UTI where options for oral antibiotic 
therapy appear to be limited (Falagas & Karageorgopoulos, 2009). For hospital-acquired UTI 
caused by ESBL-producing E. coli, carbapenems are considered the treatment of choice 
(Falagas & Karageorgopoulos, 2009). In our study, the lowest resistance rate reported was 
for meropenem, a carbapenem. 
 
This study has some limitations. As most UTIs are treated empirically, it is possible that 
samples submitted to the laboratory included patients with recurrent UTIs and 
asymptomatic bacteriuria thereby overestimating the resistance rates. In addition, inclusion 
of the first positive E. coli UTI per person per year may have underestimated the resistance 
rates reported in our study. Evidence suggests that analysis of antimicrobial resistance data 
should include each individual positive isolate in order to ensure sensitivity, but this positive 
isolate should only be included once to guarantee specificity (Cornaglia et al., 2004). This 
approach of using only the first positive isolate per patient per year is also consistent with 
published studies on resistance in UTI pathogens including E. coli (McGregor et al., 2013; 
Swami et al., 2012). It is unlikely that repeated isolates are correlated but there is a small 
possibility that this could occur although it was not accounted for in the analysis. The 5-year 
period prevalence study could therefore have overestimated the resistance. The use of 
routinely collected microbiology data also posed some limitations as clinical information on 
patients including comorbidities and presence of indwelling urethral catheters was often 
missing. The incompleteness of this information prevented its inclusion in the analysis. This 
study was based on retrospective antimicrobial susceptibility data from a National 
Association of Testing Authorities, Australia (NATA) accredited clinical microbiology 
laboratory. The stepwise laboratory testing protocol involved routine first-line antibiotic 
sensitivity testing followed by more extensive testing with second-line antibiotics only for 
isolates resistant to at least three of the routine antibiotics. Although this laboratory 
approach is widely used (Cornaglia et al., 2004) there is the potential for testing bias and/or 
selection bias with consequent overestimation of resistance rates. Given the lack of 
consensus on an appropriate denominator using this testing approach and to prevent 
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possible overestimation of the resistance rates against second-line antibiotics, the 
denominator therefore included all isolates tested, which, in turn, may have under-
estimated resistance rates of broad spectrum antimicrobials. Determining the resistance 
rate can be influenced by the extent of laboratory testing which in turn influences the 
selection of the denominator. Using the total number of isolates tested or the number of 
isolates tested against second-line antibiotics alone as the denominator will either 
underestimate or overestimate the resistance rates respectively. Although using all isolates 
for calculating resistance rates for second-line antibiotics has its limitations, this was an 
appropriate denominator choice to make the findings relevant for use in the clinical setting. 
For ideal comparison of susceptibility patterns, all isolates would need to be tested against 
the extended panel of antibiotics in a properly designed prospective study. Regardless of 
these limitations, our reported resistance rates are low compared to other studies. The use 
of ecological data to account for the effects of age and sex on resistance also poses 
limitations to interpretation of these results at the individual patient level. Although our 
data are from a single tertiary hospital and may not be generalisable to other populations, 
the data were reported by a NATA accredited laboratory and are therefore satisfactory to 
provide recommendations to guide local empirical therapy.  
 
5.2.7 Conclusion 
Antimicrobial resistance poses grave concerns for antimicrobial effectiveness in treating 
infections such as UTI. This study demonstrates the increasing resistance of urinary E. coli to 
commonly prescribed antimicrobials. Amoxycillin-clavulanate and nitrofurantoin are still 
effective for empirical treatment of UTI in this population. Overuse of ampicillin and 
trimethoprim should be avoided given the high resistance rates reported. In developing local 
antimicrobial prescribing guidelines, the choice of antimicrobial in the treatment of UTI 
should be based on setting (community or hospital) of acquisition. 
 
5.3 Analysis of supplementary antimicrobial use data at the Canberra Hospital  
Increasing use of antimicrobials in hospitals has been noted in a number of countries (de 
With et al., 2004; Janknegt, Lashof, Gould, & Van der Meer, 2000; Müller-Pebody et al., 
2004). Compared with Denmark, Canada, Sweden, Norway and the Netherlands, 
antimicrobial use in Australian hospitals is higher (Australian Commission on Safety and 
Quality in Health Care, 2016). In 2014, 24.3% of antimicrobial prescriptions in Australian 
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hospitals were said to be non-compliant with the therapeutic guidelines (Australian 
Commission on Safety and Quality in Health Care, 2016). Despite the high usage of 
antimicrobials in Australia, to my knowledge there are no published studies investigating 
antimicrobial use patterns and trends in Australian hospitals, although a limited number of 
studies have investigated changes in antimicrobial use in the community (Meumann et al., 
2015).  
 
Regular monitoring of antimicrobial use data can inform the development of antimicrobial 
stewardship programs (McNeil et al., 2010). Antimicrobial stewardship is described as a 
combined set of strategies aimed at improving the appropriateness and unintended effects 
of antimicrobial use, such as AMR, toxic effects and costs (McKenzie et al., 2013; Schuts et 
al., 2016). A cross sectional survey of acute care hospitals in the US in 2011 found that 64% 
of hospitals surveyed had an antimicrobial stewardship policy (Pogorzelska-Maziarz et al., 
2015). Hospital antimicrobial stewardship programs have been shown to decrease 
inappropriate antimicrobial use. Implementation of an antimicrobial stewardship program at 
a tertiary hospital showed a decrease in broad spectrum antimicrobial use of 17% and 10% 
in intensive care and non-intensive care units, respectively, following implementation of the 
program (Cairns et al., 2013). In addition, findings from a recent systematic review showed 
that antimicrobial stewardship had beneficial effects on patients’ clinical outcomes, such as 
decreased mortality and hospital AMR (Schuts et al., 2016). Although policies restricting 
antimicrobial use have been in existence in some hospitals for years, it was not until the last 
five to ten years that formal antimicrobial stewardship programs were developed (Cairns, 
Roberts, Cotta, & Cheng, 2015). Guidelines for implementing antimicrobial stewardship in 
hospitals in Australia were published in 2011 (Duguid & Cruickshank, 2011) and 
antimicrobial stewardship is now one of the mandatory requirements of the National Safety 
and Quality Health Service Standards (Standard 3.14), that all hospitals must meet for 
accreditation (Australian Commission on Safety and Quality in Health Care, 2012).  
 
Data on antimicrobial usage for inpatients in acute care settings in Australia is managed by 
NAUSP (SA Health, 2016). The data are expressed in the internationally recognised defined 
daily dose (DDD) per 1000 occupied bed days (OBD), as recommended by the WHO (SA 
Health, 2016). As described previously in the literature review chapter (Chapter Two), the 
DDD is defined as “the assumed average maintenance dose per day for a drug used for its 
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main indication in adults” (WHO Collaborating Centre for Drug Statistics Methodology, 2015, 
p. 22). The OBD is the total number of bed days of all patients admitted during a specific 
month with the exclusion of those admitted and discharged on the same day (National 
Antimicrobial Utilisation Surveillance Program, 2015). Using the DDD/1000 OBD as the 
measure of antimicrobial use facilitates benchmarking between Australian hospitals and 
jurisdictions as well as other countries (Australian Commission on Safety and Quality in 
Health Care, 2016). The data submitted to NAUSP by participating hospitals are aggregated 
as most hospitals in Australia do not have the systems in place to provide patient-level data 
(McNeil et al., 2010). 
 
The NAUSP provides bimonthly and annual reports on antimicrobial usage to contributing 
hospitals (SA Health, 2016). Hospitals use the data to compare their antimicrobial use to 
other hospitals and to their previous reports, but there is no evidence of whether any 
suspected increase or decrease in usage noted is statistically significant. Statistical 
significance does not necessarily imply clinical significance (LeFort, 1993), especially in 
relation to antimicrobial use, which is recognised as the main factor contributing to 
antimicrobial resistance (López-Lozano et al., 2000), but it is still important to demonstrate 
whether or not any increase or decrease in antimicrobial usage is a true difference or likely 
to be due to chance alone. Hence the analysis of these data as part of the research program 
aims to evaluate trends and seasonal variation in antimicrobial use at the Canberra Hospital 
over a five-year period. The results of this analysis have the potential to identify specific 
antimicrobials that require targeted interventions to minimise overuse and also improve 
antimicrobial prescribing at the hospital.  
 
5.3.1 Methodological approach to calculating antimicrobial use trend 
Monthly data on antimicrobial use for the Canberra Hospital for the five-year study period 
(January 2009 to December 2013) were retrospectively obtained from NAUSP. An 
amendment was submitted to the ACT Health Human Research Ethics Committee to obtain 
these data from NAUSP, with additional approval received from the Executive Director 
Performance Information Branch, ACT Health (See Appendices F.3 and F.4 respectively). The 
antimicrobial agents assessed for this analysis were: ampicillin; amoxycillin-clavulanic acid; 
cefazolin; ceftriaxone; ciprofloxacin; gentamicin; meropenem; nitrofurantoin; piperacillin-
tazobactam; trimethoprim, and trimethoprim-sulphamethoxazole. These were 11 of the 12 
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antimicrobials included in the analysis for resistance prevalence reported in section 5.2. 
Antimicrobial use data on the 12th antimicrobial, nalidixic acid, was unavailable. The 
antimicrobial usage rates were calculated in DDD per 1000 OBD, using the total number of 
DDD for each drug consumed as the numerator and the number of OBD as the denominator.   
 
Changes in antimicrobial use over time or trend were undertaken for the 11 antimicrobials. 
A time series analysis was performed separately for each antimicrobial to identify trends 
and seasonal variation in antimicrobial use over the five-year period. Time series analysis is a 
statistical analysis technique applied to observations with a time-ordered sequence (Wei, 
2013). The methodological concepts of the time series analysis have been previously 
described in the methods chapter in section 3.4.5. The trend analysis followed an ecological 
study design because antimicrobial use data were aggregated at the hospital level and not 
individual patient data. A significance level of P < 0.05 was used. Data were analysed using 
STATA statistical software (version 13, StataCorp). 
 
5.3.2 Results of analysis of antimicrobial use data 
For the overall five-year period, antimicrobial usage at the Canberra Hospital was highest for 
amoxicillin-clavulanate, cefazolin and ampicillin, and lowest for trimethoprim and 
nitrofurantoin. Overall antimicrobial use decreased by 10.7%, from 409.3 DDD/1000 OBD in 
2009 to 365.4 DDD/1000 OBD in 2013. Total antimicrobial use peaked in 2010 to 418.0 
DDD/1000 OBD. Ampicillin, gentamicin and ciprofloxacin demonstrated a gradual decrease 
in the antimicrobial usage rates over the five-year period, while broad spectrum antibiotics, 
piperacillin-tazobactam and meropenem, demonstrated a gradual increase in usage rates 
over the same period. Table 3 provides details of the overall five-year and yearly 
antimicrobial usage at the Canberra Hospital for each of the antimicrobials included in the 
analysis. These rates were standardised for bed days for all years. 
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Table 3 Overall 5-year and yearly antimicrobial use at the Canberra Hospital* 
Antimicrobial 
agent 
2009 2010 2011 2012 2013 Overall 
5-year 
AMC 75.8 88.3 86.7 82.8 76.6 82.0 
Cefazolin 81.3 80.1 81.2 77.3 81.9 80.3 
Ampicillin 68.3 65.4 59.0 43.4 38.8 54.3 
Gentamicin 52.5 48.6 43.7 32.7 20.7 39.0 
Ciprofloxacin 44.0 38.6 34.0 33.0 24.1 34.4 
Ceftriaxone 35.1 32.8 36.7 34.6 29.4 33.6 
PIT 8.6 14.8 26.1 31.5 39.5 24.7 
TMP-SMX 16.7 22.0 14.7 24.2 23.9 20.5 
Meropenem 16.0 17.0 19.2 19.5 19.3 18.3 
Trimethoprim 9.0 8.4 9.9 8.9 9.6 9.2 
Nitrofurantoin 2.0 2.0 1.4 1.6 1.6 1.7 
Total 409.3 418.0 412.6 389.5 365.4 398.0 
                *Expressed in defined daily dose/1000 occupied bed days 
                 AMC=Amoxicillin-clavulanate; TMP-SMX=Trimethoprim-sulphamethoxazole; 
PIT=Piperacillin-tazobactam 
 
Trend analysis of antimicrobial use 
Trend analysis showed that antimicrobial use was relatively stable for amoxicillin-
clavulanate, cefazolin, trimethoprim-sulphamethoxazole, trimethoprim and nitrofurantoin, 
with no significant change over the five-year period. Ampicillin, gentamicin and ciprofloxacin 
showed decreasing trends, although these did not reach statistical significance (Figure 3). 
Trend analysis for piperacillin-tazobactam and meropenem demonstrated gradual increase 
in their use, but significance was only found for meropenem. Seasonal patterns (periodic 
repetitive fluctuations over time) of antimicrobial usage were observed for ceftriaxone, 
predominantly during the winter months.  
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Figure 3 Trend of antimicrobial use for Canberra Hospital from 2009 to 2013 
1=Summer; 2=Autumn; 3=Winter; 4=Spring 
AMC=Amoxycillin-clavulanate; TMP-SMX=Trimethoprim-sulphamethoxazole 
 
5.3.3 Discussion  
The finding of a decrease in overall antimicrobial use from 2009 to 2013 is consistent with 
the latest national report on antimicrobial use and resistance in acute care hospitals 
(Australian Commission on Safety and Quality in Health Care, 2016). When antimicrobial use 
data from 2005 to 2014 were evaluated, total antimicrobial use in Australian hospitals 
peaked in 2010 and declined gradually thereafter (Australian Commission on Safety and 
Quality in Health Care, 2016). One possible explanation for the decrease in overall 
antimicrobial use is the implementation of antimicrobial stewardship initiatives, as 
demonstrated in other studies (Kaki et al., 2011; Schuts et al., 2016), but it is not possible to 
say whether this accounted for the findings observed at the Canberra Hospital. The 
infectious diseases and microbiology departments provided clinical services to the hospital 
in regards to control of antimicrobial use prior to the implementation of formal 
antimicrobial stewardship initiatives at the hospital in 2013 (A. Das, personal 
communication, 26 August, 2016). Despite demonstrating a decrease in overall quantity of 
antimicrobial use at the hospital over the study period, effective monitoring of antimicrobial 
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use also requires data on the quality or appropriateness of antimicrobial prescribing (Duguid 
& Cruickshank, 2011), which was not possible in this study. Data on appropriateness of 
antimicrobial use would provide evidence to show that any reported decrease in 
antimicrobial use is associated with effective prescribing in accordance with prescribing 
guidelines (Duguid & Cruickshank, 2011). These guidelines are developed based on local 
resistance patterns (Antibiotic Expert Groups, 2014). Hence, to enable adequate 
interpretation of the decrease in overall antimicrobial use at the hospital, data on the 
appropriateness of antimicrobial use must also be evaluated.  
 
The decreasing trend for antimicrobial use was evident for ampicillin, gentamicin and 
ciprofloxacin, although statistical significance was not demonstrated. Gentamicin and 
ciprofloxacin, the most frequently used aminoglycoside and fluoroquinolone respectively, 
are recognised as antimicrobials most likely to promote spread of resistance in hospitalised 
patients (Australian Commission on Safety and Quality in Health Care, 2016). Hence the 
decreasing antimicrobial usage rates observed for these antimicrobials are notable. 
Reduction in gentamicin use may be attributed to the recommendation provided in the 
recent Australian therapeutic guidelines on its empirical use, which states that empirical 
therapy with the aminoglycoside class of antibiotics should not extend beyond 48 hours, 
given its ‘post-antibiotic’ or long lasting effect in the body (Antibiotic Expert Groups, 2014). 
Through the national pharmaceutical subsidy scheme, ciprofloxacin use has been restricted 
in Australia since the early 1990s as it is classified as a reserve antimicrobial drug (Cheng et 
al., 2012). 
 
Although a decrease in overall antimicrobial use was noted, findings showed that use of the 
broad spectrum antimicrobials, piperacillin-tazobactam and meropenem, increased. The 
newer broad spectrum antimicrobials are costly and have been associated with the 
emergence of resistance (Kritsotakis et al., 2006). They are also regarded as last resort 
antimicrobials (ESPAUR Writing Committee, 2015). The exact reason for the observed 
increases in use is not clear. Results from the English Surveillance Programme on 
Antimicrobial Use and Resistance showed that from 2010 to 2014 prescribing of broad 
spectrum antimicrobials, specifically piperacillin-tazobactam and carbapenems, increased by 
55% and 36% respectively in UK hospital patients (ESPAUR Writing Committee, 2015). An 
increased use of broad spectrum and newer antimicrobials was also noted in hospitals in 
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Greece (Kritsotakis et al., 2006) and Denmark (Müller-Pebody et al., 2004). A possible reason 
proposed for this shift in antimicrobial use was that in a bid for doctors to cover for all 
possible causes of bacterial infections in patients, and because of pressure to ensure quick 
recovery of patients, doctors in hospitals were more likely to use broad spectrum 
antimicrobials for empirical therapy (Müller-Pebody et al., 2004). They were also less likely 
to change this to narrow spectrum antimicrobials when the microbiological results were 
available, as there was already clinical improvement in the patient’s condition (Müller-
Pebody et al., 2004).  
 
The results of analysis of the antimicrobial use data from Canberra Hospital also showed 
that five-year antimicrobial usage rates were highest for the broad spectrum antimicrobials, 
amoxicillin-clavulanate and cefazolin, consistent with national data, with amoxicillin-
clavulanate recognised as the most commonly used antimicrobial in Australian hospitals, 
with cefazolin ranking third (Australian Commission on Safety and Quality in Health Care, 
2016). These findings are also comparable to published findings from a general hospital in 
Spain where, over a five-year period from 1996 to 2000, amoxicillin-clavulanate was the 
most frequently used antimicrobial (Hermosilla, Canut, Ulibarrena, Abasolo, & Carlos, 2003). 
Other recent data from outpatients in 33 European countries, including Spain, also showed 
that amoxicillin-clavulanate was the most frequently used penicillin (Versporten et al., 
2011).  
 
A seasonal pattern of antimicrobial use, specifically in the winter months, was shown for 
ceftriaxone. This finding is consistent with national data and is said to reflect the use of 
ceftriaxone in the treatment of lower respiratory tract infections (Australian Commission on 
Safety and Quality in Health Care & SA Health, 2015). Seasonal variation in antimicrobial use 
has also been demonstrated in published national and international studies (Achermann et 
al., 2011; Meumann et al., 2015; Sun et al., 2012). The seasonality of antimicrobials has been 
attributed to the possible inappropriate prescribing of antimicrobials for respiratory tract 
infections during the winter months (Suda, Hicks, Roberts, Hunkler, & Taylor, 2014). This 
further emphasises the need to assess the appropriateness of antimicrobial use.  
 
Limitations to the analysis of the antimicrobial use data included the inability to compare 
the data directly with AMR data on E. coli UTI, because the indications (including organisms) 
165 
 
for which these antimicrobials were used were not available. Stratification of the data based 
on hospital wards or intensive care unit was not done, which may have allowed important 
antimicrobial use patterns within specific hospital areas to be identified. Despite these 
limitations, these results provide important information on the antimicrobial use trends at 
the Canberra Hospital and complement the main study two findings.  
 
5.4 Summary 
This chapter reports on the second study of the research program. The first and main part of 
the chapter discusses the analysis of AMR E. coli UTI data from the Canberra Hospital, which 
is incorporated in the thesis as a publication. This study is the first of its kind in Australia. 
The findings have highlighted the increasing resistance of urinary E. coli to commonly 
prescribed antimicrobials both in the hospital and community setting. Study two also 
identified low levels of ESBL-producing E. coli UTI. Although the levels of ESBL-producing E. 
coli are low, their presence further emphasises the need for the development of effective 
AMR control policies, as infection with this bacterium is usually non-responsive to the 
conventional empirical antimicrobial agents used in the treatment of UTI.  
 
The second part of this chapter provides time series analysis of supplementary antimicrobial 
use data at the Canberra Hospital. These data comprise all antimicrobials used during the 
five-year period (not limited to those used to treat UTI) but the findings complement the 
main study findings. A decrease in overall antimicrobial use was noted over the study 
period, but with an increasing use of newer broad spectrum antimicrobials signifying the 
need for evaluation of appropriateness of antimicrobial use or quality of antimicrobial 
prescribing at the hospital. The seasonal use of ceftriaxone at the hospital, particularly in the 
winter months, further emphasises the importance of undertaking further research on the 
appropriateness of antimicrobial prescribing.  
 
The findings on AMR and antimicrobial use presented in this chapter provide baseline data 
for the hospital for which future interventions can be measured against. Continued 
monitoring of AMR and antimicrobial use in both hospital and community settings is 
important for several reasons. Analysis of the data can identify areas with high antimicrobial 
usage and resistance, which can inform the development of interventions aimed at limiting 
overuse and misuse of antimicrobials and implementation of antimicrobial resistance 
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control policies. Antimicrobial use data can also be linked to AMR surveillance data to 
provide information on the antimicrobial use and resistance association for specific 
bacterium-drug combinations.  
 
The next chapter presents the findings of the third study. Study three reports on the five-
year risk and incidences of single drug-, multidrug-, extensively drug- and pandrug-resistant 
E. coli UTI in a cohort of ACT residents. 
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Chapter 6: Study three – Incidence of antimicrobial resistance in E. coli UTI 
 
6.1 Overview 
Evaluating not only the prevalence, but also the incidence, of AMR in urinary E. coli is 
important to gain a better understanding of the magnitude and impact of the issue of AMR. 
Incidence quantifies the number of new cases of a condition, in this instance newly 
diagnosed cases of resistant E. coli UTI in people at risk during a specified time period 
(Buttner & Muller, 2011; Porta, 2014). Evidence from the review of the literature (Chapter 
Two) highlighted the lack of Australian data on the incidence of antimicrobial resistant E. coli 
UTI over time, including estimates on the risk of disease occurrence. These evidence gaps 
will be addressed in the third study of the research program. Furthermore, study one 
identified the lack of inclusion of potential risk factors for AMR in the design and analysis of 
published AMR studies, demonstrating the need to collect these data and include them in 
the analysis of microbiological laboratory data.  
 
The emergence of multidrug-resistant urinary E. coli has been reported frequently overseas 
(Eshetie et al., 2015; Khawcharoenporn, Vasoo, & Singh, 2013; Yadav, Adhikari, Khadka, 
Pant, & Shah, 2015). Multidrug-resistant infections are a major concern and pose a serious 
threat to public health as there are only a limited number of antimicrobials effective against 
multidrug-resistant bacteria, leading to difficulty in treatment and potentially high mortality 
rates (Eshetie et al., 2015; Nikaido, 2009). In Australia, prevalence of multidrug-resistant E. 
coli has been investigated by AGAR, although not specifically in E. coli UTI. There are no 
available incidence data on multidrug-, extensively drug- and pandrug-resistant E. coli UTI in 
Australia. Given the high mortality associated with infections caused by these bacteria, 
knowledge of the extent of multidrug-resistance in urinary E. coli, including potential risk 
factors, will contribute to the development of interventions aimed at controlling AMR.  
 
This chapter presents the results of the third study undertaken as part of this research 
program. The study aim was to evaluate the incidence and risk of antimicrobial resistant E. 
coli UTI in a cohort of ACT residents over a five-year period. In study three, I investigated the 
incidence and risk of single drug-resistant, multidrug-resistant, extensively drug-resistant 
and pandrug-resistant E. coli UTI. The manuscript reporting the findings of study three is 
presented in section 6.2. While the thesis was under examination, the manuscript was 
168 
 
finalised and submitted to the Medical Journal of Australia with feedback received from the 
journal.  Given the narrowed focus of request from the journal for the manuscript to be 
presented as a short report focusing on the incidence findings, the previously submitted 
version of the manuscript has been included in the thesis and a revised short report focusing 
on the incidence findings is being prepared for resubmission to the Medical Journal of 
Australia.  
 
6.2 Publication three: Incidence of single-drug-, multidrug-, and extensively drug-
antimicrobial resistance of Escherichia coli urinary tract infections: an Australian 
laboratory-based retrospective cohort study 
 
6.2.1 Abstract  
Objectives: To evaluate incidence and risk of antimicrobial resistant Escherichia coli (E. coli) 
urinary tract infections (UTI) in a cohort of Australian Capital Territory (ACT) residents. 
Design, setting and participants: Laboratory-based retrospective cohort study of ACT 
residents who submitted urine samples to ACT Pathology between January 2009 and 
December 2013. 
Main outcome measures: Incidence and risk for single-drug, multidrug-, extensively drug- 
and pandrug-resistant E. coli UTI. 
Results:  A total of 146,915 urine samples from 57,837 ACT residents were identified over 
five years. Mean age of people in the cohort was 48 years (standard deviation=26 years) and 
64.4% were females. Five-year incidence of single-drug resistant E. coli UTI was high for 
ampicillin, trimethoprim and cefazolin (6.8%, 3.5% and 1.9% respectively). No pandrug-
resistant E. coli UTI was detected. Five-year incidences of multidrug- and extensively drug-
resistant E. coli UTI were 1.9% and 0.2% respectively. In multivariate logistic regressions, 
female sex and age over 38 years were significantly associated with single- and multidrug-
resistance. Compared to hospitals, office-hours general practices, community and specialist 
health services, risk of single-drug resistance was significantly higher in samples from after-
hours general practices (adjusted-odds ratio (OR) and 95% confidence intervals (CI) 2.6 (2.2–
3.1)). There was higher risk of resistance to ciprofloxacin (OR 1.3) with high socioeconomic 
status. 
Conclusions: In this cohort, incidence of multidrug- and extensively drug-resistant E. coli UTI 
are low in comparison to international data. Our findings have significant implications for 
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antimicrobial prescribing given identified risk factors for resistance development, especially 
in patients attending after-hours general practices. 
 
6.2.2 Introduction  
Escherichia coli (E. coli) is recognised as the most common cause of urinary tract infections 
(UTI) (Nicolle, 2008). The prevalence of resistance in urinary E. coli is increasing in Australia 
(Australian Group on Antimicrobial Resistance, 2013; Fasugba et al., 2016) but the resistance 
incidence is not well described. Australian studies that investigated urinary E. coli resistance 
provided no separate data on incidence of single- and multidrug-resistant (MDR) isolates nor 
did they identify patient risk factors for resistance development (Kennedy et al., 2008; 
Meumann et al., 2015). Recent data from the United States (US) showed that incidence of 
fluoroquinolone-resistant E. coli bacteriuria had significantly increased from 464 to 1116 per 
100,000 person years between 2005 and 2009 in patients older than 80 years (Swami et al., 
2012). 
 
The emergence of E. coli resistance to multiple antimicrobials poses a significant threat to 
public health with limited antimicrobials available for treating MDR infections. These 
infections may complicate UTI treatment leading to poorer patient outcomes (Magiorakos et 
al., 2012). In Australia, MDR E. coli prevalence increased from 4.5% in 2008 to 7.6% in 2012 
(Australian Group on Antimicrobial Resistance, 2013). In the US, incidence of MDR E. coli was 
37 per 100,000 person-years in 2009 (Swami et al., 2012). 
 
The recently developed Australian antimicrobial resistance strategy lists E. coli as a priority 
organism for resistance surveillance due to its impact in hospital and community settings 
(Australian Commission on Safety and Quality in Health Care, 2016). Given the newly 
established Antimicrobial Use and Resistance in Australia (AURA) surveillance system 
(Australian Commission on Safety and Quality in Health Care, 2016), evaluating incidence 
and resistance trends at a jurisdictional level will contribute important information to 
understanding the distribution and impact of resistant E. coli UTI. This study, the first of its 
kind in Australia, evaluated incidence and five-year risk of resistant E. coli UTI in a large 
cohort of Australian Capital Territory (ACT) residents. The study also provides novel 
information on incidence of MDR, extensively drug-resistant (XDR) and pandrug-resistant 
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(PDR) E. coli UTI, with evidence to inform clinicians, policy makers and other stakeholders 
about emerging trends that may impact on public health. 
 
6.2.3 Methods 
Study design, setting and population: We utilised a laboratory-based retrospective cohort 
design (Buttner & Muller, 2011) using data from a cohort of ACT residents who had urine 
samples processed at ACT Pathology. Based on available data from Medicare statistics 
(Medicare Australia, 2016) and ACT Pathology (A. Das, personal communication, 11 
November, 2016), it is estimated that ACT Pathology processes approximately 100% of urine 
samples from inpatients, emergency department and specialist outpatient clinic patients of 
public hospitals, and at least 13% of urine samples from patients in the community and 
private hospitals whose residential status is ACT. The population of the ACT in 2011 was 
367,985. The study cohort comprised 57,873 ACT residents whose urine samples were 
processed at ACT Pathology during the period of 1st January 2009 to 31st December 2013, 
of whom an estimated 71% were inpatients, emergency department and specialist 
outpatient clinic patients of public hospitals and the remaining 29% were patients in the 
community and from private hospitals. Residence in the ACT was based on postcode, and 
those with postcodes from NSW and elsewhere were excluded. Samples collected outside 
ACT and from patients without unique identifiers were also excluded. 
Ethics approval was granted by ACT Health and Australian Catholic University (ETHLR.14.223 
and 2014276N). 
 
Bacterial isolation and identification and antimicrobial susceptibility testing: Urine samples 
were processed based on microbiology laboratory standards described elsewhere (Fasugba 
et al., 2016). 
 
Definitions: The incidence of single-drug resistance was separately assessed for ampicillin, 
amoxycillin-clavulanate, trimethoprim, norfloxacin, gentamicin, cefazolin, ceftriaxone, 
trimethoprim-sulphamethoxazole, nalidixic acid, ciprofloxacin, meropenem, piperacillin-
tazobactam and nitrofurantoin. Non-susceptibility to at least one agent in three or more 
antimicrobial categories was defined as MDR; non-susceptibility to at least one agent in all 
but two or fewer antimicrobial categories was defined as XDR; and non-susceptibility to all 
agents in all antimicrobial categories was defined as PDR based on published international 
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standardised definitions (Magiorakos et al., 2012). For these definitions to be comparable, 
isolates must be tested against all antimicrobial agents within the antimicrobial categories. 
In cases of incomplete testing, it is difficult to distinguish reliably between XDR and PDR 
isolates. In ACT Pathology nine of the 13 potential antimicrobial categories were tested for 
hence these isolates were classified as ‘possible PDR’ or ‘possible XDR’ (Magiorakos et al., 
2012).  
 
6.2.4 Data analysis 
All ACT residents who submitted urine samples to ACT Pathology during the five years were 
followed until they developed their first antimicrobial resistant E. coli UTI or died or were 
right censored at the end of follow-up (December 2013). Follow-up was based on presence 
or absence of a subsequent urine sample submitted to ACT Pathology during the study five-
year period. Five-year cumulative incidence of resistance were calculated by dividing 
number of incident cases of antimicrobial resistant E. coli UTI by total number of individuals 
with urine samples included in the study. The incidence was expressed per 100,000 people 
whose urine samples were tested by ACT Pathology, that is, the number of people with a 
resistant E. coli UTI among every 100,000 people submitting urine samples to ACT Pathology 
for testing.  
 
Data were also analysed yearly to establish the changing cumulative incidence. Kaplan-
Meier (KM) curves were plotted to show the effect of sex and age on resistance incidence to 
any antimicrobials tested. Differences in resistance between sexes and between age groups 
were evaluated using the Log-rank test (Cox, 1972). Multivariate logistic regression models 
were constructed for each antimicrobial to determine the effect of age, sex, socioeconomic 
status (SES), and urine sample origin on risk of resistance. The Hosmer–Lemeshow test was 
performed to assess goodness of fit of logistic regressions with P > 0.05 indicating good fit.  
 
Age was assessed within five categories based on age distribution in the data (≤23, 24-37, 
38-56, 57-73 and ≥74 years). The Australian Socio-Economic Indexes for Areas (SEIFA) based 
on residential postcodes derived from 2006 Australian census data was used to determine 
SES (Australian Bureau of Statistics, 2008). This validated ecological index score ranks areas 
in Australia based on relative socioeconomic indicators of advantage and disadvantage, with 
lower scored areas being more disadvantaged than higher scored areas (Walker & Hiller, 
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2005). For this analysis, SES was assessed within three categories (low, middle and high) 
based on the dataset SEIFA score distribution.  
 
The sample origin refers to the health service requesting the urine sample test and was 
grouped into seven categories, namely: public acute hospitals; private acute hospitals; GP 
clinics; after-hours GP clinics; community health services including Aboriginal and Torres 
Strait Islander and youth health services; specialist health services including minor surgical 
and procedural outpatient units; and ‘others’. This last category included samples sent from 
non-acute hospitals, correctional services, dialysis clinics, dental clinics, hospice, ambulance 
services and a life insurance organisation. Further analyses were performed to determine 
levels of MDR, XDR and PDR for isolates. A significance level of 0.05 was used. Data were 
analysed using STATA statistical software (version 14, StataCorp). 
 
6.2.5 Results 
A total of 196,385 urine samples were processed over the five-year period. When restricted 
to samples belonging to ACT residents and collected within the ACT, there were 163,792 
samples. Of these, unique patient identifiers were missing for 16,877 samples (10.3%) 
resulting in 146,915 samples belonging to 57,837 ACT residents over five years being 
included in the final analysis. The mean age of people in the cohort at first sample submitted 
was 48 years (standard deviation=26 years) and most were female (64.4%, n=37,234). Of all 
included samples, positive cultures accounted for 15.9% (n=23,486) with 56.9% (n=13,371) 
of positive cultures being E. coli UTIs. 
 
Overall 5-year and yearly incidence of single-drug resistant E. coli UTI per 100,000 people 
whose urine samples were tested by ACT Pathology are shown in Table 1. Five-year 
resistance incidence (expressed as percentages) was highest for ampicillin, trimethoprim 
and cefazolin (6.8%, 3.5% and 1.9% respectively) and lowest for meropenem, nitrofurantoin 
and piperacillin-tazobactam (0.002%, 0.5% and 0.5% respectively).  
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Table 1 Overall five-year and yearly cumulative incidence of antimicrobial resistant 
E. coli UTI per 100,000 people whose urine samples were tested by ACT Pathology 
 
Antibiotic 
2009* 2010* 2011* 2012* 2013* 5-year total* 
Rate (n) Rate (n) Rate (n) Rate (n) Rate (n) Rate (n) 
Ampicillin 4697.8 (722) 5181.6 (863) 5814.6 (1015) 5247.3 (956) 5469.0 (835)   6760.4 (3910) 
Trimethoprim 2322.9 (357) 2635.8 (439) 3001.8 (524) 2629.1 (479) 2908.0 (444) 3483.9 (2015) 
Cefazolin 1067.1 (164) 1495.0 (249) 1638.4 (286) 1432.6 (261) 1644.0 (251) 1974.5 (1142) 
TMP-SMX 943.5 (145) 1296.9 (216) 1598.3 (279) 1427.1 (260) 1441.0 (220) 1751.5 (1031) 
Nalidixic acid 982.5 (151) 1128.8 (188) 1409.3 (246) 905.6 (165) 615.7 (94) 1345.2 (778) 
AMC 481.5 (74) 732.5 (122) 928.0 (162) 1092.3 (199) 1152.7 (176) 1201.7 (695) 
Ciprofloxacin 442.4 (68) 450.3 (75) 658.8 (115) 697.1 (127) 903.9 (138) 824.7 (477) 
Norfloxacin 396.9 (61) 438.3 (73) 658.8 (115) 680.6 (124) 884.2 (135) 802.3 (464) 
Ceftriaxone 214.7 (33) 366.3 (61) 618.7 (108) 735.5 (134) 792.5 (121) 741.7 (429) 
Gentamicin 292.8 (45) 420.3 (70) 532.8 (93) 526.9 (96) 635.3 (97) 629.4 (364) 
PIT 39.0 (6) 402.3 (67) 383.8 (67) 499.5 (91) 576.4 (88) 539.4 (312) 
Nitrofurantoin 240.7 (37) 276.2 (46) 297.9 (52) 384.2 (70) 648.4 (99) 506.6 (293) 
Meropenem 0.0 (0) 6.0 (1) 0.0 (0) 0.0 (0) 0.0 (0)  1.7 (1) 
Any antibiotic¥ 5446.0 (837)  5619.9 (936) 6261.5 (1093) 5554.6 (1012) 5901.2 (901) 7311.9 (4229) 
*Number of residents (2009=15,369; 2010=16,655; 2011=17,456; 2012=18,219; 2013=15,268; five year     
period=57,837) 
¥Resistance to at least one of the thirteen antibiotics 
 AMC=Amoxycillin-clavulanate; TMP-SMX=Trimethoprim-sulphamethoxazole; PIT=Piperacillin-tazobactam 
 
Risk of developing a resistant UTI was significantly higher in females compared to males 
(Kaplan-Meier analysis, Log-rank test P<0.001). Ages below 23 years and over 38 years were 
significantly associated with resistant infection; risk of resistance was highest for people 
over 74 years.  
 
A separate multivariate logistic regression model was constructed for each antimicrobial 
(excluding meropenem which had only one resistant isolate identified) adjusting for age, 
sex, SES and sample origin. Although results varied for each antimicrobial, consistent 
findings included significantly higher odds of resistance in females and older people 
(Appendix S1). The risk of ampicillin, cefazolin, trimethoprim and trimethoprim-
sulphamethoxazole resistance was significantly higher in people aged below 23 years. 
Significantly higher odds of ciprofloxacin, norfloxacin and nalidixic acid resistance (odds 
ratios (OR) 1.3, 1.3 and 1.2 respectively) were seen in people with high SES. The multivariate 
logistic regression model for resistance to any of the 13 antimicrobials tested found higher 
odds of resistance in females and older aged people (Table 2). Samples from after-hours GP 
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clinics had the highest odds of being resistant (ORs and 95% confidence intervals (CIs) 2.6 
(2.2-3.1); P<0.05). The Hosmer–Lemeshow tests showed good fit for all regression models 
(P>0.05). 
 
Table 2 Multivariate logistic regression model for the effects of age, gender, 
socioeconomic status and urine source on the risk of developing urinary E. coli resistance 
to any of the 13 antimicrobial agents tested or a multidrug-resistant infection 
Variable Categories N Any resistance* Multidrug-resistance 
   Odds ratio 95% CI Odds ratio 95% CI 
Age (years) ≤23 11,570 1.3 1.2–1.5 1.0 0.8–1.3 
 38–56 11,566 1.3 1.1–1.4 1.6 1.3–2.0 
 57–73 11,567 1.9 1.7–2.1 2.5 2.1–3.1 
 ≥74 11,567 2.9 2.6–3.2 3.3 2.7–4.0 
 24–37 (reference) 11,567 1.0  1.0  
Gender Female 37,234 3.3 3.0–3.5 2.6 2.2–3.0 
 Male (reference) 20,593 1.0  1.0  
SES Middle 20,450 1.0 1.0–1.1 1.0 0.9–1.1 
 High 16,168 1.0 0.9–1.1 1.0 0.9–1.2 
 Low (reference) 21,051 1.0  1.0  
Sample origin Private acute hospitals 1,313 0.7 0.6–0.9 1.0 0.7–1.5 
 GP clinics 12,446 1.1 1.0–1.2 1.0 0.9–1.2 
 After-hours GP clinics 1,024 2.6 2.2–3.1 1.6 1.1–2.3 
 Community health services 1,284 1.4 1.1–1.7 1.5 1.0–2.1 
 Specialist health services 533 1.1 0.8–1.4 1.8 1.1–2.9 
 Others# 363 1.3 0.9–1.9 2.3 1.3–4.0 
 Public acute hospitals 
(reference) 
40,874 1.0  1.0  
*Antimicrobials include ampicillin, amoxycillin-clavulanate, cefazolin, ceftriaxone, trimethoprim, 
trimethoprim-sulphamethoxazole, nalidixic acid, ciprofloxacin, norfloxacin, gentamicin, nitrofurantoin 
and piperacillin-tazobactam 
#non-acute hospitals, correctional services, dialysis clinics, dental clinics, a hospice, ambulance services 
and a life insurance organisation 
N=Number of residents (missing: Gender=10; SES=168) 
SES=Socioeconomic status; GP=General practice 
Hosmer Lemeshow test for Any resistance model: Chi square statistic=8.13; P=0.42 
Hosmer Lemeshow test for multidrug- resistance model: Chi square statistic=7.65; P=0.47 
 
Further analyses showed no possible PDR E. coli but 5-year incidence of MDR and possible 
XDR E. coli was found to be 1.9% and 0.2% respectively. Female sex and age over 38 years 
were significantly associated with MDR (Table 2). After adjusting for age, sex and SES, urine 
samples from after-hours GP clinics, specialist health services and the “other” category were 
associated with significantly higher odds of MDR (OR and 95% CIs 1.6 (1.1-2.3), 1.8 (1.1-2.9) 
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and 2.3 (1.3-4.0) respectively). Given the low incidence of possible XDR E.coli UTI, and 
because this group was a subset of MDR, logistic regression analysis was not performed. 
 
6.2.6 Discussion  
To our knowledge, this is the first study examining incidence and risk of developing a 
resistant E. coli UTI in Australia. Notably, this study is the first in Australia to assess the risk 
of E. coli UTI resistance related to the health service requesting the urine sample test. This 
study has identified (1) high incidence of resistance to ampicillin, trimethoprim and 
cefazolin; (2) presence of MDR and possible XDR E. coli UTI in this cohort; (3) significantly 
higher risk of resistance in females and people over 38 years; (4) significantly higher risk of 
resistance to some antimicrobials in the high socioeconomic group; and (5) risk of resistance 
varied by health service requesting urine sample. 
 
The UTI resistance incidence was highest for ampicillin, trimethoprim and cefazolin 
consistent with national and territory blood culture prevalence (Australian Commission on 
Safety and Quality in Health Care, 2016). The high resistance for these three antimicrobials, 
recommended for first-line UTI therapy raises concern about selection of an appropriate 
empirical treatment agent for UTI. The low resistance for last-line antimicrobials such as 
meropenem, ceftriaxone, ciprofloxacin and gentamicin in comparison to published 
European data is notable (Allocati, Masulli, Alexeyev, & Di Ilio, 2013; van der Donk et al., 
2012). Our study also reports MDR and possible XDR E. coli UTI in this cohort, although in 
relatively low numbers compared to countries like the Netherlands (van der Donk et al., 
2012). Globally, Australia is considered one of the countries with high antimicrobial use 
(Australian Commission on Safety and Quality in Health Care, 2016). Despite this, the 
incidence of single-drug resistant, MDR and XDR E. coli is relatively low. Likely reasons may 
be that many people acquire resistant bacteria through food, water, travel and the 
environment rather than through antimicrobial use (Collignon, 2015). Although no PDR E. 
coli UTI were identified in our study, the presence of MDR and possible XDR isolates raises 
concern because these pathogens are associated with poorer patient outcomes due to 
limited availability of drugs for treatment.  
 
Resistance risk was higher in females and people over 38 years in this study. There are 
inconsistent findings for the effect of sex on resistance (Lagacé-Wiens et al., 2011; McGregor 
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et al., 2013; Sahm et al., 2001). Possible explanations include higher predisposition to UTIs in 
females resulting in more antimicrobial prescriptions (Al-Badr & Al-Shaikh, 2013). Our 
finding of higher resistance risk in older age groups has been previously described and may 
be due to increasing cumulative exposure to antimicrobials and healthcare settings with age 
(Lagacé-Wiens et al., 2011). We also found a significantly higher risk of ampicillin, cephazolin 
and trimethoprim-sulphamethoxazole resistance in people below 23 years, supported by a 
recent systematic review (Bryce et al., 2016). Interventions aimed at reducing further 
development and spread of resistance should take account of patient age and gender. 
Ciprofloxacin and nalidixic acid resistance were found to be significantly associated with high 
SES, consistent with published studies (Kristiansson et al., 2009). This may be due to higher 
antimicrobial use by more affluent families (Kristiansson et al., 2009), including overseas 
colonisation with resistant E. coli as those with high SES are more likely to travel often 
(Kennedy & Collignon, 2010). Socioeconomic status in the ACT is relatively uniform across 
postcodes hence further research is needed to confirm the possible association between SES 
and resistance.  
 
The highest resistance risk was noted in samples from after-hours GP clinics. Patients 
receiving treatment from these clinics typically require medical services outside regular 
office-hours usually between 6pm to 8.30am on weekdays and during weekends. Evidence 
shows higher resistance in hospital compared to community settings (Fasugba et al., 2015), 
hence higher resistance risk in samples from after-hours GP clinics is surprising. The reason 
for this finding is unknown but it could be postulated that patients attending after-hours GP 
clinics are similar to patients presenting at emergency departments. These patients are 
likely to be too unwell to wait for appointments during regular office-hours, and more likely 
to require antimicrobials. In the UK, when compared to regular office-hours GPs and 
hospitals, after-hours GPs and other community health services had higher antimicrobial 
prescribing rates (Public Health England, 2015). As antimicrobial use is a major factor 
contributing to resistance (Australian Commission on Safety and Quality in Health Care, 
2016), this finding highlights the importance of judicious antimicrobial prescribing by 
clinicians. Education campaigns should be tailored towards clinicians consulting in after-
hours clinics and health services should develop systems that continuously monitor 
antimicrobial prescriptions to ensure their rational use. 
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Our study has limitations. This study comprised patients whose samples were processed by 
ACT Pathology which captures all inpatient public hospital samples, samples from 
outpatients attending public hospital emergency departments and specialist clinics and 
approximately 13% of private hospital and community samples. Hence the calculated 
resistance incidence is based on sample data and may not be directly generalised to the 
total ACT population. These findings are however the most reliable estimates to date of ACT 
E. coli UTI resistance incidence. Population-level analysis based on setting of infection onset, 
that is community versus inpatients, was considered.  This analysis was not possible because 
data from Medicare statistics website used to estimate the proportion of community 
samples processed by ACT Pathology does not separate community from private hospital 
inpatient samples. In defining incident UTI, there was a possibility that pre-existing 
infections (not verified) were carried over from the year before study commencement. Due 
to insufficient data, UTI was not classified based on setting of acquisition. Exclusion of 
samples from patients treated empirically without laboratory culture and likely inclusion of 
multiple samples from people with recurrent UTI potentially overestimated resistance 
incidence. Patient risk factors including comorbidities and urinary tract instrumentation 
which could influence resistance incidence could not be accounted for in analysis because 
retrospective data were used. Given the composition of de-identified data, 10% of samples 
were excluded due to lack of unique patient identifiers thereby underestimating resistance 
incidence. 
 
6.2.7 Conclusion 
The detection of single drug-resistant, MDR and possible XDR E.coli UTI emphasises the need 
for continued monitoring of resistance to ensure suitable empirical therapeutic agents 
remain available. This study highlights the importance for development of interventions 
aimed at reducing resistance based on patient risk factors. Higher risk of resistance in 
patients attending after-hours GP clinics necessitates further research to investigate 
antimicrobial prescribing practices within these health services. 
 
6.3 Summary 
This is the first Australian study to examine incidence and risk of antimicrobial resistant E. 
coli UTI. Incidence studies as opposed to prevalence studies are able to provide information 
on the rate at which new cases of a disease occur as well as identify at risk groups. This five- 
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year study has identified that incidence of single drug-resistance to urinary E. coli was 
highest for ampicillin, trimethoprim and cefazolin. Kaplan-Meier curves and Log-rank tests, 
showing the effect of sex and age on the incidence of resistance to any of the antimicrobials 
tested, were also produced and are included as appendices (Appendix G). Evidence obtained 
from study three also demonstrates potential patient risk factors that may influence 
resistance development. The detection of MDR and XDR E. coli UTI, although relatively low, 
emphasises the need for continued surveillance of AMR in urinary E. coli infections. Close 
monitoring of resistance in this pathogen with concurrent implementation of strategies is 
necessary to prevent further development of MDR. If not, there is the possibility that PDR   
E. coli UTI may subsequently emerge, leading to dire public health ramifications for patients 
with PDR infections. The findings of the third study of the research program will also 
contribute to policy and practice, especially measures targeted towards health service 
providers who prescribe antimicrobials for patients with UTI.  
 
The sample used for study three was previously described in the introduction chapter 
(Chapter One) and the limitation of the representativeness of the sample was discussed in 
detail in the methods chapter (Chapter Three). Given that the whole ACT population was not 
sampled but only a subset, albeit a considerable one, the findings of the incidence of 
resistance should be interpreted with caution. However, these are the most comprehensive 
results available to date in Australia reporting on the incidence of resistance in E. coli UTI 
and are therefore noteworthy. Furthermore, study three provides evidence of a new 
methodological approach to identifying incident cases of resistant E. coli UTI using 
microbiological laboratory data. The inclusion of private laboratories in the surveillance of 
AMR has been identified as being important to appropriately estimating AMR prevalence 
and incidence (Gandra, Merchant, & Laxminarayan, 2016). Whilst there may be barriers to 
obtaining data from private laboratories, effort should be made to include private 
laboratories in all surveillance activities to ensure a complete picture of the risk and burden 
of AMR. The new methodological approach demonstrated in study three can then be 
replicated using a dataset more representative of a geographical population.   
 
The next chapter, Chapter Seven, is the final chapter of the thesis. The discussion and 
conclusion of the research program is presented by synthesising the results of the three 
studies undertaken in the research program. The contribution of the research program to 
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knowledge is detailed as well as recommendations for policy, clinical practice and future 
research.  
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Chapter 7: Discussion and conclusion 
 
7.1 Overview 
The thesis subject of AMR in E. coli UTI has been investigated in this research program. 
Urinary tract infections caused by the E. coli bacterium are common and resistance to 
antimicrobials used to treat urinary E. coli infections is increasing, prompting the need for 
continued research in this area. This research program is the first of its kind in Australia to 
have comprehensively and rigorously examined AMR in urinary E. coli infections in a large 
sample of ACT residents. This research is also the first to compare urinary E. coli resistance 
to ciprofloxacin in hospital and community settings at a global level.  
 
The findings of the three studies undertaken over the last three years are synthesised in this 
chapter to address the overall aim of the research program. The first part of the chapter 
reviews the main findings of the research program against each study aim. The strengths 
and limitations of the research are also outlined. The novel contributions of the research 
findings to knowledge are discussed. Finally, the chapter ends with a summary of 
recommendations for policy, clinical practice and research.  
 
7.2 The study aims achieved 
The overall aim of the research program was to contribute to the body of knowledge about 
AMR in E. coli UTI. Based on the gaps identified from the review of literature in Chapter Two, 
three specific aims were identified and each aim was addressed in a separate study. The 
three separate but interrelated studies focused on providing knowledge about AMR in 
urinary E. coli infections. A summary of the main findings from each study undertaken is 
presented in Table 1, alongside the individual study aims.  
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Table 1 Summary of main findings from research study 
Study Aim Main findings 
Study 
One 
Systematically review the 
literature and conduct a 
meta-analysis of 
observational studies 
published in the last ten 
years investigating 
ciprofloxacin resistance in 
community-acquired and 
hospital-acquired E. coli UTI 
 
• Resistance to ciprofloxacin was statistically 
significantly higher in the hospital compared to 
the community setting across the world 
• Resistance statistically significantly varied by 
region and country  
• Resistance was highest in developing countries 
compared to developed countries 
• A statistically significant rise in resistance over 
time was seen in studies reporting on community-
acquired E. coli UTI 
• Poor methodological quality of published studies 
investigating AMR in E. coli UTI was identified 
Study 
Two 
(a) Evaluate AMR temporal 
trends and compare the 
prevalence of AMR in 
hospital-acquired and 
community-acquired E. coli 
UTI at the Canberra Hospital 
over a five-year period 
 
(b) Evaluate trends and 
seasonal variation in 
antimicrobial use at the 
Canberra Hospital over a 
five-year period 
 
 
• Prevalence of resistance for hospital- and 
community-acquired E. coli UTI combined was 
high for ampicillin and trimethoprim  
• Resistance for hospital- and community-acquired 
E. coli UTI combined was low for meropenem, 
nitrofurantoin, piperacillin-tazobactam and 
ciprofloxacin  
• Resistance to amoxycillin-clavulanate, cefazolin, 
gentamicin and piperacillin-tazobactam was 
statistically significantly higher in hospital- 
compared to community-acquired E. coli UTI  
• Statistically significant increases in resistance over 
the five-year study period were noted for 
amoxycillin-clavulanate, trimethoprim, 
ciprofloxacin, nitrofurantoin and trimethoprim-
sulphamethoxazole for hospital- and community-
acquired E. coli UTI combined 
• Ciprofloxacin resistance was found to be 
associated with older age  
• Using supplementary data, overall antimicrobial 
usage (assessed only for inpatients at the hospital) 
decreased over the study period 
• Using supplementary data, an increase in the use 
of newer broad spectrum antimicrobials was 
noted among hospital inpatients only 
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Study Aim Main findings 
Study 
Three 
Evaluate the incidence and 
risk of antimicrobial 
resistant E. coli UTI in a 
cohort of ACT residents 
 
• Incidence of resistance was highest for ampicillin, 
trimethoprim and cefazolin  
• Incidence of multidrug- and extensively drug-
resistant E. coli UTI was low 
• Female sex and age over 38 years were 
statistically significantly associated with single- 
and multidrug-resistance 
• People with high socioeconomic status had higher 
odds of resistance to ciprofloxacin, norfloxacin 
and nalidixic acid  
• Higher odds of resistance were noted in samples 
sent from after-hours GP clinics  
 
A detailed discussion of how each aim was achieved is provided in the sections below.   
 
7.2.1 Study one: Systematic review of ciprofloxacin resistance in E. coli UTI 
Study one addressed a research gap in global knowledge of ciprofloxacin resistance in E. coli 
UTI. Ciprofloxacin, a high priority critically important antimicrobial, is recommended for 
second-line treatment of UTI. Despite the recommendations in internationally recognised 
treatment guidelines that ciprofloxacin should not be used as an empirical therapeutic agent 
for UTI, evidence from individual studies shows that resistance to this agent is increasing. 
Hence, ciprofloxacin was selected as an appropriate antimicrobial to examine for global 
evidence on AMR in E. coli UTI. Study one systematically reviewed the literature and meta-
analysed studies investigating ciprofloxacin resistance in hospital- and community-acquired 
E. coli UTI. This systematic review of the literature also informed the research aims for 
studies two and three.  
 
The findings from study one (presented in Chapter Four) showed that: across the world 
ciprofloxacin resistance is present in both hospital- and community-acquired UTI, although 
higher in hospital-acquired UTI; ciprofloxacin resistance is increasing internationally in the 
community; developing countries have higher resistance to ciprofloxacin compared to 
developed countries; and there is a lack of methodological rigour in the design and analysis 
of published studies investigating AMR in E. coli UTI. Higher resistance in hospital as 
opposed to community settings may not be surprising due to the effect of antimicrobial use 
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in hospitals, but the novel finding identified from this systematic review is the increasing 
resistance to ciprofloxacin in the community setting. The exact cause for this increasing 
international trend in the community is not certain but a strong possibility may be an 
increase in prescribing of ciprofloxacin in the community. The use of non-prescription 
antimicrobials and over-the-counter prescribing is relatively common in developing 
countries especially those countries without policy regulation on antimicrobial use hence 
this may account for the higher resistance in developing countries.  
 
In summary, the study synthesised findings from published studies worldwide to estimate 
global resistance of urinary E. coli to ciprofloxacin, and also highlighted the notable increase 
in resistance in the community setting. Of particular importance is the poor methodological 
quality of the design and analysis of AMR studies identified during the systematic review. 
Studies two and three provided an opportunity for me to address some of these 
methodological issues using my own microbiological laboratory dataset. 
 
7.2.2 Study two: Prevalence of antimicrobial resistance in E. coli UTI 
The lack of published Australian studies that directly compare resistance patterns over time 
for hospital- and community-acquired UTI identified from the review of literature presented 
in Chapter Two, as well as the lack of methodological rigour in the design and analysis of 
AMR studies identified in study one, prompted the need to undertake the second study of 
the research program. Study two utilised retrospective microbiological laboratory data to 
evaluate AMR temporal trends and seasonal variation of E. coli UTIs from 2009 to 2013 in 
patients attending a tertiary referral hospital in Canberra, Australia. The prevalence of 
resistance in hospital- and community-acquired E. coli UTI was also compared. Previous 
international studies identified from the literature review utilised varying criteria to classify 
patients, based on the setting of infection acquisition into hospital- and community-
acquired. Internationally accepted criteria from the CDC were applied in study two for the 
classification of UTI. Linkage of microbiological laboratory data with patient administrative 
data from a tertiary referral hospital, the Canberra Hospital, was undertaken to ensure UTI 
was appropriately classified. In addition, antimicrobial use data from the hospital inpatients 
was evaluated for changes over time.  
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Major findings from study two (detailed in Chapter Five) were that: resistance was highest 
for ampicillin and trimethoprim; resistance to amoxycillin-clavulanate, cefazolin, gentamicin 
and piperacillin-tazobactam were statistically significantly higher in hospital- compared to 
community-acquired UTI; and an increase in resistance over the five years was noted for 
amoxycillin-clavulanate, trimethoprim, ciprofloxacin, nitrofurantoin and trimethoprim-
sulphamethoxazole, with seasonal pattern observed for trimethoprim resistance for 
hospital- and community-acquired E. coli UTI combined. In addition, ciprofloxacin resistance 
was found to be associated with increasing age. Additional analysis of antimicrobial use data 
for inpatients only showed that overall antimicrobial use at the hospital decreased over the 
study period but with an increase in the use of newer broad spectrum antimicrobials. 
 
In summary, study two confirmed the increasing resistance of urinary E. coli to commonly 
prescribed antimicrobials, identified differences in resistance patterns based on the setting 
of infection acquisition and provided information on inpatient antimicrobial use at the 
hospital. Findings from analysis of inpatient antimicrobial use data emphasise the need to 
consider not only the level of antimicrobial usage but also the appropriateness of this usage 
in addressing AMR.  
 
7.2.3 Study three: Incidence of antimicrobial resistance in E. coli UTI 
The third study in the research program focused on the incidence of antimicrobial resistant 
E. coli UTI using retrospective laboratory-based data from a cohort of ACT residents. As 
identified from the literature review, there are no incidence data on AMR in E. coli UTI in 
Australia. Determining the incidence of resistance among E. coli UTI provides a better 
understanding of the impact of AMR by making available information on the risk of 
development of resistance in individuals. Study three utilised microbiological laboratory 
data to evaluate the incidences and risk of multidrug-, extensively drug- and pandrug-
resistant E. coli UTI in a cohort of ACT residents.  
 
Study three (discussed in Chapter Six) found high incidence of single-drug resistance of 
urinary E. coli to ampicillin, trimethoprim and cefazolin. The incidence of multidrug- and 
extensively drug-resistant E. coli UTI was relatively low. Higher odds of resistance to any of 
the 13 antimicrobials tested were noted in females and people aged 38 years and above. 
Higher odds of resistance to some antimicrobials for people in the high socioeconomic 
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group were also seen. Urine samples belonging to people attending after-hours GP clinics 
had higher odds of being antimicrobial resistant. 
 
In summary, study three provided new insights, not previously shown in Australia, into 
patient and health service characteristics that have the potential to influence the risk of 
development of AMR. 
 
Overall, the findings show resistance of urinary E. coli to antimicrobials is increasing. The 
burden of resistance is higher in the hospital compared with the community setting but is 
increasing in the community. Also, patient risk factors play an important role in the 
development of AMR in E. coli UTI. The overall findings from the research program highlight 
the methodological issues with analysing AMR data. To address some of the methodological 
issues with analysing microbiological laboratory data, a new method for clearly identifying 
incident cases of resistant E. coli UTI was developed and good quality evidence of the impact 
of the choice of denominator used for calculating resistance prevalence was demonstrated.  
 
7.3 Strengths of the research program  
The strengths of the individual studies undertaken have been highlighted in Chapters Four, 
Five and Six, but it is important to also highlight the strengths of the research program as a 
whole. Comprehensive analysis of antimicrobial susceptibility test data from 54 published 
studies and a large dataset comprising 196,385 observations from one central testing 
microbiology laboratory, ACT Pathology, ensured large enough datasets (Hussein, 2011) to 
provide sound and reliable results for evaluating AMR in E. coli UTI.  
 
The consistent application of definitions for infection cut-off (studies one and two) and 
antimicrobial susceptibility testing methodology (studies two and three) during the research 
program is another very important strength. Surveillance studies are strengthened by the 
use of standardised data collection and assessment methods because this allows for 
comparison of results between various sites both locally and internationally (Masterton, 
2008). For studies one and two, the 48 hour timeframe to define infection cut-off as 
recommended by CDC (Centers for Disease Control and Prevention, 2016) was used for 
classifying hospital- and community-acquired UTI. For studies two and three, a single 
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uniform antimicrobial susceptibility testing methodology, namely the Clinical and Laboratory 
Standards Institute (CLSI) criteria, was employed over the study period from 2009 to 2013.  
 
Existing data and/or datasets, either published or routinely collected microbiological 
laboratory data, were utilised for the analysis detailed in the research program. The use of 
readily accessible data and existing datasets for health research has been identified as a 
useful source of rich data to answer novel and significant research questions (Cheng & 
Phillips, 2014; Hussein, 2011; Schneeweiss & Avorn, 2005) and the findings from this 
research program confirm this. Using existing data for the research program allowed timely 
extraction and retrieval of data from published data and microbiological laboratory data 
respectively. The use of existing data also eliminated the constraints associated with 
designing questionnaires as well as data collection, providing time for preparation and 
comprehensive analysis of the data. The processes undertaken with these datasets can now 
easily be replicated using similar databases. 
 
7.4 Limitations of the research program 
The limitations of the research program undertaken as well as their potential impact on the 
findings are discussed in this section. The limitations discussed here relate primarily to the 
large laboratory database used for studies two and three, including the supplementary 
study on antimicrobial use provided in Chapter Five. Specific limitations for each study 
undertaken in the research program have already been identified in the relevant chapters 
(Chapters Four, Five and Six). 
 
Secondary data sources were used for the research program. Secondary data are those 
which are not collected primarily for the purpose of the research to be undertaken (Cheng & 
Phillips, 2014). Study one synthesised existing published data while studies two and three 
evaluated existing routinely collected data from a laboratory database. Although the use of 
secondary data for health research has its advantages, a general limitation of using these 
datasets for research is incompleteness of data (Cheng & Phillips, 2014; Schneeweiss & 
Avorn, 2005). Given that secondary data were analysed in the research program, some 
variables of interest were not adequately documented and could not be included in the 
analysis. For example, in identifying potential individual risk factors for resistance 
development, the presence of urinary catheters has been shown to increase the odds of 
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development of AMR in patients (Ko et al., 2008). Presence of comorbidities in patients have 
also been shown to be risk factors for acquiring antimicrobial resistant infections (Nouvenne 
et al., 2014) as well as prior antimicrobial use (Hillier et al., 2007). These potential risk 
factors could not be taken into consideration in analysis given the lack of information in 
regards to these variables in the published data and laboratory dataset. The lack of 
information on important variables has been reported as a limitation of systematic reviews 
(Gopalakrishnan & Ganeshkumar, 2013), as systematic reviews rely on data from other 
studies which may not have been adequately documented. The issue of missing or 
incomplete data on potential risk factors has also been identified as a common problem in 
database studies (Sorenson, Sabroe, & Olsen, 1996). This research program provides 
empirical evidence of the impact of missing or incomplete data on research findings.  
 
Another limitation noted during the research program for all three studies was the potential 
for selection bias. As stated in the literature review chapter (Chapter Two), the majority of 
patients with a UTI are treated empirically while awaiting results of the urine sample 
submitted to the microbiology laboratory for processing. This would likely have led to the 
increased selection of samples from patients who were unresponsive to initial antimicrobial 
therapy due to a resistant infecting bacterium as well as samples from those with 
complicated and recurrent UTI. Hence, evaluating resistance based on selection of samples 
from these patients has the potential to skew the data to more resistant cases and falsely 
elevate the resistance prevalence and incidence reported in the thesis. Therefore, the 
results from this research program need to be interpreted in this context.  
 
For studies two and three, the protocol used by the microbiology laboratory involved testing 
first for resistance against routine first-line antimicrobials, followed by more extensive 
testing with second-line antimicrobials only for isolates resistant to at least three of the 
routine antimicrobials. The microbiology laboratory procedures arguably lead to the 
presence of testing bias with potential for overestimation of resistance for the second-line 
antimicrobials (Hindler & Stelling, 2007). Frequent claims from developed countries appear 
to be that this testing approach is commonly used in laboratories (Cornaglia et al., 2004; 
Standing Medical Advisory Committee & Sub-Group on Antimicrobial resistance, 1998) and 
is mainly attributed to the availability of funds provided to laboratories (Bax et al., 2001). 
Despite these limitations, with the potential for overestimation of resistance, the prevalence 
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and incidence reported in studies two and three of the research program was found to be 
lower when compared to data in published international literature. 
 
The incidence of resistance evaluated in study three of this research program was based 
on microbiological laboratory data belonging to all public hospital inpatients, outpatients 
attending public hospital emergency departments and specialist clinics, and approximately 
13% of private hospital and community patients. The remaining data belonging to patients 
in the community and those attending private health services were not included. Given that 
a subset of the ACT population, albeit considerable, was sampled, the calculated incidence 
of resistance cannot be generalised to the whole ACT population. However, the novel 
methodological approach was tested and the incidence is the most comprehensive available 
to date in Australia and therefore noteworthy. 
 
In spite of the limitations described above, the findings of the research program contribute 
significantly to knowledge, as described in the next section.  
 
7.5 Contribution to knowledge 
The research program I have undertaken has not only confirmed existing evidence but also 
contributed new knowledge about AMR in E. coli UTI in hospital and community settings. 
The three main contributions to knowledge from the research program are: 
1) Confirmation of existing evidence and improved understanding of the increase in 
resistance of urinary E. coli to antimicrobials, both globally and locally. 
2) Identification of a new methodological approach, which can be applied by researchers to 
calculating incidence and prevalence of resistance using routinely collected antimicrobial 
susceptibility test data. 
3) Identification of a hitherto unrecognised and potentially important patient group that 
may be at high risk of developing an antimicrobial resistant urinary E. coli infection, 
specifically those receiving care at after-hours GP clinics. 
These knowledge contributions are woven through the research program and have been 
deemed significant by two peer reviewed journals. The three main contributions of this 
research program to knowledge will now be discussed in subsequent paragraphs of this 
section. 
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First, the findings from the research program confirmed the results from previously 
published studies, including prominent reports from the WHO that AMR in urinary E. coli is 
increasing. The increasing AMR to E. coli UTI identified both internationally in the systematic 
review and locally in the ACT using regional microbiological laboratory data, has implications 
for UTI treatment. The increase in resistance is especially important for antimicrobial agents 
like ciprofloxacin, which is considered a reserve antimicrobial for use in severe life 
threatening infections such as septicaemia. The research findings have also improved 
understanding of AMR in E. coli UTI by extending knowledge on the AMR trends as well as 
site of infection acquisition of urinary E. coli. This knowledge contribution is significant, both 
internationally in developed and developing countries and in Australia with the newly 
developed AURA Surveillance System, because the research has the potential to inform AMR 
surveillance by highlighting which antimicrobials to monitor closely. The findings emphasise 
the need for continued surveillance of AMR at the local, national and international levels. 
Monitoring of resistance through surveillance is considered an important means of 
controlling AMR, as the data obtained can provide information on new and emerging 
resistance patterns and also help identify antimicrobials that require interventions to be put 
in place to prevent further increases in resistance. 
 
The second major contribution to knowledge of the research program is the new insight 
provided on the methodological approaches to calculating resistance incidence and 
prevalence, using routinely collected antimicrobial susceptibility test data from a regional 
microbiology laboratory. Incidence and prevalence are two separate statistical terms which 
have both been described extensively in the methods chapter of the thesis (Chapter Three). 
These terms are often used interchangeably in AMR surveillance studies with the prevalence 
most frequently reported as opposed to incidence (Bax et al., 2001). The method used by 
other researchers for calculating incidence involved the inclusion of the first positive urinary 
E. coli isolate per patient per year as incident cases (Swami et al., 2012). This approach for 
calculating incidence is not ideal because the first isolate may not be a true reflection of the 
first occurrence of the outcome, which is an antimicrobial resistant infection. By including all 
urine samples in the dataset used for the research program with the presence of multiple 
observations per person, I was able to ‘follow-up’ each person who submitted a urine 
sample until they developed a resistant E. coli UTI, as opposed to restricting the dataset to 
the first isolate per patient. This unique method to clearly identify incident cases of resistant 
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E. coli UTI in a laboratory dataset provides a new methodological approach not 
demonstrated in previously published studies and can now be used by other researchers 
analysing antimicrobial susceptibility test data for incidence of resistance. Furthermore, in 
estimating prevalence of resistance, different denominator choices have previously been 
applied. For example, some studies used the total number of isolates tested as the 
denominator (Alós, Serrano, Gómez-Garcés, & Perianes, 2005; Wu, Lee, Chen, Tuan, & Chiu, 
2016). It is not clear from these studies if all isolates were tested against each antimicrobial, 
as if this were the case then it may be appropriate to use all isolates tested as the 
denominator. Meanwhile, other studies have used the number of isolates tested against 
each specific antimicrobial as the denominator (Kibret & Abera, 2014; Talan et al., 2016). 
The research I have undertaken provides empirical evidence to confirm that using these 
approaches will underestimate or overestimate the resistance prevalence respectively. 
Although there may be no ideal solution to this issue, the limitations of whichever 
denominator is used need to be clearly identified, something not done in other studies 
(Kibret & Abera, 2014; Wu et al., 2016). This will ensure proper interpretation of the 
resistance prevalence. Given the increasing resistance noted in the research program, 
perhaps it may be better to overestimate the resistance prevalence, as it could be argued 
that underestimation could cause complacency with the use of antimicrobials. To effectively 
address the increase in AMR, it is important to provide precise estimates of the true picture 
of the incidence and prevalence of AMR by applying appropriate methodological techniques 
to the available data, which has been achieved in the research program.  
 
The third major original contribution to knowledge is the demonstrated potential for 
identification of previously unknown patient groups at high risk of developing an 
antimicrobial resistant urinary E. coli infection; in this case through the health service 
providing patient care. It has been demonstrated from my research that analysis of 
antimicrobial susceptibility data can identify potential high risk groups for antimicrobial 
resistant E. coli UTI, such as patients attending after-hours GP clinics. Information on 
available patient characteristics were included as part of the analysis of the laboratory data 
used in the research program as evidence shows that certain risk factors such as age and 
presence of comorbidities may be associated with a higher risk of resistance (Blaettler et al., 
2009; Nouvenne et al., 2014). Given the limitation of using secondary data, as discussed 
previously in section 7.4, the previously identified risk factors identified from the literature 
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were likely to be incomplete. Hence, I sought to identify other potential risk factors. The 
identification of patients attending after-hours GP clinics as potentially at high risk of 
resistant E. coli UTI demonstrates the significance and importance of improving the quality 
of AMR data, as key findings such as this are able to be detected when valid and reliable 
AMR data are collected. To adequately manage AMR, insights on patient risk factors will 
assist with developing targeted interventions to control further development and spread of 
AMR.  
 
After-hours GP clinics were developed as an alternative health service provider to address 
the increasing use of emergency department services attributed to low acuity patient 
presentations (Buckley, Curtis, & McGirr, 2010). Australian GPs are significantly more likely 
than GPs in Canada, Germany, New Zealand and UK to provide after-hours (before 8.30am, 
after 6pm and during weekends) patient care (Schoen et al., 2006). With the growing 
demand for after-hours care by patients (Salisbury, 2000) there is potential to use the 
research findings for the development of interventions targeted specifically towards 
patients attending after-hours GP clinics. Detection of a higher risk of resistance in patients 
attending after-hours GP clinics, a community health service, as opposed to a hospital 
setting might be unexpected. However evidence from study one, where an increasing 
resistance in the community was noted worldwide, supports this finding and emphasises the 
need to monitor resistance, particularly in community settings. Data from other countries 
suggest that prescribing in after-hours GP clinics is high in comparison to office hours GP 
clinics (ESPAUR Writing Committee, 2015; Huibers, Moth, Christensen, & Vedsted, 2014), 
although exact reasons for this are not known. High prescribing in this setting could account 
for the higher resistance risk found in this research program. Whilst there is no published 
evidence, it could be postulated that patients with UTI presenting to after-hours clinics are 
similar to patients presenting to the emergency department. These patients are likely to be 
too unwell to wait for an appointment with a GP during regular office hours and may be 
more likely to require antimicrobials. Another possible hypothesis could be that GPs working 
after-hours may be fatigued, which could affect their clinical decision, hence lead to 
inappropriate prescribing. General practitioners consulting during regular office hours have 
been found to prescribe antimicrobials more towards the end of the working day as 
opposed to earlier in the day (Linder et al., 2014). This hypothesis could be tested in after-
hours clinics. A direct impact of this research program is to inform and direct decision-
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making among the Royal Australian College of General Practitioners to develop specific 
protocols for after-hours GP clinics. This knowledge from my research may influence the 
way empirical treatment guidelines are developed, with the potential for guidelines to be 
tailored specifically to particular patient groups on the basis that those who attend after-
hours GP clinics are more likely to have a resistant urinary E. coli infection. There is a need to 
replicate this study in other populations to determine whether similar findings will be seen. 
 
Both national and international surveillance systems monitoring AMR and antimicrobial use 
in hospital and community settings have the potential to benefit from the knowledge 
provided in the research program. The knowledge generated from this research program 
will contribute specifically to ACT Health, as the data used for studies two and three were 
provided by this organisation and have not previously been analysed in such a way as 
undertaken in the research program. Feedback on the findings from the research program 
will be provided to staff of ACT Health with the aim of influencing clinical practice. The 
findings of the research program form the basis of recommendations for policy and clinical 
practice as well as potential areas for further research. 
 
7.6 Recommendations 
Antimicrobial resistance is a problem for not only humans but also animals and plants 
(Robinson et al., 2016). One Health is an initiative that recognises the interactions between 
the health of humans and animals as well as the environment (Gibbs, 2014). Given the 
complex web of interactions between humans, plants and animals in the environment, with 
the potential for transmission of resistance from one group to the other (Collignon, 2015; 
Hristovski, Cvetkovik, Cvetkovik, & Dukoska, 2010), other sectors such as the veterinary, 
agricultural and environmental health sectors are also directly involved in controlling the 
development and further spread of AMR. My research program on AMR in urinary E. coli 
infections in humans will contribute to the wider work of One Health.  
 
This thesis focuses on microbiological laboratory data, which is only one aspect of what 
informs therapeutic management of E. coli UTI, which are often treated empirically. 
Therefore, the thesis could only inform some aspects of decision-making about prescribing 
given that the thesis aim is not about prescribing practices for treatment of UTI.  
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Based on the findings of this research program, which contributes to the body of knowledge 
about AMR in E. coli UTI, recommendations for policy, clinical practice and research are 
proposed. A summary of the recommendations is presented in Table 2. A brief discussion of 
each recommendation is provided thereafter. 
 
Table 2 Summary of recommendations for addressing AMR in E. coli UTI 
Topic Recommendation 
Policy 1. Linkage of microbiological laboratory and clinical databases  
2. Compulsory completion of minimum patient data on the 
microbiological laboratory request form when requesting AST for 
urine samples 
3. Development and implementation of policy limiting use of 
ciprofloxacin as an empirical agent for UTI management 
4. Increased state and territory governments funding to microbiology 
laboratories to improve the range of testing urine samples and all 
other specimens sent for microbiological laboratory processing 
Clinical practice 1. Ongoing education of GPs who consult at after-hours clinics on the 
judicious use of antimicrobials 
2. Education of healthcare staff on the importance of adequately 
completing laboratory request forms 
Research Design 
1. Well-designed prospective cohort studies undertaken using patient-
based real-time AMR data with the aim of identifying other potential 
risk factors for AMR development 
2. Examination of the association between policy regulation on 
antimicrobial use and AMR  
3. Future studies aimed at linking AMR data to antimicrobial use data  
Methodology 
4. Uptake of the new methodological approach for clearly identifying 
incident cases of resistant E. coli UTI  
5. Further evaluation of the impact of the denominators selected for 
calculating resistance prevalence  
Reporting 
6. Establishment of an expert panel to develop a standardised 
classification system for infections, based on the setting of acquisition 
to allow consistency in reporting as well as comparison of data 
7. Improved compliance with reporting guidelines during journal 
submission processes 
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7.6.1 Policy 
Linkage of microbiological laboratory and clinical databases is highly recommended. This 
research program has highlighted the weaknesses in the collection and quality of laboratory 
based data for research purposes and demonstrates the need for improvement in the data 
collection systems for AMR surveillance. Laboratory data do not contain detailed clinical 
information of patients and AMR surveillance should ideally involve collection and analysis 
of both clinical and microbiological data. Surveillance systems that combine clinical and 
laboratory data are recommended as the combination of both datasets strengthens the 
quality and richness of the data, thereby enhancing understanding of AMR (World Health 
Organization, 2002, 2015a). For example, to address the research gap of differences in AMR 
prevalence based on setting of infection acquisition, I had to manually link microbiological 
data to the hospital administrative system to obtain additional information needed to 
stratify samples into hospital- and community-acquired UTI. This recommendation reiterates 
national and international calls for integration of hospital and laboratory information 
systems, which will allow for easy extraction of clinical and laboratory data concurrently 
(Cornaglia et al., 2004; World Health Organization, 2002), although there are ethical issues 
that still need to be overcome. Linkage of data poses issues of patient privacy and 
confidentiality as data linkage requires the use of potentially identifying information to 
ensure accurate linkage, identified 20 years ago (Sibthorpe, Kliewer, & Smith, 1995) but still 
relevant (Xafis, 2015). Recommended safeguards to ensure protection of patient privacy 
includes: the submission to the overseeing ethics committee of a detailed research protocol, 
which conforms to the National Health and Medical Research Council guidelines; the 
adherence of researchers to ethical codes of conduct; and the organisation releasing the 
data undertaking the linkage before release to the researchers, without any identifying 
information (Sibthorpe et al., 1995). Evidence from the Western Australia Data Linkage 
System highlights the benefits of population level data linkage for health research (Trutwein, 
Holman, & Rosman, 2006). The recently developed AURA surveillance system should over 
time look at ways that the surveillance system can be linked with clinical data to improve 
the quality of the overall surveillance data. To appropriately control AMR, collection and 
analysis of accurate data must be done. 
 
Compulsory completion of minimum patient data on the microbiological laboratory request 
form, when requesting AST for urine samples, is recommended. A limitation identified in all 
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three studies of the research program was the incompleteness of the AMR data, which 
prevented the detailed analysis of potential patient risk factors that may contribute to 
development of AMR. Study one of the research program identified issues with the 
reporting of AMR data in published studies, and studies two and three identified issues with 
the collection of AMR data in the microbiological laboratory dataset. To improve the quality 
of AMR data and allow for detailed analysis, compulsory completion of a minimum set of 
patient data fundamental to AMR control is recommended. The WHO, through the global 
AMR surveillance system, requires that data on the patient’s age, gender, type of specimen, 
date of collection, site of specimen collection (i.e. hospital or community) and  current 
antimicrobial use, are collected (World Health Organization, 2015b). Completion of these 
patient parameters is dependent on the requesting clinician and, in most cases, is poorly 
documented on the laboratory request form. Compulsory completion may be achieved 
through implementation of an electronic medical record system with electronic ordering of 
laboratory tests. Evidence suggests that the use of electronic medical records with 
electronic ordering of tests improves the quality of medical notes and test orders (Burke et 
al., 2015; Georgiou et al., 2012). By using this system, the requesting clinician will be unable 
to submit the electronic request form unless the mandatory patient parameters are 
completed. This approach will contribute to having more reliable AMR data with the 
potential for better AMR control. The ACT Pathology, through ACT Health, is in the process 
of trialling an electronic medical record system with electronic test orders (A. Das, personal 
communication, 11 August, 2016). 
 
Development and implementation of policy limiting use of ciprofloxacin as an empirical 
agent for UTI management is recommended. The overall knowledge provided by the 
research program provides a platform on which to institute this recommendation at local, 
national, regional and international levels. An increasing resistance trend to ciprofloxacin 
was clearly identified in all three studies in the research program, prompting the need for a 
renewed effort in the further prevention of spread of resistance to this antimicrobial agent. 
Australia currently has a policy restricting ciprofloxacin use, which requires that clinicians 
adhere to specific indications authorised by the Pharmaceutical Benefits Scheme for using 
ciprofloxacin and other fluoroquinolones (Cheng et al., 2012). Countries without a similar 
policy need to ensure the development of policies limiting use of ciprofloxacin. 
Implementation of these policies is also recommended and this could be achieved, for 
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example, by ensuring that clinicians obtain permission to prescribe ciprofloxacin. Regular 
monitoring of ciprofloxacin resistance alongside usage rates should be advocated in 
antimicrobial use and resistance surveillance systems worldwide. This is extremely relevant 
to the recently developed AURA Surveillance System, which undertakes surveillance of 
antimicrobial use and resistance in Australia. 
 
It is recommended that state and territory governments increase funding to microbiology 
laboratories to improve the range of testing urine samples and all other specimens sent for 
microbiological laboratory processing. This recommendation improves on current 
microbiological laboratory procedures, in which isolates are first tested against first-line 
antimicrobials with isolates that are identified as being resistant subjected to further testing 
against second-line agents. The use of this two phase approach has been attributed to 
availability of insufficient funds (Bax et al., 2001), hence the need to effectively utilise 
available resources. Given the potential for testing bias using this approach, with the 
resultant effect of overestimation of resistance (Hindler & Stelling, 2007), increased funding 
by state and territory governments to microbiology laboratories, to improve the quality of 
testing urine samples and all other specimens sent for laboratory processing, is 
recommended. Improvements in the quality of laboratory testing will ultimately improve the 
AMR data quality, enabling better interpretation of resistance. 
 
7.6.2 Clinical practice 
Whilst further exploration is needed to identify the exact cause, it is recommended that 
ongoing education on the judicious use of antimicrobial agents, and other risk factors 
contributing to AMR, is targeted specifically towards GPs who consult at after-hours clinics. 
This recommendation is guided by knowledge gained from the research program, which 
identified that patient groups receiving care at after-hours GP clinics were at high risk of 
developing an antimicrobial resistant urinary E. coli infection. As previously discussed the 
exact reason for this finding is unknown but may be as a result of inappropriate prescribing, 
therefore warranting the need for open discussion and considering the requirement for 
clinicians to receive approval from the infectious diseases or microbiology units prior to 
prescribing all antimicrobial agents. Currently in Australia, Pharmaceutical Benefits Scheme 
approval is required by clinicians for prescribing specific antimicrobials such as 
fluoroquinolones, in accordance with antimicrobial stewardship practices in hospitals 
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(Duguid & Cruickshank, 2011). Evidence from published studies shows that implementation 
of antimicrobial restriction policies in hospitals leads to decreased use of restricted 
antimicrobials, with subsequent decrease in their resistance as well as reduction in hospital 
costs for purchasing antimicrobials (Falagas et al., 2007; Martin et al., 2005). However, these 
studies have also shown that only restricting the use of some antimicrobials favours the use 
of unrestricted antimicrobials (Falagas et al., 2007; Martin et al., 2005). Therefore it may be 
worthwhile restricting the prescription of all antimicrobials to prevent the unwanted effect 
of subsequent increase in the use of unrestricted antimicrobials. This is an important 
consideration, especially given the increasing resistance noted for some antimicrobials in 
the research program. Limitations to the implementation of prescribing restrictions include 
additional time to contact the infectious diseases unit for approval as well as extra costs to 
hospitals for staff dedicated specifically for this purpose (Paterson, 2006b). Despite these 
limitations, implementation of restriction policies for all antimicrobials may eventually 
promote the judicious use of antimicrobials by clinicians.  
 
Education of healthcare staff on the importance of adequately completing microbiological 
laboratory request forms is also recommended. As previously highlighted in section 7.4, 
incompleteness of data was a limitation noted in the research program, affecting the level of 
analysis undertaken, particularly in relation to individual patient risk factors for 
development of resistant E. coli UTI. Also noted in section 7.6.1, the quality of AMR data is 
dependent on the requesting clinician collecting the data and often tends to be poorly 
documented. Adequately completed laboratory request forms provide detailed information 
that, as well as being important for pathology staff, can be included in the analysis of AMR 
data and subsequently inform the development of AMR control policies and interventions.  
 
7.6.3 Research 
A number of areas that warrant further research were identified, as well as further testing of 
new methods and recommendations for the reporting of the findings of research. These 
recommendations are discussed below.   
 
Design 
It is recommended that well-designed prospective cohort studies using patient-based real-
time AMR data are undertaken with the aim of identifying other potential risk factors for 
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AMR development. This research program focused on retrospective routine susceptibility 
data but there is a need to conduct prospective studies using patient-based real-time data, 
because this will help identify other predictors of AMR in patients with UTI not identified in 
the research program. Effective monitoring of resistance patterns with the use of real-time 
data will also provide detailed insights to guide the development of appropriate responses 
to controlling AMR.  
 
Examination of the association between policy regulation on antimicrobial use and AMR is 
recommended. The first study in the research program found that developing countries 
have higher resistance to ciprofloxacin compared to developed countries. The reason for the 
higher resistance in developing countries was thought to be as a result of the use of non-
prescription antimicrobials and over-the-counter prescribing, which is relatively common in 
developing countries (Sosa et al., 2010). If an association exists between policy regulations 
on antimicrobial use and AMR in countries that have such policies, in comparison to those 
that do not, this may provide further evidence to justify policy development regulating non-
prescription antimicrobial use in countries lacking this policy.   
 
It is also recommended that future studies should aim at linking AMR data to antimicrobial 
use data to enhance the interpretation of findings to inform development of interventions. 
Analysis of hospital antimicrobial use data (reported in Chapter Five) undertaken as part of 
the research program could not be linked to the only available AMR data because the latter 
comprised both hospital and community data. Furthermore, analysis of data on 
antimicrobial use should also include data on the appropriateness of use. Data on the 
appropriateness of antimicrobial use will provide information on effectiveness of prescribing 
practices in accordance with therapeutic guidelines.   
 
Methods 
Uptake of the new methodological approach for clearly identifying incident cases of 
resistant E. coli UTI is recommended for use internationally. The research program provides 
good quality evidence on a suitable and rigorous approach to calculating resistance 
incidence, given that most studies report on prevalence of resistance. The research program 
finding supports a minimum dataset that comprises: the unique patient identifier; all urine 
samples processed over a minimum of one year for each individual patient; date of urine 
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sample submission to the laboratory; all urine culture results with colony counts; 
antimicrobials tested; and antimicrobial susceptibility test results are recommended for 
calculation of the incidence of resistance. The approach discussed in the methods chapter 
(Chapter Three) of the thesis can be applied by other researchers to provide estimates of 
resistance incidence. 
 
Further evaluation of the impact of denominators selected for calculating resistance 
prevalence is recommended. The research undertaken provides empirical evidence on how 
resistance prevalence may either be overestimated or underestimated, depending on the 
choice of denominator, which is using only the number of isolates tested against each 
antimicrobial agent or using the total number of isolates tested respectively. The impact of 
whichever denominator is selected on the resistance prevalence must be clearly evaluated 
in publications or reports on AMR, to enable clinicians to adequately interpret the resistance 
prevalence. Although using the number of isolates tested against each antimicrobial agent 
as the denominator may overestimate the resistance prevalence, clinicians may be more 
likely to refrain from overjudicious use of antimicrobials given higher resistance prevalence 
as opposed to using a denominator which appears to underestimate the resistance thereby 
giving a false impression that resistance is low, favouring greater use of antimicrobials.  
 
Reporting 
Establishment of an expert panel to develop an internationally accepted standardised 
classification system for infections, based on the setting of acquisition to allow consistency 
in reporting as well as comparison of data, is recommended. As highlighted in the methods 
chapter (Chapter Three), there are many definitions being applied to classify infections 
based on the setting of acquisition into the broad healthcare-associated infections, including 
hospital-acquired as well as community-acquired. An expert panel comprising 
representatives from notable organisations, such as the CDC and WHO, could develop a 
standardised classification system that can be used internationally thus facilitating 
consistency in reporting as well as comparison of data. This approach was used for defining 
multidrug-, extensively drug- and pandrug-resistant bacteria and the proposed definitions 
have been taken up internationally and frequently cited in published literature (Ansari et al., 
2015; Basak, Singh, & Rajurkar, 2016; Bhatt, Tandel, Shete, & Rathi, 2015).  
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Improved compliance with reporting guidelines during journal submission processes is 
recommended. In regards to the methodological aspects of research, the poor reporting of 
research studies, which have been highlighted as a major issue (Altman & Simera, 2010), 
were also identified in the research program. This necessitates recommending better 
compliance with reporting guidelines during journal submission processes. Currently some 
peer reviewed journals add to the journal submission process the compulsory completion of 
reporting guidelines depending on the study design (such as the PRISMA guidelines for 
systematic reviews, STROBE guidelines for observational studies and CONSORT guidelines 
for randomised controlled trials), to optimise transparency and accuracy of reporting. All 
journals should include the completion of reporting guidelines as a compulsory component 
of the submission process, and not use tick boxes but mandate that prospective authors 
include the page numbers from their manuscript which provide the required information. 
Journals should aim to ask peer reviewers to assess the completed guidelines along with the 
manuscript as part of the peer review process.  
 
7.7 Summary and conclusion 
In the research program undertaken, I have obtained, collated, analysed and evaluated 
antimicrobial resistance data to evaluate antimicrobial resistance patterns in E. coli UTI. The 
overall research findings have contributed insight and new knowledge to better understand 
AMR patterns and trends in urinary E. coli infections. The research program provides an 
indication of the current state of ciprofloxacin resistance globally and also makes available 
information on AMR at a jurisdictional level. Hence the findings are applicable not only 
nationally but also on a wider scale. The research undertaken in the thesis has been 
especially timely because it coincided with the development of the AURA surveillance 
system, with the recent release of the first national report. Dissemination of the research 
findings at the local level to ACT Health staff, including my collaboration with ACT Pathology, 
will inform local and national level surveillance activities, improvements in the surveillance 
system and support the national agenda for monitoring of AMR in this critically important 
bacterium. It is hoped that the recommendations made in the thesis, based on the evidence 
from the research undertaken, can be instituted to help maintain the effectiveness of 
currently available antimicrobials. 
 
201 
 
The health and economic implications of antimicrobial resistant urinary E. coli infections 
justify the need to continue to undertake research in this area. Furthermore, the resistance 
patterns of microorganisms to antimicrobials are constantly changing, therefore regular 
surveillance must continue. The findings of this research program establish a baseline 
against which subsequent future progress in ACT jurisdictional level surveillance can be 
compared. In accordance with the One Health concept, AMR surveillance in humans alone 
cannot tackle the problem of resistance, hence the findings will add to the wider work on 
AMR being undertaken by other sectors directly involved with tackling the issue of AMR, 
such as the veterinary, agricultural and environmental health sectors.  
 
In conclusion, the research program emphasises the urgency for all levels of government, 
including all public and private healthcare services, healthcare professionals, academic 
institutions and the general public, to be united and work together towards tackling the 
issue of AMR. Without a concerted effort on all sides, resistance may continue to rise and 
with the lack of development of new antimicrobial agents, global healthcare may return to 
the ‘pre-antibiotic era’, where antimicrobials were unavailable and death from infection was 
common.  
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Ciprofloxacin resistance in community- and
hospital-acquired Escherichia coli urinary
tract infections: a systematic review and
meta-analysis of observational studies
Oyebola Fasugba1*, Anne Gardner1, Brett G. Mitchell1,2 and George Mnatzaganian3
Abstract
Background: During the last decade the resistance rate of urinary Escherichia coli (E. coli) to fluoroquinolones such as
ciprofloxacin has increased. Systematic reviews of studies investigating ciprofloxacin resistance in community- and
hospital-acquired E. coli urinary tract infections (UTI) are absent. This study systematically reviewed the literature and
where appropriate, meta-analysed studies investigating ciprofloxacin resistance in community- and hospital-acquired
E. coli UTIs.
Methods: Observational studies published between 2004 and 2014 were identified through Medline, PubMed,
Embase, Cochrane, Scopus and Cinahl searches. Overall and sub-group pooled estimates of ciprofloxacin resistance
were evaluated using DerSimonian-Laird random-effects models. The I2 statistic was calculated to demonstrate the
degree of heterogeneity. Risk of bias among included studies was also investigated.
Results: Of the identified 1134 papers, 53 were eligible for inclusion, providing 54 studies for analysis with one paper
presenting both community and hospital studies. Compared to the community setting, resistance to ciprofloxacin was
significantly higher in the hospital setting (pooled resistance 0.38, 95 % CI 0.36-0.41 versus 0.27, 95 % CI 0.24-0.31 in
community-acquired UTIs, P < 0.001). Resistance significantly varied by region and country with the highest resistance
observed in developing countries. Similarly, a significant rise in resistance over time was seen in studies reporting on
community-acquired E. coli UTI.
Conclusions: Ciprofloxacin resistance in E. coli UTI is increasing and the use of this antimicrobial agent as empirical
therapy for UTI should be reconsidered. Policy restrictions on ciprofloxacin use should be enhanced especially in
developing countries without current regulations.
Keywords: Antimicrobial resistance, Escherichia coli, Urinary tract infection, Systematic review, Meta-analysis
Background
Urinary tract infections (UTI) are one of the most frequent
bacterial infections affecting people both in the community
and in hospitals [1]. It is estimated that about 150 million
people per annum are diagnosed with UTI worldwide [2].
A recent World Health Organisation (WHO) report on
antimicrobial resistance (AMR) surveillance specified nine
bacteria of international concern which are responsible for
some of the most common infections in community and
hospital settings [3]. Escherichia coli (E. coli), the pathogen
most often implicated in UTIs, is listed as one of the nine.
In all six WHO regions (Africa, Americas, Eastern Mediter-
ranean, European, South-East Asia and Western Pacific)
high rates of antimicrobial resistance have been observed in
this pathogen [3].
Ciprofloxacin is the most commonly prescribed
fluoroquinolone for UTIs because it is available in oral
and intravenous preparations [4]. It is well absorbed
from the gastrointestinal tract after oral administration.
It also has a documented safety profile, broad Gram
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negative organism coverage and high urinary excretion
rate [4]. During the last decade the resistance rate of E.
coli to fluoroquinolones such as ciprofloxacin has in-
creased [5]. A 10 year analysis of urinary E. coli speci-
mens in Switzerland, found an increasing trend in
resistance to ciprofloxacin, from 1.8 to 15.9 % [6]. Fluor-
oquinolones are ranked as one of four of the highest pri-
ority critically important antimicrobials [7] as they have
an important role in the treatment of more severe infec-
tions, such as septicaemia. Therefore resistance to fluor-
oquinolones can have serious clinical consequences.
They are one of few available therapies for serious
Salmonella spp. and E.coli infections [5]. Resistance to
fluoroquinolones emerges quickly, and this is likely to be
related to the biology of resistance as well as a direct re-
sponse to drug pressure [8]. They should therefore be
used with caution and reserved for severe infections,
and preceded by antimicrobial susceptibility testing of
the bacteria involved [5]. The most recent Infectious
Diseases Society of America (IDSA) guidelines recom-
mend that fluoroquinolones should be reserved for
important uses due to their propensity for ecological un-
favorable effects of antimicrobial therapy such as the se-
lection of drug-resistant pathogens and colonisation or
infection with multidrug-resistant organisms [9].
Recent prescribing guidelines recommend reserving
ciprofloxacin use for more severe infections and resist-
ance to this agent is increasing prompting further re-
search in this area [6, 10, 11]. Published quantitative
syntheses of overall ciprofloxacin-resistant E. coli UTI
prevalence and incidence in hospital and community set-
tings are absent. This systematic review of observational
studies therefore aims to compare ciprofloxacin resist-
ance in both settings. Knowledge about ciprofloxacin re-
sistance in community- and hospital-acquired E. coli
UTIs will provide information for control of resistant
pathogens. This review also has the potential to provide
a basis for which future interventions can be evaluated.
The findings will, in addition, make available informa-
tion on ciprofloxacin resistance in various regions of the
world providing some evidence for further regulatory
control of ciprofloxacin use globally.
Methods
Protocol and registration
The protocol for conducting this review has been regis-
tered and can be accessed on the International prospect-
ive register of systematic reviews (PROSPERO) (available
at http://www.crd.york.ac.uk/prospero/ with registration
number: CRD42014014473). Prior to registration, the
protocol was reviewed by a reviewer external to the
study team. Ethics approval was not sought as this re-
view synthesized data from published studies for which
approval had already been obtained.
Search strategy
We conducted a systematic review of observational (cross
sectional, cohort and case control) studies published in
the last 11 years (2004–2014) reporting on ciprofloxacin
resistance in community- and hospital-acquired E. coli
UTIs. This time limit is based on changes in the micro-
biology and epidemiology of antimicrobial resistant patho-
gens which occurred in the past decade with subsequent
changes in treatment regimens and patient outcomes [12].
Reporting of this review complied with the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA) [13].
The electronic bibliographic databases MEDLINE/
PubMed, EMBASE, Cochrane, CINAHL and Scopus were
searched. Searches were conducted for words in the title or
abstract or within the full text of the papers. These included
both keywords only and keywords with medical subject
headings (MeSH) using the search terms ‘resistance’, ‘urinary
tract infection’ and ‘Escherichia coli’ from 1st January 2004
to 31st December 2014 (see Additional file 1). The refer-
ence lists of papers identified from the electronic databases
were hand-searched for additional papers.
Inclusion and exclusion criteria
Papers were included if they reported prevalence or inci-
dence rates of ciprofloxacin resistance in community- or
hospital-acquired E. coli UTIs. Papers reporting on urinary
E. coli ciprofloxacin susceptibility in which resistance rate
could be calculated were also included. We included pa-
pers involving adults and/or children. Only peer reviewed
manuscripts were considered. Grey material which in-
cludes unpublished literature, conference abstracts, letters
to editors, newsletters and reports were excluded. Non-
peer reviewed literature were also excluded. Papers
written in languages other than English were also excluded.
In addition, papers not clearly specifying the setting
(hospital-acquired or community-acquired); drug (cipro-
floxacin) or sample (urine) were excluded. Papers that
focused on specific sub-populations (e.g. diabetics and pa-
tients with recurrent UTI) were also excluded as these did
not represent the general population. This review included
only papers that used the Centers for Disease Control and
Prevention (CDC) definition of microbiologically confirmed
UTI (≥105 colony forming unit/ml) [14].
Definitions
For the purpose of this review, a study was defined as all
data from a published paper with the only distinction be-
ing ‘hospital’ or ‘community’ setting. Therefore, if a single
paper meeting the eligibility criteria reported data on both
settings, they were included as two separate studies.
Community-acquired UTI was defined as positive sam-
ples obtained from (i) outpatient clinics; (ii) general prac-
tice (GP) clinics; (iii) emergency departments; (iv) within
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48 h of hospital admission or (v) from nursing homes or
residential aged care facilities [15–17].
Hospital-acquired UTI was defined as positive samples
obtained (i) after 48 h of hospital admission or (ii) within
48 h of hospital discharge [15].
Important changes in healthcare delivery over the last
few years have seen some usually inpatient procedures
now more often than not performed on an outpatient
basis [18]. Patients transition freely within sometimes
loosely defined levels of the health care system, for ex-
ample between long-term care or rehabilitation services,
to acute-care centres [19, 20]. This study only considered
hospital-acquired UTIs as opposed to a wider definition of
healthcare associated UTIs, to avoid this confusion.
Study selection
The titles and abstracts of all papers identified in the elec-
tronic databases were examined and assessed for relevance
and appropriateness to the principal objective of the sys-
tematic review. Irrelevant studies were excluded. Full texts
of the potentially relevant papers were printed and care-
fully assessed against the systematic review inclusion and
exclusion criteria. Those not meeting the criteria were ex-
cluded. The remaining papers deemed to have data rele-
vant to the systematic review and meta-analysis were
assessed for quality and risk of bias.
The study selection process and other stages of the re-
view were performed by the lead author (OF). At each
stage, 10 % of papers identified were also screened
against the study criteria independently by other authors
(AG, GM and BM). Discrepancies in either the applica-
tion of inclusion or exclusion of papers, quality assess-
ment or on data extraction were discussed among all
authors to make the final decision.
Data extraction process
Data were extracted by one author (OF) and 10 % of pa-
pers eligible for data extraction were independently ex-
tracted by another author (AG). Data extraction was
compared between AG and OF demonstrating 100 %
agreement for all items except the study design. This
variable was therefore assessed by all authors. Where
there was missing information on the study design of pa-
pers to be included in the meta-analysis, attempts were
made to contact the authors. When there was no re-
sponse, consensus on the study design was reached by
all authors. Agreement between authors was assessed
using Kappa coefficient. The agreement between all au-
thors in deciding on the study design was 71 % (Kappa
(95 % CI) = 0.429 (0.154–0.703), P Value = 0.003). Papers
for which no agreement could be reached on the design,
based on insufficient information, were assigned as non-
classifiable. Any other missing information in the in-
cluded papers was recorded as ‘not stated’.
The first author, year of study, country of study, study
setting, age and sex distribution, co-morbidities, sample
size, study design, study aim, antimicrobial susceptibility
testing method, ciprofloxacin resistance rate, risk factors
for ciprofloxacin resistance (i.e. previous antibiotic use)
and mortality data (if reported) were extracted. Where
the ciprofloxacin resistance rate was not available, the
susceptibility rate was used to determine resistance.
Risk of bias in individual studies
Quality and risk of bias of the final papers included
in the review was conducted using a modified version
of the Newcastle-Ottawa Scale (NOS) which is a risk
of bias assessment tool for observational studies rec-
ommended by the Cochrane Collaboration [21, 22].
Content validity and inter-rater reliability of this tool
have been established [22]. Studies were rated by
assigning a judgment of ‘Low risk’ of bias, ‘High risk’
of bias, or ‘Unclear risk’ of bias according to pub-
lished criteria [21].
Statistical analysis
Pooled ciprofloxacin resistance proportions (with 95 %
confidence intervals) in patients with E. coli UTI were
separately calculated and compared between hospital
and community settings using a random-effects meta-
analysis model based on DerSimonian and Laird method
[23, 24]. This method incorporates an estimate of the
between-study variation into both the study weights and
the standard error of the estimate of the common effect.
The precision of an estimate from each included study
was represented by the inverse of the variance of the
outcome pooled across all studies. If the value of the
pooled prevalence was within the 95 % CI, then the ef-
fect size was statistically significant at the 5 % level (P <
0.05). The heterogeneity among studies was assessed by
using the I2 statistic with a P value of <0.05 considered
statistically significant, and I2 values below 25 % indicat-
ing low heterogeneity, 25–75 % moderate heterogeneity
and over 75 % high heterogeneity [25]. Subgroup ana-
lyses were done by risk of bias, study duration, age
group, UTI symptoms, world region and economy of
country (categorised as developed and developing using
the World Bank classification [26]). A meta-regression
analysis was used to determine the effect of measured
covariates on the observed heterogeneity in resistance
estimates across studies [23]. Assessment of publication
bias was estimated using funnel plots. Further analysis
was undertaken to examine pooled ciprofloxacin resist-
ance over time using the median study year. For studies
occurring over 2 years, the first year was used; for stud-
ies occurring over 4 years, the 2nd year was used; for
those over 6 years, the 3rd year was used. The non-
parametric Spearman’s rho correlation coefficient was
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calculated to determine significance in resistance trend
over time. Statistical analyses were undertaken using Stata
statistical softwareversion 13 [27].
Results
Study selection
Electronic database searches identified 15,062 potential
studies and 31 additional studies were identified through
hand searching. After 11,397 duplicates were removed,
3696 articles remained for title and abstract screening.
We assessed 1134 as potentially eligible and retrieved
the full text of these articles. After applying inclusion
and exclusion criteria, 53 papers (5 %) were deemed to
have data relevant to the systematic review and meta-
analysis. These 53 papers consisted of 54 studies com-
prising three hospital-acquired E. coli UTI studies and
51 community-acquired E. coli UTI studies. There was
one paper that compared resistance in both hospital and
community settings hence reported as two studies [15].
The PRISMA flow chart describing the papers identified
from the search strategy and reasons for exclusion is
shown in Fig. 1.
Study characteristics
Geographically, 53 of the 54 studies were carried out in
Asia (28 %; n = 15), Europe (24 %; n = 13), Middle East
(15 %; n = 8), Africa (13 %; n = 7), North America (11 %;
n = 6) and South America (7 %; n = 4). The remaining
study was conducted in multiple countries [28]. There
were 17 (31 %) studies conducted in developed countries
and 36 (67 %) in developing countries. The majority of
the studies (80 %) followed a cross sectional design. The
duration of studies ranged from 2 months to 84 months
(median = 15.5; IQR = 12.0-30.0). The mean age and sex
proportion of patients with an E. coli UTI were stated in
13 % (n = 7) and 44 % (n = 24) of studies respectively.
Most study populations included patients of both sexes al-
though 19 % (n = 10) included only women. Antimicrobial
susceptibility testing and interpretation was performed
using the disk diffusion method (74 %) and Clinical and
Laboratory Standards Institute (CLSI) criteria (83 %) re-
spectively in most studies. Table 1 provides further details
on the description of the included studies.
Pooled ciprofloxacin resistance
Figures 2 and 3 show the forest plots of studies report-
ing on ciprofloxacin resistance in community acquired
E. coli UTI by region and economy, respectively. Figure 4
shows the forest plot of studies reporting on ciprofloxacin
resistance in hospital acquired E. coli UTI. Compared with
the community-setting, resistance to ciprofloxacin in E
coli UTIs was significantly higher in the hospital-setting
(P < 0.001). Overall, the pooled rate for ciprofloxacin re-
sistance in patients with community-acquired E. coli UTIs
was 0.27 (95 % CI: 0.240-0.310), compared with 0.38
(95 % CI: 0.360-0.410) in the hospital setting. There was
substantial heterogeneity among the community-setting
studies (I2 = 98.8 %, P < 0.0001), but very little in the hos-
pital ones (I2 = <0.010 %, P = 0.641). Further analysis of
studies reporting on community-acquired E. coli UTI by
region (Fig. 3) showed that Asia had the highest pooled re-
sistance. Analysis by economy based on the World Bank
classification (Fig. 4) showed a higher pooled resistance in
developing countries.
Resistance over time in community-acquired UTI studies
Figure 5 shows the scatter plot of ciprofloxacin resistance
in 47 studies reporting on community-acquired UTI using
the median study year for each study. Four studies did not
provide data on the year(s) the study was conducted and
were excluded from this analysis [29–32]. The results of
the Spearman’s rho correlation test showed a statistically
significant rise in resistance over time (n = 47, rs =
0.431, P = 0.003). Similar findings were observed for devel-
oping countries. There was no significant rise in resistance
over time in developed countries.
Subgroup analyses
Sub-group analysis was conducted within each major
setting. For community-acquired UTI studies (Table 2),
there was a significant difference in the pooled resistance
within each subgroup examined (risk of bias, study dur-
ation, economy, region, age group and UTI symptoms).
The subgroup analyses results for studies reporting on
hospital-acquired E. coli UTI (see Additional file 2)
showed no difference in the pooled resistance within the
subgroups examined (region, economy and UTI symp-
toms). When both settings were compared (see Additional
file 3), there were significant differences noted for risk of
bias (high), study duration (>12 months), economy (devel-
oped), region (Americas), age group (adults and children)
and UTI symptoms (P < 0.001). There were no data avail-
able on mortality for comparison between settings.
Meta-regression analyses
Random effects meta-regression analyses of studies
reporting on community-acquired E. coli UTI showed
that country’s economy (P = 0.008), Asia as a region (P =
0.002), high risk of bias (P = 0.003), year of study (P =
0.020) and studies using only children as the study popu-
lation (P = 0.030) were the study factors significantly ac-
counting for the observed heterogeneity, responsible for
61 % of the between study variance (Adjusted R2) in cipro-
floxacin resistance.
Risk of bias
When studies were assessed for risk of bias using the
Newcastle-Ottawa scale, 30 % (n = 16) were assessed as
Fasugba et al. BMC Infectious Diseases  (2015) 15:545 Page 4 of 16
253
having a low risk of bias; 22 % (n = 12) unclear risk of bias
and 48 % (n = 26) were deemed to have a high risk of bias.
Further analysis of the 16 low risk studies only was con-
sistent with findings reported from the analysis of all stud-
ies. An increasing resistance trend over time was also
observed, however this increase did not reach statistical
significance because of reduced statistical power.
Discussion
The findings of this systematic review and meta-analysis
highlight the higher ciprofloxacin resistance in hospital-
acquired E.coli UTI when compared to community-
acquired UTI. There is also substantial evidence that
ciprofloxacin resistance in community-acquired E. coli
UTI has been increasing in recent years. Resistance was
Fig. 1 PRISMA flow diagram of study selection. (*54 studies from 53 papers)
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Table 1 Description of studies included in meta-analysis
Study author Country Designa Setting Risk of bias Study durationb
(months)
Number of
positive E. coli
UTI samplesc
Number of
ciprofloxacin
resistant E. coli
Proportion resistant
(95 % CI)
Standard error Weightd (%)
Ahmad, 2012 India Cross sectional Community Unclear 24 318 48 0.15 (0.11, 0.19) 0.02 2.09
Akoachere et al., 2012 Cameroon Cross sectional Community Low 12 43 11 0.26 (0.13, 0.39) 0.07 1.61
Akram et al., 2007 India Cross sectional Community High 12 61 42 0.69 (0.57, 0.80) 0.06 1.70
AlSweih et al., 2005 Kuwait Cross sectional Community High 12 1535 81 0.05 (0.04, 0.06) 0.01 2.15
Al-Tawfiq et al., 2009 Saudi Arabia Cohort Community High 12 2281 592 0.26 (0.24, 0.28) 0.01 2.14
Ansbach et al., 2013 USA Cross sectional Community High 7 98 2 0.02 (−0.01, 0.05) 0.01 2.12
Arabi et al., 2013 Iran Cross sectional Community Low 33 103 23 0.22 (0.14, 0.30) 0.04 1.91
Araujo et al., 2011 Brazil Cross sectional Community Unclear 24 391 36 0.09 (0.06, 0.12) 0.01 2.12
Arslan et al., 2005 Turkey Cross sectional Community Low 5 514 135 0.26 (0.22, 0.30) 0.02 2.09
Astal, 2005 Palestine Cross sectional Community High 6 252 30 0.12 (0.08, 0.16) 0.02 2.09
Azap et al., 2010 Turkey Cohort Community Unclear 12 464 139 0.30 (0.26, 0.34) 0.02 2.08
Bahadin et al., 2011 Singapore Cross sectional Community Unclear 12 90 22 0.24 (0.16, 0.33) 0.05 1.86
Biswas et al., 2006 India Cross sectional Community High 36 354 124 0.35 (0.30, 0.40) 0.03 2.05
Bouchillon et al., 2013 USA Cross sectional Community High 24 723 234 0.32 (0.29, 0.36) 0.02 2.10
Bouchillon et al., 2013 USA Cross sectional Hospital High 24 253 103 0.41 (0.35, 0.47) 0.03 11.83
Dash et al., 2013 India Cross sectional Community Low 30 397 212 0.53 (0.48, 0.58) 0.03 2.05
Dimitrov et al., 2004 Kuwait Cross sectional Community High 84 780 92 0.12 (0.10, 0.14) 0.01 2.13
Farshad et al., 2011 Iran Cross sectional Community Low 12 90 8 0.09 (0.03, 0.15) 0.03 2.01
Ghadiri et al., 2012 Iran Cross sectional Hospital High 24 200 80 0.40 (0.33, 0.47) 0.03 9.41
Gobernado et al., 2007 Spain Cross sectional Community Low 12 2292 418 0.18 (0.17, 0.20) 0.01 2.14
Ho et al., 2010 Hong Kong Cross sectional Community Low 24 271 35 0.13 (0.09, 0.17) 0.02 2.09
Hoban et al., 2011 Multiple countries Cross sectional Hospital High 24 1643 624 0.38 (0.36, 0.40) 0.01 78.76
Ismaili et al., 2011 Belgium Cohort Community High 24 189 5 0.03 (0.00, 0.05) 0.01 2.13
Kashef et al., 2010 Iran Cross sectional Community High 30 578 180 0.31 (0.27, 0.35) 0.02 2.09
Kiffer et al., 2007 Brazil Cross sectional Community Unclear 48 22679 2699 0.12 (0.11, 0.12) 0.002 2.15
Killgore et al., 2004 USA Case–control Community Low 12 120 40 0.33 (0.25, 0.42) 0.04 1.89
Kimando et al., 2010 Kenya Cross sectional Community Unclear 6 92 6 0.07 (0.01, 0.12) 0.03 2.05
Kothari et al., 2008 India Cross sectional Community High 6 361 260 0.72 (0.67, 0.77) 0.02 2.06
Kurutepe et al., 2005 Turkey NC Community High 72 880 174 0.20 (0.17, 0.22) 0.01 2.12
Lau et al., 2004 Taiwan Cross sectional Community Unclear 13 80 14 0.17 (0.09, 0.26) 0.04 1.89
Ljuca et al., 2010 Bosnia & Herzegovina Cross sectional Community High 36 43 4 0.09 (0.01, 0.18) 0.04 1.87
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Table 1 Description of studies included in meta-analysis (Continued)
Longhi et al., 2012 Italy NC Community Low 6 154 36 0.23 (0.17, 0.30) 0.03 1.98
Martinez et al., 2012 Colombia Cross sectional Community High 2 102 39 0.38 (0.29, 0.48) 0.05 1.83
Miragliotta et al., 2008 Italy Cohort Community Low 60 2589 422 0.16 (0.15, 0.18) 0.01 2.14
Molina-Lopez et al., 2011 México Cross sectional Community High 48 119 65 0.55 (0.46, 0.64) 0.05 1.86
Moreira et al., 2006 Brazil Cross sectional Community Unclear 15 544 65 0.12 (0.09, 0.15) 0.01 2.12
Murugan et al., 2012 India Cohort Community High 12 204 144 0.71 (0.64, 0.77) 0.03 2.00
Muvunyi et al., 2011 Rwanda Cross sectional Community Low 6 72 23 0.32 (0.21, 0.43) 0.05 1.75
Mwaka et al., 2011 Uganda Cross sectional Community High NS 27 9 0.33 (0.16, 0.51) 0.09 1.32
Ni Chulain et al., 2005 Ireland Cross sectional Community High 5 723 18 0.02 (0.01, 0.04) 0.01 2.15
Olson et al., 2012 USA Cross sectional Community Unclear 16 95 4 0.04 (0.00, 0.08) 0.02 2.08
Otajevwo, 2013 Nigeria Cross sectional Community High 6 5 4 0.80 (0.45, 1.15) 0.18 0.63
Prakash et al., 2013 India Cross sectional Community Low NS 23 16 0.70 (0.51, 0.88) 0.10 1.26
Randrianirina et al., 2007 Madagascar Cross sectional Community Low 28 607 100 0.16 (0.14, 0.19) 0.02 2.12
Rani et al., 2011 India Cross sectional Community Unclear 6 208 151 0.73 (0.67, 0.79) 0.03 2.01
Shaifali et al., 2012 India Cross sectional Community Unclear 12 46 28 0.61 (0.47, 0.75) 0.07 1.54
Shariff et al., 2013 India Cross sectional Community High 18 491 160 0.33 (0.28, 0.37) 0.02 2.08
Sire et al., 2007 Senegal Cross sectional Community Low 33 1010 157 0.16 (0.13, 0.18) 0.01 2.13
Sood et al., 2012 India NC Community High 30 214 160 0.75 (0.69, 0.81) 0.03 2.02
Stratchounski et al., 2006 Russia NC Community Low 48 423 18 0.04 (0.02, 0.06) 0.01 2.14
Vellinga et al., 2012 Ireland Case–control Community Low 9 633 78 0.12 (0.10, 0.15) 0.01 2.12
Wang et al., 2014 China Cross sectional Community High 8 129 91 0.71 (0.63, 0.78) 0.04 1.92
Yildirim et al., 2010 Turkey Cross sectional Community Unclear 24 450 85 0.19 (0.15, 0.23) 0.02 2.10
Yolbas et al., 2013 Turkey Cross sectional Community High 12 113 24 0.21 (0.14, 0.29) 0.04 1.93
aNon-classifiable design
bNot stated
cStudy denominator
dWeights are from random effects analysis using DerSimonian-Laird model
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also found to be significantly higher in developing coun-
tries reporting on E. coli UTI in community settings.
Antimicrobial resistance has been described as an inter-
national hazard to public health threatening the successful
prevention and treatment of bacterial, viral, parasitic and
fungal infections [3, 33]. As such, research into its
prevention and reduction is very important. Our esti-
mated pooled ciprofloxacin resistance of 27 and 38 % in
community- and hospital-acquired E. coli UTI respectively
could not be compared to any other systematic review
findings because, to our knowledge, this is the first sys-
tematic review and meta-analysis comparing ciprofloxacin
NOTE: Weights are from random effects analysis
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resistance in community- and hospital-acquired E. coli
UTI. However, national data from five WHO regions show
at least 50 % resistance to fluoroquinolones (ciprofloxacin,
norfloxacin or ofloxacin) in E. coli [3]. Data on E. coli in
the WHO report are from various settings and sources
(including blood and urine) hence cannot be directly com-
pared with the results from our systematic review. An-
other recent review on global fluoroquinolone resistance
NOTE: Weights are from random effects analysis
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epidemiology reported a range of 2 to 69 % for fluoro-
quinolone resistance in uncomplicated community-
acquired UTI and up to 98 % in complicated cases, with
fluoroquinolone resistance in healthcare associated UTIs
ranging from 6 to 62 % [34]. The findings from our sys-
tematic review are within the above reported ranges.
However, the latter ranges were wide and the data were
from a number of different Gram negative uropathogens
and not specifically E. coli accounting for the higher rates.
Available published data show relatively high rates of urin-
ary E. coli resistance to ciprofloxacin [35–41] prompting
the need for a renewed effort in the further prevention of
spread of resistance to this antimicrobial agent.
We found that urinary E. coli resistance to ciprofloxa-
cin was higher in the hospital compared to the commu-
nity setting. Our finding is comparable to individual
studies which have assessed urinary E.coli resistance to
ciprofloxacin in both, hospital and community settings
[31, 41–45]. However, often studies do not apply the cri-
terion of 48 h post admission used in our systematic re-
view for identifying hospital acquired UTI [45, 46]. The
Canadian national surveillance study (CANWARD), a
large population-based study undertaken from 2007 to
2009, further confirms our finding of higher resistance
in the hospital setting [47]. Inpatients had a significantly
higher urinary E. coli resistance to ciprofloxacin. Similar
findings were reported by Cullen et al. in Dublin [16].
This is not an unusual finding and may be attributed to
the selective pressure resulting from antimicrobial use in
hospital settings [47]. Patients in hospital, already acutely
ill, become more at risk of developing a resistant infec-
tion because of potential immune deficiency and relative
high exposure to antimicrobial agents [48]. Furthermore,
hospitalized patients are more likely to be exposed to
practices that result in cross infection or transmission of
organisms. These and other risk factors enable the
spread of resistance. This has significant implications for
patient care as antimicrobial resistance may lead to
treatment failure resulting in death.
The results of our systematic review showed a signifi-
cant rise in resistance over time in the community set-
ting. This finding is supported by a number of US-based
studies investigating antimicrobial resistance trend in
outpatients. A fivefold increase (from 3 to 17.1 %) in cip-
rofloxacin resistance was observed from 2000 to 2010 by
Sanchez et al. [17] in comparison with other antibiotics
investigated [49]. Our findings are also consistent with
Blaettler et al. [6] who found that over a 10 year period
(1997–2007), similar to the timeframe for our review, re-
sistance increased significantly for ciprofloxacin from 1.8
to 15.9 % in Switzerland. This increase coincided with a
rise in ciprofloxacin use in Switzerland [6]. These find-
ings suggest that with increase in the use of fluoroquino-
lones generally over time, resistance ciprofloxacin is
likely to further increase. It is now known that anti-
microbial overuse or misuse is a risk factor for the devel-
opment of AMR [50]. The specific effect of ciprofloxacin
use on the development of its resistance in UTI patho-
gens is also clearly documented. A recent Irish study in-
volving 72 general practices found higher ciprofloxacin
resistance levels (5.5 %) in practices with 10 prescrip-
tions per month compared with resistance levels of 3 %
in practices with one prescription per month [51]. Wide
spread use of this agent may have thus resulted in a rise in
ciprofloxacin resistance. In the Netherlands and United
States, an association has also been shown between high
Table 2 Subgroup analyses of pooled ciprofloxacin resistance in community setting
Subgroup Community Setting N = 51 P value*
Pooled resistance
Risk of bias Low and unclear n = 28 studies 0.221 <0.0001
High n = 23 studies 0.337
Study durationa ≤12 monthsn = 25 studies 0.323 <0.0001
>12 monthsn = 24 studies 0.219
Economy Developedn = 16 studies 0.141 <0.0001
Developingn = 35 studies 0.345
Region Africa, Asia and Middle Eastn = 29 studies 0.361 <0.0001
Europe, North and South American = 22 studies 0.174
Age groupa Adults and children bn = 24 studies 0.265 <0.0001
Adults onlyn = 19 studies 0.302
UTI symptoms Symptomatic and asymptomatic patients n = 11 studies 0.185 <0.0001
Symptomatic patients only n = 40 studies 0.295
n = number of studies reporting on community acquired UTI
*Comparing pooled resistance for difference in subgroup in community setting
aStudies with missing information on this sub-analysis were not included
bStudies reporting resistance in adults and children or children only
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fluoroquinolone prescriptions and a rise in bacterial resist-
ance [52, 53]. Furthermore, changes in antimicrobial pre-
scribing practices have been shown to precede changes in
resistance rates. A study by Gottesman et al. [54] in Israel
found a significant decrease in E. coli resistance to cipro-
floxacin following a nationwide restriction on cipro-
floxacin use. Resistance decreased from 12 % in the
pre-intervention period to 9 % in the intervention period.
Our results pose a strong argument for the development
of more stringent criteria limiting ciprofloxacin use. In
addition, other strategies such as adequate surveillance
and monitoring, reinforcement of existing infection pre-
vention and control measures as well as new technological
advancement will help reduce the widespread problem of
antimicrobial resistance [55–57] but these aspects are not
within the scope of this paper.
Our finding of a significant rise in resistance over time
also has implications for the development of treatment
guidelines. The national recommendations for first-choice
empiric antibiotic treatment of UTIs vary considerably [5].
In countries like Spain, Taiwan and Turkey, the treatment
choice for uncomplicated UTIs are fluoroquinolones [5, 58,
59]. In 2000, fluoroquinolones were prescribed for treat-
ment of uncomplicated UTIs in Switzerland in 64 % of
cases [60]. There is concern that resistance to ciprofloxacin
resulting from its first-line use may be associated with an
increase in multidrug resistance [61]. The most recent IDSA
guidelines [9] advise using nitrofurantoin, trimethoprim-
sulphamethoxazole, fosfomycin or pivmecillinam for
first-line treatment of acute uncomplicated cystitis. Fluor-
oquinolones should be reserved for important uses other
than acute cystitis or used as an alternative only when
these recommended agents cannot be used [9]. We rec-
ommend that ciprofloxacin should not be used as a first
line treatment option for UTIs as continuous increases in
resistance to ciprofloxacin further weaken the effective-
ness of this drug.
Additional findings from the meta-analysis showed that
resistance was significantly higher in developing countries
compared to developed countries. A major factor account-
ing for this difference is the use of over the counter or
non-prescription antibiotics which occur commonly in de-
veloping countries [62, 63]. Although this review did not
directly consider antimicrobial resistance in relation to pre-
scribing for the included studies, evidence shows that over
the counter or non-prescription use results in unnecessary
and excessive use of antibiotics. Some of the included stud-
ies in our review clearly state that there are no restrictions
for over the counter prescribing of antimicrobials within
their countries [29, 64–73]. A recent systematic review in-
vestigating global non-prescription antimicrobial use found
that resistance was common in communities with frequent
non-prescription antimicrobial use [74]. Non-prescription
use was highest in Africa, Asia and Middle East at 100, 58
and 39 % respectively [74]. In our review, further analyses
by region showed that Asia had the highest pooled resist-
ance to ciprofloxacin with a significantly higher resistance
in Africa, Asia and Middle East combined compared with
Europe and the Americas. Our finding is supported by a
recent paper by Dalhoff [75] reporting that fluoroquino-
lone resistance was highest in the Asia-Pacific region and
moderate to low in Europe and North America. Further-
more, there is evidence to show that countries that have
developed control policies to regulate non-prescription use
have seen a decrease in antimicrobial use and resistance
rates [74]. Based on our findings, we therefore emphasize
the need for the development of policies restricting over
the counter antimicrobial use in countries that do not have
such policies thereby contributing to the prevention of
patient morbidity and mortality associated with resistant
infections. It is noteworthy to mention that another im-
portant factor contributing to antimicrobial resistance is
the use of antibiotics in livestock for growth promotion
[76]. Extensive antimicrobial use in food animal produc-
tion has been associated with antimicrobial resistance glo-
bally [76]. This has considerable implications for human
health with the need to protect the efficacy of these antimi-
crobials to ensure their effectiveness for the treatment of
humans.
A large variation in ciprofloxacin resistance was found
in studies reporting on community-acquired UTI. This
variation highlights the significance of local resistance
monitoring to guide the development of local antibiotic
guidelines. The random effects meta-regression model
confirmed that a number of factors significantly accounted
for the variations in ciprofloxacin resistance. These in-
clude economy (developed and developing), Asia as a re-
gion, year of study, studies including only children and
studies with a high risk of bias. The first three factors have
been discussed in detail in the preceding paragraphs. We
found that resistance was lower in studies involving only
children. This finding is in line with a number of studies
which have compared resistance in adults and children
showing significantly higher ciprofloxacin resistance in
adults compared to children [77, 78]. Increased age has
also been shown to be significantly associated with cipro-
floxacin resistance [6, 47]. Given that children are less ex-
posed to antimicrobials with limited ciprofloxacin use in
the paediatric age group, this finding is expected [77–79].
Although the importance of intrafamilial cross-infection
of resistant pathogens is yet to be confirmed, it has been
suggested that fluoroquinolone resistance may to some
extent be dependent on cross-infection with transfer from
adults to children [78]. Given this assumption, it is neces-
sary to also monitor resistance levels in children to pre-
vent further resistance development in this vulnerable age
group. Other likely causes of higher resistance in adults
may be the greater likelihood of comorbidities with more
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frequent contact with healthcare settings [47]. The last
factor found to account for heterogeneity between studies
was high risk of bias. Most of the studies included in the
review were found to have a high risk of bias as assessed
using the NOS scale. These studies lacked methodological
rigour including absence of the inclusion of possible con-
founding factors (such as age, sex and previous use of an
antimicrobial) in the design and analysis of the studies.
The poor reporting of observational studies poses limita-
tions for conducting meta-analysis of these studies. Better
presentation of definitions would enable inclusion in sys-
tematic reviews of some categories that had to be ex-
cluded in this review. Observational studies are more
prone to confounding bias [80] further emphasizing the
need for adherence to reporting guidelines such as such as
that based on the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) Statement
[81] to ensure clear and comprehensive reporting prior to
publication acceptance. The poor quality of many studies
initially retrieved for this review resulted in a large num-
ber being excluded. Therefore the information provided in
this systematic review and meta-analysis of 54 observa-
tional studies may not sufficiently address ciprofloxacin
resistance globally but may provide satisfactory evidence
to inform future interventions.
In addition, this systematic review highlights the weak-
nesses in the quality of antimicrobial resistance data that
are being collected in various regions. These weaknesses
have implications for development of effective surveil-
lance systems to monitor resistance globally and strat-
egies to prevent further resistance development. The
need for the implementation of national and global sur-
veillance systems to detect and continuously monitor
AMR cannot be overemphasized. These systems would
enable prospective studies to be conducted and would
play a major role in curtailing the widespread effect of
antimicrobial resistance and help healthcare providers in
deciding on the most appropriate empirical therapy for
UTI to ensure proper management of patients. Govern-
ments need to put in place policies to restrict over the
counter use and inappropriate prescribing of ciprofloxa-
cin and other antimicrobials to prevent further develop-
ment of resistance.
Strengths and limitations
There are a number of notable strengths to our review.
To our knowledge, this is the first systematic review to
compare the overall prevalence of ciprofloxacin resist-
ance in community- and hospital-acquired E. coli UTI.
We undertook a comprehensive literature search process
to identify and screen articles against eligibility criteria.
Given that generic versions of ciprofloxacin were first
marketed at different times in various countries, our
choice of 2004 as the start date was therefore made on
the basis of changes in the epidemiology of antimicrobial
resistant pathogens which had resulted in changes to
treatment regimens. A further strength of this systematic
review is the development of a peer reviewed, registered
protocol prior to undertaking the review. For studies to
be included in the review, they were restricted to those that
used a standard laboratory UTI criterion of ≥105 cfu/mL as
recommended by the CDC. Although applying the inter-
nationally recognised CDC criteria may definitely be con-
sidered a strength as it ensures the quality and uniformity
of included studies, this criterion limited the number of
hospital-acquired UTI studies included in our systematic
review. Despite this, resistance was still found to be higher
in the hospital setting compared to the community setting
similar to published studies. While lower counts of uro-
pathogens are relevant for acute episodes of uncomplicated
cystitis, the use of different colony counts makes compari-
son of data between studies difficult. Including all urinary
E.coli isolates was considered but not done because this
existing surveillance criterion (≥105 cfu/mL and 48 h cut
off) is usually applied to defining infections not isolates.
Also, including all isolates carries the risk of including du-
plicates. This approach poses some degree of ascertainment
bias as our systematic review focuses on laboratory identi-
fied UTIs which may not only underestimate the total
number of UTIs but also lead to selection of samples from
complicated cases thereby overestimating resistance. An-
other limitation is the wide variation of resistance estimates
between studies and the inclusion of studies having sub-
stantial clinical and methodological heterogeneity. Visual
inspection of the funnel plot (Fig. 6) showed asymmetry
suggesting evidence of publication bias, with studies report-
ing high resistance rates being more likely to be published
posing a limitation to this review. Also, the quality and risk
of bias of some of the studies included in the review
were assessed as high. These limitations were addressed
by undertaking a random effects meta-analysis with subse-
quent subgroup analyses and random effects meta-
regression to explain the sources of heterogeneity. For
studies in which the design was not stated, the review au-
thors faced difficulties in categorising such studies hence
some of these studies were grouped as non-classifiable.
These studies did not provide clear and explicit informa-
tion on the methods used for conducting the studies. This
emphasizes the need for implementation and adherence
to clear reporting standards prior to publication of papers.
Furthermore, in some included studies, adjustments were
not made for important confounding factors relevant to
antimicrobial resistance such as antibiotic use and patient
demographics including age and sex. For this systematic
review, studies on samples obtained from emergency de-
partment (ED) patients were classified as community-
acquired samples. Included papers did not provide any in-
formation on whether some of these patients may have
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returned from a recent hospitalisation and represented to
the ED. Ideally, these should be considered as hospital-
acquired infections as some of these patients may have
been discharged in the previous 48 h. For the purpose of
this review and to overcome inherent variations in how in-
dividual studies have defined these patients, we classified
all papers reporting on ED patients as community-
acquired UTI studies. It was not possible to determine the
potential effect of samples obtained from nursing home or
residential aged care studies on the pooled resistance be-
cause this participant group did not meet the inclusion
criteria for analysis. Furthermore, classification of this set-
ting as hospital or community remains controversial. Fi-
nally, validity issues may have arisen from the use of
different antimicrobial susceptibility test and interpret-
ation methods with differing breakpoints which tend to
change over the years. To date, there is still no worldwide
consensus on the most suitable antimicrobial susceptibil-
ity testing method with the fact that various countries and
even laboratories within the same country use different
tests and interpretative criteria. Subgroup analysis for
AST method was considered but not done because almost
all studies used the disk diffusion method and CLSI
criteria.
Conclusions
Ciprofloxacin resistance in E. coli UTI is increasing. The
use of this antimicrobial agent as empirical therapy for
UTI should be reconsidered and efforts should be made to
limit its use to clinical conditions for which there are clear
therapeutic indications. Policy restrictions on ciprofloxacin
use need to be developed and enforced especially in devel-
oping countries that are yet to have such policies put in
place. Further research is needed to describe ciprofloxacin
resistance in hospital-acquired E. coli UTI using widely ac-
cepted definitions.
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Abstract
This study describes the antimicrobial resistance temporal trends and seasonal variation of
Escherichia coli (E. coli) urinary tract infections (UTIs) over five years, from 2009 to 2013,
and compares prevalence of resistance in hospital- and community-acquired E. coli UTI. A
cross sectional study of E. coli UTIs from patients attending a tertiary referral hospital in
Canberra, Australia was undertaken. Time series analysis was performed to illustrate resis-
tance trends. Only the first positive E. coli UTI per patient per year was included in the anal-
ysis. A total of 15,022 positive cultures from 8724 patients were identified. Results are
based on 5333 first E. coli UTIs, from 4732 patients, of which 84.2% were community-
acquired. Five-year hospital and community resistance rates were highest for ampicillin
(41.9%) and trimethoprim (20.7%). Resistance was lowest for meropenem (0.0%), nitrofur-
antoin (2.7%), piperacillin-tazobactam (2.9%) and ciprofloxacin (6.5%). Resistance to
amoxycillin-clavulanate, cefazolin, gentamicin and piperacillin-tazobactam were signifi-
cantly higher in hospital- compared to community-acquired UTIs (9.3% versus 6.2%;
15.4% versus 9.7%; 5.2% versus 3.7% and 5.2% versus 2.5%, respectively). Trend analy-
sis showed significant increases in resistance over five years for amoxycillin-clavulanate,
trimethoprim, ciprofloxacin, nitrofurantoin, trimethoprim-sulphamethoxazole, cefazolin, cef-
triaxone and gentamicin (P<0.05, for all) with seasonal pattern observed for trimethoprim
resistance (augmented Dickey-Fuller statistic = 4.136; P = 0.006). An association between
ciprofloxacin resistance, cefazolin resistance and ceftriaxone resistance with older age was
noted. Given the relatively high resistance rates for ampicillin and trimethoprim, these anti-
microbials should be reconsidered for empirical treatment of UTIs in this patient population.
Our findings have important implications for UTI treatment based on setting of acquisition.
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Introduction
Urinary tract infections (UTIs) are predominantly bacterial infections affecting people both in
the community and in hospitals [1]. Over 80% are caused by Escherichia coli (E. coli), a Gram
negative bacillus [2]. Data from the combined National Ambulatory Health Care Surveys in
the United States (US) for 2009–2010 showed that UTIs accounted for approximately 9.8 mil-
lion visits to ambulatory care settings such as primary care, outpatient and emergency depart-
ments [3]. Visits due to UTI were estimated to be 0.8% of all ambulatory care visits [3]. In
Australia, national data on UTI are unavailable but recent estimates from 82 hospitals and 17
aged care facilities reported a point prevalence of 1.4% and 1.5% respectively for healthcare
associatedUTIs [4].
While UTIs are a major infection burden globally, the growing problem of antimicrobial
resistance (AMR) can result in treatment failures and increased cost of healthcare [5]. There is
evidence to show that the AMR pattern of urinary E. coli is increasing [6]. In Switzerland, an
analysis of urinaryE. coli specimens obtained from a university hospital from 1997 to 2007
found an increasing trend in resistance to trimethoprim/sulfamethoxazole, ciprofloxacin and
amoxycillin/clavulanic acid (from 17.4% to 21.3%, 1.8% to 15.9%, and 9.5% to 14.5%, respec-
tively) [6]. The Australian Group on Antimicrobial Resistance (AGAR) which undertakes
AMR prevalence surveyswithin Australia also noted a gradual rise in overall percentage of E.
coli strains resistant to beta-lactam antibiotics and ciprofloxacin [7]. From 2009 to 2011, resis-
tance of hospital-onset E. coli isolates to ampicillin and ciprofloxacin increased from 48% to
51% and 8% to 11% respectively [7]. Furthermore, the resistance rates of urinaryE. coli to vari-
ous antimicrobials show large inter-country variability [8]. Only a few studies have shown that
E. coli resistance rates differ for hospital-acquired and community-acquired UTIs [9–11]. Mea-
suring and comparing the levels of AMR in both hospital- and community-acquired UTIs is
essential because although effects of AMR are mainly felt in healthcare facilities, the greatest
use of antimicrobials occurs in the community [12]. Comparing resistance rates in hospital-
and community-acquired UTIs may influence therapeutic recommendations for UTIs based
on setting of acquisition.
The prevalence of AMR including hospital and community urinaryE. coli resistance levels
is not completely known in Australia. Obtaining this information is important because it not
only provides knowledge about the health status of a population, but also contributes to disease
management decisions [13]. This study describes the AMR temporal trends and seasonal varia-
tion of E. coli UTI over five years at an Australian tertiary hospital. The study also compares
the prevalence of resistance between hospital- and community-acquired E. coli UTIs.
Materials and Methods
Study design and setting
A retrospective cross sectional design was used. The study was conducted with data from ACT
Pathology which is based at a tertiary referral hospital, the CanberraHospital and Health Ser-
vices. This is Australian Capital Territory’s (ACT) main hospital which provides acute and spe-
cialist care services to over 600,000 people in the surrounding region. The 600 bed publicly-
funded hospital which includes an emergency department and intensive care unit, offers a
comprehensive range of health services such as acute inpatient and day services, outpatient ser-
vices, women's and children's services and pathology services. Solid organ transplant services
are not offered in Canberra.
Human research ethics approval was granted by ACT Health Human Research Ethics Com-
mittee’s Low Risk Sub-Committee and Australian Catholic University Human Research Ethics
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Committee. Consent from patients was not obtained as a waiver of consent was granted by the
ethics committees.
Urine sample and data collection
The microbiology records of inpatients and those attending CanberraHospital who had urine
samples processed at ACT Pathology from January 2009 to December 2013 were retrospec-
tively reviewed.Demographic data and clinical information such as date of birth, gender,
admission date, specimen collection date and antimicrobial susceptibility test result were
obtained from the microbiology laboratory database and administrative record system.
Bacterial isolation and identification
Urine samples were analysed and processed based on the microbiology laboratory standards
[14]. For this study, a culture with presence of107 colony forming unit (cfu) per litre of urine
was considered positive for UTI based on the laboratory recommendations. This 107 cfu/L cut-
off is commonly used as it increases the sensitivity of the urine culture test making it a practical
threshold [15]. The criterion has also been used by several studies reporting on antimicrobial
resistance of urinaryE. coli [1,16,17]. Cultures with three or more bacterial species isolated
were considered contaminated and excluded. Only the first positive E. coli UTI per patient per
year was included in the final analysis.
Definitions
Urine cultures were classified based on the setting of acquisition of infection (hospital-acquired
and community-acquired, also known as hospital-onset and community-onset) using criteria
from the Centers for Disease Control and Prevention definitions [18]. Positive E. coli urine cul-
tures obtained within the first 48 hours of admission (including cultures from non-admissions
such as outpatient clinics) were defined as community-acquired UTIs. Positive cultures
obtainedmore than 48 hours after admission and within 48 hours of discharge were defined as
hospital-acquired UTIs.
Antimicrobial susceptibility testing
Antimicrobial susceptibility was performedby a disc diffusionmethod and the automated min-
imum inhibitory concentration (MIC) method using Vitek2 (BiomerieuxDiagnostics). Inter-
pretation was based on Clinical Laboratory Standard Institute (CLSI, formerly NCCLS) criteria
[19]. Based on a stepwise laboratory testing protocol used during the study period, all signifi-
cant E. coli (>107cfu/L) isolated after overnight incubation on culture had disc susceptibility
testing done. The antibiotic discs used for these tests were ampicillin (10μg), amoxycillin-clavu-
lanate (augmentin) (30μg), cephalexin/cefazolin (30 μg), trimethoprim (5μg), nalidixic acid
(30 μg), ciprofloxacin (5 μg), nitrofurantoin (300 μg) and gentamicin (10μg). The isolates
which were found to be resistant to at least three of the routinely tested antibiotics were then
sent for Vitek2 testing to determine the MICs for ceftriaxone, trimethoprim-sulphamethoxa-
zole, meropenem and piperacillin-tazobactamin addition to the routinely tested antibiotics.
Direct susceptibility testing method on urine specimens for E. coli has been validated at ACT
Pathology and is comparable to the CLSI recommendedmethods.
The quality control strains used for disc diffusion tests were E. coli ATCC 25922, E. faecalis
ATCC 29212 and for Vitek E. coli ATCC 25922, P. aeruginosa ATCC 27853, E. faecalis ATCC
29212, S. aureus ATCC 29213.
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Extended spectrum beta lactamase (ESBL) confirmation
Detection of ESBL-producing isolates was performedwith combination discs of cefotaxime
(30μg), cefotaxime/clavulanic acid (30/10μg), ceftazidime (30μg) and ceftazidime/clavulanic
acid (30/10μg) whenever required according to CLSI guidelines [15]. Extended spectrumbeta
lactamase production was inferred when the zone diameter of the disc with clavulanate was
5mm larger than the disc without clavulanate for the same antibiotic. K. pneumoniae ATCC
700603 was used as the quality control strain.
Statistical analysis
The overall 5-year and yearly resistance rates of E. coli to the routinely tested first-line antimi-
crobials on over 4,000 isolates (ampicillin, amoxycillin-clavulanate, cephalexin/cefazolin, cipro-
floxacin, gentamicin, nalidixic acid, and trimethoprim)were calculated by dividing the number
of urinaryE. coli isolates resistant to each antimicrobial by the number of isolates tested against
an individual antimicrobial agent. For the isolates which were sent for further susceptibility test-
ing on Vitek2 against second-line antimicrobials (ceftriaxone, trimethoprim-sulphamethoxa-
zole, meropenem, piperacillin-tazobactamand nitrofurantoin), the denominator used in
calculating the resistance rates was the total number of isolates included in the study. This
denominator was used based on the assumption that isolates were initially not tested for the
Vitek2 antibiotics because they were considered highly unlikely to be resistant to these antibiot-
ics. Hence in order not to overestimate the resistance rates of these isolates the denominator
included all isolates tested on both antibiotic discs and Vitek2. The binomial exact 95% confi-
dence intervals (CI) of the resistance percentages were calculated. The 5-year resistance rates
were compared for community- and hospital-acquired isolates. The chi-square test was used to
check for statistically significant differences in AMR between both groups. Mean differences in
age between the two groups were tested using Student’s t-tests. A time series analysis was per-
formed separately for all antimicrobials tested to identify patterns in resistance (trends and sea-
sonal variation) over the five year period. Seasonality is a pattern that shows periodic repetitive
fluctuations over time. An autoregressive (AR) model was constructed to assess time-varying
resistance patterns (i.e., resistance is non-stationary, or changing, over time) and multiple time
seriesmodels were fitted to also account for age and sex. The analysis on age and sex followed
an ecological study design because these variables were aggregated for each season. The Dickey-
Fuller (DF) and the augmented Dickey-Fuller (ADF) tests were used to assess a unit root in the
time series data. Both DF and ADF statistics are negative numbers; the more negative, the stron-
ger the rejection of the null hypothesis (that there is unit root at some level of confidence).
These unit root tests investigate whether a time series variable (e.g., resistance) is non-stationary
using the ARmodel [20]. Urinary E. coli isolates for which the antimicrobial showed an inter-
mediate susceptibility category (amoxycillin-clavulanate, trimethoprim, and ciprofloxacin) were
excluded from the final analysis. A significance level of P< 0.05 was used. Data were analysed
using STATA statistical software (version 13, StataCorp).
Results
A total of 106,512 urine samples from 47,727 patients attending CanberraHospital from 2009
to 2013 were processed by ACT Pathology. Of these, 14.1% (n = 15,022) had positive cultures
with E. coli being the most common organism isolated in 7670 (51.1%) samples. The distribu-
tion of samples by study year is shown in S1 Table.
Of the 7670 E. coli cultures, most (7103 isolates) could be further classified as community-
or hospital-acquired UTI based on available data. The data were then restricted to the first pos-
itive E. coli UTI per patient per year of which there were 5346 positive E. coli UTIs but only
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5333 had susceptibility test results. Hence 5333 E. coli UTIs belonging to 4732 patients in the
5-year periodwere included in the final analysis. The majority (84.2%, n = 4492) of UTIs were
classified as community-acquired and 15.8% (n = 841) as hospital-acquired. The mean age of
all patients was 57.0 years (SD = 27.5) and patients were mostly female (80.2%, n = 3795).
There was a significant difference in age between patients with hospital- and community-
acquired E. coli UTI (mean age 67.2 years versus 55.1 years, P<0.001) but no significant differ-
ences in gender.
Antimicrobial resistance
All 5333 isolates had routine susceptibility testing performed against first-line antimicrobials
and the overall 5-year and stratified (hospital- and community-acquired) AMR rates are sum-
marised in Table 1. Of the 5333 isolates, 1599 (29.9%) were sent for further antimicrobial sus-
ceptibility testing for second-line antimicrobials on Vitek2. The overall 5-year resistance rates
to these second-line antimicrobials are reported in Table 2.
The highest overall 5-year resistance rates to urinaryE. coli for both hospital and commu-
nity isolates combined were seen for ampicillin (41.9%; 95% CI = 40.6–43.3) and trimethoprim
(20.7%; 95% CI = 19.6–21.8). The lowest resistance rates were for meropenem (0.0%), nitrofur-
antoin (2.7%; 95% CI = 2.3–3.2) and piperacillin-tazobactam(2.9%; 95% CI = 2.5–3.4). Resis-
tance to amoxycillin-clavulanate, cephalexin/cefazolin, gentamicin and piperacillin-
tazobactamwas significantly higher in hospital- compared to community-acquired UTIs
(P<0.001, P<0.001, P = 0.043 and P = 0.002, respectively). For ampicillin, trimethoprim, nali-
dixic acid, ciprofloxacin, ceftriaxone and trimethoprim-sulphamethoxazole, resistance rates
were also higher for hospital- compared with community-acquired UTI but this did not reach
statistical significance (Fig 1).
Trend analysis showed a significant increase in resistance to amoxycillin-clavulanate, tri-
methoprim, ciprofloxacin, nitrofurantoin, trimethoprim-sulphamethoxazole, cefazolin, ceftri-
axone and gentamicin over the five year period (Fig 2). There was no significant increase in
resistance for ampicillin, nalidixic acid, meropenem and piperacillin-tazobactam.A seasonal
pattern was only observed for trimethoprim (ADF statistic = -4.136; P = 0.006) with higher
resistance rates for this antimicrobial seen in the summer months. Regression analysis indi-
cated an association between increasing age and resistance to ciprofloxacin (regression coeffi-
cient = 0.01; P = 0.004), cefazolin (regression coefficient= 0.004; P = 0.038) and ceftriaxone
(regression coefficient= 0.01; P = 0.002).
ESBL production
Overall 5-year prevalence of ESBL-producing E. coli isolates was 1.9% (95% CI = 1.5–2.3;
n = 100). Extended spectrumbeta-lactamase production was low by international standards
but was significantly higher in hospital-acquired (3.0%; 95% CI = 1.9–4.4; n = 25) compared
with community-acquired UTIs (1.7%; 95% CI = 1.3–2.1; n = 75, P = 0.01). The levels of ESBL-
producing E. coli increased from 0.7% (95% CI = 0.0–3.8) in hospital-acquired UTIs in 2009 to
6.5% (95% CI = 3.2–11.6) in 2013. An increase was also noted for community-acquired UTIs
(0.6%; 95% CI = 0.2–1.4 in 2009 to 3.7%; 95% CI = 2.5–5.3 in 2013). The increasing trend in
ESBL production over the five years was statistically significant for both hospital (P = 0.035)
and community-acquired UTIs (P<0.001).
Discussion
This study provides information about the AMR pattern of E. coli UTIs in an Australian ter-
tiary hospital. To our knowledge this is the first Australian study to compare AMR in
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Table 1. Resistance profile of urinary E. coli isolates sent for routine susceptibility testing from 2009 to 2013 by setting.
COMMUNITY HOSPITAL TOTAL
Antibiotic Year Number of
community
isolates tested
R n (%) 95% CI of
resistance
percentage
Number of
hospital
isolates
tested
R n (%) 95% CI of
resistance
percentage
Total
number of
isolates
tested*
R n (%) 95% CI of
resistance
percentage
Ampicillin 2009 835 331 (39.6) 36.3–43.1 143 71 (49.7) 41.2–58.1 978 402 (41.1) 38.0–44.3
2010 897 358 (39.9) 36.7–43.2 182 70 (38.5) 31.4–45.9 1079 428 (39.7) 36.7–42.7
2011 1037 443 (42.7) 39.7–45.8 189 91 (48.2) 40.8–55.5 1226 534 (43.6) 40.8–46.4
2012 939 412 (43.9) 40.7–47.1 173 74 (42.8) 35.3–50.5 1112 486 (43.7) 40.8–46.7
2013 784 315 (40.2) 36.7–43.7 154 71 (46.1) 38.1–54.3 938 386 (41.2) 38.0–44.4
Total 4492 1859
(41.4)
39.9–42.8 841 377
(44.8)
41.4–48.3 5333 2236
(41.9)
40.6–43.3
AMC 2009 785 24 (3.1) 2.0–4.5 133 6 (4.5) 1.7–9.6 918 30 (3.3) 2.2–4.6
2010 832 49 (5.9) 4.4–7.7 172 11 (6.4) 3.2–11.2 1004 60 (6.0) 4.6–7.6
2011 981 61 (6.2) 4.8–7.9 170 17 (10.0) 5.9–15.5 1151 78 (6.8) 5.4–8.4
2012 895 71 (7.9) 6.2–9.8 161 19 (11.8) 7.3–17.8 1055 89 (8.4) 6.8–10.3
2013 754 58 (7.7) 5.9–9.8 145 23 (15.9) 10.3–22.8 899 81 (9.0) 7.2–11.1
Total 4247 263 (6.2) 5.5–6.9 781 76 (9.3) 7.7–12.0 5027 338 (6.7) 6.0–7.5
Cefazolin 2009 821 60 (7.3) 5.6–9.3 129 14 (10.9) 6.1–17.5 950 74 (7.8) 6.2–9.7
2010 885 96 (10.9) 8.9–13.1 179 24 (13.4) 8.8–19.3 1064 120 (11.3) 9.4–13.3
2011 1019 103 (10.1) 8.3–12.1 178 30 (16.9) 11.7–23.2 1197 133 (11.1) 9.4–13.0
2012 917 82 (8.9) 7.2–11.0 168 26 (15.5) 10.4–21.8 1085 108 (10.0) 8.2–11.9
2013 776 89 (11.5) 9.3–13.9 151 30 (19.9) 13.8–27.1 927 119 (12.8) 10.8–15.2
Total 4418 430 (9.7) 8.9–10.6 805 124
(15.4)
13.0–18.1 5223 554 (10.6) 9.8–11.5
Trimethoprim 2009 830 153 (18.4) 15.9–21.2 143 28 (19.6) 13.4–27.0 973 181 (18.6) 16.2–21.2
2010 897 172 (19.2) 16.6–21.9 181 33 (18.2) 12.9–24.6 1078 205 (19.0) 16.7–21.5
2011 1036 217 (20.9) 18.5–23.6 189 42 (22.2) 16.5–28.8 1225 259 (21.1) 18.9–23.5
2012 939 200 (21.3) 18.7–24.1 173 40 (23.1) 17.1–30.1 1112 240 (21.6) 19.2–24.1
2013 784 181 (23.1) 20.2–26.2 154 36 (23.4) 16.9–30.9 938 217 (23.1) 20.5–26.0
Total 4486 923 (20.6) 19.4–21.8 840 179
(21.3)
18.6–24.2 5326 1102
(20.7)
19.6–21.8
Nalidixic acid 2009 826 63 (7.6) 5.9–9.7 143 12 (8.4) 4.4–14.2 969 75 (7.7) 6.1–9.6
2010 892 73 (8.2) 6.5–10.2 182 12 (6.6) 3.5–11.2 1074 85 (7.9) 6.4–9.7
2011 1034 109 (10.5) 8.7–12.6 188 22 (11.7) 7.5–17.2 1222 131 (10.7) 9.0–12.6
2012 755 56 (7.4) 5.7–9.5 140 17 (12.1) 7.2–18.7 895 73 (8.2) 6.4–10.1
2013 585 33 (5.6) 3.9–7.8 103 11 (10.7) 5.5–18.3 688 44 (6.4) 4.7–8.5
Total 4092 334 (8.2) 7.3–9.0 756 74 (9.8) 7.8–12.1 4848 408 (8.4) 7.6–9.2
Ciprofloxacin 2009 808 33 (4.1) 2.8–5.7 139 7 (5.0) 2.0–10.1 947 40 (4.2) 3.0–5.7
2010 701 35 (5.0) 3.5–6.9 150 4 (2.7) 0.7–6.7 851 39 (4.6) 3.3–6.2
2011 795 52 (6.5) 4.9–8.5 156 10 (6.4) 3.1–11.5 951 62 (6.5) 5.0–8.3
2012 749 56 (7.5) 5.7–9.6 143 11 (7.7) 3.9–13.3 892 67 (7.5) 5.9–9.4
2013 631 60 (9.5) 7.3–12.1 135 17 (12.6) 7.5–19.4 766 77 (10.1) 8.0–12.4
Total 3684 236 (6.4) 5.6–7.2 723 49 (6.8) 5.1–8.9 4407 285 (6.5) 5.8–7.2
Gentamicin 2009 514 17 (3.3) 1.9–5.2 85 5 (5.9) 1.9–13.2 599 22 (3.7) 2.3–5.5
2010 893 23 (2.6) 1.6–3.8 182 2 (1.1) 0.1–3.9 1075 25 (2.3) 1.5–3.4
2011 1036 38 (3.7) 2.6–5.0 189 12 (6.4) 3.3–10.8 1225 50 (4.1) 3.0–5.3
2012 931 40 (4.3) 3.1–5.8 172 12 (7.0) 3.7–11.9 1102 52 (4.7) 3.5–6.1
2013 783 36 (4.6) 3.2–6.3 154 10 (6.5) 3.2–11.6 937 46 (4.9) 3.6–6.5
(Continued )
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hospital- and community-acquired E. coli UTI and assess AMR temporal trends and seasonal
variation of E. coli UTI over time. Our results showed that overall resistance was highest for
ampicillin and trimethoprim.We also found significantly higher resistance rates in hospital-
compared to community-acquired UTIs for amoxycillin-clavulanate, cephalexin/cefazolin,
gentamicin and piperacillin-tazobactamwith an increasing resistance trend for eight of the
twelve antimicrobials tested which include the four commonly used antimicrobials for first
line treatment of UTI in Australia.
In Australia, trimethoprim, cephalexin, amoxycillin-clavulanate or nitrofurantoin are recom-
mended for first line treatment of UTI [21]. The Infectious Diseases Society of America (IDSA)
and European Society for Microbiology and Infectious Diseases recommend trimethoprim-sul-
phamethoxazole as an appropriate treatment choice if local resistance rates do not exceed 20%.
The IDSA guidelines also recommend that amoxycillin or ampicillin should not be used alone
for empirical treatment because of the relatively poor efficacy and the relatively high prevalence
of AMR to these agents worldwide [22]. Given the high levels of resistance to ampicillin and tri-
methoprim identified in this study, the appropriateness of these antimicrobials in the manage-
ment of UTI in this patient population should be assessed. The IDSA suggests that beta-lactam
agents, including amoxycillin-clavulanate are appropriate choices for therapy when other rec-
ommended agents cannot be used [22]. Based on our findings, the majority of UTIs have very
low resistance to amoxycillin-clavulanate and nitrofurantoin which are commonly used for UTI
treatment in Canberra. Ciprofloxacin, which is recommended in Australia for complicated
UTIs, was also found to have a low resistance rate. Through the national pharmaceutical subsidy
scheme, the use of quinolones in humans has been restricted in Australia. Quinolone use in
food-producing animals is also not permitted. Therefore, fluoroquinolone resistance in the com-
munity has been slow to emerge and has remained at low levels in important pathogens such as
E. coli compared to most countries [23]. Our overall resistance rates are also generally lower
than reported for other single site studies [9,24], demonstrating that resistance may vary geo-
graphically, as shown in a recent meta-analysis [25]. The explanation for the varying resistance
rates is not clearly understood but possible reasons have been postulated. A study conducted in
the United States demonstrated a geographic gradient in resistance with the highest resistance
rates noted in the Pacific region and lowest rates in the South Atlantic region [26]. It was sug-
gested that geographic clustering of resistance phenotypes may have accounted for the geo-
graphic differences in resistance. It is therefore possible that the lower rates we found in
comparison to those reported for other single site studies may be due to lower levels of bacteria
with resistance phenotypes in our locality. Another possible suggestion for geographic variation
Table 1. (Continued)
COMMUNITY HOSPITAL TOTAL
Antibiotic Year Number of
community
isolates tested
R n (%) 95% CI of
resistance
percentage
Number of
hospital
isolates
tested
R n (%) 95% CI of
resistance
percentage
Total
number of
isolates
tested*
R n (%) 95% CI of
resistance
percentage
Total 4157 154 (3.7) 3.2–4.3 782 41 (5.2) 3.8–7.0 4938 195 (3.9) 3.4–4.5
*Note that not all 5333 isolates were tested against each antimicrobial. Isolates not tested: AMC = 3; Cephazolin = 110; Trimethoprim = 3; Nalidixic
acid = 485; Ciprofloxacin = 893; Gentamicin = 395
Number of isolates with intermediate susceptibility to an antimicrobial: AMC = 303; Trimethoprim = 4; Ciprofloxacin = 33
R = Resistant
n = Number of isolates
AMC = Amoxycillin-clavulanate; TMP-SMX = Trimethoprim-sulphamethoxazole
doi:10.1371/journal.pone.0164306.t001
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in resistance is the differences in antimicrobial use [26,27]. Several studies have demonstrated
an association between antimicrobial use and resistance [28–30]. Hence it is probable that the
lower resistance noted may be as a result of lower antimicrobial use resulting in lower antimi-
crobial selection pressure. This emphasizes the need for continuous local monitoring of resis-
tance patterns to ensure appropriate treatment for people in the locality.
The sample size of the data was able to detect some significant differences between com-
munity- and hospital-acquired UTI resistance rates but for some antimicrobials the differ-
ences observed could not be confirmed statistically, possibly due to an insufficient sample
size. Overall, we found lower rates of antibiotic resistance for community- compared with
Table 2. Resistance profile of urinary E. coli isolates sent for further testing on Vitek2 from 2009 to 2013 by setting.
Year Setting N Antibiotic
Ceftriaxone TMP-SMX MER PIT NIT
R n (%) 95% CI of
resistance
percentage
R n (%) 95% CI of
resistance
percentage
R n
(%)
95% CI of
resistance
percentage
R n
(%)
95% CI of
resistance
percentage
R n (%) 95% CI of
resistance
percentage
2009 CA 835 12 (1.4) 0.7–2.5 58 (6.9) 5.3–8.9 0 (0.0) - 2 (0.2) 0.0–0.9 14 (1.7) 0.9–2.8
HA 143 2 (1.4) 0.2–5.0 12 (8.4) 4.4–14.2 0 (0.0) - 0 (0.0) - 4 (2.8) 0.8–7.0
Total 978 14 (1.4) 0.8–2.4 70 (7.2) 5.6–9.0 0 (0.0) - 2 (0.2) 0.0–0.7 18 (1.8) 1.1–2.9
2010 CA 897 22 (2.5) 1.5–3.7 76 (8.5) 6.7–10.5 0 (0.0) - 27
(3.0)
2.0–4.3 15 (1.7) 0.9–2.7
HA 182 4 (2.2) 0.6–5.5 11 (6.0) 3.1–10.6 0 (0.0) - 4 (2.2) 0.6–5.5 5 (2.7) 0.9–6.3
Total 1079 26 (2.4) 1.6–3.5 87 (8.1) 6.5–9.9 0 (0.0) - 31
(2.9)
2.0–4.1 20 (1.9) 1.1–2.8
2011 CA 1037 46 (4.4) 3.3–5.9 99 (9.5) 7.8–11.5 0 (0.0) - 19
(1.8)
1.1–2.8 17 (1.6) 1.0–2.6
HA 189 13 (6.9) 3.7–11.5 30 (15.9) 11.0–21.9 0 (0.0) - 9 (4.8) 2.2–8.8 3 (1.6) 0.3–4.6
Total 1226 59 (4.8) 3.7–6.2 129 (10.5) 8.9–12.4 0 (0.0) - 28
(2.3)
1.5–3.3 20 (1.6) 1.0–2.5
2012 CA 939 43 (4.6) 3.3–6.1 102 (10.9) 8.9–13.0 1 (0.1) 0.0–0.6 33
(3.5)
2.4–4.9 35 (3.7) 2.6–5.1
HA 173 13 (7.5) 4.1–12.5 22 (12.7) 8.1–18.6 0 (0.0) - 15
(8.7)
4.9–13.9 5 (2.9) 0.9–6.6
Total 1112 56 (5.0) 3.8–6.5 124 (11.1) 9.4–13.1 1 (0.1) 0.0–0.5 48
(4.3)
3.2–5.7 40 (3.6) 2.6–4.9
2013 CA 784 45 (5.7) 4.2–7.6 87 (11.1) 9.0–13.5 0 (0.0) - 30
(3.8)
2.6–5.4 42 (5.4) 3.9–7.2
HA 154 15 (9.7) 5.6–15.6 25 (16.2) 10.8–23.0 0 (0.0) - 16
(10.4)
6.1–16.3 4 (2.6) 0.7–6.5
Total 938 60 (6.4) 4.9–8.2 112 (11.9) 9.9–14.2 0 (0.0) - 46
(4.9)
3.6–6.5 46 (4.9) 3.6–6.5
Total CA 4492 168
(3.7)
3.2–4.3 422 (9.4) 8.6–10.3 1 (0.0) 0.0–0.1 111
(2.5)
2.0–3.0 123
(2.7)
2.3–3.3
HA 841 47 (5.6) 4.1–7.4 100 (11.9) 9.8–14.3 0 (0.0) - 44
(5.2)
3.8–7.0 21 (2.5) 1.6–3.8
Total 5333 215
(4.0)
3.5–4.6 522 (9.8) 9.0–10.6 1 (0.0) 0.0–0.1 155
(2.9)
2.5–3.4 144
(2.7)
2.3–3.2
R = Resistant
N = Number of isolates tested
CA = Community isolates; HA = Hospital isolates
TMP-SMX = Trimethoprim-sulphamethoxazole; MER = Meropenem; PIT = Piperacillin-tazobactam; NIT = Nitrofurantoin
doi:10.1371/journal.pone.0164306.t002
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hospital-acquired E. coli UTIs, consistent with other studies [9,31]. The difference in resis-
tance rates is however only small and supports the view that E. coli, a bacterium carried in
the bowel and acquired in the community, is brought into hospital usually by patients them-
selves rather than being hospital-acquired. This findingmay also have been partially dictated
by our methodology from using the first positive UTI per person per year. The different
resistance rates for hospital- and community-acquired urinary E. coli isolates seen in this
study are comparable with findings reported previously [10,11]. Similar results have been
seen in blood culture isolates of E. coli in Canberra [32]. While the difference in resistance
rates was not large and most antimicrobial use occurs in the community, the proportion of
patients receiving antimicrobials is much higher in the hospital and hence explains the dif-
ference seen [33]. We agree with recommendations that to accurately represent E. coli resis-
tance rates, antibiograms should be stratified by setting of infection onset [34].
The increasing resistance trend noted in our study for the eight antimicrobials is consistent
with previously reported Australian data and published studies from other developed countries
[6,7,9,35,36]. The increasing trend may be attributable to antimicrobial overuse or misuse
which is a known risk factor for the development of AMR [37]. However, clinical data on hos-
pital antimicrobial use at the study location showed stable rates for most antimicrobials tested
(data not shown). We also found seasonal increases in trimethoprim resistance especially in
summer months. The literature suggests a possible seasonality with UTI incidence [38,39] but
this was not demonstrated in our study. It is possible that seasonality in UTI may lead to sea-
sonal variation in antimicrobial use with subsequent seasonal resistance patterns although to
Fig 1. Five-year resistance rates of hospital- and community-acquired E. coli UTIs by selected antibiotics.
amp = ampicillin; tri = trimethoprim; cef = cefazolin; amc = amoxycillin-clavulanate; cip = ciprofloxacin; pit = piperacillin-
tazobactam; gen = gentamicin; nit = nitrofurantoin. ** 0.001 < p value < 0.05. ** p < 0.001
doi:10.1371/journal.pone.0164306.g001
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our knowledge, this is yet to be demonstrated in published studies. Evidence currently exists to
show higher use of antimicrobials in winter months which is likely related to the increased inci-
dence of respiratory tract infections during that periodwith consequent increases in resistance
during winter [40,41]. Therefore the seasonal trimethoprim resistance is a potentially impor-
tant finding which should be explored in future studies especially in relation to antimicrobial
use. The ecological analysis conducted in this study showed an association between older age
and resistance to ciprofloxacin, cefazolin and ceftriaxone consistent with published studies
[6,34,42]. The association between increasing age and increased resistance is not surprising
given that the physiological changes caused by aging and increased comorbidities predispose to
a higher risk of infection leading to more contact with healthcare settings and hence more fre-
quent exposure to antibiotics [42].
It is worth emphasizing that our overall ESBL rate of 1.9% was low compared to most other
published studies [31]. Results from the 2009–2011 SMART study in the United States
reported an ESBL rate of 6.8% for E. coli UTI [31]. Although our reported ESBL rate is rela-
tively low, the presence and increasing trend of ESBL-producing E. coli in both hospital and
community-acquired UTIs pose considerable public health concern. This is because this organ-
ism renders many of the conventional empirical treatment options for UTI ineffective espe-
cially in community-acquired UTI where options for oral antibiotic therapy appear to be
limited [43]. For hospital-acquired UTI caused by ESBL-producing E. coli, carbapenems are
considered the treatment of choice [43]. In our study, the lowest resistance rate reported was
for meropenem, a carbapenem.
This study has some limitations. As most UTIs are treated empirically, it is possible that sam-
ples submitted to the laboratory included patients with recurrent UTIs and asymptomatic
Fig 2. Seasonal antimicrobial resistance rates for E. coli UTIs. 1 = Summer; 2 = Autumn; 3 = Winter;
4 = Spring. P = significance level for an increasing trend. AMC = Amoxycillin-clavulanate;
TMP-SMX = Trimethoprim-sulphamethoxazole
doi:10.1371/journal.pone.0164306.g002
Time Series Analysis of Antimicrobial Resistant E. coli
PLOS ONE | DOI:10.1371/journal.pone.0164306 October 6, 2016 10 / 14
275
bacteriuria thereby overestimating the resistance rates. In addition, inclusion of the first positive
E. coli UTI per person per year may have underestimated the resistance rates reported in our
study. Evidence suggests that analysis of antimicrobial resistance data should include each indi-
vidual positive isolate in order to ensure sensitivity, but this positive isolate should only be
included once to guarantee specificity [44]. This approach of using only the first positive isolate
per patient per year is also consistent with published studies on resistance in UTI pathogens
including E. coli [17,34]. It is unlikely that repeated isolates are correlated but there is a small
possibility that this could occur although it was not accounted for in the analysis. The 5-year
period prevalence study could therefore have overestimated the resistance. The use of routinely
collectedmicrobiology data also posed some limitations as clinical information on patients
including comorbidities and presence of indwelling urethral catheters was often missing. The
incompleteness of this information prevented its inclusion in the analysis. This study was based
on retrospective antimicrobial susceptibility data from a National Association of Testing
Authorities, Australia (NATA) accredited clinical microbiology laboratory. The stepwise labora-
tory testing protocol involved routine first-line antibiotic sensitivity testing followed by more
extensive testing with second-line antibiotics only for isolates resistant to at least three of the
routine antibiotics. Although this laboratory approach is widely used [44] there is the potential
for testing bias and/or selection bias with consequent overestimation of resistance rates. Given
the lack of consensus on an appropriate denominator using this testing approach and to prevent
possible overestimation of the resistance rates against second-line antibiotics, the denominator
therefore included all isolates tested, which, in turn, may have under-estimated resistance rates
of broad spectrumantimicrobials. Determining the resistance rate can be influenced by the
extent of laboratory testing which in turn influences the selection of the denominator. Using the
total number of isolates tested or the number of isolates tested against second-line antibiotics
alone as the denominator will either underestimate or overestimate the resistance rates respec-
tively. Although using all isolates for calculating resistance rates for second-line antibiotics has
its limitations, this was an appropriate denominator choice to make the findings relevant for use
in the clinical setting. For ideal comparison of susceptibility patterns, all isolates would need to
be tested against the extended panel of antibiotics in a properly designed prospective study.
Regardless of these limitations, our reported resistance rates are low compared to other studies.
The use of ecological data to account for the effects of age and sex on resistance also poses limi-
tations to interpretation of these results at the individual patient level. Although our data are
from a single tertiary hospital and may not be generalisable to other populations, the data were
reported by a NATA accredited laboratory and are therefore satisfactory to provide recommen-
dations to guide local empirical therapy.
Conclusions
Antimicrobial resistance poses grave concerns for antimicrobial effectiveness in treating infec-
tions such as UTI. This study demonstrates the increasing resistance of urinaryE. coli to com-
monly prescribed antimicrobials. Amoxycillin-clavulanate and nitrofurantoin are still effective
for empirical treatment of UTI in this population. Overuse of ampicillin and trimethoprim
should be avoided given the high resistance rates reported. In developing local antimicrobial
prescribing guidelines, the choice of antimicrobial in the treatment of UTI should be based on
setting (community or hospital) of acquisition.
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resistance have been observed in bacteria that cause common infections such as urinary tract infection 
(UTI) and pneumonia (World Health Organisation, 2014). Fluoroquinolones are recommended as the drugs 
of choice for UTIs in regions where the level of resistance to other antimicrobials namely co-trimoxazole is 
high (Rafalsky, Andreeva, & Rjabkova, 2006). Ciprofloxacin is the most frequently prescribed 
fluoroquinolone for UTIs because of its availability in oral and intravenous formulations. This antimicrobial 
agent has shown an excellent activity against pathogens commonly encountered in complicated UTIs. It is 
well absorbed in oral doses and is rapidly excreted from the body (El Astal, 2005). Use of fluoroquinolones 
has been linked to infection with methicillin-resistant S. aureus and with increasing fluoroquinolone 
resistance in gram-negative bacilli, such as Pseudomonas Aeruginosa (Gupta et al., 2011). Resistance to 
fluoroquinolones such as ciprofloxacin has been on the increase since their introduction for UTI treatment 
as reported in a number of studies worldwide (El Astal, 2005; Karlowsky, Kelly, Thornsberry, Jones, & 
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Sahm, 2002). Quantitative syntheses of overall ciprofloxacin-resistant E. coli UTI prevalence are absent 
and the increases in resistance to this antimicrobial agent have highlighted the need to assess the overall 
prevalence of urinary E. coli resistance to ciprofloxacin in both hospital and community settings to ensure 
adequate and appropriate therapy for patients with UTIs. In the era of increasing antimicrobial resistance 
(Schito et al., 2009), it is necessary to undertake continuous research in this area to ensure patients are 
effectively treated resulting in good clinical outcomes. References: 1) Centers for Disease Control and 
Prevention. (2014). CDC/NHSN Surveillance Definitions for Specific Types of Infections. Retrieved from 
http://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf. 2) El Astal, Z. (2005). Increasing 
ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Gaza Strip, Palestine. BioMed 
Research International, 2005(3), 238-241. 3) Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., 
Miller, L. G., . . . Schaeffer, A. J. (2011). International clinical practice guidelines for the treatment of acute 
uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of 
America and the European Society for Microbiology and Infectious Diseases. Clinical infectious diseases, 
52(5), e103-e120. 4) Karlowsky, J. A., Kelly, L. J., Thornsberry, C., Jones, M. E., & Sahm, D. F. (2002). 
Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female 
outpatients in the United States. Antimicrobial Agents and Chemotherapy, 46(8), 2540-2545. 5) Liberati, A., 
Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., . . . Moher, D. (2009). The PRISMA 
statement for reporting systematic reviews and meta-analyses of studies that evaluate health care 
interventions: explanation and elaboration. Annals of internal medicine, 151(4), W-65-W-94. 6) Rafalsky, V., 
Andreeva, I., & Rjabkova, E. (2006). Quinolones for uncomplicated acute cystitis in women. Cochrane 
Database Syst Rev, 3. 7) Schito, G. C., Naber, K. G., Botto, H., Palou, J., Mazzei, T., Gualco, L., & 
Marchese, A. (2009). The ARESC study: an international survey on the antimicrobial resistance of 
pathogens involved in uncomplicated urinary tract infections. International Journal of Antimicrobial Agents, 
34(5), 407-413. doi: http://dx.doi.org/10.1016/j.ijantimicag.2009.04.012 8) United States Interagency Task 
Force on Antimicrobial Resistance. (2011). A Public Health Action Plan to Combat Antimicrobial 
Resistance: Interagency Task Force on Antimicrobial Resistance. 9) World Health Organisation. (2012). 
The evolving threat of antimicrobial resistance: options for action. GPS Publishing, France. 10) World 
Health Organisation. (2014). Antimicrobial resistance: global report on surveillance.  
19 Participants/population 
Give summary criteria for the participants or populations being studied by the review. The preferred format 
includes details of both inclusion and exclusion criteria. 
Inclusion criteria: •studies reporting E. coli UTI •studies reporting prevalence rates of ciprofloxacin 
resistance in E. coli UTI •studies of hospital populations •studies of community populations •studies of 
outpatient populations •studies of general practice (GP) populations •studies of nursing home or residential 
aged care populations •studies involving adults and/or children •peer reviewed letters with data Exclusion 
criteria: •articles published over 10 years ago •articles not relevant to principal study objective or review 
question •non-peer reviewed literature •studies not reporting prevalence of ciprofloxacin resistance or data 
from which prevalence rates cannot be calculated •Papers written in languages other than English will first 
be considered for translation and if this is not possible, they will be excluded  
20 Intervention(s), exposure(s) 
Give full and clear descriptions of the nature of the interventions or the exposures to be reviewed 
Exposure (1): Being in a community setting OR Exposure (2): Being in a hospital setting  
21 Comparator(s)/control 
Where relevant, give details of the alternatives against which the main subject/topic of the review will be 
compared (e.g. another intervention or a non-exposed control group). 
Not Applicable  
22 Types of study to be included initially 
Give details of the study designs to be included in the review. If there are no restrictions on the types of 
study design eligible for inclusion, this should be stated. 
Observational (cross sectional; prospective and retrospective cohort; case-control) studies  
23 Context 
Give summary details of the setting and other relevant characteristics which help define the inclusion or 
exclusion criteria. 
•Community: studies using -Samples obtained from outpatient clinics -Samples obtained from general 
practice (GP) clinics -Samples obtained within 48 hours of hospital admission -Samples from nursing 
homes or residential aged care facilities (RACFs) •Hospital: studies using -Samples obtained after 48 hours 
of hospital admission 
24 Primary outcome(s) 
Give the most important outcomes. 
Prevalence of ciprofloxacin resistant E. coli UTI in both settings 
Give information on timing and effect measures, as appropriate. 
25 Secondary outcomes 
List any additional outcomes that will be addressed. If there are no secondary outcomes enter None. 
Mortality associated with resistance in both settings 
  Give information on timing and effect measures, as appropriate. 
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26 Data extraction, (selection and coding) 
Give the procedure for selecting studies for the review and extracting data, including the number of 
researchers involved and how discrepancies will be resolved. List the data to be extracted. 
Selection of studies Stage 1: The titles and abstracts of all publications identified on the electronic 
databases will be examined and assessed for relevance and appropriateness to the principal study 
objective or review question. Those that are clearly not relevant will be excluded. Stage 2: Full texts of the 
potentially relevant papers will be printed and carefully assessed against the criteria. Assessment will be 
performed independently by the reviewers and a consensus made on those that meet all the criteria. After 
applying the inclusion and exclusion criteria, articles not meeting the criteria will be excluded. Stage 3: The 
remaining articles will be deemed to have data relevant to the systematic review and meta-analysis and will 
be assessed for quality and risk of bias. This assessment will be performed by four reviewers. OF, who is a 
student will be the lead author. Her three supervisors will act as mentors and will be involved in all stages 
including the literature search, data extraction, analysis and report writing. Data extraction and 
management: A paper-based data extraction form has been designed for the purpose of extracting data for 
the systematic review and meta-analysis. For all eligible studies meeting the inclusion and exclusion 
criteria, the following data will be extracted: first author; year of publication; country/place of study; year 
study was conducted; study population; study setting (Hospital setting/Community setting/Hospital with 
RACFs/Community with RACFs); age and sex distribution; sample size; study design; Antimicrobial 
susceptibility testing method; prevalence of ciprofloxacin resistance; numerator; denominator; 95% 
confidence intervals; standard error; mortality data (if reported) The discrepancies in either the decision on 
inclusion or exclusion of studies, quality assessment or on data extraction will be discussed with 
supervisors to make the final decision.  
27 Risk of bias (quality) assessment 
State whether and how risk of bias will be assessed, how the quality of individual studies will be assessed, 
and whether and how this will influence the planned synthesis. 
Quality and risk of bias assessment of the final papers included in the review will be conducted using a 
validated risk of bias tool for observational studies or separate tools depending on the specific type of 
observational study design.  
28 Strategy for data synthesis 
Give the planned general approach to be used, for example whether the data to be used will be aggregate 
or at the level of individual participants, and whether a quantitative or narrative (descriptive) synthesis is 
planned. Where appropriate a brief outline of analytic approach should be given. 
Based on the data obtained from eligible studies, the following forms of analysis will be used – tabulation, 
meta-analysis and narrative (descriptive). Measures of effect: The pooled proportions or pooled odds ratio 
will be calculated and compared across both hospital settings and community settings. The level of 
resistance will be evaluated using a random-effects meta-analysis model using DerSimonian and Laird 
method. This method incorporates an estimate of the between-study variation into both the study weights 
and the standard error of the estimate of the common effect. The precision of an estimate from each 
included study will be represented by the inverse of the variance of the outcome pooled across all studies. 
The pooled effect size (ES) (estimated by the pooled proportion) with 95% CI will be calculated. If the value 
of the pooled proportion ‘zero’ is not within the 95% CI, then the ES is statistically significant at the 5% level 
(P 
29 Analysis of subgroups or subsets 
Give any planned exploration of subgroups or subsets within the review. ‘None planned’ is a valid response 
if no subgroup analyses are planned. 
Subgroup analyses will be done by sex, age, time period, and region. Meta-analyses using Mantel-
Haenszel fixed-effect models may also be considered in the sub-analyses. 
Review general information 
30 Type of review 
Select the type of review from the drop down list. 
Epidemiologic 
31 Language 
Select the language(s) in which the review is being written and will be made available, from the drop down 
list. Use the control key to select more than one language. 
English 
Will a summary/abstract be made available in English? 
Yes 
32 Country 
Select the country in which the review is being carried out from the drop down list. For multi-national 
collaborations select all the countries involved. Use the control key to select more than one country. 
Australia 
33 Other registration details 
List places where the systematic review title or protocol is registered (such as with he Campbell 
Collaboration, or The Joanna Briggs Institute). The name of the organisation and any unique identification 
number assigned to the review by that organization should be included. 
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Not Applicable 
34 Reference and/or URL for published protocol 
Give the citation for the published protocol, if there is one. 
Not Applicable 
Give the link to the published protocol, if there is one. This may be to an external site or to a protocol 
deposited with CRD in pdf format. 
 
I give permission for this file to be made publicly available 
Yes 
35 Dissemination plans 
Give brief details of plans for communicating essential messages from the review to the appropriate 
audiences. 
-Conference presentation -Publication submission to a high ranking peer reviewed journal (Q1) 
Do you intend to publish the review on completion? 
Yes 
36 Keywords 
Give words or phrases that best describe the review. (One word per box, create a new box for each term) 
ciprofloxacin resistance 
urinary tract infection 
escherichia coli 
hospital 
community 
37 Details of any existing review of the same topic by the same authors 
Give details of earlier versions of the systematic review if an update of an existing review is being 
registered, including full bibliographic reference if possible. 
Not Applicable 
38 Current review status 
Review status should be updated when the review is completed and when it is published. 
Ongoing 
39 Any additional information 
Provide any further information the review team consider relevant to the registration of the review. 
40 Details of final report/publication(s) 
This field should be left empty until details of the completed review are available.  
Give the full citation for the final report or publication of the systematic review. 
Give the URL where available. 
 
 
   
 
 
  
   
 
 
284
Appendix E: Data extraction form with quality and risk of bias assessment 
tool 
Review title  Comparing the prevalence of ciprofloxacin 
resistance in community-acquired versus 
hospital-acquired E. coli UTIs : systematic 
review and meta-analysis 
Study ID (year first full report of study was 
published, surname of first author and study 
setting e.g. 2001SmithHospital) 
 
Name of publishing journal 
 
 
Notes:  
 
 
 
 
 
 
 
1. General information 
Date form completed 
(dd/mm/yyyy) 
 
Name/initials of person 
extracting data 
 
Study author email address  
Notes:  
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2. Characteristics of included studies 
Participants  
 Description 
 
Location in 
text or source 
(pg & 
¶/fig/table) 
Sample size 
(total number 
of study 
participants) 
                                                                      Not stated  
Number of 
participants on 
whom 
resistance was 
reported 
                                                                      Not stated  
Country/place 
of study                                                                       Not stated  
Informed 
consent 
obtained 
   
Yes No Unclear/not stated 
 
Age 
distribution of 
all participants 
Mean……………..    SD…………………… 
Median……………….    IQR…………………… 
 Not stated 
 
Age 
distribution of 
participants 
with positive 
UTIs 
Mean……………..    SD…………………… 
Median……………….    IQR…………………… 
 Not stated 
 
Age 
distribution of 
participants 
with E. coli 
UTIs 
Mean……………..    SD…………………… 
Median……………….    IQR…………………… 
 Not stated 
 
Age 
distribution of 
participants 
with resistant 
UTIs 
Mean……………..    SD…………………… 
Median……………….    IQR…………………… 
 Not stated 
 
Sex 
distribution of 
all participants 
 
Male (n; %)……………………… 
Female (n; %)…………………….  
 Not stated 
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Sex 
distribution of 
participants 
with positive 
UTIs 
Male (n; %)……………………… 
Female (n; %)…………………….  
 Not stated 
 
Sex 
distribution of 
participants 
with E. coli 
UTIs 
Male (n; %)……………………… 
Female (n; %)…………………….  
 Not stated 
 
Sex 
distribution of 
participants 
with resistant 
UTIs 
Male (n; %)……………………… 
Female (n; %)…………………….  
 Not stated 
 
Study setting 
 
 Hospital   
              After 48 hours of hospital admission 
              Within 48 hours of hospital discharge 
 Community 
              Outpatients 
              General practice clinic 
              Emergency department 
              Within 48 hours of admission  
              Nursing home/RACF 
 
Co-morbidities List all co-morbidities if present and state proportion 
  Diabetes mellitus________ n; % 
  Cancer_________________ n; % 
  Spinal cord injury________ n; % 
  Other_________________ n; % 
  Not stated 
 
Notes:   
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Methods 
 Descriptions as stated in report/paper 
 
Location in 
text 
(pg & 
¶/fig/table) 
Aim/ Objective 
of study 
Primary 
aim   
Secondary 
aim   
Study duration Start date: 
End date: 
Total duration: 
        Not stated 
 
Study design  Cross sectional 
 Retrospective cohort 
        Prospective cohort 
        Case control 
        Nested case control 
        Not stated 
  
Antimicrobial susceptibility 
testing method 
        Clinical and Laboratory Standards 
Institute (CLSI)    
             (formerly NCCLS) 
        European Committee on 
Antimicrobial Susceptibility testing 
(EUCAST) 
        Other______________________ 
        Not stated 
 
Notes:    
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Results 
 Description Location 
in text or 
source (pg 
& 
¶/fig/table) 
Total number of urine 
samples 
                                                                      Not stated  
Number of positive 
UTI samples 
                                                                      Not stated  
Number of positive 
E.coli UTI samples 
                                                                      Not stated  
Prevalence of 
ciprofloxacin 
susceptible E. coli 
strains  
                                                                      Not stated  
Prevalence of 
ciprofloxacin 
intermediate E. coli 
strains 
                                                                      Not stated  
Prevalence of 
ciprofloxacin resistant 
E. coli strains 
                                                                      Not stated  
95% confidence 
interval of resistance 
prevalence 
                                                                      Not stated  
Standard error                                                                       Not stated  
Mortality rate of 
participants with 
resistant infections 
Crude/adjusted mortality rate_______________% 
In-hospital mortality rate__________________ % 
30-day mortality rate_____________________% 
90-day mortality rate_____________________% 
 
For studies 
reporting 
resistance 
in two or 
more of 
the defined 
settings: 
State p-
value if 
differences 
noted  
                                                                      
 Not 
stated 
Age Settings___________________________________ 
p value____________________________________ 
 
Gender Settings___________________________________ 
p value____________________________________ 
 
Ciproflox
-acin 
resistance  
Settings___________________________________ 
p value____________________________________ 
 
Other Settings___________________________________ 
p value____________________________________ 
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Risk 
factors for 
ciprofloxac
-in 
resistance 
 Not 
stated 
Age OR________________________________________ 
95% CI_____________________________________ 
p value_____________________________________ 
 
Gender OR________________________________________ 
95% CI_____________________________________ 
p value_____________________________________ 
Prior use 
of 
antibiotic 
OR________________________________________ 
95% CI_____________________________________ 
p value_____________________________________ 
Other OR________________________________________ 
95% CI_____________________________________ 
p value_____________________________________ 
Number of missing 
participants 
                                                                       Not 
stated 
 
Reasons missing                                                                        Not 
stated 
 
Notes: 
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Study quality and risk of bias assessment: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 
GA Wells, B Shea, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell, 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 
Cohort Studies 
Bias  High quality*   
Selection 
(max 4*) 
Representativeness of 
exposed cohort 
 Truly representative of the target 
population 
Somewhat representative of target 
population 
Selected group of 
participants 
No description of 
derivation of cohort 
Selection of non-exposed 
cohort 
Drawn from the same community as 
the exposed cohort 
Drawn from a different 
source 
No description of 
derivation of non-exposed 
cohort 
Ascertainment of 
exposure (UTI 
measurement) 
Confirmed laboratory diagnosis Self-report of UTI No description 
Demonstration that 
outcome of interest was 
not present at start of 
study 
Yes No  
Comparability 
(max 2*) 
Comparability of cohorts 
on basis of design or 
analysis 
Study controls for important factor 
(antibiotic use) 
Fails to control for an 
important factor 
 
Study controls for any additional 
factor (age, gender etc) 
Does not control for any 
factors 
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Outcome 
(max 3*) 
Assessment of outcome 
(Ciprofloxacin resistant E. 
coli UTI) 
Standard laboratory test (e.g. CLSI or 
EUCAST) 
Record linkage (e.g. identified 
through ICD codes on database records) 
Self-report No description 
Was follow-up long 
enough for outcome to 
occur 
Yes (>=12 months) No (<12 months)  
Adequacy of follow up of 
cohorts 
Complete follow up-all subjects 
accounted 
Subjects lost to follow up unlikely to 
introduce bias – small number lost 
(>80% follow up), or description 
provided of those lost 
Follow up rate <20% 
and no description of those 
lost 
No statement 
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Cross-sectional Studies 
Bias  High quality*   
Selection 
(max 2*) 
Representativeness 
of sample 
 Truly representative of the target 
population 
Somewhat representative of target 
population 
Selected group of 
participants 
No description of 
sample 
Sampling strategy Probability sampling Non-probability sampling No description of 
sampling strategy 
Ascertainment of 
exposure (UTI 
measurement) 
Confirmed laboratory diagnosis Self-report of UTI No description 
Comparability 
(max 2*) 
Comparability of 
participants  on basis 
of design or analysis 
Study controls for important factor 
(antibiotic use) 
Fails to control for an 
important factor 
 
Study controls for any additional factor 
(age, gender etc) 
Does not control for any 
factors 
 
Outcome 
(max 1*) 
Assessment of 
outcome 
(Ciprofloxacin 
resistant E. coli UTI) 
Standard laboratory test (e.g. CLSI or 
EUCAST) 
Record linkage (e.g. identified through 
ICD codes on database records) 
Self-report No description 
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Case-control Studies 
Bias  High quality*   
Selection 
(max 4*) 
Is the case definition 
adequate? 
 Yes, with independent validation 
 
Yes, e.g. record linkage or 
based on self-report 
No description  
Representativeness of the 
cases 
Consecutive or obviously 
representative series of cases 
Potential for selection bias 
or not stated 
 
Selection of controls Community controls Hospital controls No description 
Definition of controls No history of disease (endpoint) No description of source  
Comparability 
(max 2*) 
Cases and controls on the 
basis of the design or 
analysis 
Study controls for important factor 
(antibiotic use) 
Fails to control for an 
important factor 
 
Study controls for any additional 
factor (age, gender etc) 
Does not control for any 
factors 
 
Exposure 
(max 3*) 
Ascertainment of exposure Secure record  
Structured interview where blind to 
case/control status 
Interview not blinded to 
case/control status 
Written self-report or 
medical record only 
No description 
Same method of 
ascertainment for cases 
and controls 
Yes  No   
Non-response rate Same rate for both groups  Non respondents described Rate different and no 
designation 
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Other 
Study funding sources 
(including role of funders) 
  
Possible conflicts of 
interest (for study 
authors) 
  
Is there any additional 
study in the reference list 
of this article that might 
be included in the review?  
 Yes                     No 
If yes, state reference(s): 
 
Notes:  
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From: Kylie Pashley on behalf of Res Ethics
To: Anne Gardner; Oyebola Fasugba
Cc: Res Ethics
Subject: 2014 276N Registration of External Ethics Approval
Date: Friday, 17 October 2014 12:05:17 PM
Dear Pamela,
Principal Investigator: Prof Anne Gardner
Student Researcher: Ms Oyebola Fasugba
Ethics Register Number: 2014 276N
Project Title:  Antimicrobial resistance and urinary tract infections in an Australian population-based
sample
Risk Level: Multi Site
Date Approved: 17/10/2014
Ethics Clearance End Date: 30/09/2015
The Australian Catholic University Human Research Ethics Committee has considered your
application for registration of an externally approved ethics protocol and notes that this application
has received ethics approval from ACT Health [Reference: ETHLR.14.223]. 
The ACU HREC accepts the ethics approval with no additional requirements, save that ACU HREC is
informed of any modifications of the research proposal and that copies of all progress reports and
any other documents be forwarded to it.  Any complaints involving ACU staff must also be notified
to ACU HREC (National Statement 5.3.3)
We wish you well in this research project.
Regards,
Kylie Pashley
on behalf of ACU HREC Chair, Dr Nadia Crittenden
Ethics Officer | Research Services
Office of the Deputy Vice Chancellor (Research)
res.ethics@acu.edu.au
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From: Cohen, Sarit (Health)
To: Oyebola Fasugba
Cc: Bailey, Andrew (Health); Anne Gardner
Subject: RE: ETHLR.14.223 ACT Health ethics approval to obtain antimicrobial use data
Date: Monday, 4 January 2016 11:38:42 AM
Dear Bola,
An apology for not getting back to you sooner. Hope you had a good break.
I have a note here from Phil Ghirardello accepting and okay to release the data.
Kind regards
Sarit
Sarit Cohen
Personal Assistant to Phil Ghirardello | Executive Director Performance Information Branch
Level 3, 11 Moore Street Canberra City
Phone: 6205 0549 | Email: sarit.cohen@act.gov.au
Care   Excellence   Collaboration   Integrity
From: Oyebola Fasugba [mailto:oyebola.fasugba@myacu.edu.au] 
Sent: Thursday, 17 December 2015 2:49 PM
To: Cohen, Sarit (Health)
Cc: Bailey, Andrew (Health); Anne Gardner
Subject: RE: ETHLR.14.223 ACT Health ethics approval to obtain antimicrobial use data
Dear Sarit,
Please find attached the signed data release form for processing. Can you kindly notify me of
when most likely I will get final approval/confirmation from your office?
Thank you for your assistance.
Kind regards,
Bola
Oyebola Fasugba MPHTM MBBS
PhD Candidate & Research Associate | School of Nursing, Midwifery and Paramedicine
(Signadou Campus)
Australian Catholic University
223 Antill Street, Watson, ACT 2602
PO Box 256, Dickson ACT 2602
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APPENDIX G: Additional/Supplementary files 
Study one: Systematic review of ciprofloxacin resistance in E. coli UTI 
Additional file 1: Search strategy by database 
EMBASE Search strategy 1: Keywords only  
# Searches Results 
1 resistance.mp. 798263 
2 urinary tract infection.mp. 80151 
3 Escherichia coli.mp. 358062 
4 1 and 2 and 3 3709 
5 4 and 2004:2014.(sa_year). 2423 
EMBASE Search strategy 2: Keywords and subject headings 
# Searches Results 
1 antibiotic resistan*.mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
123069 
2 antimicrobial resistan*.mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
12903 
3 drug resistan*.mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
114373 
4 bacterial resistan*.mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
5524 
5 antibiotic resistance/ 114397 
6 drug resistance/ 58485 
7 1 or 2 or 3 or 4 or 5 or 6 225773 
8 urinary tract infection*.mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
83408 
9 uti.mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
9689 
10 bacteriuria.mp. [mp=title, abstract, subject headings, heading 
word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
10917 
11 pyuria.mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
3890 
12 urinary tract infection/ 75810 
13 bacteriuria/ 8487 
14 pyuria/ 3150 
15 8 or 9 or 10 or 11 or 12 or 13 or 14 91929 
16 Escherichia coli.mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
358062 
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17 e coli.mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
125639 
18 Escherichia coli/ 294320 
19 16 or 17 or 18 371005 
20 7 and 15 and 19 3284 
21 20 and 2004:2014.(sa_year). 2160 
CINAHL Search strategy 1: Keywords only 
# Searches Results 
1 resistance 55753 
2 urinary tract infection 7192 
3 escherichia coli 4970 
4 1 AND 2 AND 3 235 
5 4 Limiters-Published date 20040101-20141231 208 
CINAHL Search strategy 2: Keywords and subject headings 
# Searches Results 
1 antibiotic resistan* 4759 
2 antimicrobial resistan* 3316 
3 drug resistan* 33393 
4 bacterial resistan* 6765 
5 (MH “Drug Resistance, Microbial”) 12164 
6 (MH “Drug Resistance”) 4838 
7 1 OR 2 OR 3 OR 4 OR 5 OR 6 36416 
8 urinary tract infection* 7781 
9 uti 1081 
10 bacteriuria 740 
11 pyuria 129 
12 (MH “Urinary Tract Infections”) 5924 
13 (MH “Bacteriuria”) 518 
14 8 OR 9 OR 10 OR 11 OR 12 OR 13 8169 
15 escherichia coli 4970 
16 e coli 1428 
17 (MH “Escherichia Coli”) 2722 
18 15 OR 16 OR 17 5191 
19 7 AND 14 AND 18 270 
20 19; Limiters – Published Date: 20040101-20141231 236 
SCOPUS Search strategy 1: Keywords only 
# Searches Results 
1 TITLE-ABS-KEY ( resistance ) 1,406,458 
2 TITLE-ABS-KEY ( urinary tract infection ) 87,237 
3 TITLE-ABS-KEY ( escherichia coli ) 411,648 
4 ( TITLE-ABS-KEY ( resistance ) ) AND ( TITLE-ABS-KEY ( 
urinary tract infections ) ) AND ( TITLE-ABS-KEY ( 
escherichia coli ) ) 
4,353 
5 ( TITLE-ABS-KEY ( resistance ) ) AND ( TITLE-ABS-KEY ( 
urinary tract infections ) ) AND ( TITLE-ABS-KEY ( 
2472 
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escherichia coli ) ) AND ( LIMIT-TO ( PUBYEAR , 2014-2004 
) 
SCOPUS Search strategy 2: Keywords and subject headings 
# Searches Results 
1 TITLE-ABS-KEY ( antibiotic  resistan* ) 186424 
2 TITLE-ABS-KEY ( antimicrobial  resistan* ) 56777 
3 TITLE-ABS-KEY ( drug  resistan* ) 507251 
4 TITLE-ABS-KEY ( bacterial  resistan* ) 181814 
5 1 OR 2 OR 3 OR 4 597338 
6 TITLE-ABS-KEY ( urinary  tract  infection ) 87237 
7 TITLE-ABS-KEY ( uti ) 7656 
8 TITLE-ABS-KEY ( bacteriuria ) 11141 
9 TITLE-ABS-KEY ( pyuria ) 3187 
10 6 OR 7 OR 8 OR 9 94035 
11 TITLE-ABS-KEY ( escherichia  coli ) 411648 
12 TITLE-ABS-KEY ( e  coli ) 168002 
13 11 OR 12 429893 
14 5 AND 10 AND 13 5184 
15 14 AND ( LIMIT-TO ( PUBYEAR , 2014-2004 ) 2777 
PubMed Search strategy 1: Keywords only 
# Searches Results 
1 Search resistance 610335 
2 Search urinary tract infection 54,476 
3 Search escherichia coli 318047 
4 Search ((resistance) AND urinary tract infection) AND 
escherichia coli 
2,416 
5 4 AND Filters: Publication date from 2004/01/01 to 
2014/12/31 
1243 
PubMed Search strategy 2: Keywords and subject headings 
# Searches Results 
1 Search antibiotic resistance 146589 
2 Search antimicrobial resistance 165154 
3 Search bacterial resistance 116736 
4 Search drug resistance 375235 
5 Search "Drug Resistance, Microbial"[Mesh] 125068 
6 Search "Drug Resistance, Bacterial"[Mesh] 60535 
7 1 OR 2 OR 3 OR 4 OR 5 OR 6 409413 
8 Search urinary tract infection 54469 
9 Search uti 5705 
10 Search bacteriuria 8749 
11 Search pyuria 1976 
12 Search "Urinary Tract Infections"[Mesh] 38550 
13 Search "Bacteriuria"[Mesh] 6931 
14 Search "Pyuria"[Mesh] 906 
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15 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 56345 
16 Search escherichia coli 318008 
17 Search e coli 333732 
18 Search "Escherichia coli"[Mesh] 232783 
19 16 OR 17 OR 18  333732 
20 7 AND 15 AND 19 2623 
21 20 AND Filters: Publication date from 2004/01/01 to 
2014/12/31 
1301 
 
MEDLINE Search strategy 1: Keywords only  
# Searches Results 
1 resistance.mp. 574974 
2 urinary tract infections.mp. 37313 
3 Escherichia coli.mp. 311661 
4 1 and 2 and 3 1923 
5 4 and 2004:2014. (sa_year) 964 
 
MEDLINE Search strategy 2: Keywords and subject headings  
# Searches Results 
1 antibiotic resistan*.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
19772 
2 antimicrobial resistan*.mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique 
identifier] 
8841 
3 drug resistan*.mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
197925 
4 bacterial resistan*.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
3438 
5 Drug Resistance, Microbial/ 54415 
6 Drug Resistance/ 39696 
7 1 or 2 or 3 or 4 or 5 or 6 208986 
8 urinary tract infection*.mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique 
identifier] 
43114 
9 uti.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
5172 
10 bacteriuria.mp. [mp=title, abstract, original title, name of 8646 
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substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
11 pyuria.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
1890 
12 Urinary Tract Infections/ 32461 
13 Bacteriuria/ 7048 
14 Pyuria/ 925 
15 8 or 9 or 10 or 11 or 12 or 13 or 14 49102 
16 Escherichia coli.mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
311661 
17 e coli.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
120235 
18 Escherichia coli/ 227408 
19 16 or 17 or 18 324796 
20 7 and 15 and 19 1886 
21 20 and 2004:2014.(sa_year). 933 
 
COCHRANE Search strategy  
Cochrane Database of Systematic Reviews 
# Searches Cochrane reviews 
1 resistance in Title, Abstract, Keywords 
(Word variations have been searched) 
263 
2 urinary tract infection in Title, Abstract, 
Keywords (Word variations have been 
searched) 
77 
3 Escherichia coli in Title, Abstract, 
Keywords (Word variations have been 
searched) 
3 
4 1 and 2 and 3 1 
5 4 and Publication Year from 2004 to 2014 
(Word variations have been searched) 
1 
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Additional file 2: Subgroup analyses of pooled ciprofloxacin resistance in hospital 
setting 
Subgroup Hospital setting                            
N=3 
P value* 
Pooled resistance 
Region 
 
Middle East 
n=1 study 
0.400** 0.880 
North America 
n=1 study 
0.407** 
Economy Developed 
n=1 study 
0.407 0.880 
Developing 
n=1 study 
0.400 
UTI 
symptoms 
Symptomatic and 
asymptomatic patients               
n=1 study  
0.380 
 
0.356 
Symptomatic patients 
only                                                     
n=2 studies 
0.404 
*Comparing pooled resistance for difference in subgroup in hospital setting 
n=number of studies reporting on hospital acquired UTI 
**Middle East only; North America only 
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Additional file 3: Subgroup analyses of pooled ciprofloxacin resistance by setting 
 
Subgroup Community Setting            
N=51 
Hospital setting     
N=3 
P value* 
Pooled resistance Pooled resistance 
Risk of bias 
 
Low and 
unclear C=28 
studies 
H= 0 study 
0.221 - - 
High 
C=23 studies 
H=3 studies 
0.337 (10262) 0.385 <0.0001 
Study 
duration 
 
≤12 months        
C=25 studies 
H=0 study 
0.323 - - 
>12months 
C=24 studies 
H=3 studies 
0.219 (34328) 0.385 <0.0001 
Study       
design 
Cross 
sectional 
C=40 studies 
H=3 studies 
0.271 (36909)  0.385 <0.0001 
Cohort 
C=5 studies 
H=0 study 
0.287 - - 
Case control 
C=2 studies 
H=0 study 
0.224 - - 
Economy 
 
Developed             
C=16 studies 
H=1 study 
0.141 (12996) 0.407 <0.0001 
Developing            
C=35 studies 
H=1 study 
0.345 (32064) 0.400 0.103 
Region 
 
Africa 
C=7 studies 
H=0 study 
0.203 - - 
Asia and 
Middle East                              
C=22 studies 
H=1 study 
0.390 (8866)  0.400** 0.774 
Europe 
C=13 studies 
H=0 study 
0.156 - - 
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North and 
South 
America                
C=9 studies 
H=1 study 
0.207 (24871) 0.407** <0.0001 
Age group 
 
Adults and 
children ǂ 
C=24 studies 
H=2 studies 
0.265 (33090) 0.382 <0.0001 
Adults only 
C=19 studies 
H=0 study 
0.302 - - 
UTI 
symptoms 
Symptomatic 
and 
asymptomati
c patients               
C=11 studies 
H=1 study  
0.185 (27984)  0.380 
 
<0.0001 
Symptomatic 
patients only    
C=40 studies 
H=2 studies 
0.295 (17076) 0.404 <0.0001 
Overall 0.27 0.38 <0.0001 
*Comparing pooled resistance for difference in subgroup in community and hospital settings 
ǂ Studies reporting resistance in adults and children or children only 
C= number of studies reporting on community acquired UTI 
H= number of studies reporting on hospital acquired UTI 
**Middle East only; North America only 
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Study two: Prevalence of antimicrobial resistance in E. coli UTI 
 
 
S1 Table. Distribution of all Canberra Hospital urine samples from 2009 to 2013 
 2009 2010 2011 2012 2013 Overall 
five year 
period 
Total 
number of 
urine 
samples 
19,455 20,005 22,070 22,496 22,486 106,512 
Proportion 
of positive 
urine 
samples  
14.2% 
(n=2,767) 
14.8% 
(n=2,951) 
14.3% 
(n=3,167) 
13.7% 
(n=3,075) 
13.6% 
(n=3,062) 
14.1% 
(n=15,022) 
Proportion 
of positive 
samples 
where E. 
coli was 
isolated  
49.5% 
(n=1,370) 
50.6% 
(n=1,494) 
53.6% 
(n=1,699) 
49.6% 
(n=1,526) 
51.6% 
(n=1,581) 
51.1% 
(n=7,670) 
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Study three: Incidence of antimicrobial resistance in E. coli UTI 
 
Supplementary Table S1 Multivariate logistic regression models for the effects of age, gender 
and socioeconomic status on antimicrobial resistant E. coli UTI* 
Antibiotic Variable Categories Odds ratio 95% CI 
Ampicillin Age (years) ≤23 1.3 1.2-1.5 
 38-56 1.3 1.1-1.4 
 57-73 1.9 1.7-2.1 
 ≥74 2.8 2.5-3.1 
 24-37 (reference) 1.0  
Gender Female 3.1 2.8-3.4 
 Male (reference) 1.0  
SES Middle 1.0 0.9-1.1 
 High 1.0 0.9-1.0 
 Low (reference) 1.0  
Sample origin Private acute hospitals 0.7 0.6-0.9 
 GP clinics 1.1 1.0-1.2 
 After-hours GP clinics 2.5 2.1-3.0 
 Community health services 1.5 1.2-1.8 
 Specialist health services 1.0 0.7-1.5 
 Others# 1.4 0.9-2.0 
 Public acute hospitals  
(reference) 
1.0  
AMC Age ≤23 1.2 0.9-1.7 
 38-56 1.5 1.1-2.0 
 57-73 2.9 2.2-3.8 
 ≥74 4.2 3.2-5.4 
 24-37 (reference) 1.0  
Gender Female 2.8 2.3-3.5 
 Male (reference) 1.0  
SES Middle 1.0 0.8-1.2 
 High 1.1 0.9-1.3 
 Low (reference) 1.0  
Sample origin Private acute hospitals 0.8 0.5-1.3 
 GP clinics 0.9 0.7-1.1 
 After-hours GP clinics 2.1 1.3-3.1 
 Community health services 1.3 0.8-2.1 
 Specialist health services 2.2 1.3-3.8 
 Others# 1.7 0.8-3.7 
 Public acute hospitals  
(reference) 
1.0  
Cefazolin Age ≤23 1.5 1.2-1.8 
 38-56 1.4 1.1-1.7 
 57-73 2.6 2.1-3.2 
 ≥74 3.8 3.1-4.6 
 24-37 (reference) 1.0  
Gender Female 2.6 2.3-3.0 
 Male (reference) 1.0  
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SES Middle 1.0 0.9-1.1 
 High 0.9 0.8-1.1 
 Low (reference) 1.0  
Sample origin Private acute hospitals 0.9 0.6-1.3 
 GP clinics 0.9 0.8-1.1 
 After-hours GP clinics 1.7 1.2-2.5 
 Community health services 1.6 1.2-2.3 
 Specialist health services 1.4 0.8-2.3 
 Others# 1.6 0.9-3.0 
 Public acute hospitals  
(reference) 
1.0  
Ceftriaxone Age ≤23 1.1 0.7-1.6 
 38-56 1.1 0.8-1.7 
 57-73 2.2 1.6-3.1 
 ≥74 3.4 2.5-4.7 
 24-37 (reference) 1.0  
Gender Female 2.7 2.1-3.5 
 Male (reference) 1.0  
SES Middle 0.9 0.7-1.2 
 High 1.1 0.9-1.4 
 Low (reference) 1.0  
Sample origin Private acute hospitals 1.1 0.6-1.9 
 GP clinics 0.9 0.7-1.2 
 After-hours GP clinics 1.1 0.5-2.3 
 Community health services 1.8 1.0-3.0 
 Specialist health services 2.7 1.5-5.1 
 Others# 2.0 0.8-5.0 
 Public acute hospitals  
(reference) 
1.0  
Trimethoprim 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age ≤23 1.2 1.1-1.5 
 38-56 1.2 1.0-1.4 
 57-73 2.0 1.7-2.3 
 ≥74 2.8 2.4-3.2 
 24-37 (reference) 1.0  
Gender Female 3.4 3.0-3.9 
 Male (reference) 1.0  
SES Middle 1.1 1.0-1.2 
 High 1.1 0.9-1.2 
 Low (reference) 1.0  
Sample origin Private acute hospitals 0.7 0.5-0.9 
 GP clinics 1.1 1.0-1.3 
 After-hours GP clinics 2.2 1.7-2.8 
 Community health services 1.5 1.1-1.9 
 Specialist health services 1.3 0.9-2.0 
 Others# 1.7 1.0-2.7 
 Public acute hospitals  
(reference) 
1.0  
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TMP-SMX Age ≤23 1.3 1.1-1.7 
 38-56 1.1 0.9-1.4 
 57-73 2.2 1.8-2.7 
 ≥74 2.7 2.2-3.4 
 24-37 (reference) 1.0  
Gender Female 2.8 2.3-3.2 
 Male (reference) 1.0  
SES Middle 1.1 0.9-1.2 
 High 1.1 0.9-1.2 
 Low (reference) 1.0  
Sample origin Private acute hospitals 0.8 0.6-1.3 
 GP clinics 1.0 0.9-1.2 
 After-hours GP clinics 1.9 1.3-2.7 
 Community health services 1.7 1.2-2.4 
 Specialist health services 1.7 1.0-2.8 
 Others# 1.7 0.9-3.3 
 Public acute hospitals  
(reference) 
1.0  
Nalidixic acid Age ≤23 0.9 0.7-1.1 
 38-56 0.8 0.7-1.1 
 57-73 1.7 1.4-2.1 
 ≥74 1.9 1.5-2.4 
 24-37 (reference) 1.0  
Gender Female 2.9 2.4-3.5 
 Male (reference) 1.0  
SES Middle 1.2 1.0-1.4 
 High 1.2 1.0-1.5 
 Low (reference) 1.0  
Sample origin Private acute hospitals 1.0 0.7-1.6 
 GP clinics 1.0 0.9-1.2 
 After-hours GP clinics 1.7 1.1-2.5 
 Community health services 1.8 1.2-2.6 
 Specialist health services 1.5 0.8-2.7 
 Others# 1.4 0.6-3.2 
 Public acute hospitals  
(reference) 
1.0  
Ciprofloxacin Age ≤23 1.1 0.8-1.5 
 38-56 1.1 0.8-1.5 
 57-73 2.5 1.9-3.4 
 ≥74 2.7 2.1-3.8 
 24-37 (reference) 1.0  
Gender Female 2.4 1.9-3.0 
 Male (reference) 1.0  
SES Middle 1.1 0.9-1.4 
 High 1.3 1.0-1.6 
 Low (reference) 1.0  
Sample origin Private acute hospitals 1.3 0.8-2.2 
 GP clinics 1.0 0.8-1.3 
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 After-hours GP clinics 1.1 0.6-2.1 
 Community health services 1.8 1.1-3.0 
 Specialist health services 1.5 0.7-3.2 
 Others# 2.2 1.0-5.0 
 Public acute hospitals  
(reference) 
1.0  
Norfloxacin Age ≤23 1.1 0.8-1.6 
 38-56 1.1 0.8-1.6 
 57-73 2.7 1.9-3.6 
 ≥74 2.9 2.1-3.9 
 24-37 (reference) 1.0  
Gender Female 2.4 1.9-3.1 
 Male (reference) 1.0  
SES Middle 1.1 0.9-1.4 
 High 1.3 1.0-1.6 
 Low (reference) 1.0  
Sample origin Private acute hospitals 1.3 0.8-2.2 
 GP clinics 1.0 0.8-1.3 
 After-hours GP clinics 1.0 0.5-2.0 
 Community health services 1.9 1.1-3.1 
 Specialist health services 1.5 0.7-3.3 
 Others# 2.3 1.0-5.2 
 Public acute hospitals  
(reference) 
1.0  
Gentamicin Age ≤23 1.1 0.7-1.6 
 38-56 1.3 0.9-1.9 
 57-73 2.3 1.6-3.2 
 ≥74 3.0 2.1-4.2 
 24-37 (reference) 1.0  
Gender Female 2.3 1.8-2.9 
 Male (reference) 1.0  
SES Middle 1.1 0.8-1.4 
 High 1.2 0.9-1.6 
 Low (reference) 1.0  
Sample origin Private acute hospitals 1.5 0.8-2.5 
 GP clinics 1.1 0.8-1.4 
 After-hours GP clinics 0.3 0.1-1.3 
 Community health services 1.5 0.8-2.8 
 Specialist health services 3.2 1.7-6.0 
 Others# 1.5 0.5-4.6 
 Public acute hospitals  
(reference) 
1.0  
PIP Age ≤23 1.5 0.9-2.4 
 38-56 1.7 1.0-2.7 
 57-73 3.7 2.4-5.7 
 ≥74 4.9 3.3-7.6 
 24-37 (reference) 1.0  
Gender Female 2.4 1.9-3.2 
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Male (reference) 1.0 
SES Middle 1.0 0.7-1.2 
High 0.9 0.6-1.2 
Low (reference) 1.0 
Sample origin Private acute hospitals 0.8 0.4-1.7 
GP clinics 0.9 0.7-1.3 
After-hours GP clinics 1.8 0.9-3.5 
Community health services 1.6 0.8-3.0 
Specialist health services 2.7 1.3-5.4 
Others# 0.5 0.1-3.8 
Public acute hospitals  
(reference) 
1.0 
Nitrofurantoin Age ≤23 1.0 0.6-1.8 
38-56 1.8 1.2-2.9 
57-73 3.2 2.1-4.9 
≥74 4.7 3.1-7.0 
24-37 (reference) 1.0 
Gender Female 3.8 2.7-5.2 
Male (reference) 1.0 
SES Middle 0.9 0.7-1.2 
High 0.9 0.7-1.2 
Low (reference) 1.0 
Sample origin Private acute hospitals 1.5 0.9-2.7 
GP clinics 0.7 0.5-1.0 
After-hours GP clinics 2.6 1.5-4.6 
Community health services 1.3 0.6-2.6 
Specialist health services 2.0 0.9-4.6 
Others# 1.2 0.3-4.8 
Public acute hospitals  
(reference) 
1.0 
*A separate model was run for each antibiotic
AMC=Amoxycillin-clavulanate; TMP-SMX=Trimethoprim-sulphamethoxazole;
PIP=Piperacillin-tazobactam
#non-acute hospitals, correctional services, dialysis clinics, dental clinics, hospice, ambulance
services and a life insurance organisation
SES=Socioeconomic status; GP=General practice
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Log rank test: P < 0.001
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Figure (a) Kaplan-Meier curves of incidence of resistance to any antimicrobial agent by sex 
Log rank test:
24-37 years versus ≤23 years: P=0.0001
24-37 years versus 38-56 years: P=0.001
24-37 years versus 57-73 years: P<0.001
24-37 years versus ≥74 years: P<0.001
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Figure (b) Kaplan-Meier curves of incidence of resistance to any antimicrobial agent by age group 
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